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A randomised, prospective, multicenter phase III trial of adjuvant
chemotherapy with gemcitabine vs. observation in patients with
resected pancreatic cancer (PC)
J. Langrehr, H. Oettle, S. Post, K. Gellert, K. Ridwelski, H. Schramm, C.
Zu¨lke, G. Fahlke, L. Roll, P. Neuhaus, H. Riess Charite` - Universita¨tsmedizin
Berlin - Campus Virchow Klinikum; Ruprecht-Karls-Universita¨t, Mannheim;
Oskar-Ziethen-Krankenhaus, Berlin; Otto-von-Guericke-Universita¨t, Magde-
burg; Wald-Klinikum, Gera; Universita¨t Regensburg, Regensburg; for the
German pancreatic cancer study group (supported by AIO; CAO; Deutsche
Krebsgesellschaft E.V.)
Background. Chemotherapy with Gemcitabine (G) is standard therapy in
advanced, inoperable PC. The value of adjuvant therapy has not been clearly
defined yet, and no randomised trial with G in the adjuvant setting is available.
Methods. This study was designed to evaluate the efficacy and toxicity of
adjuvant G in patients (pts) with resectable pancreas cancer. Within 6 weeks
after operation, pts were randomised to receive G or observation (O) after
stratification for positive or negative resection margins, nodal tumor
involvement and tumor stage. G was administered at a dosage of 1 g/m2
days 1, 8 and 15 every 4 weeks for 6 months. Pts in the O arm received no
specific postoperative treatment, but were followed similar to the G group.
Primary endpoint was disease free survival (DFS), secondary endpoints
included overall survival (OS) and side effects in both groups. The study was
powered to detect a significant difference with 90% probability at a
significance level of 0.05.
Results. Between 07/98 and 12/04, 368 patients were included. Excluding 12
ineligible pts, 179 pts were randomised to G and 177 to O. Pts characteristics
were well balanced (G/O) with regard to median age (62/61 y), tumor status
(T3/T4 86/86%), nodal status (N neg: 29/27%; N pos: 71/73%), resection
margin R0: 81/84%; R1: 19/16%). February 28th 243 events (68%) have
occurred for DFS. Analysis shows a difference in median DFS [G:14.2
months (m), O: 7.5 m, pB/0.05]. Subgroup analysis demonstrated increased
DFS in pts with (n/62) or w/o (n/294) microscopic resection margin
involvement and in those with (n/256) or w/o (n/100) positive lymph
nodes. Grade 3/4 toxicities per pt were: leucocytes (G: 8.4%; O: 0%), platelets
(G: 2.8%; O: 0%), diarrhea (G: 2.2%; O: 1.1%), nausea (G: 4.5%; O: 0.6%).
Conclusion. Preliminary results demonstrate an increased DFS in pts with
resected PC when treated with G for 6 months after resection. The most
recent survival data will be presented at the meeting. Final results will be
expected in late 2005.
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The impact of margins on outcome following hepatic resection for
colorectal metastasis
Chandrakanth Are, MD, Mithat Gonen, PhD, Kathleen Zazzali, DO, Ronald
P. Dematteo, MD, William R. Jarnagin, MD, Yuman Fong, MD, Leslie H.
Blumgart, MD, Michael D.’ Angelica, MD
Memorial Sloan Kettering Cancer Centre, New York, NY
Introduction. The optimal margin width in hepatic resection for colorectal
metastasis (CRM) is unclear.The aim of this study was to analyze the impact
of margins on survival in a large single institution series and ascertain the
optimal margin width.
Material and methods. All patients undergoing hepatic resection for CRM
from 1991 to 2003 were identified. The effect of tumor related and technical
factors on margin width and survival was analyzed. The associations between
clinical risk factor and margins were tested using Cochran-Armitage trend test.
Survival curves were estimated using Kaplan-Meier methods and compared
with log-rank test. Multivariate analysis was done using Cox regression.
Results. A total of 1119 patients underwent hepatic resection and of
these,1019 patients that had clear description of margin width on final histo-
pathology were included. Analysis of margin width as a continuous variable
suggested the following grouping: Group I: involved and B/1 mm (n/112,
10.9%), Group II- 1/10 mm (n/563, 55%), Group III- /10 mm (n/344,
33.7%). Bilateral resections (p/B/0.01) and multiple tumours (p/B/0.01)
were associated with a higher likelihood of positive margins. There was a
statistically significant difference in median survival between the three groups:
30, 42 and 55 months in Groups I, II and III respectively (pB/0.01). Margin
width retained its significance (pB/0.01) in multivariate analysis after adjusting
for established risk factors (bilateral resection, multiple hepatic tumors, size/5
cm, and node positive primary). After adjustment, survival in Group III was
significantly better than either Group I or II (pB/0.01), but there was no
difference between Group I and Group II (p/0.31).
Conclusion. This study provides evidence that margin width of /1 cm is opt-
imal and an independent predictor of survival following hepatic resection for
CRM. However subcentimeter resections are also associated with acceptable
survival and therefore should not preclude patients from undergoing resection.
3
11C-acetate is superior to 18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) in evaluating patients with hepatocel-
lular carcinoma: Results of a pilot trial
Sean C. Glasgow, MD, Farrokh Dehdashti, MD, Barry A. Siegel, MD,
William C. Chapman, MD
Washington University, St. Louis, MO
Introduction. Although FDG-PET is widely accepted for the evaluation for
metastatic tumors within the liver, its sensitivity for detecting hepatocellular
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Impact of Margins, Biological and Technical Factors on Survival
n
Median Survival
(months)
Uni-variate
p
Multi variate
p
Less than lobectomy vs Lobectomy or more 380 vs 728 51 vs 41 B/0.01 NS
Unilateral resection vs Bilateral resection 637 vs 471 52 vs 36 B/0.01 0.03
1 tumour vs ]/2 tumours 777 vs 329 51 vs 37 B/0.01 0.02
Size B/5 cm vs Size /5 cm 745 vs 362 51 vs 34 B/0.01 B/0.01
Node negative primary vs Node positive primary 420 vs 637 57 vs 37 B/0.01 B/0.01
DFI /12 months vs DFI B/12 months 608 vs 489 46 vs 40 0.13 NS
Metachronous vs Synchronous 714 vs 386 45 vs 42 0.18 NS
Margin /1 cm vs Negative margin 1/10 mm vs
Positive margin
344 vs 563
vs 112
55 vs 42
vs 30
B/0.01 B/0.01
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carcinoma (HCC) is poor. Adequate pretransplantation staging of patients
with HCC is crucial to assure optimization of scarce resources, and
determination of recurrent disease post-ablation is often difficult using
standard tomographic imaging. 11C-acetate (AC) may be a better PET
radiopharmaceutical for the detection of HCC; however, extensive data
providing direct comparison between the two tracers are lacking and the
potential impact of AC-PET in the management of patients with HCC is
unknown.
Methods. Adult patients with either a history of biopsy-proven or suspected
HCC (AFP/200 mg/dL or arterially-enhancing hepatic mass) were pro-
spectively enrolled in this IRB-approved trial. Subjects underwent synchro-
nous FDG- and AC-PET, and the imaging studies were interpreted
independently in a blinded manner by two nuclear radiologists. Further
evaluations and therapies were performed at the discretion of the treating
surgeon. Participants were then followed to determine whether either
functional imaging test influenced treatment decisions.
Results. Thirty patients participated, with a total of 46 separate HCC
lesions greater than 1 cm diameter evaluated by both FDG- and AC-PET.
AC-PET was positive in 39 lesions (sensitivity 84%), whereas FDG-PET
was positive in only 13 (sensitivity 28%, pB/0.001). Only one lesion was
undetectable by either PET modality (false-negative rate 3%). The
sensitivity of AC-PET in patients with normal serum AFP levels was
70%, compared to only 30% for FDG-PET. In seven patients evaluated
following HCC-specific treatment (RF ablation or transplantation), the
specificity of AC-PET was 100%. Additionally, AC-PET was the sole
diagnostic modality to detect HCC in two subjects: HCC recurrence
following liver transplantation in one patient allowed timely RF ablation,
while HCC metastatic to the adrenal gland was detected in a second
patient.
Conclusions. This pilot study demonstrated the utility of AC-PET in the
management of patients with HCC, while confirming the lack of sensitivity of
standard FDG-PET for this malignancy. The superiority of AC-PET was
independent of clinical features such as AFP. AC-PET may have a role in
screening certain patients prior to liver transplantation, particularly those
beyond UNOS stage 2. It may also prove useful in following disease
progression after ablative procedures.
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Effect of exending-4 tretment in a minimal islet mass transplant
model in streptozotocin-induced diabetic mice
Yong Wang, MD, Jose Avilar, MD, Qi Meirigeng, MD, Barbaro Barbara,
PhD, Joseph Kuechle, MD, Mark Brown, MD, Enciro Benedetti, MD, Jose
Oberholzer, MD
University of Illinois at Chicago, Chicago, IL
Background. Exendin-4 (EX-4), a long acting agonist of GLP-1 receptor
and potent intestinal insulinotropic hormone, augments insulin secretion in
rodent models of diabetes and in human subjects. EX-4 and GLP-1 have
been demonstrated to promote replication and differentiation of beta-cells
in vivo and in vitro . In this study, we examined the effect of EX-4 on minimal
mass islet transplants and the native pancreas of streptozotocin-induced
diabetic mice.
Methods. Two hundred isogeneic C57/BL6 islets were transplanted
under the kidney capsule of streptozotocin-induced diabetic C57/BL6
mice. For the control group, islets were transplanted without EX-4
treatment. In the treatment group, mice were treated with daily
intraperitoneally injection of EX-4 at 0.8 ug/kg for 28 consecutive
days following islet transplantation. Islet function was monitored by
daily glycemia and intraperitoneal glucose tolerance test (IPGTT,
2 gram/kg glucose) at week 2 and 4. Islet grafts and native pancreas
were procured for histological evaluation at different time points
following transplantation.
Results. Ex-4 treatment improved the rate of successful reversal of
diabetes with a minimal islet mass: 86% of mice treated with EX-4
reversed diabetes (treatment group, n/12/14), while only 43% of control
mice reached normoglycemia (control group, n/6/14; p/0.0126). During
the observation period, the Ex-4 treated mice showed significantly lower
blood glucose level than the control group (mean glucose level, treatment
group, 198///41.64 mg/dl vs. control group, 295///115.21 mg/dl; p/
0.0148). Ex-4 treatment also improved the function of the islet graft: Ex-4
treated animals showed significantly improved response to IPGTT at week
2 and 4 (mean AUC/SD of glycemia following glucose challenge at
4 weeks posttranplant: 674.14///229.17 glycemia/minutes in the
treatment group vs. 1024.76///337.22 for the control group, p/0.007;
IPGTT at week 2 showed similar patterns). Ex-4 treatment showed also
the potential to promote regeneration of the native pancreas. After islet
graft removal by graft-bearing nephrectomy at day 28 and 48, 27% (n/
3/11) of the treated group showed sustained normoglycemia for up to one
week, while all of the control mice (n/9/9) became diabetic the day
following nephrectomy.
Conclusion. Our results indicate that Ex-4 allows for better islet engraft-
ment and function after transplantation, and that Ex-4 may also promote
regeneration of the native pancreas.
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Clinical and economic validation of the International Study Group of
Pancreatic Fistula (ISGPF) classification scheme
Wande Pratt, Shishir Maithel, Tsafrir Vanounou, Zhen Huang, Mark P.
Callery, Charles M. Vollmer
Beth Israel Deaconess Medical Center, Boston, MA
Background. Definitions of postoperative pancreatic fistula (POPF) vary
widely precluding accurate comparisons of surgical techniques and experi-
ences. The ISGPF has proposed a POPF classification scheme based on
clinical parameters; yet, it has not been rigorously tested or validated.
Applying this clinical grading system, we analyzed our experience with POPF
following pancreaticoduodenectomy (PD) in a pancreatico-biliary surgical
specialty unit.
Methods. 160 consecutive patients underwent PD from 10/01 to 10/05, with
a single drain placed. Pancreatic fistula, per ISGPF criteria, was any
measurable drainage on or after POD 3, with an amylase content /3/
serum activity. Cases were divided into four categories: no fistula (Grade
NF); biochemical fistula without clinical sequelae (Grade A); fistula requiring
any therapeutic intervention (Grade B); and fistula with severe clinical
sequelae (Grade C). Clinical and economic outcomes were analyzed across
all grades.
Results. Two-thirds of all patients had no evidence of fistula (Grade NF).
Grade A fistulas occurred 16.2% of the time, Grade B 12.5%, and Grade
C 3.8%. Overall, there were five readmissions (3.1%), three re-operations
(1.9%), and no deaths attributable to POPF. There are no significant
differences between Grades NF and A across all measurable outcomes.
Conversely, costs, length of stay (LOS), ICU duration, and disposition
acuity progressively increased from Grade A to C (Table). Resource
utilization similarly escalated by grade, as measured by higher radiology,
pharmacy, nutrition, laboratory, and transfusion costs. Furthermore, we
identified eight patients (15.4% of all fistulas) who developed Grade B and
C fistulas without biochemical evidence. These select patients had more
severe clinical outcomes and greater hospital costs than their counterparts,
grade for grade.
Conclusion. Biochemical evidence of leakage alone has no clinical conse-
quence, and does not result in increased resource utilization. Increasing
POPF grade has negative clinical and economic impacts on patients and their
healthcare resources. These findings validate the ISGPF classification scheme
for POPF. However, in its current form, it fails to identify 15% of patients
who, despite no initial biochemical evidence, may emerge with a clinical
manifestation of fistula.
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Extent of lymph node dissection and staging for extrahepatic
cholangiocarcinomas: information from a large U.S. database
Roderich E. Schwarz, MD, David D. Smith, PhD
UMDNJ-RWJMS, New Brunswick, NJ; City of Hope Cancer Center,
Duarte, CA
Background. Cholangiocarcinomas (CC) are associated with high recur-
rence rates even after R0 resection. We investigated the relationship between
lymph node (LN) numbers examined after resection of cholangiocarcinomas
and survival.
Methods. An extrahepatic CC data set was created from the SEER 1973/
2000 database. Relationships between the number of LNs examined and
overall survival (OS) were analyzed for all M0 stage subgroups.
Results. Out of a cohort of 10,275 patients with extrahepatic CC, 1,518
individuals were retrieved based on M0 stage, available resection information,
and at least 1 LN examined. The median age was 68 (range: 22/102),
genders were split evenly. The median tumor size was 2 cm (0/10). Primary
cancer sites included gallbladder (30%), extrahepatic bile ducts (25%), and
intrapancreatic bile duct/ampulla (45%). Transmural tumors were identified
in 47%, positive LNs in 42% of patients. The median number for total LNs
examined was 4 (range: 1/39), for positive LNs 0 (0/34), and for negative
LNs 3 (0/37). At a median follow up of 24 months (83 for survivors),
median OS was 37 months for LN negative, and 16 m for LN postive
cancers, with a 5-year OS of 40% versus 14%. Multivariate OS analysis
Outcomes according to POPF grade
Grade N (%)
Total Cost
(median)
Direct
cost
(median)
LOS
(median
days)
ICU
duration
(median
days)
Discharged
to
extended
care
facilities
NF 108 (67.5%) $18,855 $7,270 8 0 17.6%
A 26 (16.2%) $18,075 $7,064 8 0 3.8%
B 20 (12.5%) $24,283 $9,279 11 0 40.0%
C 6 (3.8%) $119,083 $46,526 27 10 83.3%
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yielded these prognostic variables: number of positive LNs, T category, age,
grade (all at pB/0.0001), total number of LNs examined (or number of
negative LNs obtained, p/0.0003), and primary site (p/0.002). The OS
impact of the total number of LNs examined was obvious, for both LN
negative (median OS, 1 vs. 10 or more LNs examined: 27 vs. 51 m., p/
0.002) and LN positive disease (10 vs. 22 m., pB/0.0001). A cutpoint
analysis yielded the ability to detect greatest survival differences through
negative LN counts of between 1 and 3, but best survival outcomes were
consistently observed with 10 or more negative LNs (Figure).
Conclusions. Survival prediction of extrahepatic biliary cancer is strongly
influenced by total LN counts and numbers of negative LNs obtained.
Although the resulting incremental benefit is small, benefits are stage
independent. Based on these data, dissection and examination of 10 or
more LNs should be considered for curative intent operations.
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Identification of an expression signature in colorectal cancer pre-
dictive of metastasis-an opportunity to increase the resectability rate
of liver metastases
Michael P. Powar, Satyajit Bhattacharya, Brian R. Davidson, Rebecca Hands,
Ayan Banerjea, Shafi Ahmed, Xia Han, Edwin Clark, Fei Huang, Peter Shaw,
Stephen A. Bustin, Sina Dorudi, PhD
Barts and the London, London, United Kingdom; Royal Free Hospital,
London, United Kingdom; Bristol-Myers Squibb, New Jersey, NJ
Introduction. The development of liver metastases is the principal cause of
distant treatment failure in colorectal cancer patients. Hepatic resection
provides the only chance of cure but is feasable in only 15/25% of patients.
Metastasis is a step-wise process modulated by numerous genetic and
epigenetic changes. DNA microarrays now allow global tumour gene
expression profiling in a single experiment. We aimed to identify an
expression signature in primary colorectal cancer that contributes to the
development of liver metastases and to assess it’s predictive value on an
independent set of primary tumours.
Methods. Tumour samples from 3 distinct groups were snap frozen at
operation: 32 ‘‘non-metastatic’’ colorectal primary tumours (patients with
disease-free survival /3 years), 17 ‘‘metastatic’’ colorectal primary tumours
(patients who developed liver metastases) and 26 colorectal liver metastases.
Total RNA was extracted, quantified and quality assessed. Microarray
experiments were performed using the Affymetrix HG-U133A GeneChip.
Data analyses were performed using GeneSpring 6.2 (SiliconGenetics).
Primary tumours were randomly allocated to form a training set (n/34)
and test set (n/15). Genes common to a three-way comparison of the
expression profiles of ‘‘non-metastatic’’ primaries, ‘‘metastatic’’ primaries
and colorectal liver metastases constituted a metastatic signature. This
signature was utilised in an algorithm to predict the development of liver
metastases in an independent test set of 15 primary tumours with known
clinical outcome.
Results. 100 genes constituting the metastatic signature were identified by a
three-way comparison of the expression profiles of ‘‘non-metastatic’’ pri-
maries, ‘‘metastatic’’ primaries and colorectal liver metastases. The genes
identified are involved in biological processes pivotal to metastasis. Prediction
of clinical outcome in an independent test set of 15 primary tumours was
correct in 14 cases (93%) (Sensitivity 100%; Specificity 90%).
Discussion. We have identified a distinct gene expression signature in
colorectal cancer that is predictive of the development of liver metastases.
This signature may improve prognostic stratification of patients, resulting in
targeted treatment and surveillance. Hence allowing metastases to be
detected earlier in their natural history, thereby increasing the resectability
rate of colorectal liver metastases.
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Optimizing donor-recipient pairing improves liver transplant graft
survival
Beau Kelly Jr., MD, Irene D. Feurer, PhD, John Kelly Wright Jr., MD, David
Lee Gordon, MD, Sunil K. Geevarghese, MD, Charles Wright Pinson, MD,
MBA, Ravi S. Chari, MD
Vanderbilt University Medical Center, Nashville, TN
Introduction. Currently, cadaveric liver graft allocation is prioritized by
recipient MELD score, without defined weighting of donor factors. However,
with increased use of extended criteria liver donors and the nationwide
increase in MELD scores, it is unclear that the present allocation system opti-
mizes liver donor-recipient pairings. We hypothesize that statistical modeling
that incorporates both donor- and recipient-specific factors, can improve the
identification of liver allografts at increased risk of failure, and more
appropriately match a donor liver with a recipient to optimize graft survival.
Methods. The UNOS/STAR data, consisting of 56,814 grafts from 1988 to
July 2004 were analyzed. Recipients B/18 years old, living-donor recipients,
multi-organ transplant recipients and donors after cardiac death were
excluded. Individual variables having/40,000 valid observations were
considered for further analysis and the sample was split at random into
training and validation samples. Proportional hazards regression models of
graft survival were developed in the training sample using a sequential process
to identify the final covariate set, and the utility of a resulting prognostic
index (PI) was tested in the validation sample. PI values were stratified by
quintile in the validation sample and the effect of this stratification on graft
survival was tested by Kaplan-Meier methods and the log-rank test.
Results. A model comprising 5 donor and 9 recipient covariates predictive of
graft outcome was developed in the training sample (model n/15,872,
model pB/0.001, all covariate main effects pB/0.05). Adding recipient
covariates to the donor set significantly improved the model (change pB/
0.001). The significant donor variables included, age, gender, race, HCV Ab
status, and liver type (whole vs. split). The recipient covariate set included
age, race, previous liver transplant, albumin, creatinine, medical condition,
tumor, mechanical ventilation, and functional status. Statistically significant
differences in graft survival were observed in the validation sample (n/
15,683, all pairwise pB/0.01) when cases were stratified on the basis of
calculated PI values.
Summary. This is the first demonstration of a statistical model in a large
patient population that identifies cadaveric liver donor and recipient factors
that significantly impact graft failure after liver transplantation.
Conclusion. In the future, a system that incorporates both donor and
recipient factors should be used to optimize donor liver allocation and
improve use and success of cadaveric liver grafts.
Parallel Free Paper Session I: Transplantation
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Pretransplant chemoembolization is ineffective in preventing hepa-
tocellular carcinoma recurrence
Swee H. Teh, MD, Jonathan Schwartz*, MD, Brett C Sheppard, MD,
Stephen C. Rayhill, MD, John M. Ham**, MD, David L. Scott, MD, John
Kaufman #, MD, Zubin Irani, MD, Susan L. Orloff**, MD
Depart of Surgery, Oregon Health & Science University, Portland, OR; Dept
of Medicine, *Oregon Health & Science University, Portland, OR; Depart
of Surgery, Oregon Health & Science University and Portland VAMC,
**Portland, OR; Depart of Radiology, #Oregon Health & Science University,
Portland, OR
Introduction. The role of pretransplant chemoembolization for hepatocel-
lular carcinoma (HCC) in liver transplant candidates is unclear.
Aim. To determine the utility of pretransplant transarterial chemoemboliza-
tion (TACE) in preventing HCC recurrence in allograft.
Methods. A retrospective study of all liver transplant recipients that received
pretransplant TACE and patients with incidental HCC from March 1997 to
August 2005 were identified. The TACE regimen involved transcatheter
delivery of adriamycin suspended in ethiodol. Patients underwent 1/3 TACE
procedures.
Results. There were 30 patients, 18 (60%) had TACE pretransplant, and 12
(40%) had incidental HCC discovered in the explant. Mean age at
transplantation was 53 yrs; 29 male/1 female. Etiology of cirrhosis was
HCV in 20 (67%), HCV/ETOH in 5 (17%), PSC in 2 (7%), hepatitis B in
1 (3%), hemachromatosis in 1 (3%), and autoimmune hepatitis in 1 (3%). In
the TACE group: 11 patients completed 3 TACE procedures, 2 completed 2
TACE, and 5 completed 1 TACE procedure. Radiographic and pathologic
confirmation of tumor size reduction (15 & 13 patients respectively), no
tumor size change (2 & 3), and tumor size increase (1 & 2). The degree of
histologic tumor necrosis was B/30% in 5 patients (27%), 30%/70% in 2
patients (11%), and /70% in 11 patients (61%). Using the Simplified
Staging System, tumors in the TACE and incidental HCC groups were sT1
in 11 and 3 patients, respectively, sT2 in 6 and 8 patients, and sT3 in 1
patient in each group. Microscopic vascular invasion was present in 4 TACE,
and 3 incidental HCC patients. Mean follow-up was 33.6 months. There
totalled three HCC recurrences in the allograft: 2 in the TACE group (3 &
18 mo.) and 1 in the incidental HCC group (36 mo.); all had micro-
scopic vascular invasion. Analysis revealed that microvascular invasion was
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predictive of HCC recurrence in the allograft (p/0.008). Etiology of
cirrhosis, TACE or incidental HCC, Simplified HCC Stage, radiographic
& pathological tumor size reduction, or degree of tumor necrosis were not
predictive of tumor recurrence.
Conclusions. Using TACE liver targeted therapy induced tumor size
reduction both radiologically and pathologically in the majority of treated
patients. However, these responses lack correlation with risk of HCC
recurrence. TACE may result in tumor downstaging and/or prevention of
disease progression while on the wait list. Microvascular invasion remains an
important predictor of tumor recurrence.
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Liver transplantation in very small infants
Kristin Mekeel, MD, Regino Gonzalez- Peralta, MD, Max Langham, MD,
Alan W. Hemming, MD
University of Florida, Gainesville, FL
Introduction. This study examines the results of liver transplantation (LT)
in children 5 kg or less. Reports suggest an increased morbidity and mortality
in children weighing 5 kg or less as compared with larger children. However,
over half of all children needing LT are B/1 year of age. Improving outcomes
in very small children is a major goal in pediatric liver transplantation.
Methods. All children under 21 years of age transplanted from January 1990
to June 2005 were included in this study. 168 primary liver transplants were
done: 61 in children less than one year of age and 20 in infants weighing 5 kg
or less at LT ( 2/5 kg). These 20 infants underwent 23 transplants. Whole
organs were used in 39% of transplants, and reduced or split grafts were used
in 61%. Arterial reconstruction using aortic conduits was done in 22%.
Analysis included Fischer’s exact or Chi square test for non-parametric
analysis while patient survival was calculated using the Kaplan Meier method
with differences in survival assessed using the log rank test.
Results. 5 yr survival for infants 5 kg or less was 75%, and graft survival was
60% which was not different than patients transplanted that were /5 kg.
There were 3 perioperative deaths, one from primary graft non-function and
two from portal vein thrombosis. There were no bile leaks or hepatic artery
thromboses. Bacterial, fungal and viral infections made up the vast majority
of the post-operative complications (65%), with viral infections resulting in
two graft losses requiring retransplantation. Rejection occurred in 25% of
patients, of which one patient required OKT3. 5 of the 23 liver transplants in
infants 5 kilograms or less were done prior to 1996, with a graft survival of
only 20%. Improvements in technique and post-operative care after 1996 led
to improved graft and patient survival of 72% and 81% respectively.
Conclusions. Liver transplantation for infants weighing less than 5 kilo-
grams can be technically challenging but can have equivalent graft and
patient survival when compared to larger children requiring liver transplanta-
tion. Infants should not be denied liver transplantation based on weight
alone.
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Peld score is a less accurate predictor of waitlist survival among
pediatric liver transplant candidates with chronic liver disease
designated as UNOS status 1
John E. Scarborough, MD, Carlos E. Marroquin, MD, William A. Cecilio,
RN, Pietrobon Ricardo, MD, PhD, Theodore N. Pappas, MD
Duke University School of Medicine, Durham, NC
Background. It is currently unknown whether PELD score or clinical
judgment is more accurate for predicting waitlist (WL) mortality for such
patients. Our objective for this study was to compare the WL survival of
pediatric OLT candidates with chronic liver disease and equivalent laboratory
PELD scores based on whether they were designated Status 1.
Methods. WL survival data and laboratory PELD scores for all pediatric
patients listed for 10 OLT since the implementation of PELD scoring (Feb.
2001) were obtained through the UNOS OPTN database. Exclusion criteria
included acute/fulminant liver failure or previous OLT. Patients were
grouped according to whether they were designated as Status 1 at the time
of OLT. Subgroup analysis was performed by stratification by lab PELD
score and comparing status 1 to non-status 1 patients.
Results. A total of 2,178 pediatric met inclusion criteria. 26% had been
listed as status 1 and 74% were listed with a PELD score at the time of
removal from the WL. The area under the receiver-operator characteristic
(ROC) curve for the lab PELD score was significantly lower for status 1
patients than for non-status 1 patients (0.72 vs. 0.81, respectively; p/0.004),
signifying less accuracy in predicting WL survival. Further comparisons of
subgroups using the log-rank test demonstrated that the significant differ-
ences in WL survival existed between status 1 and non-status 1 patients with
lab PELD scores of 7 to 16 (p/0.002) or 17 to 27 (p/0.01). No significant
differences were seen between status 1 and non-status 1 patients when the
PELD score was 27 points [Figure]. Among status 1 patients, no good
correlation was found between WL mortality and INR, albumin, serum
bilirubin, creatinine, age, history of mechanical ventilation or history of
dialysis, signifying a failure to identify risk factors other than Status 1
designation.
Conclusion. The ability of PELD to predict WL mortality is signifi-
cantly lower for patients designated as Status 1. Further efforts should
focus on identifying characteristics that mark patients as being at high risk for
WL mortality (specifically, risk in excess of that predicted by the PELD
score).
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Temporal trends in orthotopic liver transplantation in the United
States
John E. Scarborough, MD, Marroquin E. Carlos, MD, William A. Cecilio,
RN, Pietrobon Ricardo, MD, PhD, Theodore N. Pappas, MD
Duke University School of Medicine, Durham, NC
Purpose. The objective of this study was to determine potential trends in
the demographic profile of patients undergoing orthotopic liver transplant
(OLT) and the postoperative morbidity and mortality associated with this
procedure.
Methods. The Nationwide Inpatient Samples Database was reviewed over a
12 year period from 1990 to 2001. Recipient characteristics, postoperative
morbidity and mortality, and postoperative length of stay were assessed.
Averages of these variables were calculated for three time periods (Period I/
1990/1993, Period II/1994/1997, Period III/1998/2001) and com-
pared through trend analysis techniques.
Results. A total of 7007 patients underwent liver transplantation. The
percentage of patients undergoing OLT who were under 37 years old
decreased significantly from 36.03% in Period I to 17.87% in Period III,
while the percentage of patients who were 47 years of age or older
increased from 42.03% in Period I to 61.94% in Period III (pB/0.001).
The percentage of OLT patients who were female decreased significantly
over this same time period from 45.88% to 38.33% (pB/0.001). The
percentage of OLT recipients who were of Caucasian ethnicity decreased
significantly from Period I (79.55%) to Period III (71.04%), while the
percentage of OLT recipients who were Hispanic increased significantly
over this same time period (6.7% to 13.01%, pB/0.001). The overall
postoperative mortality after OLT decreased significantly from 15.28% in
Period I to 8.06% in Period III (pB/0.001), as did the overall incidence
of postoperative complications. Postoperative length of stay also decreased
from a mean of 29.869/2.29 days in Period I to 16.69/2.19 days in
Period III.
Conclusions. Temporal trend analyses of OLT procedures in the United
States from 1990 to 2001 indicate that recipients are increasing significantly
in age. Furthermore, changes in the ethnicity of OLT recipients appear to
reflect similar changes in the ethnicity of the United States population as a
whole. Finally, postoperative mortality, morbidity, and hospital length of stay
after OLT have decreased by approximately half from over the 12 year period
from 1990 to 2001.
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Persistence of reduction of blood product transfusion requirements
during liver transplantations
Luc Massicotte, MD, Andre Roy, MD
CHUM, Montreal, PQ, Canada
Liver transplantation (OLT) is a surgery that can be associated with massive
blood loss and the need for allogenic blood product transfusion [1].
Transfusion is associated with a significant decrease in the survival rate
[2,3]. Earlier, we described strategies for reducing RBC transfusion for 61
consecutive OLT (0.39/0.7 RBC un./pt) [4].
The aim of the present prospective survey was to evaluate whether
anesthesiologists could keep intraoperative RBC transfusions as low, for
150 OLT, even after the arrival of 2 new junior surgeons. These results were
compared to our recent series (2002) [4].
After approval of the ethics committee of the CHUM a prospective survey
was undertaken. OLT were prospectively studied during a 2-year period
(2002/2004). A low CVP was maintained in all patients prior to the
anhepatic phase by restricting volume infusion, by phlebotomy without
volume replacement or by a combination of both techniques. Coagulation
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defects were not corrected before, during or after the OLT, so no plasma, no
platelets or cryoprecipitate were to be given unless there was uncontrollable
bleeding. The decision to use the Cell Saver (CS) was made jointly by the
anesthesiologist and the surgeon based upon the likelihood of a large enough
potential blood loss to prime the CS.
The 2 new junior surgeons joined the group of 4 surgeons at the 82nd and
103rd OLT.
The mean number of intraoperative RBC units transfused per patient was
0.49/1.0 (median: 0, max: 8). 9 units of plasma were transfused to 3 patients
and 5 units of platelets to 1 patient. No albumin, nor cryoprecipitate were
transfused. 78% of the patients received no blood products during their OLT.
The arrival of 2 new surgeons was associated with an increase of the length of
surgery (2219/52 min. vs 2449/66 min.). However, the CVP decreased
(8.19/4.2 mmHg vs 6.49/3.8 mmHg)and there was no significant increase of
the blood loss.
There was a significant increase in the use of CS (13% vs 41%), this increase
was not associated with decreased transfusion. However, the final Hb had a
tendency to be higher (84.6 g/l vs 89.5 g/l).
We still continue to think that it is neither useful nor necessary to correct
coagulation defects prior to OLT [5]. Our study also seems to underline the
practice of decreasing CVP before the anhepatic phase, by fluid restriction,
by avoiding routine plasma transfusion and by using phlebotomy in order to
reduce blood losses and hence diminish the transfusion of blood products.
References
[1] Anesth Analg 2003;97:671/9.
[2] Can J Anesth 2005;52:148 /55.
[3] Liver Transpl 2003; 9:1320/9.
[4] Can J Anesth 2005;52:545 /6.
[5] Liver Transpl 1997;6:659/63.
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Risk factors for biliary complications following liver transplantation
during the MELD era: Effect of donor and recipient characteristics
Theodore H. Welling III, MD, David G. Heidt, MD, Michael J. Englesbe,
MD, Shawn J. Pelletier, MD, John C. Magee, MD, Randall S. Sung, Darrell
A. Campbell, MD, Jeffrey D. Punch
University of Michigan Medical Ctr., Ann Arbor, MI
Risk Factors for Biliary Complications Following Liver Transplantation
During the MELD Era: Effect of Donor and Recipient Characteristics
Biliary complications are a significant cause of morbidity following liver
transplantation. Since the initiation of MELD, criteria for transplantation
have shifted from wait-time to illness severity. We sought to examine risk
factors for biliary complications during the MELD era at a single, high
volume liver transplant center. Retrospective review of procurement and
individual patient records was performed. Univariate analysis was performed
using an unpaired t-test for continuous variables and a chi-squared test for
nominal variables. A univariate logistic regression was used to evaluate risk
factors for biliary complications. 256 (18% pediatric) transplants in 238
patients over a three year period were evaluated (7/02/6/05). A bile leak was
noted in 18.4% of patients with an overall stricture rate of 23.0%. The all
cause cumulative mortality rate was 15.6%. Patients with a bile leak, when
compared to those without, had a mean age of 50 v. 42 years (pB/0.005), a
mean donor age of 42 v. 32 years (pB/0.005), and a mean MELD of 25 v. 22
(pB/0.05). Risk factors associated with an increased risk of bile leak were
donor age (OR/1.03, CI 1.01/1.05), recipient age (OR/1.03, CI 1.01/
1.05), warm ischemia (OR/1.02, CI 1.00 /1.04) and MELD (OR/1.06,
CI 1.01/1.12). Variables protective against biliary leak were placement of an
intra-operative stent (OR/0.22, CI 0.05/0.96) and a roux-en-y choledo-
chojejunostomy (OR/0.27, CI 0.09 /0.78). Variables such as recipient
diagnosis, sex, and preservation method did not appear to be risk factors for
bile leaks. Not surprisingly, bile leaks increased the risk for stricture (OR
3.89, 95% CI 1.9/7.8). We conclude that biliary complications following
liver transplantation during the MELD era may be increased in patients with
higher donor or recipient age, higher MELD score, or longer warm ischemia
time. However, use of intra-operative stents or roux-en-y choledochojeju-
nostomy may decrease the frequency of biliary complications following liver
transplantation. Modeling of these risk factors is currently being performed
to further stratify patients at highest risk for biliary complications following
liver transplantation.
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Liver transplantation for hepatocellular carcinoma: Outcomes of live
donor versus cadaveric transplants
Christopher Reverte, James V. Guarrera, MD, John Renz, MD, PhD,
Benjamin Samstein, MD, Anand Khakhar, MD, Milan Kinkhabwala, MD,
Jean C. Emond, MD
Columbia University Medical Center, New York, NY
Introduction. Adult-to-adult living-donor liver transplantation (LDLT) for
hepatocellular carcinoma (HCC) has been advocated. The aim of the study
was to compare outcomes of LDLT versus cadaver whole organ (CWO) liver
transplantation (LTX) for HCC.
Methods. Between 01/98 and 10/05, 92 LDLT and 475 CWO procedures
were performed at our center. (Mean and median follow-up/3 yr). Inclusion
criteria were: histologically proven HCC and no previous surgical resection.
From this group, 64 CWO and 17 LDLT recipients were identified. Staging
by AJCC and CLIP pre- and post-LTX was performed utilizing cross-
sectional imaging and explant pathology. Vascular invasion (VscIN), multi-
focality (Mult), and poorly differentiated (PD) histology were recorded.
Explant pathology was compared to the published criteria of Mazzaferro
(Milan). Outcome variables included patient and graft survival, recurrence,
and surgical complications including primary nonfunction.
Results. Demographic data including age, indication for transplantation,
Child’s-Pugh, and physiologic MELD score at LTX were not significantly
different between groups. Median wait-time was lower for CWO (143 d) vs
LDLT (301 d) reflecting the application of LDLTafter the diagnosis of HCC
in patients already listed. Recurrence data (RECURR) are summarized
below:
Tumor Characteristics
AJCC STAGE I II IIIA VascInv Mult PD /Milan
CWO (%) 41 54 5 43 54 58 38
RECURR (%) 20 7 100 50 50 75 50
LDLT (%) 14 86 / 33 85 16 71
RECURR (%) / 33 / 50 100 / 100
HCC recurrence was associated with vascular invasion, multifocality, and
tumors exceeding Mazzaferro criteria. Kaplan-Meier 6 mo, 1-, 2-, and 3-year
recurrence-free and overall survival were not significantly different.
Conclusion. The data suggest LDLT for HCC yields acceptable results that
equal CWO.
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Preoperative assessment of hepatocellular tumor grade using percu-
taneous fine-needle biopsy: implications for transplant eligibility
Timothy M. Pawlik, MD, MPH, Ana L. Gleisner, MD, Robert A. Anders,
MD, PhD, Warren Maley, MD, Michael A. Choti, MD, MBA
Johns Hopkins University School of Medicine, Baltimore, MD
Introduction. Studies have shown that tumor grade may predict biologic
progression of hepatocellular carcinoma (HCC), microscopic vascular
invasion, and posttransplant tumor recurrence. Some centers have adopted
protocols for selecting HCC patients (pts) for transplantation based on tumor
grade as determined by preoperative fine-needle biopsy (FNB). The validity
of FNB to predict final nuclear grade has not been previously assessed.
Methods. One hundred eighty-one pts who underwent hepatic resection
and/or open radiofrequency ablation for HCC between Jan 1984 and Dec
2004 were identified. Clinicopathologic, FNB, and surgical pathology data
were collected. Analyses were performed using chi-square and kappa
statistics.
Results. The majority of pts had a solitary HCC lesion (86%); median
tumor size was 7 cm (range, 2-20 cm). Eighty-six pts (48%) had cirrhosis
and 51 pts (28%) had viral hepatitis. 104 (69%) of the 151 pts who
underwent hepatic resection had a FNB. Overall, no clinical factor
predicted which pts underwent FNB. However, among pts with cirrhosis,
those with tumors 5/2 cm (size 5/2 cm, 100% vs. size /2 cm, 70%; p/
0.09) or normal (B/20 ng/mL) alpha fetoprotein (AFP) levels (normal
AFP, 95% vs. elevate AFP, 64%, p/0.01) were more likely to be biopsied.
FNB was positive in 93 pts (FNB sensitivity 89%). Pathologic analysis
revealed 68% of HCCs to be well-differentiated on FNB vs. 34% on final
examination of the surgical specimen (Figure). Of those tumors initially
classified by FNB as well- or moderately-differentiated, 39% and 19%,
respectively, were later re-classified based on the final specimen. The
overall percent agreement of FNB and surgical pathology to determine
nuclear grade was poor (kappa/0.46, pB/0.0001). Whereas final patho-
logic tumor grade predicted the presence of microscopic vascular invasion
(well- 8%, moderate- 36%, poor- 67%; p/0.001), FNB grade did not
(well- 19%, moderate- 33%, poor- 50%; p/0.22).
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Conclusions. Selection of candidates for transplantation based on FNB
tumor grade may be misleading, as FNB tumor grade often did not correlate
with grade on final pathology. FNB grade was also a poor predictor of micro-
scopic vascular invasion. Clinico-morphologic criteria (tumor size, number)
should remain the major determinants of eligibility for transplantation.
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Minimizing cold ischemia time improves the cost-effectiveness of
liver transplantation
Derek E. Moore, MD, MPH, Robert Russell, MD, D. Lee Gorden, MD, J.
Kelley Wright, MD, Ravi S. Chari, MD, C. Wright Pinson, MD, MBA
Vanderbilt University, Nashville, TN
Background. The ever widening gap between the availability of donor
organs and the number of liver transplant candidates requires optimization of
posttransplant outcomes. The aim of this study was to evaluate the effects of
cold ischemia time (CIT) on graft survival and to analyze the cost-
effectiveness of minimizing CIT.
Methods. A Markov-based decision analytic model was created to simulate
outcomes for liver transplantation in recipients of organs with /12 hours of
CIT (high CIT) versus recipients of organs with B/12 hours of CIT (low
CIT). Baseline values and ranges were determined from the UNOS database
(24,000 transplants between 1995 and 2004) and Medicare cost data.
Sensitivity analyses were conducted to test model strength and parameter
variability.
Results. Recipients of organs with /12 hours of CIT had a five-year survival
of 61% versus 67% for recipients of organs with B/12 hours of CIT (PB/
0.001). After transplantation, recipients of organs with high CIT gained 4.9
QALYs (Quality Adjusted Life Years) at a cost of $65,000/QALY versus 5.5
QALYs at $57,000/QALY for recipients of organs with low CIT.
Conclusions. Minimizing CIT improves long term graft survival and
ensures the cost-effective use of the limited donor supply.
Parallel Free Paper Session II: Pancreas
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Plasma Tumour M2-Pyruvate Kinase (Tu-M2-PK) is a metabolic
marker of disseminated malignancy in patients with pancreatic/peri-
ampullary cancer
Kolitha S Goonetilleke, MBBS, Priyantha Siriwardena, MBBS, M France,
MBBS, Ajith K Siriwardena, MD, MBBS
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom
Introduction. Recent evidence has shown that a wide range of human
tumours express the enzyme tumour pyruvate kinase (Tu-M2-PK), a
component of the aerobic glycolysis pathways. As Tu-M2-PK is expressed
by all cancer-bearing cells whilst the conventional cancer marker carbohy-
drate antigen (CA 19-9) is expressed principally by biliary endothelium, this
study tests the hypothesis that Tu-M2-PK is a molecular marker of
disseminated malignancy.
Methods. From July 2002 to March 2004, serum levels of Tu-M2-PK and
CA19-9 were measured on admission to hospital in 77 patients with
subsequently histopathologically confirmed pancreatic/peri-ampullary malig-
nancy (42 male, 35 female). The median age (range) of the study population
was 68 (26/82) years. The possible correlation between preoperative serum
levels of Tu-M2-PK and CA19-9 and location of tumour, degree of
differentiation and survival was analysed. Survival curves were calculated
by the Kaplan-Meier method.
Results. The mean survival of patients with a cut-off of /27 m/ml for Tu-
M2-PK was 341 days compared to 580 days for those with levels B/27 m/ml
and this difference in survival was significant P/0.003. This finding was
independent of resection status (resection vs no-resection), site of primary
tumour and presence of metastatic disease.
Survival according to Tu-M2-PK levels
Group 1/Tu-M2-PK/27 m/ml
Group 2/Tu-M2-PKB/27 m/ml
Log rank P/0.00372
Conclusions. This study provides the first data that suggest that an elevated
Tu-M2-PK over 27 m/ml sampled on admission in patients with pancreatic/
peri-ampullary cancer is associated with adverse survival regardless of
conventional markers of cancer stage. If further verified, measurement of
Tu-M2-PK may become an important molecular marker for occult dis-
seminated malignancy.
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Hemaglobin A1c can be helpful in predicting progression to diabetes
after Whipple procedure
Lisa Lynn Hamilton, Dhiresh R. Jeyarajah, MD
Southwestern Medical School and Methodist Dallas Medical Center, Dallas,
TX
Purpose. Normoglycemic patients undergoing pancreaticoduodectomy
(Whipple procedure) often inquire whether they will be diabetic post-
operatively. There is limited information on this issue. We therefore looked
at a more subtle measurement of long term glycemic control, hemoglobin
A1C (HgA1c), as a prognostic tool in predicting progression to diabetes post
Whipple.
Methods. A retrospective review over a six year period of all patients
undergoing Whipple procedures at a single institution was conducted. 27
patients had no prior history of diabetes, complete follow up, and measured
pre-operative HgA1c values. Post operative diabetes was defined as the need
to oral hypoglycemic agents or insulin. These charts were analyzed for
progression to diabetes after Whipple.
Results. Of the 27 patients, 10 were considered to have post-operative
diabetes. The average pre-operative HgA1c value for these patients was 6.39/
0.66. This was statistically different from the 17 patients without post-
operative diabetes (Average HbA1c 5.29/0.39, pB/0.001). The positive
predictive value, negative predictive value, sensitivity, and specificity were
82%, 94%, 90%, and 88%, respectively.
Conclusion. This study demonstrates that progression to diabetes is very
unlikely after Whipple operation if the pre-operative HgA1c value is in the
normal range. The apparent utility of HgA1c in predicting post-operative
diabetes in this small study suggests that this lab test may be very helpful in
counseling patients for Whipple operation.
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Radioactive Colloidal 32P as an adjunct to standard therapy for
locally advanced unresectable pancreatic cancer: A randomized
trial
Alexander Rosemurgy II, German Luzardo, Jennifer Cooper, Hemant
Chheda, Larry Carey, Mark Bloomston, Emmanuel Zervos, Robert Carroll,
Shane Grundy, Thomas Black, Bruce Kudryk, Bruce Zwiebel, Steve Goldin,
Sam Al- Saadi, Paul Chervenick
USF Department of Surgery, Tampa, FL
Introduction. To determine the added efficacy of 32P in treating locally
advanced unresectable pancreatic cancer, a standard chemoradiation regimen
was utilized with or without 32P in a prospective randomized trial.
Methods. 39 patients with biopsy proven locally advanced unresectable
adenocarcinoma of the pancreas underwent randomization to receive 5-FU
and radiation therapy followed by gemcitabine, with or without 32P. 32P dose
was determined by tumor size (0.5 mCi/gm tissue) and volume (1 mL
suspension/4 cm3 tumor), and a single dose was administered at months
0,1,2,6,7 and 8. To be considered evaluable, patients must have completed
at least 33% of chemoradiation or, if randomized to receive it, 2 doses
of 32P. Maximum tumor cross-sectional area and tumor liquefaction were
determined at intervals by CT scan. Data, where appropriate, are reported as
median, mean9/SD.
Results. 30 patients were evaluable. Tumor cross-sectional area did not
significantly decrease in patients receiving 32P or in patients not receiving 32P
(19.7 cm2 to 17.4 cm2, p/0.08; 24.1 cm2 to 17.4 cm2, p/0.09, Wilcoxon
matched-pairs signed-ranks test). Tumor liquefaction occurred in 14 patients
receiving 32P and in 1 patient not receiving 32P. Serious adverse events
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(SAEs) occurred more often with 32P than without 32P (8.0 SAEs, 9.49/7.1
vs. 4.0 SAEs, 3.39/2.4; p/0.04, Mann-Whitney Test) (Table). 32P led to a
survival disadvantage (5.2 months, 7.29/5.3 vs. 12.6 months, 11.99/7.2; p/
0.05, Mann-Whitney Test) (Figure). Death was due to disease progression
(21 patients), GI hemorrhage (4 patients) and stroke (1 patient). 3 patients
not receiving 32P and 1 receiving 32P are alive at 17.0 months, 19.49/4.2 and
9.5 months, respectively.
Conclusions. 32P promoted tumor liquefaction, but did not decrease tumor
size. The addition of 32P to standard therapy for locally advanced
unresectable pancreatic cancer was associated with decreased survival.
Total Serious Adverse Events 32P No 32P
Gastrointestinal 21 5
Hematologic 12 4
Pulmonary 4 0
Metabolic/Nutritional 10 4
Vomiting/Dehydration 19 7
Jaundice/Cholangitis 6 1
Major DVT 2 1
Patients without SAEs 2 4
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A phase I study of the erbB1/erbB2 tyrosine kinase inhibitor lapatinib
with chemotherapy for advanced pancreaticobiliary cancer
David A. Iannitti Sr., MD, Murray Resnick, MD, J. Marie Suga, Joshua
Shipley, MD, Howard Safran, MD
Brown Medical School, Providence, RI
Background. Therapies that block aberrant growth factor signal transduc-
tion pathways have substantial promise in pancreaticobiliary cancer. Epider-
mal growth factor receptor (EGFR) is a tyrosine kinase cell surface receptor
encoded by the c-erbB-1 protooncogene and is commonly expressed in
pancreaticobiliary cancer. ErbB2 (HER2) is frequently amplified in biliary
cancer and is the preferred heterodimer partner for other ErbB receptors.
Lapatinib (GW572016) reversibly inhibits ErbB1 and ErbB2 tyrosine kinases
and is active against pancreatic cancer cell lines. We are completing a phase I
evaluation of lapatininb and gemcitabine (gem), and lapatinib with the
combination of gemcitabine and oxaliplatin (GEMOX).
Methods. Patients with advanced adenocarcinoma of the pancreas
or bile ducts were treated with lapatinib and either weekly gemcitabine
(1 gm/m2/week, 3 weeks on, 1 week off) or GEMOX (gemcitabine 1 g/m2
over 100 minutes and oxaliplatin 100 mg/m2, every 14 days). Cohort 1:
Weekly gem/lapatinib, 1000 mg/day. Cohort 2: Weekly gem/lapatinib,
1500 mg/day. Cohort 3: GEMOX/lapatinib 1000 mg/day. Cohort 4:
GEMOX/lapatinib 1500 mg/day. Tumor tissue is being evaluated for
erbB1/erbB2 expression by immunohistochemisty and for gene amplification
by FISH.
Results. Seventeen patients have been treated; pancreatic cancer (n/
12), biliary cancer (n/5). The median age was 62 (48/78). Dose
limiting toxicities include grade 3 diarrhea in one of six patients in
cohort 2 and grade 3 nausea in one patient in cohort 4. Grade 2 fatigue
occurred in four of 17 patients. No decline in cardiac function has been
detected in serial echocardiograms. Five of the first 12 patients have
responded including two patients with pancreatic cancer and diffuse liver
metastases, one patient with a locally advanced pancreatic cancer and
one two patients with biliary cancer and hepatic and peritoneal
carcinomatosis.
Conclusions. Lapatinib can be administered will full dosage gem. Accrual is
continuing at cohort 4 with GEMOX/lapatinib. Dramatic responses have
been demonstrated in patients with diffuse liver and peritoneal metastases
suggesting that erbB1/erbB2 signaling may be important in pancreaticobiliary
cancers. We are evaluating tumor expression of erbB1/erbB2 in relationship
to response.
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Intraoperative ultrasound of the pancreas: Utility in experienced
hands
Abhishek Mathur, MD, Thomas J. Howard, MD, Attila Nakeeb, MD, John
G. Touzios, MD, Stuart D. Wilson, MD, Henry A. Pitt, MD
Indiana University, Indianapolis, IN; Medical College of Wisconsin, Mil-
waukee, WI
Introduction. In recent years surgeons have been employing ultrasonogra-
phy (US) with increased frequency in the pre- and intraoperative manage-
ment of their patients. Preoperative US of selected breast and trauma patients
has become routine. Similarly, intraoperative ultrasound (IOU) is the gold
standard in liver surgery and has been shown to equal cholangiography in the
detection of bile duct stones. Endoscopic ultrasound (EUS) and IOU also
have been demonstrated to be very accurate in the localization of pancreatic
neuroendocrine tumors. However, the utility of IOU in surgery of the
pancreas has not been established in a large series of patients.
Methods. The medical records of patients undergoing pancreatic surgery
from October, 1997 through September, 2005 were reviewed. Patient
demographics, pre- and postoperative diagnoses, operative findings and the
procedure performed were recorded. The operating surgeon evaluated
whether IOU helped to a) establish or confirm the diagnosis, b) determine
respectability, c) localize a lesion, d) characterize or localize the pancreatic
duct and/or e) choose the final operation.
Results. Over an 8 year period, 925 patients underwent pancreatic surgery
including 269 pancreatoduodenectomies, 155 palliative bypasses, 172 distal
pancreatectomies, 58 pancreatojejunostomies, 25 enucleations, 26 sphincter-
oplasties/ampullary resections. IOU was performed on 301 patients (33%)
with a mean age of 60.1 years, and 50% were male. IOU was employed in 137
of 403 patients (34%) with periampullary malignancy, in 79 of 408 patients
(19%) with pancreatitis, and in 73 of 101 patients (72%) with cystic tumors.
The utility of IOU was
Conclusions. These data suggest that intraoperative ultrasound of the
pancreas has multiple utilities even for the experienced pancreatic surgeon.
We conclude that intraoperative ultrasound facilitates pancreatic surgery and
that routine employment should be considered.
Department of Surgery, Indiana University and Medical College of Wiscon-
sin, Indianapolis, IN 46202 and Milwaukee, WI 53226.
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Delayed pancreatic necrosectomy reduces complications and mor-
tality in infected pancreatic necrosis
John B. Conneely, MD, Majella Doyle, MD, Suzanne Shine, MD,
Frances Colreavy, MD, Dermot Phelan, MD, Helen Fenlon, MD, Gerry
Mcentee, MD
Mater Misericordiae Hospital, Dublin 7, Ireland
Introduction. Necrotising pancreatitis can be a lethal condition, with
mortality due to infected necrosis as high as 35%. Surgery is associated with
major complications including haemorrhage and fistula formation and
reoperation is common. Optimal timing of surgical intervention is particu-
larly controversial. Since 1999 we have employed a policy of delayed
surgical intervention for pancreatic necrosis, facilitated by aggressive
radiological drainage, targeted antimicrobial therapy and critical care
support.
Methods. All patients with necrotising pancreatitis and accompanying organ
dysfunction were referred to critical care services. Organ dysfunction was
assessed by serial SOFA and APACHE II scores. Pancreatic collections were
drained radiologically. Antimicrobial therapy was determined by microbio-
logical culture. Necrosectomy was performed when resolution of the
pancreatitic process was confirmed radiologically and the patient’s clinical
status had improved.
Results. From January 1999 until December 2004, 210 patients were
admitted with acute pancreatitis. Twenty nine of these developed infected
necrosis, all of whom underwent delayed necrosectomy. Mean peak
APACHE II and SOFA scores were 12 (range 8/17) and 3.5 (0/11)
respectively. Combined critical care support and radiological drainage
reduced immediate preoperative scores to 5 (1/8) and 0.7 (0/7) respectively
(pB/0.0004 one sample t-Test). Median interval to necrosectomy was 42 days
(8/98). No fistula or major haemorrhage was encountered. Reoperation rate
was 0% and mortality was 6.9%.
Conclusion. Necrosectomy for infected pancreatic necrosis should be
delayed until organ dysfunction has settled and the inflammatory process
can be demonstrated radiologically to have resolved. This approach reduces
complications and mortality.
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Management of adenocarcinoma of the body and tail of the pancreas
by the RAMPS procedure
Steven M. Strasberg, MD, David A. Linehan, MD, William G. Hawkins, MD
Washington University in St Louis, St Louis, MO
Introduction. Adenocarcinoma of the body and tail of the pancreas is a
highly malignant tumor. Reported 5 year survival with standard distal
pancreatectomy is about 15% with median survival of 10 months (Ann
Surg 223:506/512). Negative margin rate (R0 resection rate) is only about
70%. We described Radical Antegrade Modular Pancreato-Splenectomy
(RAMPS) in 2003 (Surgery133:521/7) with the aim of improving the
Confirm
Diagnosis
(n/301)
Determine
Resectability
(n/191)
Localize
Lesion
(n/223)
Pancreatic
Duct
(n/261)
Choose
Operation
(n/301)
Periampullary
cancer
85% 99% 98% 66% 83%
Pancreatitis 92% 100% 97% 80% 76%
Cystic tumor 97% 100% 100% 76% 95%
Overall 90% 100% 99% 74% 84%
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chance of obtaining an R0 resection particularly on the posterior margin and
to rationalize the lymph node dissection based upon the drainage of this
portion of the pancreas. The operation is modular in that the posterior
margin is either directly on the anterior surface of the adrenal gland (anterior
RAMPS) or in a more posterior plane in which the adrenal gland is removed
(posterior RAMPS)-based on preoperative CT guided staging of the tumor.
We present the results in 23 patients with adenocarcinomas who have been
resected with this procedure.
Results. From 1999 to 2005 13 females and 10 males, of average age 65
years were resected. Mean operative time was 6.2 hr. The anterior
RAMPS was performed in 15/23 (65%) of patients and the posterior
RAMPS in 8/23 patients (35%). Mean tumor size was 5.1 cm. The
tumor invaded outside of the pancreas in 16/23 (70%) patients. Mean
lymph node count was 14 nodes. Lymph node metastases were present in
11/23 (44%) patients. R0 resection was achieved in 20/23 (87%)
procedures. Mean blood loss was 630 ml; 4/23 (17%) patients received
intraoperative transfusion. There were no postoperative deaths but post-
operative complications occurred in 10/23 (43%) patients. Two patients
had neoadjuvant chemoradiation and 80% of the other patients received
adjuvant chemoradiation. Mean followup is 14 months (range 1/75
months). Median survival is 43 months. Actuarial 5 year overall survival
is 42%.
Conclusions. RAMPS resulted in a striking improvement in R0 resection
rate in comparison with reported results in series of distal pancreatectomies.
This has been associated with very good mean and overall survival rates
for resected patients, although as mean follow-up times are short these should
be taken as approximations. On the basis that the RAMPS approach provides
an R0 resection rate of almost 90% this operation should be adopted as the
new standard procedure for adenocarcinoma of the body and tail of the
pancreas.
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Interferon receptor alpha/beta predict adjuvant therapy outcomes in
resected pancreatic cancer
Reza F. Saidi, Frances Williams, Steve Remine, Michael J Jacobs
Providence Hospital, Southfield, MI
Aim. Interferons (IFN) are known to have antiproliferative and immunor-
egulatory activities that are modulated through specific cellular-surface
ligands, known as IFN-alpha, -beta, and -gamma receptors. The presence
of these receptors and their impact on response to adjuvant therapy in
patients with pancreatic cancer has not been determined.
Methods. Slides were prepared from 46 patients with pancreatic adenocar-
cinoma. Immunohistochemistry (IHC) was subsequently used to determine
the expression of IFN-alpha/beta receptor-chain 2 (IFNalpha/betaR) and
IFN-gamma receptor-chain 1 (IFNgammaR). The correlation between IFN-
receptor expression, tumor characteristics, and overall patient’s response to
adjuvant therapy was analytically determined.
Results. The IHC performed for pancreatic adenocarcinoma demonstrated
a high IFNalpha/betaR expression in 2.17% (2/46) of patients, moderate
expression in 19.56% (9/46) of patients, and faint or no expression in 76.08%
(35/46) of patients. IHC confirmed a high expression of IFNgammaR in
52.12% (24/46) of patients, moderate expression in 34.78% (16/46) of
patients, and faint or no expression in the remaining 13.04% (6/46) of
patients. Thirty-Two (69.7%) received adjuvant therapy.
Clinicopathological survey failed to demonstrate any significant correlation
between IFNalpha/betaR and IFNgammaR expression with regard to tumor
size, vascular invasion, perineural invasion, lymph node metastases, or stage
of disease. Use of adjuvant therapy was associated with increased survival in
patients with IFNalpha/betaR -positive tumors compare to parents with IFN
alpha/betaR -negative tumors (24 months) versus 14.7 months in log rank
test, p/0.012). The expression of IFNgammaR, however, had no impact on
patient survival (20 months vs. 17 months; p/0.656, log rank test).
Conclusion. The IFNalpha/betaR is associated with improved survival for
patients with resectable pancreatic cancer who received adjuvant therapy.
Parallel Free Paper Session III: Liver
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Emergency repair of complicated Umbilical Hernia in patients with
liver cirrhosis and ascites: Mesh or not
Ibrahim K. Marwan, MD, Maher Ali Osman, MD, El-Sefi T., Shawki A.,
Hammad E., Sadek A., Ibrahim T,Soliman E, Abdel-Dayem H., Abou-
El-Ela, Soliman H.
National Liver Institue, Cairo, Egypt
Background. repair of umbilical hernia (UH) in cirrhotic liver patients with
ascites has received little attention in comparison to other surgical problems
of cirrhosis. The timing and methods of UH repair continues to be a matter
of debate.
Aim. To compare herniorrhaphy (primary suture) with hernioplasty (poly-
propylene mesh) in patients with a primary complicated UH in the setting of
liver cirrhosis and ascites.
Patients and Methods. A randomized clinical trial including 40 consecutive
adult cirrhotic patients, admitted to the Emergency Department of the
National Liver Institute with complicated primary UH. Patients with
recurrent UH or malignant ascites were excluded. Patients were randomly
allocated into two equal groups ‘‘A’’ underwent direct suture repair
whereas group ‘‘B’’ underwent hernioplasty with polypropylene mesh
(on-lay technique). The population studied included 26 males and 14
females with a mean age of 45 years. Patients presented with complicated
UH in the form of irreducibility (20%), obstruction (30%), strangulation
(22.5%) and rupture (27.5%). The majority of patients (no/36)underwent
general anesthesia, while local anesthetic was administered in 4 cases. The in-
hospital morbidity and mortality were reported. The mean postoperative
follow-up was 24 months. Patients were followed for late complications
hernia recurrence.
Results. There were no significant anesthetic complications or surgical
procedure-related deaths. The mean duration of surgery was greater for mesh
repair than for suture repair (58.3 versus 40 min). The mean postoperative
stay was longer for the mesh group (11.2 versus 9.2 days). Rates of early
complications such as seroma, hematoma, wound infection and ascetic fluid
leak were similar in the two groups. Postoperative hematemesis occurred in 2
(10%) patients of group ‘‘B’’, while none of group ‘‘A’’ patients suffered this
complication. Hospital mortality reported in 4 (10%) patients, distributed
equally between the two groups. The hernia recurrence rate (11%) was
similar after both methods of repair.
Conclusion. Umbilical hernia exposes cirrhotic patients to potentially life-
threatening complications such as rupture and strangulation. Emergency
surgery should be considered cautiously and preferably done in specialized
centers for such decompensated patients. Mesh hernioplasty is not-in this
study-a superior method concerning the mortality and hernia recurrence
rates in such a group of patients. The direct suture procedure has the
advantage of shorter operative time and lower cost.
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Perioperative hepatitis B virus activity in patients undergoing
hepatectomy for hepatocellular carcinoma and its influence on
patient long time survival
Tao Chen
Sun yat-sen University, 2nd Hospital, Guangzhou, China
Objective. This study aims at defining the activity of hepatitis B virus (HBV)
in relation to surgical intervention in patients with hepatocellular carcinoma
(HCC).
Methods. Eighty consecutive HCC patients undergoing partial hepatectomy
were prospectively studied. The preoperative serum samples were detected
for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg),
hepatitis B e antibodies (HBeAb), hepatitis B core antibodies (HBcAb),
branched DNA assay [bDNA]) and liver enzymes. The patients were further
monitored for the virus activity by detecting HBV DNA in sera 5 days (D5)
and 1 month (M1) after the hepatectomy. The HBV markers, preoperative
HBV DNA titer, alanine aminotransferase (ALT), aspartate aminotransferase
(AST), operation duration, blood loss and blood transfusion volume during
operation were analyzed for prediction of postoperative changes of serum
HBV DNA level. 6 years postoperative overall survival and recurrence free
survival were further investigated and analyzed with HBV replication status of
patient in preoperative period or whether or not patients encountered one
episode of HBV replication enhancement in perioperative period.
Results. The positive rates of HBsAg, HBeAg, HBeAb and HBcAb were
82%, 29%, 70%, and 97%, respectively. HBV DNA could be detected in
46% of the patients by bDNA assay. In the 57 (71%) sero-HBeAg negative
patients, HBV DNA could be detected in 17 (30%) patients by bDNA assay.
Perioperative HBV DNA presentation had five types. Overall, 44 (55%)
patients had one episode of increase of viral HBV DNA levels, which might
imply that viral replication had once been enhanced by surgery. Recurrence
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free survival in patient with HBV replication enhancement were signifi-
cantly shorter compared to patients with non HBV replication enhancement
(P/0.0438).
Conclusion. More than half of the HCC patients had active HBV even at the
stage of chronic liver disease. 30% sero-HBeAg negative patients might be
infected by pre-core mutants. Reactivation or aggravation of HBV activity
occurred in 55% of the patients after hepatectomy but the occurrence was
unpredictable. Reactivation or aggravation of HBV activity or simply HBV
DNA replication enhancement in perioperative period might result in poor
overall or recurrence free long time survival.
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Health related quality of life following liver resection: A prospective
study
Dowmitra Dasgupta, MD, Galina Velikova, MD, Sarah Brown, PhD, K.
Rajendra Prasad, MD, Giles J. Toogood, MD, J. Peter A. Lodge, MD
St James’s University Hospital, Leeds, United Kingdom
Introduction. Health related quality of life (HRQOL) assessment is as
important an indicator of treatment efficacy as survival and mortality. There
are no reported prospective longitudinal studies using a validated HRQOL
instrument from Western centres assessing HRQOL after liver resections for
malignancies.
Materials and methods. Consenting patients undergoing liver resections
for primary or secondary liver tumors during a 1 year period from July
2002 were enrolled. They were asked to complete the generic HRQOL
questionnaire EORTC QLQ C30 [European Organization for Research
and Treatment of Cancer] pre operatively, 6 months post operatively and
1 year post operatively. Results were analysed according to diagnosis of
liver malignancy, major or minor resections and presence or absence of
complications.
Results. 103 patients were enrolled in this study. Patient compliance at each
stage was 99, 97 and 97%. Regardless of diagnosis, after a reduction in
HRQOL scores at 6 months, patients showed a return to baseline levels in all
aspects of quality of life except for some categories of physical functioning by
1 year. Pain, dyspnoea and fatigue were the symptoms showing a mild to
moderate improvement in both major and minor resections over time. All
other aspects of HRQOL showed little change from baseline at 1 year.
Surprisingly there was an increase in global HRQOL over time in patients
who had a post operative complication. However, those experiencing a post
operative complication showed a worsening of insomnia, appetite, dyspnoea
and pain compared to base values. All other parameters either showed no
change or a return to baseline by 1 year, after a dip at 6 months.
Conclusion. The general trend is for HRHRQOL to worsen slightly at 6
months and then return to baseline at 1 year, although some physical
symptoms improve. Liver resection for malignancy can be justified from a
HRHRQOL point of view.
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Conventional predictors of survival poorly predict and significantly
under predict survival after H-graft portacaval shunts
Sarah Cowgill, MD, Donald Thometz, Whalen Clark, Desiree Villadolid,
Elizabeth Carey, Daphne Pinkas, Steven Rakita, MD, Emmanuel Zervos,
MD, Alexander Rosemurgy II, MD
University of South Florida, Tampa, FL
Objective. This study was undertaken to evaluate our ability to predict
survival after 8 mm prosthetic H-graft portacaval shunts (HGPCS).
Methods. Since 1988, 170 patients have been prospectively followed after
HGPCS. Using preshunt data, predictors of survival after shunting (MELD
Score, Emory Score, Child Pugh Score, Discriminant Function (DF), and
Child Class) were determined and related to actual survival.
Results. Preshunt scores were determined (Table 1). Child Class was: A
10%, B 28%, and C 62%. Actual 5 and 10 year survival by Child Class was:
A 67% and 33%, B 49% and16%, C 29% and 7%. Survival correlated with
all predictors of survival (pB/0.01 for each). Actual survival was better than
predicted by MELD (pB/0.001, Mantel-Haenszel Chi-Square (Table 2)). By
Multiple Variable Regression Analysis-Computed Model, explained variation
in survival was greatest for Child Class (18%), followed by MELD (14%),
with DF, Emory Score, and Child Pugh Score not significantly contributing.
Conclusions. Following HGPCS, actual survival is better than predicted by
MELD. Child Class explains only a minor variation in survival, though it
better explains survival than MELD, Emory Score, Child Pugh Score, or DF.
Conventional predictors of survival poorly and under predict survival after
HGPCS and should be used with caution.
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IVC stenting: A safe and effective treatment for intractable ascites in
patients with polycystic liver disease
Jayleen M. Grams, MD, PhD, Swee H. Teh, MD, Vicente E. Torres, MD,
PhD, James C. Andrews, MD, David M. Nagorney, MD
Mayo Clinic College of Medicine, Rochester, MN; Oregon Health Sciences
University, Portland, OR
Introduction. Symptomatic refractory ascites in patients with polycystic
liver disease (PLD) is uncommon and the therapeutic options are limited.
The aim of the study was to examine the safety and effectiveness of inferior
vena cava (IVC) stenting in PLD patients with intractable ascites secondary
to hepatic venous outflow obstruction.
Methods. We performed a retrospective study from January 1996 through
January 2005 of all PLD patients who had intractable ascites treated with an
IVC stent.
Results. There were seven PLD patients who underwent IVC stenting for
intractable ascites. Six were female and the mean age was 54.6 years. Five
patients developed ascites after hepatic resection and cyst fenestration. All
patients had symptomatic ascites despite aggressive medical therapy and
frequent therapeutic paracentesis. Pre-procedural imaging included Doppler
abdominal ultrasound in two patients, MRI in three patients, and CT scan
in three patients. Based on both clinical and radiological features, all seven
patients underwent IVC venogram. Six patients had intrahepatic- and 1
patient had infrahepatic- vena caval stenosis. Two patients additionally had
hepatic vein (HV) stenosis. The mean pressure gradient across the stenosis
was 14.5 mmHg. IVC stenting was performed in all patients and hepatic
vein stenting was also performed in two patients. There was a significant
decrease in the post-stent pressure gradient to a mean of 2.8 mmHg (p/
0.008). Pulmonary edema developed in one patient. The mean follow up
was 16.9 months and all IVC/HV stents were patent radiologically without
secondary intervention. Overall therapeutic response was 85.7% (6/7
patients) both objectively, as determined by decreased diuretic requirement
or decreased frequency of paracentesis, and subjectively based on sympto-
matic improvement. Three patients did not require any further therapeutic
intervention.
Conclusion. IVC stenting is a safe and effective therapeutic modality
in PLD patients who have intractable ascites secondary to hepatic venous
outflow obstruction. Complete resolution of ascites was not achieved
in all patients likely due to an underlying multifactorial etiology of the
ascites. This study suggests that IVC stenting could be considered as a first-
line intervention in the treatment of intractable ascites in selected PLD
patients.
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Comparison of liver parenchymal transection in laparoscopic liver
resection
Alan J. Koffron, MD, Laura Kulik, MD, Renee Ziomek, RN, Michael
Abecassis, MD
Northwestern University Medical School, Chciago, IL; Northwestern Uni-
versity Medical School, Chicago, IL
Laparoscopic liver resection (LLR) is being performing in greater numbers
and centers. Patient selection, operative strategy, and vascular management
have been clarified by multiple series. In contrast, liver parenchymal
transection (LPT) remains the facet of this surgical approach that has the
most technical variability, inherent hemorrhage potential, and is usually the
major operative concern by those both experienced and initiating an LLR
pursuit. In this study we analyze our LLR experience to determine differences
in the technique of LPT with regard to operative conduct, outcome, LPT
device cost, in attempts to identify the technique(s) most suitable for centers
at the initial stages of an LLR endeavor.
We performed 153 LLR at our institution from 7/01 to 9/05. This series
consisted of 64 segementectomies, 26 left lateral segmentectomies, 22 left
lobectomies, 37 right lobectomies, and 4 trisegmentectomies. All cases were
performed by the same operative team using three methods of LPT
including: Cavitron Ultrasound Aspirator/Argon beam coagulator/endoclip
(CUSA), sequential stapling (SS), or Saline-enhanced Cautery (SEC,
TissueLink Endo SH2.0 Sealing Hook). The experience was then analyzed
for operative time (OT), blood loss (BL), complications, and transection-
associated device cost (TADC) with respect to magnitude of resection and
technique of LPT. TADC is expressed in units relative to a single endostapler
application (1.0 unit) at our institution.
Table 1. Preshunt Scores: median (mean9/SD).
MELD Score Emory Score DF Child Pugh Score
13 (159/5.5) 0 (0.79/1.11) 68 (709/10.4) 8 (8.29/2.15)
Table 2. Actual Survival vs. Predicted Survival by MELD.
Time After
Shunting 3 Months 6 Months 12 Months 24 Months
Predicted Survival 69% 60% 54% 43%
Actual Survival* 81% 80% 74% 66%
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Results. The table below demonstrates mean values for the various
resections and LPT techniques.
In summary, our experience finds that SEC provides a safe and device
associated cost advantage in LLR particularly in resections of large
magnitude (lobectomy). While SS provides slightly shorter operative times,
greater blood loss and biliary leaks were associated with this method of LPT.
This study suggests that SEC may be the preferred method of LPT in LLR
during the initial experience with LLR and extended resections, however, as
with the open surgery, surgeon experience and preference should be
considered in this approach to liver surgery.
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Resection of Hepatocellular Carcinoma (HCC) with Macroscopic
Vascular Invasion: Results of 98 consecutive cases at a single center
Sasan Roayaie, MD, Parissa Tabrizian, MD, Francesco D’amico, MD,
Myron E. Schwartz, MD
Mount Sinai Medical Center, New York, NY
Purpose. Studies of the natural history of patients with HCC and
macroscopic vascular invasion (MVI) have found median survivals of 2 to
4 months. Our aim was to describe the outcome of patients with HCC and
MVI undergoing hepatic resection and determine predictors of survival.
Methods. We reviewed charts of patients undergoing resection for HCC
from 6/92 to 11/04. Only patients with pathologically proven MVI were
included. Selection criteria for resection required that patients have Child’s A
liver function and platelets /100,000 /ul. Cases with tumor occluding the
main portal were resected as long as the portal branch to the uninvolved half
of the liver was patent and tumor did not extend beyond the SMV-splenic
vein confluence.
Results. Ninety-eight patients with pathologically proven MVI were resected
(table 1). Fifty-one (52%) had MVI identified on preoperative imaging and
21 (21%) required portal or vena caval thrombectomy. Median follow up of
surviving patients was 22.99/5.4 months. Median and 5 year survival of the
entire cohort was 169/7 months and 33%. Platelets B/100,000/ul, bilirubin
/1.0 mg/dl and AFP/10 ng/ml correlated with decreased survival on
univariate analysis. Preoperatively identified MVI, presence of cirrhosis, and
the need for thrombectomy did not correlate with survival. Only platelet
count and bilirubin were significant on multivariate analysis. The best
candidates (platelet /100,00 and bilirubin B/1.0) had median and 5 year
survival of 299/22 months and 42%. Actuarial recurrence was 70% at 2
years. Tumor size /10 cm and AFP /10 ng/ml predicted recurrence.
Perioperative mortality was 12.2% and was significantly higher in those
requiring vena caval thrombectomy (4/6, 67%) compared to those requiring
portal (3/15, 20%) or no thrombectomy (5/77, 6.9%; p/0.009).
Conclusions. Well-selected patients with MVI can undergo resection with
acceptable results. Bilirubin and platelet count are useful tools in choosing
candidates that will benefit most from surgery. Patients requiring vena caval
thrombectomy should not be considered for resection given the high rate of
perioperative mortality.
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The added value of neoadjuvant or adjuvant chemotherapy in colo-
rectal liver metastases: Improved midterm results of high risk
patients with resectable disease
Menahem Ben-haim, MD, Nir Lubezky, MD, Richard Nakache, MD, Arie
Figer
Tel-Aviv Sourasky Medical Center, Tel-aviv, Israel
Introduction. The idea of adding chemotherapy to surgery in patients with
hepatic colo-rectal metastases, who are at high risk for recurrence, is
appealing but not established.
Methods. A non-randomized prospective study of patients with colo-rectal
cancer and metastases confined to the liver, as defined by CT and PET-CT.
The risk of recurrence following metastasectomy was categorized according
to the MSKCC clinical score (0/5) and high risk was defined as MSKCC
score ]/2. Patients were either first operated on, and then treated
(‘‘adjuvant’’, group 1) or treated pre-operatively, operated on and treated
again (‘‘neoadjuvant’’, group 2). Chemotherapy was Oxaliplatin (FOLFOX)
or Irinotecan (FOLFIRI) based.
Results. Of 95 patients who underwent liver resections for colo-rectal
metastases (2002/2005), 46 were at high risk of recurrence (MSKCC]/2).
The 2 groups were comparable for demographics, characteristics of disease
(including MSKCC scores), protocols of treatment and follow-up. In group 1
(N/16) the 1, 2 and 3 years overall survival rates were 100%, 94% and 69%,
and the disease free survival rates were 54%, 45% and 45%, respectively. In
group 2 (N/30), the 1, 2 and 3 years overall survival rates were 93%, 93%
and 79% and the disease free survival rates were 92%, 49% and 49%,
respectively.
Conclusions. The overall survival and disease free survival rates in this
cohort of metastatic, operable but high risk patients, are much better than
historical controls, suggesting a beneficial effect of adding chemotherapy to
surgery. Within this cohort of patients who attained surgery, the results of
adjuvant vs. neoadjuvant approaches are comparable.
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Comparison of spinal morphine to PCA for analgesia after liver
resection
Luc Massicotte, Andre Roy, MD, Jean-denis Roy, MD
CHUM, Mount-royal, PQ, Canada; CHUM, Montreal, PQ, Canada
Continuous epidural anesthesia and analgesia is a technique that may be
considered in liver resection but is often avoided due to the potential
development of coagulopathies and the risk of epidural haematoma. The
aim of this prospective randomized double-blind study was to evaluate
the efficacy of one dose of intrathecal morphine (0.5 mg) compared to
patient controlled analgesia (PCA) with morphine. After approval of the
ethics committee, 40 patients scheduled for a major liver resection (]/2
segments) were enrolled. Half of the patients received 0.5 mg
intrathecal morphine with 15 mg of fentanyl at the beginning of the
case (morphine group) and the others had a simulation of spinal
anesthesia (placebo group). The primary outcome measure was PCA
morphine consumption. Secondary outcomes were: evaluation of pain at
rest and on stress on a visual analogue scale (VAS), evaluation of
sedation, nausea, pruritus and respiratory frequency. Outcome measures
were recorded at 6, 12, 18, 24 and 48 hours post spinal anesthesia or
simulation.
The patients in the placebo (PLAC) group consumed approximately 3 times
more morphine during each time interval than the morphine (MOR) group
(at 48 hours: 1249/30 mg vs. 479/21 mg, pB/0.0001). Pain evaluation by
VAS was lower for the first 18 hours in the MOR group. There was no
difference in the incidence of side effects in both groups.
In conclusion, spinal morphine (0.5 mg) given before the surgery significantly
diminishes PCA morphine consumption compared to the placebo without
any side effect increment.
Parallel Free Paper Session IV: Basic Science
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Uncoupling protein-2 promotes mitochondrial dysfunction and
injury following Ischemia/Reperfusion in the steatotic liver
Zachary P. Evans, Johathan Osorio, Justin Ellett, Bo Lu, Kenneth Chavin
Medical University of South Carolina, Charleston, SC
Ischemia/reperfusion (I/R) related liver failure and dysfunction are signifi-
cant clinical concerns, especially when using steatotic donor livers for
cadaveric or living-donor transplantation. Mitochondrial adaptations have
been thought to contribute to the increased sensitivity of steatotic livers to
damage induced by I/R. Specifically, mitochondria of steatotic hepatocytes
contain high levels of uncoupling protein-2 (UCP2) while normal lean
hepatocytes express little or none of this protein. UCP2 is a member of a
family of nuclear encoded proteins, known to uncouple the electron
transport chain from oxidative phosphorylation in order to maintain cellular
energy homeostasis and reactive oxygen species production. We propose the
hypothesis that UCP2 may ultimately sensitize the steatotic liver to injury
LPT N OT (min) BL (ml) Compl* TADC
(units)
Segmentectomy 64
CUSA 12 82 min / 3.5
SS 18 65 min 1 bile leak 3
SEC 34 41 min / 5
Left Lat. Seg. 26
CUSA 4 140 55 / 4
SS 8 70 50 1 bile leak 4
SEC 14 80 25 / 5
Left Lobectomy 22
CUSA 3 190 150 1 conv to SS 6.5
SS 6 130 450 2 bile leak 12
SEC 13 165 125 / 7.7
Right Lobectomy 37
CUSA 6 220 155 2 conv to SS 7.5
SS 9 160 550 2 bile leak 16
SEC 22 175 275 1 infection,
1conv to SS
7.7
Table 1. Patient & tumor characteristics.
Age (yr)* 57.79/11.9
Gender (n) M:F 77:21
Liver disease (n) HBV:HCV:Other: None 36:40:9:13
Transfusion (units)* 4.19/7.9
Size of largest tumor (cm)* 9.39/5.4
# tumors* 1.59/0.8
Satellites (n) Yes:No 52:46
Grade (n) Well: Mod: Poor: Missing 21:36:32:9
Metavir Fibrosis Score (n) 0/2: 3/4 29:69
*mean9/SD.
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following I/R by decreasing the efficiency of ATP synthesis following
reperfusion. In order to test this hypothesis, we employed both ob/ob
(n/9/10/group) and UCP2 knockout ob/ob (n/5/group) mice at 8 weeks
of age, and either sacrificed or subjected them to 15 minutes of total warm
hepatic ischemia, followed by 24 hours of reperfusion. Animal survival,
circulating serum ALT concentrations, liver histology (H&E, ORO), and
total liver ATP concentrations were measured. At baseline, there was no
difference in degree of steatosis or serum [ALT] between ob/ob and ob/ob
UCP2 knockout group, and there was a slight but non-significant increase
in liver ATP concentration in the knockout group (0.0189/0.006 umol/
nanogram protein vs. k.o. 0.0249/0.005). At 24 hours post-reperfusion,
100% of the knockout group survived while only 33% of the control ob/ob
group survived. Of the surviving animals, serum ALT values were
approximately 3.5 times higher in the control ob/ob group than the
knockout group (813.69/931.7 IU/L vs. 236.59/127.6, p/0.26). In
addition, hepatic necrosis was significantly less in the knockout group as
measured by centrilobular necrotic indexing (pB/0.05). Finally, ATP
concentrations significantly increased in the knockout livers following I/R
(ob/ob 0.0109/0.004 umol/nanogram protein vs. k.o. 0.0159/0.037, pB/
0.05). Although compensatory at baseline we have evidence that UCP2
expression in the steatotic liver inhibits ATP production, correlating with
increased injury and mortality after the stressors of ischemia and reperfu-
sion. Indirect downregulation of UCP2 through global decrease of hepatic
steatosis, or targeted downregulation prior to transplantion may enhance
the function of these sensitive organs, decreasing the probability of primary
nonfunction.
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A pilot study of a novel mouse model of human pancreas adeno-
carcinoma
Courtney L. Scaife, MD, Jill E. Shea, PhD, Qiang Dai, PhD, Yanchun Lui,
PhD, Xiao Zheng Shu, PhD, Matthew A. Firpo, PhD, Glenn D. Prestwich,
PhD, Sean J. Mulvihill, MD
University of Utah, Salt Lake City, UT
Introduction. An ideal animal model of pancreas cancer metastases does not
exist. Most utilize intraperitoneal or intrapancreatic cell or tumor implanta-
tion. These models do not replicate the cell signaling and biologic changes
necessary for metastases. This report of a novel mouse model of pancreas
cancer and metastases utilizes a red fluorescent protein (RFP) tagged cell line
delivered in a 3-D hyaluronan hydrogel matrix (HA). A main advantage of
this model is the ability to monitor tumor growth and metastases in vivo ,
using fluorescent intravital imaging.
Methods. MiaPaCa-2 human pancreas cancer cells were stably transfected
with RFP. Growth characteristics in vitro were examined by both MTTassays
and RFP expression. The in vivo model was established via a single 0.02 ml
intra-pancreatic injection of cell suspensions in serum-free media (5/107
cells/ml) in HA hydrogel, cells only, or HA hydrogel only through a left
subcostal incision in nude mice. Intravital images were captured weekly and
at necropsy (10/12 weeks) to monitor tumor growth and distribution of
tumor spread.
Results. In vitro cell proliferation rates were identical whether measured by
RFP intensity or MTT assay and both measures correlated with cell number.
Similar in vitro proliferation rates were obtained for cells grown with and
without HA hydrogel. Fifteen mice were injected with HA/cells, cells only,
or HA only (Table). Large intrapancreatic tumors and metastases developed
in all HA/cells animals. Small pancreatic tumors were evident in only 2 mice
treated with cells only. The figure shows primary tumor and metastases
fluorescence at necropsy.
Conclusions. This pilot study demonstrates that the HA 3-D matrix plus
cell model more reliably produces primary pancreatic tumors and metastases
than previously described models. Intra-vital imaging of RFP allows serial
assessment of the natural history of metastasis. This model may be useful in
assessment of pancreas cancer markers, biology of tumor growth, and the
mechanisms, control, and prevention of metastases.
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Interferon-gamma sensitizes pancreatic adenocarcinoma cells to
TRAIL-mediated apoptosis
Ewan M. Tytler, PhD, Sara L. McGowan, Adam Steg, Martin R. Johnson,
PhD, Selwyn M. Vickers, MD
University of Alabama at Birmingham, Birmingham, AL
Pancreatic cancer is now the 4th leading cause of cancer death in the USA.
At diagnosis, most pancreatic cancer patients are not candidates for
curative surgery. Pancreatic adenocarcinomas are ductal in origin and are
characteristically resistant to both chemotherapy and radiotherapy. There is
clearly a need for novel hypothesis-driven treatment strategies. At the
molecular level, the signaling pathways that tightly regulate the cell cycle in
normal cells are dysfunctional in pancreatic adenocarcinoma. Pancreatic
tumors are resistant to cellular signals that normally induce programmed
cell death (apoptosis). TNF-related apoptosis-inducing ligand (TRAIL,
Apo2L) is a death receptor ligand that induces tumor-specific apoptosis via
the TRAIL death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5). The
molecular basis for resistance to TRAIL is not well understood. Results. In
this study, we confirmed that Capan-1, HPAC, MIAPaCa-2 and PANC-1
pancreatic cancer cells are sensitive to TRAIL-induced apoptosis while
AsPC-1 and S2-VP10 cells are resistant to TRAIL-mediated apoptosis at
concentrations up to 100 ng/mL. Pretreatment with IFN-g (500 m/mL for
24 h) increased the sensitivity of all pancreatic cancer cells tested to
TRAIL-mediated apoptosis in vitro and also sensitized TRAIL-resistant
AsPC-1 and S2-VP10 cells to TRAIL. Inhibitor studies showed that
TRAIL-dependent apoptosis is caspase-dependent. Microfluid array analy-
sis has shown that IFN-g up-regulates the transcription of TRAIL,
Caspases 1 and 7. DR4 and DR5 transcription was not changed but the
decoy receptors TRAIL-R3 and TRAIL-R4 were down-regulated. Conclu-
sion. Pretreatment of pancreatic cancers with INF-g may provide improved
response to TRAIL to induce broad-spectrum, tumor-specific, apoptosis in
pancreatic cancer.
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Integrins on the surface of tumor cells alter sites of metastases
Kiyoshi Yoshimura, MD, PhD, Christina Y. Chia, MD, Lindsay S. Laird,
None, Norio Iizuka, MD, PhD, Jang-june Park, PhD, Drew M. Pardoll, MD,
PhD, Richard D. Schulick, MD
Johns Hopkins Medical Institutions, Baltimore, MD; Yamaguchi University,
School of Medicine, Ube, Japan
Background and objectives. We have previously reported on a substrain
of B16 murine melanoma cells with a high affinity to metastasize to
the liver. We have further characterized the differences between this substrain
and the parental B16 F0 strain that has a high affinity to metastasize to the
lungs.
Methods. A substrain of B16 murine melanoma cells (B16 KY8) was
derived from a parental strain of B16 F0 cells by repeated injection into the
spleen of B6 mice and harvesting cells from liver metastases for 8 cycles. The
B16 KY8 and B16 F0 strains were compared in terms of cell surface molecule
expression, ability to attach to collagen substrates, and ability to metastasize
to the liver versus lung.
Results. Integrin alpha2 in combination with integrin beta1 binds to
collagen type IV. B16 KY8 expresses integrin alpha2, whereas, B16 F0
does not. Both express integrin beta1. The liver expresses high amounts of
collagen type IV. B16 KY8 cells densely adhere to collagen IV coated plates,
whereas the B16 F0 cells do not. (See Figures) The B16 KY8 cells were
sorted based on high and low expression of integrin alpha2. When B6 mice
were given tail vein challenges, 80% of mice given B16 KY8 integrin alpha2-
high cells had liver metastases, 0% of mice given B16 KY8 integrin alpha2-
low cells had liver metastases, and 0% of mice given B16 F0 cells had liver
metastases. Liver metastases from the B16 KY8 integrin alpha2-high cells
could be prevented with antibody against the integrin which resulted only in
lung metastases.
Mouse Model Specimen
Group
Number
(N)
Primary
Tumor,
size
/100 mm 2
(N)
Primary
Tumor,
size
B/100 mm 2
(N)
Metastases
(N)
HA/
RFP-MiaPa-
Ca2
5 5 0 5
RFP-MiaPaCa2
only
5 0 2 0
HA only 4 0 0 0
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Conclusions. The expression of integrin alpha2 on the surface of
B16 murine melanoma cells enhances the formation of liver metastases
in B6 mice. This can be reversed by specific antibody blockade. The
differential expression of surface integrins may affect the site to which cells
metastasize.
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Donor alloantigen stimulation can maintain the donor specific
tolerance to rat liver transplants
Tsukasa Takayashiki, MD, Grace Ku, PhD, M. Wayne Flye, MD, PhD
Washington University, St. Louis, MO
Purpose. We have previously shown the spontaneous acceptance of Lewis
(LEW, RT1l) to Dark Agouti (DA, RT1a) rat orthotopic liver transplants
(OLT). This graft acceptance is eliminated by donor g-irradiation. However,
the acceptance of the g-irradiated LEW liver graft can be re-established in a
new naı¨ve DA rat by adoptive transfer (AT) of splenocytes (SC) [including T
regulatory (T-reg) cells] from a LEW to a DA liver tolerant long term (/60
days) survivor (LTS). However, the requirements to maintain T-reg cell
function remain unclear. The purpose of this study is to investigate the role of
in vitro donor Ag stimulation for the maintenance and persistence of T-reg
cell function before AT in rat OLT.
Methods. SC (1.5/108 cells) from a LEW liver graft tolerant LTS DA
recipient were AT immediately after isolation or after in vitro stimulation.
After 1, 4, 14 or 30 days the naı¨ve DA recipient received a g-irradiated
(1000R) LEW liver transplant. For in vitro alloantigen stimulation, equal
numbers of SC (2.5/106 cells/mL) from LEW to DA LTS were cultured
with 2.5/106 mitomycin-C (MMC) treated naı¨ve LEW SC in RPMI 1640
supplemented with 5% heat-inactivated fetal bovine serum, 1% L-glutamine,
100,000 U/L penicillin-streptomycin, 10 mmol/L HEPES, 1% sodium
pyruvate, 1% nonessential amino acid, and 1/105 mol/L 2-mercaptoetha-
nol for 72 hrs at 378C under 95% O2 and 5% CO2.
Results. All LEW liver grafts transplanted into DA recipients were
spontaneously accepted indefinitely (/60 days, n/32, Gp1). In contrast,
all g-irradiated LEW liver grafts were acutely rejected in a mean survival
time (MST) of 12.89/4.1 days (n/10, Gp2). However, when LTS DA SC
were AT into the naı¨ve DA recipient 1 day before OLT, all irradiated LEW
grafts were accepted longer than 60 days (n/9, Gp3). When OLT was
delayed until 4 days after AT of fresh LTS DA SC, all irradiated LEW liver
grafts were acutely rejected in a MST of 10.39/0.5 days (n/4, Gp4). In
contrast, when LTS DA SC were stimulated by MMC treated LEW SC in
vitro before cell transfer, all irradiated LEW liver grafts transplanted on day 4
(n/5, Gp5), day 14 (n/3, Gp6) and day 30 (n/2, Gp7) were again
accepted indefinitely.
Conclusion. The T-reg cells that develop after the spontaneous accep-
tance of LEW to DA OLT promptly lose their ability to induce allograft
tolerance, without alloantigen stimulation. However, the maintenance of T-
reg cell in vivo function can be maintained by prior in vitro alloantigen
stimulation.
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TLR4 and LPS. A possible cause of increased steatotic graft failure
Justin D. Ellett, Zachary Evans, Ryan Fiorini, PhD, Mark Feldmann, MD,
Bo Lu, MD, PhD, Kathy Haines, MS, Kenneth D. Chavin, MD, PhD
Medical University of South Carolina, Charleston, SC
In human transplantation, endotoxin (LPS) is thought to be a major
contributing factor to the pathogenesis of ischemia/reperfusion (I/R) injury.
Upon portal occlusion, bowel congestion causes bacterial translocation, and
the LPS is introduced into the portal circulation. Upon LPS exposure and
recognition by toll-like receptor 4 (TLR4), there is a large release of
proinflammatory cytokines, including TNF and IL-1b, which cause inflam-
mation and necrosis of the hepatocytes. In addition to this increase in portal
LPS post I/R, we see an increased sensitivity of steatotic livers to I/R injury.
Because of this, we hypothesized that steatotic livers are more sensitive to
LPS due to an upregulation of surface expressed TLR4 on hepatocytes. In
addition to increased surface expression of TLR4, we hypothesize that
steatotic animals have higher circulating levels of endotoxin pre- and post-I/
R. To test these hypotheses, we subjected male 10-week-old C57Bl6 (lean)
and ob/ob mice to 15 minutes of total hepatic ischemia and collected portal
blood at baseline and 15 minutes and measured endotoxin levels (n/5/
group). In addition, we compared baseline levels of TLR4 in lean and ob/ob
mice via flow cytometry, immunohistochemistry (IHC), Western blot, and
RT-PCR. TLR4 mRNA expression was increased in ob/ob mice (0.499/0.1
vs. 0.0469/0.05 in lean mice, pB/0.05, results are densitometry units
normalized to GAPDH) and protein expression was increased in the obese
animals (0.789/0.07 vs. 0.389/0.1 in lean animals, pB/0.05, results are
densitometry units normalized to b-actin). More importantly, we observed
significantly increased surface expression of TLR4, as demonstrated by IHC
and flow cytometry. In parallel to the TLR4 expression, we observed higher
portal circulating levels of endotoxin in ob/ob animals (0.2319/0.013 EU/mL
vs. 0.2089/0.005 EU/mL in lean, pB/0.05), as well as significantly increased
concentrations of endotoxin in the portal circulation post-ischemia in obese
animals (0.2979/0.03 EU/mL in lean vs. 0.3839/0.008 EU/mL, pB/0.001).
Due to the substantially increased levels of endotoxin in the obese animals at
baseline, coupled with the potentially increased sensitivity to endotoxin
conferred by the increased surface levels of TLR4, we propose a mechanism
of increased graft dysfunction in obese. In addition, the increased levels of
portal venous endotoxin post-I/R may contribute to the decreased graft
function regardless of graft phenotype in obese recipients.
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Pilot study of sir spheres† in liver metastases from neuroendocrine
cancer (netlm)
David Lawson Morris, PhD, Derek Glenn, MD, Richard Quinn, MD, Julia
Jenssen, None, Winston Liauw, MD, Julie King, PA-C, MPH
The University of New South Wales, Sydney, Australia
Study purpose. To assess the safety and effectiveness of selective inter-
nal radiation therapy (SIRT). Radioactive yttrium 90 micro-spheres (SIR-
Spheres†) are implanted into the liver to treat patients with unresectable
neuroendocrine liver metastases (NETLM). This is a relatively rare disease
with few treatment options. SIRT delivers and embeds high dose bionising
Sir-Spheres† into liver tumor vasculature. Clinical trial results have shown
efficacy of SIRT for colorectal metastases and primary hepatocellular cancer.
We hypothesized that SIRT would have a positive treatment role in the highly
vascular NETLM.
Method. 26 patients with NETLM have been treated from December 2003
to May 2005 with SIRT following a technetium-99 labled macroaggregated
albumin (MAA) scan to assess any percentage of lung shunting. Sir-
Spheres† were delivered as a single injection through a temporarily placed
hepatic artery catheter, with a concomitant, single 7 day systemic infusion of
225 mg/m2 5FU. Three monthly clinical monitoring, radiological (RECIST)
CT scan measurement and tumor markers, Chromagranin-A (CGA) and
serum calcitonin and serotonin assess response.
group
days
after
AT
in vitro
stimulation
irradiated liver
graft survival
(days)
MST
(days)
1 / / /60/32
(no irradiation)
/60
2 / / 8, 9, 11/4, 12,
17, 18, 20
12.89/4.1
3 1 / /60/10 /60
4 4 / 10/3, 11 10.39/0.5
5 4 / /60/5 /60
6 14 / /60/3 /60
7 30 / /60/2 /60
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Results. Median follow-up of 26 patients (15 males) is 6.8 (SD 6.1) months.
Primary tumour site was: 1 stomach; 1 caecum; 1 rectum; 1 terminal ileum; 2
medullary thyroid; 4 small bowel; 7 pancreas and 9 unknown. Complications
post SIRT were: 2 with duodenal ulcers caused by malperfusion; 1 self
resolving pancreatitis at one month; 2 with jaundice which was self-limiting.
All patients reported moderate abdominal pain or nausea from 1 to 4 weeks.
Three patients died from progressive liver disease at 4, 7 and 15 months.
Radiological response of target lesions (RECIST: PR; SD; PD) in (n/26) at
one month: 4 with PR; 17 with SD; 3 with PD and 2 patients had PR in one
side of the liver and PD in the other side of the liver due to lack of bilobar
administration of SIR-Spheres†. At 3 months (n/23) there were 14 with
SD, 4 with PR and 5 with PD. At 12 months (n/8) there was 1 with PR; 5
with SD and 2 with PD. There was a tumor marker (CGA) fall seen from
baseline in 58% (15/26) and 68% (13/19) at one and 3 months; 67% (8/12)
at 6 months and 83% (5/6) at 12 months in all evaluable patients.
Conclusion. SIRT appears to have efficacy for unresectable neuroendocrine
liver metastases.
B2
‘Simple’ pancreatic cysts demonstrated on computed tomography:
Clinicopathological characteristics and a comparison with ‘complex’
cysts
Brian K. P. Goh, MD, Yu Meng Tan, MD, Peng Chung Cheow, MD, Yaw
Fui Alexander Chung, MD, Pierce K. H. Chow, MD, PhD, Wai Keong
Wong, MD, London L. P. J. Ooi, MD
Singapore General Hospital, Singapore, Singapore; National Cancer Centre,
Singapore, Singapore
Introduction. The problem of the simple pancreatic cyst demonstrated on
computed tomography (CT) is poorly addressed and to the best of our
knowledge their clinicopathological characteristics have never been reported
in the literature. The aim of this study is to describe the frequency and
clinicopathological features of simple pancreatic cysts demonstrated on CT
scan and to compare them with complex cysts.
Methods. Between January 1990 and June 2005, 122 patients underwent
surgical treatment for a suspected pancreatic cystic neoplasm at our
institution. One-hundred and sixteen patients had a preoperative CT scan
and their clinicopathological features were retrospectively reviewed. The
cystic lesions were considered to be simple cysts on CT scan if they were
reported as a solitary, unilocular cyst in the pancreas with no communication
with the pancreatic duct. These simple cysts had fluid contents with no solid
components or mural nodules, were well-circumscribed and did not
demonstrate any calcification.
Results. Twenty-three of 116 patients (19.8%) who underwent CT had a
simple pancreatic cyst. Simple pancreatic cysts were smaller [25, range
(10/185) vs 55, range (10/240) mm, P/0.004] and were located less
frequently in the proximal pancreas [2 (8.7%) vs 30 (32.3%), P/0.024]
compared to complex cysts. These were more likely to be of a benign
pathology [14 (60.9%) vs 31 (33.3%), P/ 0.015] and were less likely to be
frankly malignant [0 vs 31 (33.3%), P/ 0.001]. On univariate analyses, cyst
size and the presence of symptoms were not predictors of the malignant poten-
tial of a simple pancreatic cyst. Of note was that 3 of 8 patients (37.5%) with
a small (5/2 cm), incidental simple pancreatic cyst had a premalignant lesion.
Conclusions. Simple pancreatic cysts depicted on CT are significantly
smaller and more likely to be benign than complex cysts. The likelihood of
these cysts being frankly malignant is extremely low. However, simple
pancreatic cysts cannot be dismissed as a significant proportion (39.1%) of
these cysts were premalignant.
B3
Tissue inhibitor of metalloproteinase-3 (TIMP-3) ameliorates hepatic
Ischemia/Reperfusion injury through inhibition of tumor necrosis
factor-alpha-converting enzyme (TACE) activity in rats
Zhenya Tang, MD, PhD, George Loss, MD, PhD, Satheesh Nair, MD, Ian
Carmody, MD, James Eason, MD, Ari J Cohen, MD
Ochsner Clinic Foundation, New Orleans, LA
Aim. We previously reported that hepatic TACE expression is increased in a
pattern similar to the pro-inflammatory cytokine TNF-a and IL-6 expression
following ischemia /reperfusion injury to the liver, suggesting that hepatic
TACE expression plays an important role in liver ischemia-reperfusion injury.
In this study, a TACE specific inhibitor, TIMP-3, has been administrated to
study its influence on the hepatic ischemia-reperfusion injury.
Methods. Male Wistar rats (n/8) were intraperitoneally injected with
TIMP-3 (a TACE specific inhibitor) at a dosage of 0 (normal saline, control
group), 10, 100 or 1000 ng/Kg body weight. One hour later, all animals were
subjected to 30 minutes of partial warm hepatic ischemia followed by 6 hours
of reperfusion. Serial serum TNF-a levels were measured by ELISA. Hepatic
TACE and TNF-a transcripts were assessed by RT-PCR. Serum ALT levels
and hepatic histology were examined.
Results. Animals subjected to ischemia/reperfusion injury without prior
TIMP-3 treatment had markedly high levels of hepatic TACE and TNF-a as
well as high serum TNF-a levels (107.279/2.86 pg/ml). Animals treated with
low-doseTIMP-3 (10 ng/kg) had similar circulating TNF-a levels compared
to control animals (110.439/6.24, p/n.s.). Increasing the TIMP-3 dose to
100 ng/kg resulted in a reduction of circulating TNF-a by nearly 50%
compared to controls (54.769/3.23 pg/ml, pB/0.05). High-dose TIMP-3
treatment (1000 ng/kg) reduced circulating TNF-a levels by approximately
75% (26.819/2.41 pg/ml, pB/0.01). Interestingly, a similar pattern of
reduced serum ALT levels was seen with increasing doses of TIMP-3. Histo-
logical evidence of reduced ischemia/reperfusion injury was evident in hepatic
specimens from the group treated with high-dose TIMP-3 (1000 ng/kg).
Hepatic TACE and TNF-a mRNA levels were unchanged among all groups.
Conclusion. TIMP-3, a specific inhibitor of TACE, significantly decreases
circulating levels of TNF-a and ameliorates biochemical and histological
evidence of hepatic ischemia/reperfusion injury. TACE inhibition did not
alter hepatic mRNA TACE levels as the inhibitor blocks enzyme activity at
the post-translational level. TACE inhibition may play an important role in
preventing liver ischemia/reperfusion injury and warrants further experi-
mental and clinical study.
B4
Effects of caspase-13 inhibition on the ischemia reperfusion induced
apoptosis and liver regeneration in the partially hepatectomized rats
Tarik Artis, MD, Sitki Yuksel, MD, Engin Ok, MD, Can Kucuk, MD, Hizir
Akyildiz, MD, Zeki Yilmaz, MD
Erciyes University Medical School, Kayseri, Turkey
Background. Caspases play important regulating role in the apoptosis
cascade. Protease (Caspase) inhibitors improves hepatic ischemia reperfu-
sion(IR) injury in rats. Caspase 13 is a new member of Caspase family. We
investigated the effects of Caspase 13 inhibitor, Z-LEED-FMK, on the
ischemia reperfusion induced apoptosis and liver regeneration in partially
hepatectomized rats.
Material and method. Fifty Wistar-Albino rats were divided into sham,
control and study groups. To control and study groups, after 30 min. of total
hepatic ischemia, 70% hepatectomy was performed and liver was reperfused.
To study group Z-LEED-FMK (10 mg/kg,SC) was given 60 min. before
surgery. At 2nd and 48th hr of reperfusion AST, ALT,LDH levels were
measured. Relative liver weight (RLW), malondialdehide( MDA), mitotic
index(MI), Caspase13 flow cytometric analysis, proliferating cell nuclear
antigen labeling index (PCNA LI)were evaluated.
Results. AST,ALT and LDH levels increased at 2nd hr in study and control
groups. In the study group these levels were significantly lower at 48th hr(pB/
0.05). Hepatic MDA level in study group was lower than control both at 2nd
and 48th hr (pB/0.05). MI, PCNA LI and RLW was significantly higher in
study group at 48th hr(pB/0.05). Caspase 13 flow cytometric level was lower
in study groups (pB/0.05). According to Suzuki scoring system IR injury was
better in study group at 2nd and 48th hr (pB/0.05)
Conclusion. Caspase 13 inhibitor, Z-LEED-FMK increases liver regenera-
tion both morphologically and functionally. This application also decreases
apoptosis and IR injury at the advanced stages of reperfusion.
B5
LBP is a mediator of increased liver injury and mortality following
lps challenge in the setting of biliary obstruction
R. M. Minter, MD, X. Bi, MD, J. Siddiqui, MS, M. R. Hemmila, MD, S.
Arbabi, MD, S. C. Wang, MD, PhD, D. G. Remick, MD, G. L. Su, MD
University of Michigan, Ann Arbor, MI
Purpose. We have previously reported that plasma and hepatic levels of
LPS-Binding Protein (LBP) are significantly elevated following common bile
duct ligation (CBDL), and that Kupffer cells isolated from these mice
demonstrate a hyper-sensitivity to LPS in the presence of LBP. Thus, in the
present studies we have sought to determine if LBP represents a potential in
vivo target for the prevention of the systemic inflammatory response and
increased mortality observed in CBDL animals challenged with LPS.
Methods. Female C57BL/6 and LBPKO mice underwent CBDL on day
zero (n/20/group). Blood (40 mL) was obtained prior to CBDL by tailvein
bleed and again four days later. On day four, all mice received an i.p. injection
of 1 mg/gram body weight of LPS (E. coli 0111:B4). Blood was again
Control group Study group
2nd hr 48th hr 2nd hr 48th hr
ALT( IU/ L) 10239/ 68.4 4199/ 24.12* 11769/ 42.58 1589/9.76*
AST(IU/ L) 14549/ 82.76 7319/ 24.1* 15119/ 49.03 2499/12.29*
LDH (IU/ L) 43089/35.49 21279/ 42.44* 41779/ 20.26 14629/ 41.63*
MDA 1559/2.89 1019/2.8 1449/3.24* 559/2.92*
MI(%) 8.69/1.17 12.99/0.73
PCNA LI 4.39/0.94 12.69/1.07 6.29/ 1.3 199/ 1.3*
RLW(g) 19.59/ 2.06 32.19/2.3*
Caspase 13
Flow
cytometry(%)
19.49/1.48 11.89/1.53 7.89/0.57* 6.2 9/0.21*
IR injury
Suzuki Score 2.59/0.97 1.89/0.63 1.29/0.78* 0.59/052*
*pB/0.05.
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obtained by tailvein bleed (40 mL) two hours following LPS injection. Mice
were monitored for 72 hours for survival, and plasma was analyzed utilizing a
validated microarray immunoassay to measure the levels of 23 inflammatory
mediators. Plasma bilirubin, AST, and ALT levels were also measured. All
values are expressed as the mean9/SEM, C57BL/6 vs LBPKO respectively,
and significance is set at a pB/0.05 level as determined by t- test. Survival
statistics were calculated using a Cox hazard ratio.
Results. Four days following CBDL, C57 and LBPKO mice had comparable
levels of cholestasis (bilirubin: 9.19/2.3 vs 8.99/1.0 mg/dL, p/0.9) and
transaminase elevation (AST: 2449/24 vs 3169/81 IU/L, p/0.4 and ALT:
1539/12 vs 2049/38 IU/L, p/0.2). However, following LPS delivery,
transaminase levels were significantly increased in the C57BL/6 mice as
compared to LBPKO mice (AST: 5259/102 vs 1399/19 IU/L, p/0.04 and
ALT: 4009/63 vs 1949/29 IU/L, p/0.01). Bilirubin levels remained
comparable. A marked survival advantage coincided with this decreased
hepatic injury in the LBPKO animals, with an 84% survival rate observed in
these mice vs only 35% in the C57BL/6 mice 72 hours following LPS
delivery, p/0.005. Surprisingly, despite the decreased liver injury and the
survival advantage observed in the LBPKO animals, there were no significant
differences in the early plasma cytokine levels between the two groups
following LPS delivery (i.e, TNF: 7.09/1.9 vs 6.09/1.5 ng/mL, p/0.7 and
IL-6: 88.99/18.1 vs 72.39/10.7 ng/mL, p/0.4).
Conclusion. The absence of LBP in vivo following CBDL and LPS
challenge leads to decreased liver injury and mortality as compared to
wild-type controls. This advantage, however, does not appear to be mediated
through alteration in the early cytokine response following LPS delivery.
Further studies are needed to elucidate the mechanism of LBP mediated
toxicity in biliary obstruction.
B6
Limiting pancreatic cancer growth via control of Bcl-XL-dependent
factors
Aram N. Demirjian, Jirong Bai, Mark P. Callery
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston,
MA
Cellular adhesion molecules (ICAM-1, CD44) and vascular endothelial
growth factor (VEGF) promote the growth and migration of pancreatic
cancer cells that have escaped apoptosis. It is not known whether they are
regulated by anti-apoptotic mechanisms that contribute to chemoresistance.
We examined whether their expression would change if a predominant anti-
apoptotic protein was genetically silenced in an animal model of pancreatic
cancer.
Methods. Bcl-XL knockdown RNAi vectors were constructed (Cancer Res
2005;65:2344/52) and introduced into Panc-1 human pancreatic cancer
cells by retroviral infection. Separate Panc-1 cells were similarly infected
using an empty control RNAi vector (Ric). After confirming the sustained
knockdown of Bcl-XL in vitro , two million Bcl-XL knockdown cells were
injected subcutaneously into the right flank of each of four, four-week-old
male nude mice. Four mice of the same age and sex were injected with RNAi
control cells (Ric). After solid tumors were established, grew, and became pal-
pable, these xenografts were harvested (8 weeks) for growth analysis. Whole
cell lysates were prepared for immunoblot analysis using fresh tumor tissue.
Results. Pancreatic cancer xenografts derived from Bcl-XL knockdown cells
were significantly smaller (weight and volume) than the control (Ric) tumors.
The associated sustained silencing of Bcl-XL was confirmed in knockdown
xenograft lysates, but not in controls. To analyze further mechanisms by
which Bcl-XL knockdown slows tumor growth in vivo , we correlated Bcl-XL
depletion with expression levels of ICAM-1, CD44, and VEGF. Compared to
control tumors, Bcl-XL knockdown xenografts demonstrated significant
depletion of ICAM-1, and near complete depletion of CD44. Additionally,
expression of VEGF was also reduced in knockdown tumors compared to
controls. There was no evidence of gross metastases in either xenograft group.
Conclusion. Cellular adhesion molecules and vascular growth factors may
be linked to anti-apoptotic Bcl-XL overexpression in pancreatic cancer cells.
This may explain, in part, why genetic inactivation of Bcl-XL dramatically
slows the growth of pancreatic cancer xenografts in vivo .
B7
Hepatic microwave ablation: A phase II trial
David A. Iannitti, MD, Caroline J. Simon, MD, Damian E. Dupuy, MD
Brown Medical School, Providence, RI
Objective. Review efficacy of hepatic microwave ablation (MWA) using
single and clustered MW antennae.
Design. Ongoing prospective phase II clinical trial utilizing the VivaWave
Microwave Coagulation System (Vivant Medical, Mountain View, CA) for
patients with hepatic malignancies via open surgical approach, laparoscopic
approach, or percutaneous approach. MW antennae were placed under direct
intra-operative ultrasound guidance or percutaneous CT fluoroscopy. Fol-
low-up data was gathered from post-ablative clinical visits in conjunction with
imaging studies.
Setting. University Teaching Hospital.
Patients. Seventeen patients with forty malignant liver lesions were
definitively treated utilizing MWA. Mean patient age was 63 years (range
39/90). Tumor histology included primary hepatocellular carcinoma (n/9)
and secondary liver metastases from colorectal (n/3), renal (n/2), breast
(n/2), and carcinoid (n/1) primaries. Nine patients were ablated percu-
taneously, five via laparotomy, and three laparoscopically.
Interventions. MW generator frequency: 915 MHz; ablation parameters: 45
Watts per antenna for 10 minutes. Repositioning and re-ablations carried out
as necessary to achieve overlapping areas of ablation, encompassing the
original tumor mass in its totality.
Main outcome measures. Technical success, ablation size, complication/
morbidity, residual/recurrence, and mortality.
Results. Forty hepatic malignancies (mean 3.2 cm greatest axis; range 0.5/
7.0) were successfully ablated. No immediate complications are reported.
One patient (percutaneous group) had a residual/recurrence at the ablative
margin, which necessitated a second and third re-treatment at 2 and 4
months respectively. Median follow-up interval is currently 243 days (81/
457). There were three treatment-unrelated mortalities. The ablation volume
(utilizing the ellipsoid volumetric equation) for triple single’clustered’
antenna MWA was 66.6 cc (15.5/152.9) and single antenna MWA was
11.6 cc (5.3/24.0).
Conclusions. Microwave ablation is technically feasible via the percuta-
neous, laparoscopic, and open surgical approaches. Differences in residual/
recurrence rates may be due to a multiplicity of factors, including the diverse
patient population enrolled in this study. Long-term reporting of survival
rates is crucial if MWA is to become a viable treatment modality for patients
with hepatic malignancies.
B8
Morbidity and mortality rates have decreased in the surgical manage-
ment of pancreatic necrosis
Thomas J. Howard, MD, Jay B Patel, MD, Kumar Sandrasegaran, MD, Jian
Yu, Atilla Nakeeb, MD, Henry A. Pitt, MD, Nicholas J. Zyromski, MD,
Keith D. Lillemoe, MD
Indiana University, Indianapolis, IN
Surgical management of patients with pancreatic necrosis (PN) has evolved
over the last 2 decades to include prophylactic antibiotics, intensive medical
management, and delayed surgical intervention. Historical data have
suggested an operative mortality rate of 24% to 39% in most large surgical
series. We present our experience in 96 consecutive patients over a 12 year
time period to assess the changes in morbidity and mortality rates as our
method of surgical management has evolved: A) after the introduction of
routine use of prophylactic antibiotics (1993/2001), and B) prophylactic
antibiotics plus delayed surgical intervention based on the International
Association of Pancreatology (IAP) guidelines (2002/2005).
Results. Ninety-six consecutive patients (54 males, 42 females, mean age
539/16 yrs.) who had surgical management of PN were classified as period A
(1993/2001) N/49, and period B (2002/2005) N/47. All patients
recieved routine prophylactic antibiotics (Imipenem) for 14 days and surgical
management consisted of pancreatic de´bridment and external drainage.
There were no significant differences in patient’s age, sex, or etiology of
pancreatitis.
Conclusions. Despite a worsening of morphologic damage as assessed by
Balthazar scoring, as treatment strategies have evolved (routine prophylactic
antibiotics and delayed surgical intervention using IAP guidelines), there is a
continuing decrease in hospital length of stay (LOS) and postoperative
morbidity and mortality rates in the surgical management of patients with
PN.
B9
Long-term results after surgery for autoimmune sclerosing pancrea-
titis
Thomas Schnelldorfer, MD, David N. Lewin, MD, David B. Adams, MD
Medical University of South Carolina, Charleston, SC
Introduction. Diagnosis and surgical management of autoimmune scleros-
ing pancreatitis, a rare cause of chronic pancreatitis, is challenging. This
study evaluates long-term operative outcome for this disease.
Methods. The histological specimens of 161 consecutive patients who
underwent pancreatic resection for chronic pancreatitis from 1995 through
2002 were re-analyzed. Eight patients were found to have histological
Variable
1993/2001
(N/49)
2002/2005
(N/47)
p
value
Infected necrosis 37/49 (76%) 34/47 (71%) 0.54
Balthazar score B/0.0001*
B/D 31 (63) 11 (23%)
E 18 (37) 36 (77%)
ICU LOS (days) 13/25 9/13 0.33
Hospital LOS (days) 38/33 26/23 0.04*
Morbidity 44 (90%) 34 (72%) 0.03*
Mortality 9 (18%) 2 (4%) 0.05*
*/statistically significant; LOS/length of stay.
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changes consistent with autoimmune sclerosing pancreatitis. This included 5
patients who underwent pancreaticoduodenectomy and 3 patients who
underwent distal pancreatectomy. Clinical and operative experiences were
retrospectively reviewed. Long-term outcome was assessed by telephone
survey applying the SF-36 quality of life questionnaire.
Results. Out of the 8 patients there were 6 males and 2 females with a mean
age of 48 years (range 22/73 years). Abdominal pain was the most common
symptom present in 7 patients followed by jaundice in 5 patients. Mean onset
of symptoms was 39/4.2 months prior to operation including two patients
with a longstanding history of chronic pain. Associations with other
autoimmune diseases were not present and none of the patients had received
glucocorticosteroids. Indication for operation was a mass suspicious for
malignancy in all 5 patients who underwent pancreaticoduodenectomy.
Endoscopic ultrasonography was utilized in 5 patients, revealing a hypoe-
choic mass in four and diffuse pancreatic enlargement in one. Intraoperative
findings included enlargement and firmness throughout the pancreatic gland
associated with severe peripancreatic inflammation in 3 patients. A localized
mass was found in two. Operative indication for the 3 patients who
underwent distal pancreatectomy was duct disruption with disconnected
tail in two and refractory pseudocyst in one case. Perioperative morbidity,
operative time, and intraoperative estimated blood loss was statistically not
different compared to patients who underwent the same operation for other
entities of chronic pancreatitis. Seven patients were alive and available for
telephone interview 549/4.5 months after operation. Good pain control was
achieved in 71%. 71% of patients returned to work. Quality of life was below
standard in 43% of patients surveyed. 71% considered their health status as
good though 14% expected worsening of their health state in the future.
Conclusion. Patients with autoimmune sclerosing pancreatitis and a mass
suspicious for malignancy or pancreatic duct disruption require operative
intervention. In the majority of patients, early postoperative outcome, long-
term pain control, and improvement in quality of life appear to be good.
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V7
Various liver resections using hanging maneuver by 3 glisson’s
pedicles and 3 hepatic veins
Seoung Hoon Kim, MD, Sang-jae Park, MD, Hyung-il Seo, MD, Joong-won
Park, MD, Chang-min Kim, MD, Woo Jin Lee, MD
National Cancer Center, Koyang, Republic of Korea
The liver can be divided into three sections by three Glisson’s pedicles. Left
pedicle supplies left hemiliver. Right hemiliver consists of the anterior and
posterior sections which are supplied by anterior Glisson’s pedicle and
posterior Glisson’s pedicle, respectively. The liver can be also divided into
three sections according to the area drained by three major hepatic veins:
right hepatic vein, middle hepatic vein, left hepatic vein.
The liver-hanging maneuver used in right hepatectomy by Belghiti et al. has
several advantages in major hepatic resection. A straight transection plane
from the anterior surface of the liver to the IVC can be obtained and the
lifting of the tape pulls the liver up and provides better exposure, easy
hemostasis of the transaction surface at the deeper parenchymal plane, and
protection of the IVC. Considering these advantages of this hanging
maneuver and the anatomic characteristics peculiar to the liver, various
anatomic liver resections which are cone-shaped with the center on IVC can
be done by positioning the hanging tape along the anteromedian surface of
retrohepatic IVC with its inferior end among 3 Glisson’s pedicles and with its
superior end among 3 hepatic veins.
We introduce this hanging technique in various liver resections which include
central bisectionectomy, right posterior sectionectomy, right hepatectomy.
V8
Left hepatectomy with portal vein thrombectomy for HCC with
vascular invasion
Luca Aldrighetti, MD, PhD, Marcella Arru, MD, Carlo Pulitano`, MD,
Marco Catena, MD, PhD, Michele Paganelli, MD, Renato Finazzi, MD,
Gianfranco Ferla, MD
Scientific Institute H San Raffaele, Vita-Salute San Raffaele University
School of Medicine, Milan, Italy
Hepatocellular carcinoma (HCC) tends to invade the intrahepatic vascula-
ture, especially the portal vein. In clinically treated series, the rate of portal
vein invasion is 34% to 40%. The presence of portal vein tumor thrombus in
patients with HCC is one of the most significant factors for a poor prognosis.
The natural history of untreated HCC is still poor, especially in patients with
portal vein tumor thrombus; the median survival of such patients is reported
to be 2.7 months. In surgically resected series, the 3-year and 5-year survival
rates are reported to range between 15% to 28% and 0% to 10%,
respectively.
The patient was a 77-year-old woman, affected by well compensated HCV-
related cirrhosis, (Stage A6 according to Child-Pugh classification), who
presented to our department for vague abdominal discomfort. Triphasic
spiral CT scan confirmed hepatocellular carcinoma of 6 cm in diameter of the
left lobe of the liver. In addition, portal vein tumor thrombosis of the left
branch extended to the right portal vein was present.
The procedure included left hepatectomy and ‘‘en-bloc’’ portal vein
thrombectomy with clamping of both the common portal vein trunk and
the right portal vein. Portal clamping and length of operation were
respectively 16 and 330 minutes. Intraoperative blood losses were 550 ml.
The patient was discharged on post operative day 6 and she is disease free at
16 months after surgery.
Liver resection should be considered a valid therapeutic option for
hepatocellular carcinoma with portal vein tumor thrombus.
V9
Laparosocpy-assisted right hepatic lobectomy employing the liver-
hanging maneuver
Hiroyuki Nitta, MD, Akira Sasaki, MD, Hidenobu Kawamura, MD,
Hidenori Itabashi, MD, Tomohiro Fujita, MD, Toru Obuchi, MD, Koichi
Hoshikawa, MD, Yuichiro Takeda, MD, Masahiro Takahashi, MD, Osamu
Funato, MD, Ryoko Sasaki, MD, Go Wakabayashi, MD, PhD
Iwate Medical University School of Medicine, Morioka, Japan
Background. Laparoscopic liver resection has been used to perform limited
liver resection. Partial resection and left lateral segmentectomy can be safely
performed laparoscopically. To perform right hepatic lobectomy laparosco-
pically, we employed the liver-hanging maneuver with minimal access.
Meticulous hepatic parenchymal dissection can be achieved under direct
vision through right sub-costal mini-laparotomy.
Methods. Indication for laparoscopy-assisted right hepatic lobectomy
includes tumor size less than 10 cm without invading right portal vein and
middle hepatic vein. Cholecystectomy and mobilization of the right liver were
performed with pneumoperitoneum. Before starting liver resection, pneu-
moperitoneum was quitted to avoid possible CO2 embolism through the cut
surface of the liver. An 8 cm of sub-costal mini-laparotomy was made, and
intra-operative ultrasonogram was performed to identify all the major vessels
and bile ducts. We started to ligate the right hepatic pedicle before
parenchymal dissection. Hepatic parenchymal dissection was performed
through the mini-laparotomy with a laparoscopic coagulating scissors and
an ultrasonic dissector using the liver-hanging maneuver. All the vessels and
bile dusts appeared on the cut surface of the liver were ligated and divided
directly through the mini-laparotomy. The right hepatic pedicle, short
hepatic veins, and the right hepatic vein were divided with GIA stapling.
Results. From November 2002 to July 2005, seventy-six patients underwent
laparoscopic liver resection. Of these 76 patients, eight patients underwent
laparoscopy-assisted right hepatic lobectomy for hepatic cancer. The 6 men
and 2 women had a mean age of 57 years (range, 24/77 years). Four had
hepatocellular carcinoma and four had colorectal metastases. Mean operation
time and blood loss were 288 minutes (range, 230/360 minutes) and 821 g
(range, 290/1498 g). Median postoperative hospital stay was 16 days (range,
10/154 days). Only one patient experienced bile leakage. One patient
required blood transfusion.
Conclusions. Laparoscopy-assisted right hepatic lobectomy emplying the
liver-hanging maneuver performed within the indications described above
was safe and associated with a favorable postoperative clinical course.
V10
Technical considerations in the managment of adults with choledo-
chal cysts
Craig P. Fischer, MD, MPH
Univ of Texas-Houston, Houston, TX
Video Submitted to AHPBA offices for review, for 2006 AHPBA meeting.
The video demonstrates technical considerations in the surgical management
of adults with choledochal cyst. Special attention is paid to recognition of
anomalous pancreatico biliary union.
V11
Inferior vena cava syndrome by compression of a giant hepatic
hemangioma. Treatment by enucleation with pringle’s maneuver
and total vascular exclusion
Juan Pekolj, MD, PhD, Martı´n De Santiban˜es, MD, Rodrigo Sa´nchez Claria´,
MD, Martı´n Palavecino, MD
Eduardo De Santiban˜es, Hospital Italiano, Buenos Aires, Argentina
Background. hemangiomas are the most frequent benign tumors of the
liver. Most of them are asymptomatic and surgical treatment is not required.
Big hemangiomas, symptomatic and/or compressing adjacent structures must
be treated.
Objective. to show technical tips for a hemangioma enucleation using
vascular clampings.
Methods. In a 49 year-old female patient with abdominal pain and lower
extremities edema, ultrasound, CT scan and MRI showed an 18 cm hepatic
hemangioma, adjacent to the hepatic veins with compression of the retro-
hepatic inferior vena cava.
Results. we performed an enucleation of the hemangioma, preserving the
right and left hepatic vein and sectioning the middle one. The enucleation
was made dissecting the field between the hemangioma and the normal liver
parenchyma. Monopolar electrocautery and Tissuelink† were employed. We
performed a 5 minutes total vascular exclusion and 3 Pringle’s maneuvers (10
minutes each one). The patient was discharged at day 7 without post-
operative complications and a complete remission of the vena cava syndrome.
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Conclusions. the enucleation is the best procedure to treat hepatic
hemangiomas. The Pringle’s maneuver reduces the tumor tension, making
easier the enucleation. Total vascular exclusion is needed when the tumor is
adjacent to hepatic or inferior vena cava veins to avoid massive bleeding or air
embolism.
V12
Retrograde laparoscopic cholecystectomy for xanthogranulomatous
cholecystitis
Leonardo Villegas, MD, Roger Walcott, MD, Leonardo Claros, MD, Charles
Vollmer Jr., MD
Beth Israel Deaconess Medical Center, Boston, MA
Background. Laparoscopic Cholecystectomy in the setting of chronic
cholecystitis poses certain technical problems. A rare cause of chronic
cholecystitis is Xanthogranulomatous Cholecystitis (XC), an inflammatory
disease of the gallbladder characterized by a focal or diffuse destructive
inflammatory process. The clinical presentation can be indistinguishable
from that of acute cholecystitis, and the diagnosis is only secured by
histological examination of the resected gallbladder. XC is present in 1% of
all cholecystectomies and frequently complicated (/30%) by perforation,
fistula, stricture and the development of malignancy. This presentation
illustrates the technique of retrograde laparoscopic cholecystectomy necessi-
tated by this disease process.
Patient and methods. A healthy 81 year-old male presented with a five-day
history of right upper quadrant pain with a fever. An abdominal ultrasound
revealed a thickened, edematous gallbladder wall with dependent sludge and
a sonographic Murphy’s sign was present. Following a rapid recovery he was
discharged and remained well without recurrent symptoms for eight weeks at
which time an elective laparoscopic cholecystectomy was performed.
Procedure. A four-port laparoscopic cholecystectomy port technique was
used. Adhesions of omentum over the fundus of the gallbladder were initially
encountered. The gallbladder was thickened and of a rubbery consistency
consistent with chronic cholecystitis. Furthermore, the duodenum was
directly adherent to the underside of the gallbladder, raising concern for a
fistulous connection. An attempt at defining the triangle of Calot and
achieving the ‘‘critical view of safety’’ was unsuccessful. The duodenum was
carefully mobilized off the gallbladder, and methylene blue dye was injected
into the stomach via a nasogastric tube to rule out an injury to the duodenum.
The thick diseased neck of the gallbladder was indistinguishable from the
common bile duct, necessitating a retrograde approach for the cholecystect-
omy. Upon dissection, the body safely tapered to a thick neck, which was
secured with endo-loop sutures. The gallbladder was retrieved and a drain
was placed adjacent to both the duodenum and the common bile duct.
Pathologic review of the specimen revealed severe necrotizing, acute and
chronic cholecystitis as well as sheets of macrophages containing bile and iron
pigment consistent with XC.
Conlusions. The technique of retrograde laparoscopic cholecystectomy in
the setting of the manifestations of XC is presented and a discussion of this
rare etiology of chronic cholecystitis ensues.
Parallel Free Paper Session V: Liver
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Successful local ablation of large and unresectable liver tumours
Neil Bhardwaj, MBBS, Andrew Strickland, Fateh Ahmad, Mosheir Elabassy,
David Lloyd
Leicester Royal Infirmary, Leicester, United Kingdom
Aims: To assess the efficacy of a new microwave ablation system in gaining
complete local control of unresectable metastatic deposits in the liver over 3
cm in diameter.
Methods. Patients with unresectable liver tumours were referred for
microwave ablation with a novel microwave system (Microsulis Ltd, UK).
Since 2001, 57 patients with a total of 203 ablations have received microwave
tumour ablation (MTA). 12 patients, with either single or multiple tumours,
had one or more tumours measuring 3 cm diameter or larger. All patients
received pre-operative cross-sectional imaging. In this group, 45 tumours
were treated in total, 19 measuring 3 cm or greater (range 3 /6.2 cm). Eleven
patients had colorectal liver metastases and 1 a parathyroid carcinoma
metastasis (4 cm diameter). All patients with colorectal secondaries under-
went a laparotomy and intra-operative ultrasound (IOUS) assessment. The
patient with the parathyroid carcinoma deposit was treated laparoscopically
for 240 seconds at 100 Watts. Most tumours were treated with 150 Watts of
power for 2/3 minutes only using an applicator measuring 6.4 mm in
diameter. The largest deposit (6.2 cm) was treated for 3 minutes at 150
Watts. All treatments were monitored in real time with IOUS and
temperature monitoring. Five patients underwent MTA alone, 3 a formal
right hemi-hepatectomy and 4 a left hemi-hepatectomy along with MTA.
Patients were followed up with cross-sectional imaging at 3 monthly intervals.
Results. There were no post-operative deaths and no microwave related
complications and all of the 45 lesions ablated appeared completely treated
on subsequent cross-sectional imaging. No ablation site recurrences have
been noted in any of the subsequent scans. Five from 12 patients are alive and
disease free (follow up 3/24 months). Of the remaining patients one
remained disease free for 12 months but developed peritoneal and pulmonary
metastases and died at three and a half years post ablation and a second
patient died (disease free) of unrelated urinary sepsis at 2 months. Five
patients died with recurrent disease between 12 and 24 months post
procedure, of these patients 2 died with hepatic disease remote from the
ablated areas.
Discussion. This study has confirms that MTA is capable of producing
complete tumour ablation of large (3/6.2 cm in diameter) liver metastases
and without the need for multiple insertions of the microwave applicator.
Over 40% of the patients initially declared inoperable remain tumour free up
to 24 months post ablation. These results compare favourably with
alternative ablative techniques, such as radiofrequency, which have much
poorer outcomes with larger tumours.
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Anatomical versus non anatomical liver resection for colorectal liver
metastases
Robert Finch, Z.Hamady, A. Al Mukhtar, K. R. Prasad, J. P. A Lodge,
G. J. Toogood.
St James University Hospital Leeds, Leeds, United Kingdom
Introduction. Liver resections for colorectal metastases have traditionally
been performed using anatomical resections based on the segmental anatomy
of the liver. Recently non-anatomical liver resections have become more
common in an attempt to preserve liver parenchyma and with the knowledge
that smaller margins do not effect long term survival. This study looked at
survival and patterns of recurrence in a large cohort of patients with
colorectal liver metastases.
Methods. All data was collected and stored on a computer data base. All
patients were operated on at St James’ University Hospital Leeds between
1995 and 2003. Statistical analysis was performed using SPSS for windows.
Results. 495 patients were available for analysis. 94 patients underwent non-
anatomical resection and 401 patients had anatomical liver resections.
Minimum follow-up for the cohort is 20 months. Survival for the entire
group is 42% at 5 years. Overall survival is significantly better for the non
anatomical group (P/0.006), although there was no significant difference in
disease recurrence between the groups. Rates of histological margin positivity
and intra hepatic recurrence were not significantly different between the
groups. Patients who had anatomical resection were more likely to have
multiple metastases ( P/0.001) and larger sized tumours ( P/0.018).
Conclusion. Where possible non anatomical resection should be performed
in preference to anatomical liver resection. It minimizes surgical risk for the
patient without compromising histological margins or increasing the rate of
intrahepatic recurrence. It is likely to facilitate re-do liver resections when
required.
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Laparoscopic versus open liver resection: A comparative study
Chandrakanth Are, MD, Michael D’ Angelica, MD, William R. Jarnagin,
MD, Ronald P. Dematteo, MD, Mary Morrogh, MD, Mithat Gonen, MD,
Leslie H Blumgart, MD, Yuman Fong, MD
Memorial Sloan Kettering Cancer Centre, New York, NY
Introduction. Laparoscopic liver resection (LLR) has been shown to be
feasible and safe in a select group of patients. The aim of this study was to
analyze our initial results of LLR (5/2 segments) and perform a comparative
outcome study with open liver resection (OLR) of the same extent.
Materials and methods. All patients that underwent LLR were entered into
a prospective database (1998/2004) Patients that underwent OLR for 5/2
segments were identified from our retrospective database (1995/1998). A
comparison was performed between the two groups to analyze differences in
outcomes using Fisher exact test for dichotomous variables and student t test
for continuous variables.
Results. (Table: 1) A total of 44 and 238 patients underwent LLR (Group I)
and OLR (Group II) during the study periods. The procedure was completed
successfully via the laparoscopic approach in 34 pts (78%) with a conversion
Comparison of Laparoscopic versus Open Liver Resections
Group I LLR
n/4 pts
Group II OLR
n/38 pts p
Estimated blood loss 150 ml 571 ml B/0.01
Transfusion 1 pt (2.9%) 68 pts (28%) B/0.01
No Pringle vs Pringle 23 vs 10 pts
(67 vs 29%)
55 vs 183 pts
(23 vs 76%)
B/0.01
Pringle time (mintues) 33 31 0.35
Length of stay (days) 5 7.6 B/0.01
Time to regular diet (days) 3 3.5 0.01
Time to oral analgesia (days) 3 4.2 B/0.01
Mortality 0 0 n/a
Morbidity 3 pts (8.8%) 70 (29%) 0.05
LLR/Laparoscopic Liver resection, OLR/Open Liver Resection.
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rate of 22% (10 pts). All patients in Group I had resection of 5/2 segments.
Of the 34 patients a hand port was used in the majority of patients (24 pts/
70%). There was a higher incidence of benign diagnosis and primary liver
malignancies in Group I when compared to Group II (50% vs 15% and 35%
vs 16.5% respectively). There was no significant difference in the mean size
(4 vs 4.19 cm, p/0.69), the ratio of anatomic versus wedge resections (73
and 23% vs 78 and 21%, p/0.82), OR time (198 vs 215 mintues, p/0.28)
and drain placement (2.9 vs 9.6%,p/0.49) between the two groups. The
estimated blood loss and the number of patients that required transfusion
were lower in laparoscopic group (150 ml vs 571 ml, p/B/0.01 and 2.9% vs
28%, p/B/0.01). Despite a lower frequency of Pringle maneuver in the
laparoscopic group (29 vs 76%), there was no difference in the actual Pringle
time in applicable patients (33 min vs 31 min, p/0.35). Patients in Group I
had a shorter length of stay (5 vs 7.6 days, p/B/0.01) and quicker
resumption of regular diet (3 vs 3.5 days, p/0.01) and oral analgesia (3 vs
4.26 days, p/B/0.01). There was no mortality in the entire study, although
morbidity was lower in Group I (8.8% vs 29%, p/0.05).
Conclusion. This study demonstrates that laparoscopic liver resection is safe
and feasible. In a select group of patients the short-term results of
laparoscopic liver resection are similar to or better than open liver resection.
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Treatment-related complications of hepatic arterial infusion pump
chemotherapy are associated with reduced patient survival
Michael Osgood, Charles Staley III, MD, Vasili Egnatashvili, MD, Wayne
Harris, MD, Keith Delman, MD, David Kooby, MD
Emory University, Atlanta, GA
Introduction. Hepatic arterial infusion pump chemotherapy (HAI) provides
survival advantages for patients with colorectal cancer (CRC) metastases
confined to the liver. Community medical oncologists are often resistant to
HAI due to concerns of treatment-related complications. We evaluated
efficacy and complication profiles of HAI when delivered in university and
community settings.
Methods. Records of patients who underwent HAI pump insertion at a
single academic medical center from 1/1/88/5/1/05 were reviewed for
patient, tumor and treatment related variables. Community records were
obtained, for patients treated outside the primary institution. Overall survival
(OS) and treatment-related complications were evaluated.
Results. Upon review, 116 patients had HAI pumps, of which, 71 (61%)
were in males, median age was 59 (range 14 /83), mean operative time (OP
time) was 2519/91 minutes, variant anatomy was observed in 47 (41%), 21
(18%) were placed for adjuvant therapy, and 69 (59%) patients received
treatment in the community. Thirty patients (26%) experienced treatment-
related complications of HAI, including 10 (8%) biliary complication.
Median OS for all patients was 18 months. Factors evaluated for association
with OS included; Op time, blood loss, presence of variant arterial anatomy,
pump study results, HAI intent (adjuvant vs. metastatic), treatment-related
complications, comorbidities, and treatment location (academic vs. commu-
nity). Factors adversely affecting patient survival on univariate analysis were;
OP time /3 hrs (p/0.03), pump intent (metastatic vs. adjuvant, 16 vs. 25
months, pB/0.001, log rank), and presence of treatment-related complica-
tions (yes vs. no, 15 vs. 25 months, pB/0.001). On multivariate analysis, only
pump intent and complications maintained independent associations with
survival in these patients. No survival difference was seen if patients received
HAI therapy in the community vs. the academic medical center (18 vs. 17
months, p/0.79).
Conclusions. Treatment-Related complications are associated with reduced
survival in patients receiving HAI therapy. Based on observed complication
and survival profiles, HAI pump chemotherapy can be delivered with similar
toxicity and efficacy in both university and community settings.
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A phase I study of Hepatic Arterial Infusion (HAI) of Oxaliplatin in
Advanced Hepatocellular Cancer (HCC)
David Iannitti, MD, Greg Soares, MD, Ryan Swan, MD, Greg Dubel, MD,
Howard Safran, MD, Ritesh Rathore, MD
Brown University Oncology Group, Providence, RI
Purpose. We performed this phase I study is to evaluate the feasibility and
determine the maximally tolerated dose of HAI-oxaliplatin given every 3
weeks in advanced HCC. Methods. Patients (pts) with unresectable or
recurrent HCC were eligible for therapy on this protocol. HAI-oxaliplatin
was administered over 2 hours via a percutaneously placed hepatic arterial
catheter or a surgically inserted hepatic arterial infusion pump. Restaging was
performed after every 2 cycles. Dose escalation levels for HAI-oxaliplatin are
90 mg/m2, 110 mg/m2, 130 mg/m2 and 150 mg/m2 given every 3 weeks.
Results. A total of 16 patients have been enrolled and toxicity data are
available for all patients who have completed at least 2 cycles of therapy. The
median age was 61 yrs (range 47/84 yrs) and there were 15 men and 1
woman. The stage distribution is: stage II-3 pts, stage III- 7 pts, stage IV- 6
pts. Seven pts had prior therapies including chemoembolization (CE) in 3
pts, radiofrequency ablation (RFA) in 3 pts, and both RFA and CE in 1 pt. A
total of 36 cycles (range 1/3) have been delivered. Levels 1 and 3 had to be
expanded to 6 pts each and level 2 was expanded by 1 pt. Major toxicities are
shown in the table below. Traditional grade 3/4 hematologic and gastro-
intestinal toxicities were infrequent. One patient suffered embolic bowel
ischemia after his HAI procedure. One pt developed a Grade 2 allergic
reaction which resolved completely with supportive measures. Conclusion.
HAI-oxaliplatin is feasible and well tolerable in this population of pts with
advanced HCC. Response data will be presented.
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Local control of colorectal liver metastasis in patients deemed
inoperable
Neil Bhardwaj, Andrew Strickland, Fateh Ahmad, Mosheir Elabassy, David
Lloyd
Leicester Royal Infirmary, Leicester, United Kingdom
Aims. To assess the efficacy of Microwave Tumour Ablation (MTA) to gain
local control of colorectal liver metastasis deemed inoperable.
Methods. All patients undergoing MTA for colorectal liver metastasis from
2003/2005 were included in the study. Twenty patients with unresectable
hepatic metastases were referred to our centre for further management. All
these patients had previously undergone surgery to remove the primary
colorectal tumour. All patients had at least one tumour ablated (range 1 to
13). Most patients (14/20) underwent a concomitant hepatic resection along
with MTA in the remaining liver. The liver resections included 6 right hemi-
hepatectomies with MTA to the left lobe and 7 left hemi-hepatectomies with
right lobe MTA. One patient underwent a wedge resection of tumours in
segments 2 and 3 with MTA to right lobe and 6/20 had MTA only. All
patients underwent preoperative cross- sectional imaging and all ablated
tumours were confirmed at laparotomy by examination and intra-operative
ultrasound imaging. In total, 74 tumours were ablated with tumour size
ranging from 0.8 /4.2 cm. All patients were followed up with 3 monthly MRI
scans.
Results. There were no post-operative deaths and no microwave related
complications. No patient has developed a recurrent liver tumour at the site
of the microwave ablation (follow up 3/24 months). Currently, 16/20
patients are alive of whom 7 remain tumour free although 7/16 patients have
developed recurrent tumour (follow up 6/24 months) in the liver but distant
to the ablated area. Two of these patients have developed lung metastases but
remain well 24 months post ablation. Four of the 20 patients died 12 months
post MTA from progressive liver/lung disease away from the ablation zone.
Of the 7 patients that are currently tumour free, 1 is 24 months post ablation,
1 is 18 months post MTA, 3 are 9 months since treatment and 2 are between
3/6 months post MTA.
Discussion. This study was designed to assess the efficacy of a new
microwave ablating system in ablating colorectal liver metastases. Excellent
local control of disease was documented in all the treated patients although
some patients did develop recurrent tumour within the liver, at sites remote
to any of the ablation zones. This novel microwave system is safe, effective
and extremely efficient in the destruction of hepatic colorectal metastases.
Despite patients being considered inoperable, 7 are alive and tumour free
(follow up 3/24 months).
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Erythropoietin attenuates liver regeneration in liver resection in rats
Ulf P. Neumann, PhD, Maximilian Schmeding, MD, Peter Neuhaus,
MD, PhD
Charite´, Virchow Clinic, Berlin, Germany
Objective. To evaluate the effect of Erythropoietin (rHuEPO) in an
experimental setting of extended liver resection on liver regeneration in rats.
Summary Background Data: rHuEPO has been proven to protect kidney and
heart tissue from ischemia and to promote regeneration of adult CNS
neurons in animal studies. However, to date no data are available, whether
rHuEPO has the ability to attenuate liver regeneration after liver resection.
Methods. Rats undergoing 70% or 90% hepatectomy were subjected to
either receive no treatment, intraportal administration of rHuEPO prior to
resection or subcutaneous injection on 7 days postoperatively. Regeneration
capacity of resected livers was studied over 7 days by means of histology
(mitotic index) and immunohistochemistry (Ki67). Additionally Western blot
analysis was performed to measure cyclin D1 expression and RNA analysis
was done to measure STAT3, IL-6, VEGF and TGF-b.
Grade 3/4 Toxicity
dose level patients (n) toxicity
90 mg/m2 6 Duodenal perforation (n/1)
Embolic bowel ischemia (n/1)
110 mg/m2 4 Non-neutropenic infection (n/1)
130 mg/m2 6 GI bleed (duodenal ulcer) (n/1)
GI bleed (variceal) (n/1)
Abdominal pain 3 (n/1)
Thrombocytopenia (n/1)
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Results. 10-day survival of rats which underwent 90% hepatectomy was
significantly increased in pretreated rats with rHuEPO. 0 out of 10
animals versus 4 out of 10 animals with intraportal administration
survived more than 10 days. Histological evaluation of liver specimen
showed that the mitotic index was significantly increased in both
rHuEPO treated groups when compared to the controls. This data was
confirmed by Ki67 expression which was significantly increased in the
treated groups up to the 4th postoperative day. rHuEPO treatment let to
increased STAT3 expression in liver tissue. Increased STAT3 expression
was also shown after rHuEPO treatment without liver resection. No
differences for VEGF and TGF-b expression could be observed between
groups.
Conclusions. rHuEPO effectively increased liver regeneration after 70%
liver resection and enhanced survival after 90% hepatectomy in rats.
Thus, rHuEPO may be helpful to reduce the necessity of blood transfusions
after liver resection but also increase the regeneration capacity of the liver
after major hepatectomy.
48
A revisit to hepatic fibrogenesis: Migration of extrahepatic fibroblasts
to cirrhotic liver in bile duct ligated rats
Gordon D. Wu, MD, Tomohito Sadahiro, MD, Hui Zhu, MD, PhD, Jeongim
Woo, PhD, Sangik Noh, MD, Achilles Demetriou, MD, Stephen A. Geller,
MD, Andrew Klein, MD
Cedars-Sinai Medical Center, Los Angeles, CA
Hepatic stellate cells (HSC), by differentiating into myofibroblasts, are
thought to play a central role in hepatic fibrogenesis. The contribution of
non-HSC fibroblastic cells to liver cirrhosis is poorly understood. A rat
model system has been developed in our laboratory to investigate the
pathogenic role extrahepatic fibroblastic cells play in the development of
cholestatic cirrhosis. The model system consists of bile duct ligation
(BDL) and systemic engraftment of syngeneic fibroblast progenitors (cell
line Ap8c3-eGFP), which express an eGFP reporter gene. Engraftment
of Ap8c3-eGFP by intravenous infusion resulted in homing of the
eGFP/ cells to the bone marrow as well as the livers. Sham-operated
control rats did not develop liver lesions while BDL rats developed
cholestatic cirrhosis characterized by enlargement of the portal fields with
bile duct proliferation, massive collagen deposition and portal-portal
septa formation. eGFP/ cells were analyzed by flow cytometry which
revealed that the population of eGFP/ cells accounted for 14.59/5.69%
of the total liver cells isolated from BDL livers and only 3.379/1.87%
from control livers(P/0.16), suggesting active migration of extrahepatic
fibroblasts into the cirrhotic livers. Fluorescent microscopic examination
of the liver sections showed a 3-fold increase in the numbers of eGFP/
cells in the BDL livers when compared with the control livers. The
majority (68%) of the eGFP/ cells were distributed to portal/periportal
areas in the cirrhotic livers while the eGFP/ cells were evenly present in
hepatic sinusoids and portal area in controls. Immunohistochemistry
displayed that eGFP/ cells in the portal tracts of cirrhotic livers co-
expressed a-smooth muscle actin (aSMA). eGFP/ cells recovered from
cirrhotic livers developed into aSMA/ myofibroblasts in culture. The
data suggest that cholestatic cirrhosis secondary to bile duct obstruction
is associated with massive migration of fibroblasts of extra hepatic origin
to the diseased livers. Thus, extrahepatic fibroblasts may represent an im-
portant source of progenitors to myofibroblasts proliferating in cirrhotic
livers.
49
Techniques for reduced blood loss, transection time and bile leak rate
during liver resection in a multinational study
David L. Morris, PhD, Koroush Haghighi, MD, Francis Chu, MBBS,
Werner Lindemann, Georg Pistorius, Martin K. Schilling, Tristan Yan,
Randall Zuckerman, Junji Machi, Steven Daniel
The University of New South Wales, Sydney, Australia; The University of
Homburg/Saarland, Homburg/saar, Germany; The Mary Imogene Bassett
Hospital, Cooperstown, NY; University of Hawaii, Honolulu, HI
Introduction. Liver resection has now become a relatively safe and standard
practice in the treatment of primary and secondary liver tumors. Recent
innovations in technology and surgical techniques have improved safety and
efficacy during liver parenchymal transections. We have previously shown in
animal and human trials that the use of radiofrequency coagulation of the
transection plane (InLine Radio Frequency (RF) Linear Coagulator, Resect
Medical, Inc., Fremont CA) prior to liver resection is a safe and effective
device which can significantly reduced intra-operative blood loss and
transection time. However, post operative bile leaks remains an important
clinical issue during liver resections with some units reporting typical leak
rates of between 10 to 15%. We would like to report our multinational
experience.
Method. From a multinational study between November 2003 to August
2005, 53 liver resections were performed using the cavitronic aspirator for
other parenchymal transection devision device after InLine RF Coagulation
of resection plane. Data was collected prospectively for tumor characteristics,
operative outcomes and postoperative complications.
Results. There were 29 men and 23 women. The median age was 62.9
years (range 30/85 years). Four patients had cirrhotic liver (3-Childs A and
1-Childs B). A total of 30% of patients (16 out of 53) had formal
lobectomies or extended resections and 26% of patients (14 out of 53) had
non-anatomical resections. The mean number of InLine RF Coagulator
deployments was 3.4 (range 1/12) with a median coagulation time of 9.4
minutes (range 3/36 minutes). The mean intraoperative blood loss was
160 mls (range 5/675 ml) with a mean transection surface area of 63 cm2
(range 7/232 cm2). The overall blood loss per transection surface area
was 3.27 mls/cm2 (range 0.14/12 mls/cm2). The median transection time
was 27 minutes (range 2/129) with 11% of the transections requiring
inflow occlusion (pringle maneuver). A total of 2% of the patients (1 out of
53) developed bile leaks requiring CT guided drainage. 11% of patients
(6 out of 53) required CT guided drainage for non-bile intra-abdominal
collections.
Conclusion. Based on our study, we have concluded that the InLine Radio
Frequency Linear Coagulator is a safe and effective technique for liver
resections which significantly aids in the reduction of blood loss, the rate of
post operative bile leaks and transection time.
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Does preoperative chemotherapy cause hepatic injury and increased
complications in patients undergoing hepatic resection for colorectal
liver metastases?
Kelly Olino, MD, Timothy M. Pawlik, MD, MPH, Amada Blackford, MD,
Michael Torbenson, MD, Richard Schulick, MD, Michael A. Choti, MD,
MBA
Johns Hopkins, Baltimore, MD
Introduction. Some investigators have suggested that preoperative che-
motherapy is associated with increased complications following hepatic
resection. The increased morbidity is thought to be secondary to drug
induced steatosis and hepatic injury. The objective of this study was to
investigate the effect of preoperative chemotherapy on liver histology and
perioperative outcome in patients (pts) undergoing hepatic resection for
colorectal liver metastases (CRLM).
Methods. Two hundred nine pts who underwent hepatic resection of CRLM
between 1999 and 2005 were evaluated. Clinicopathologic, chemotherapy,
and perioperative data were collected. In each case, a complete pathologic
review of the nontumorous liver was performed and the extent of hepatic
injury was scored. Statistical analyses were performed using logistic regres-
sion, Fisher’s exact, and Kruskal-Wallis tests.
Results. Fifty-three (25.4%) pts received no preoperative chemotherapy
while 156 (74.6%) received one or more systemic regimens. The most
recent chemotherapy regimen prior to surgery consisted of 5-fluorouracil
(n/66; 31.7%), irinotecan (n/58, 27.9%), or oxaliplatin (n/31, 15.0%)
based therapies. Median duration of chemotherapy was 6.0 months. Forty-
four (30.1%) pts had either a complete or partial response; 64 (43.8%) pts
had stable disease and 38 (26.1%) pts had disease progression. Surgery
involved hemi-hepatectomy or extended resection in 77 (40.3%) pts. On
pathologic analysis, the majority of pts had no (n/63, 32.8%) or mild
(B/5%) (n/44, 22.9%) steatosis; only 11 (5.7%) pts had severe steatosis
(/60%). Pts who received preoperative chemotherapy were at an increased
risk for steatosis (Odds Ratio [OR]/2.1, P/0.04). Pts who received
irinotecan were at a particularly high risk for steatosis (OR/5.8, P/
0.0004). Body mass index (BMI) /30 (OR/3.9; PB/0.0001) and
diabetes (OR/4.3; P/0.0006) also predicted steatosis. Duration of
chemotherapy, tumor response, and interval between last chemotherapy
and surgery were not associated with extent of liver injury (all P/NS).
Perioperative morbidity was 14.4% and there were no perioperative deaths.
Median length of stay was 5.0 days. History of chemotherapy, chemother-
apy type, and presence of steatosis had no impact on perioperative
morbidity or outcome (all P/NS).
Conclusions. While preoperative chemotherapy may be associated with
some degree of steatosis, severe hepatic injury is uncommon. Preoperative
chemotherapy for CRLM is safe and does not appear to increase periopera-
tive complications following hepatic resection.
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Prognosis and results after resection of large (/10 cm) hepatocellular
carcinoma
Shimul A. Shah, MD, Ilun Yang, None, Alice C. Wei, MD, Sean P. Cleary,
MD, Ian D. Mcgilvray, MD, PhD, Bryce R. Taylor, MD, Mark S. Cattral,
MD, Bernard Langer, MD, David R. Grant, MD, Steven Gallinger, MD,
Paul D. Greig, MD
University of Toronto, Toronto, ON, Canada
Few treatment options exist besides resection for large (/10 cm) hepato-
cellular carcinoma (HCC). We sought to examine our outcomes after
resection of large (/10 cm) HCC.
Methods. Perioperative and long-term outcomes were examined for 189
consecutive patients from 1993 to 2004 who underwent curative resection of
large HCC /10 cm (n/24; 13%) vs. those with smaller HCC B/10 cm (n/
165; 87%). Disease-free survival (DFS) and overall survival (OS) were
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determined by Kaplan-Meier analysis and patient, tumor, and treatment
characteristics were compared using log-rank test (pB/0.05).
Results. Median follow-up was 34 months. Tumors /10 cm were more
likely to be symptomatic, poorer grade and have vascular invasion (pB/
0.05). Twelve patients (50%) underwent resection of more than 4 hepatic
segments or resection of adjacent organs and tissue was performed if
necessary for oncologic clearance (diaphragm-2, IVC-2, median sternot-
omy-1). Post-operative complications were more common after resection of
/10 cm HCC (12/24, 50% vs. 35/165, 21%; p/0.04) and included
mortality (4%), hepatic insufficiency (17%), bile leak (12%) stroke (4%),
MI (4%), wound infection (4%), and aspiration (4%). Median DFS was
significantly shorter in patients with large HCC (/10 cm) group
compared to patients with smaller HCC B/10 cm respectively (8.4 vs. 38
months; p/0.001) but overall survival was not different between the two
groups (5-year survival 54% vs. 53%; p/0.43). Seventeen patients (71%)
developed recurrences (12 intrahepatic, 5 systemic); 8 of these patients
(47%) underwent additional therapy for recurrence (resection-4, TACE-3,
RFA-1). Positive margins and major vascular invasion were significant
independent factors of DFS in tumors /10 cm (pB/0.05). Median OS
after recurrence was 24 months.
Conclusion. Surgical resection remains the optimal therapy for large (/10
cm) HCC. Although recurrences are common after resection of these tumors,
overall survival is not significantly different from resection of smaller HCC.
Excellent long-term survival can be achieved in large (/10 cm) HCC with an
aggressive surgical approach, close follow-up and multi-modality therapy to
recurrences.
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Radiofrequency ablation or hepatic resection for small HCC? Mea-
suring the patients’ perceptions of risks and benefits
Michele Molinari, MD, Mark Joseph Walsh, MD, Scott Helton, MD, David
Urbach, MD
Dalhousie University, QEII Health Science Center, Halifax, NS, Canada;
University of Illinois at Chicago, Chicago, IL; University of Toronto, Toronto
General Hospital, Toronto, ON, Canada
Background. For small hepatocellular carcinomas (HCC), some observa-
tional studies suggest that radiofrequency ablation (RFA) is as effective as
hepatic resection (HR) with less morbidity and higher failure rate.
Currently, HR is recommended for subjects with compensated liver
function. However, data on patients’ preferences for either intervention
are lacking. The primary aim of this study was to identify the minimal 5-
year survival increment that cirrhotic individuals would accept to undergo
HR instead of RFA.
Patients and methods. From November 2004 to July 2005, 37 cirrhotic
individuals were enrolled. Inclusion criteria included: age /18, cirrhosis,
absence of HCC and no contraindications for HR. Exclusion criteria were:
impaired communication or cognitive function, prior treatments for liver
tumors. Probability trade off technique was used to elicit the strength of
preferences. All individuals were educated on the natural history of HCC,
therapeutic options, 5-year and 3-year disease free survival, and the
probabilities of dying or experiencing complications for each treatment.
The subjects were then asked to place themselves in the position of a
hypothetical individual affected by HCC treatable by either RFA or HR. Side
effects, probability of success and failure were compared in parallel fashion.
Preferences for either treatment were measured by systematically adjusting
the success of one treatment over the other. Diagrams illustrated probability
differences.
Results. 16 women (43%) and 21 men (57%) with average age of 47.1 years
(SD9/12.4, r 18/67.7) were recruited. RFA was favored by 28 patients
(75.6%, p/0.03). HR was preferred if the likelihood of being alive at 5 years
was at least 14.6% (SD9/9.3, r 5/50) better than RFA or if the probability of
3-year disease-free survival was at least 12.8% (SD9/7.2, r 5/40) superior to
RFA. When the likelihood of surviving was equivalent, HR was preferred if
the risk of complications or death was less than 5.9% (SD9/6.3, r 0/25%)
and 0.5% (SD9/0.9%, r 0/3) respectively. The risk of seeding tumor during
RFA made HR more attractive if the likelihood of seeding was above 3.8%
(SD9/2.3, r 0/10).
Conclusions. Although HR is recommended as a potential cure for
HCC in subjects fit for surgery, its upfront risks make the option less
attractive to educated patients. These findings should motivate physicians to
actively elicit their patients’ inclinations towards complication risks and
expected benefits before recommending one of the alternative treatments for
small HCC.
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Center volume improves outcomes for pancreatic cancer care: A
prospective evaluation of 21,981 patients from 1991/2001
Dido Franceschi, MD, Alan S Livingstone, MD, Leonidas G. Koniaris, MD
University of Miami, Miami, FL
Purpose. Determine the relationship of hospital volume in pancreatic cancer
care with long-term survival for both resected and non-surgical candidates
utilizing a large prospective cancer registry.
Methods. The Florida Cancer Data System (FCDS) prospectively collected
21,981 consecutive pancreatic cancer patients diagnosed between 1991 and
2000. Patients were divided into 3 groups based on center volume: Group I
treated in centers with /30 patients/year (9 centers), Group II between
10/30 patients/year (69 centers) and Group III B/10 patients per year (177
centers).
Results. M:F ratio was 1:1, with a mean age of 71 years. Cancer in the head
of the pancreas was the most frequent location (44%). Fourteen percent of
patients (3158) underwent a surgical procedure. Localized or regional disease
was reported in 39% of the patients. Eighty-five percent of patients had
expired at the time of this analysis. Patients treated in high volume centers
had substantially increased median survival (6.5 months-Group I versus 4.17
months-Group II and 3.17 months-Group III, pB/0.001). Limiting this
evaluation to surgical cases only, patients in high volume centers also
demonstrated a markedly improved survival (12.5 months-Group I versus
10.4 months-Group II and 8.2 months-Group III, pB/0.001). Multivariate
analysis revealed age, stage, undergoing surgery and hospital volume as
independent predictors of survival.
Conclusions. Patients with pancreas cancer treated in high volume centers
have a markedly improved survival relative to patients treated at lower volume
hospitals. These data strongly support the regionalization of pancreatic
cancer care.
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Is pancreatic cancer an appropriate target for combination adoptive
immunotherapy?
John E. Anderson, MBBS, MRCS, Ryan D. Guest, PhD, David E. Gilham,
PhD, Eric B. Austin, PhD, Ajith K. Siriwardena, MD, FRCS, Robert E.
Hawkins, PhD, FRCP
Stem Cell & Research Department, National Blood Service, Manchester,
United Kingdom; Paterson Institue for Cancer Research, Manchester,
United Kingdom; Manchester Royal Infirmary, Manchester, United King-
dom
Background. The prognosis for pancreatic cancer remains poor despite
improvements in surgical and palliative treatments. Relapse rates suggest that
treatment is either incomplete or resistant tumour cells are able to survive.
Advances in adoptive immunotherapy may help in treatment of the disease.
Here we investigate whether dual expression of the tumour specific antigens
5T4 and CEA occurs in pancreatic cancer and if this disease is appropriate
for combined dual target immunotherapy.
Methods. Blood and tissue samples were obtained from pancreatic cancer
patients undergoing a pancreaticoduodenectomy. The tissue samples were
stained using immunohistochemical techniques for 5T4 and CEA expres-
sion. CD3 staining was also employed to detect the presence of T cells
within the tumour tissue. Patient’s T cells were harvested from the donated
blood using a ficoll separation method, activated with OKT3 and then
genetically modified to express either a CEA or 5T4 targeted immune
receptor. The transduced T cells were expanded over ten days before being
co-cultured with pancreatic cancer cell lines shown to express 5T4 and
CEA. Cancer cell survival was assessed after 72 hours of co-culture using a
proliferation assay.
Results. All tumour associated stromal tissue stained positive for 5T4
expression. Pancreatic cancer cells stained positive for both CEA and 5T4. In
all cases CD3/ve T cells were seen accumulating around areas of heavily
stained 5T4 and CEA tissue. T cell transduction efficiencies were 7.7% for
5T4 (range 5.1% /9.1%) and 26.7% for CEA (range 14.1%/37.2%)
targeted immune receptors. Specific antigen targeted T cell killing was seen
in all patients at an effector:target ratio of 4:1.
Conclusion. Through our investigation we have identified: [1] expression of
5T4 and CEA within pancreatic tumour tissue; [2] that T cells are also
present and seem to localise to the tumour site; [3] patient’s T cells can be
modified to target tumour associated antigens; and [4] these modified T cells
are capable of killing CEA and 5T4 expressing tumour lines. Therefore
we conclude that pancreatic cancer patients should be an ideal group for
5T4 and CEA targeted immunotherapy. Furthermore, as CEA is expressed
by the tumour cells while 5T4 expression is associated with both tumour
and stromal cells a combined dual targeted immunotherapy may be more
effective at destroying both the pancreatic tumour and supporting architec-
ture in vivo .
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Carcinoma of the ampulla of vater. T-stage, microsatellite instability,
allelic losses of chromosome 17p and extended resection are factors
influencing survival after pancreatico-duodenectomy
Calogero Iacono, MD, Giuseppe Verlato, MD, Giuseppe Zamboni, MD,
Aldo Scarpa, MD, Ettore Montresor, MD, Paola Capelli, MD, Luca
Bortolasi, MD, Giovanni Serio, MD
University of Verona, Verona, Italy; University of Verona, Department of
Pathology, Verona, Italy; University of Verona, department of Surgery and
Gastroenterology, Verona, Italy
Objective. To evaluate the prognostic significance of different clinico-
pathological and molecular factors, as well as of extended pancreaticoduo-
denectomy in ampulla of Vater adenocarcinoma (AVAC).
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Summary background data. There are discordant data on factors affecting
prognosis, and hence therapeutic choices, in AVAC.
Patients and methods. Fifty-nine patients subjected to pancreaticoduode-
nectomy (PD) for AVAC were evaluated for clinical-pathological factors; 42
were also analyzed for both chromosome 17p and 18q allelic losses (LOH)
and microsatellite instability (MSI). Twenty-five patients, operated in the
Nineties, were also evaluated according to the extension of PD (16 standard
and 9 extended).
Results. The overall 5 and 10-year survival rates were 46% and 33%,
respectively. Sixteen patients had T-stage I/II, 14 T-stage III, and 29 T-stage
IV cancers. Chromosome 17p and 18q LOH were detected in 23 (55%) and
15 cases (36%), respectively, and in 12 cases (29%) coexisted. Five cases
were MSI-positive (12%). At univariate analysis, poor survival was associated
with cancer ulceration (P/0.051), poor differentiation (P/0.008), T-stage
IV (PB/0.001), nodal metastases (P/0.004), chromosome 17p (PB/0.001)
and 18q LOH (P/0.002) and absence of MSI (P/0.009). At multivariate
analysis, only T-stage (P/0.002) and 17p LOH (P/0.001) were indepen-
dent predictors of survival. All patients with MSI-positive cancers were long-
survivors (/12 yrs), while only 30% of MSI-negative cancer patients
survived at 5 years. Extended pancreaticoduodenectomy was associated
with a 3-year survival longer than standard resection (83% vs 31%; P/
0.018).
Conclusion. MSI and chromosome 17p status allow to better define
prognosis within ampullary cancers at the same stage. It might be suggested
that surgery alone could be adequate for patients showing MSI-positive
cancer, while patients showing allelic losses may require adjuvant therapy
after surgery. In this observational study extended PD was associated with
increased survival compared to standard procedures.
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Identification of novel biomarkers for pancreas cancer using multi-
affinity depletion, 2-D DIGE and tandem mass spectrometry
Marcus C. B. Tan, MBBS, Yiing Lin, MD, PhD, R. Reid Townsend, MD,
PhD, Peter S. Goedegebuure, PhD, James P. Malone, PhD, Kathryn
Trinkaus, PhD, Sheng Feng, PhD, David C. Linehan, MD
Barnes-Jewish Hospital/Washington University in St Louis, St Louis, MO;
Washington University in St Louis, St Louis, MO
Introduction. Pancreatic cancer is a common but lethal malignancy
associated with late presentation, treatment options of limited efficacy,
poor prognosis and lack of biomarkers for detection of early disease and
recurrence after treatment. Identification of new serum biomarkers of
disease has been hampered by the large concentration range of plasma
proteins (pg/ml to mg/ml). Two-dimensional differential gel electrophoresis
(2-D DIGE) is a novel technique that has been found to improve the
reproducibility and reliability of intra- and inter-gel image analysis. In this
study we combine use of multi-affinity depletion methods with 2-D DIGE
and high performance mass spectrometry (MALDI-TOF/TOF and LC-
QTOF) to identify plasma proteins differentially expressed in pancreas
cancer.
Methods. Plasma samples from patients before and after resection of
pancreas cancer were depleted of 12 high abundance proteins using multi-
affinity antibody columns. 2-D DIGE was performed, in which samples were
labeled with mass- and charge-matched spectrally resolvable fluorescent dyes
and then separated on the same 2-D gel. Image analysis software was used to
co-detect and differentially quantify protein features. Corresponding spots
that had significantly different abundances were identified and these proteins
sequenced using mass spectrometry.
Results. Variability between plasma samples of individual patients before
and after resection was markedly and consistently less than the variability of
plasma samples between patients. A total of 17 disease-associated proteins
were identified. These include S100 A8, S100 A9, attractin and clusterin,
which have also been identified as being over-expressed in pancreas cancer on
previously published genomic screens.
Conclusions. Comparison of plasma samples before and after resection
minimizes differences in the plasma proteome and allows for greater
reproducibility. Combined with depletion of high abundance proteins, this
technique provides greater sensitivity for the detection of low abundance
plasma biomarkers. Further study is now underway to assess the utility of the
proteins thus identified for their utility as biomarkers for pancreatic cancer by
proteomics methods and immunoassays.
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Surgical site infections, an unsolved problem in pancreatic surgery:
A single institution study
Steven R. Granger, MD, Robert E. Glasgow, MD, Nathan G. Richards,
Jeremy R. Mccandless, Jean Battaglia, RN, Sean J. Mulvihill, MD
University of Utah School of Medicine, Salt Lake City, UT
Background. Surgical site infection (SSI) has gained increasing national
attention and is a major problem following pancreatectomy. The aim of this
study was to evaluate factors contributing to SSI in this patient population.
Methods. A specially trained nurse reviewer prospectively collected SSI data
following pancreatectomy in 173 consecutive patients over a 4 year period at
a university, tertiary referral center in collaboration with the National
Surgical Quality Improvement Program (NSQIP). Data included preopera-
tive risk factors, antibiotic use, operative times, intraoperative temperature,
and postoperative course including complications, length of stay, and
mortality. All preoperative, intraoperative and postoperative variables were
prospectively defined. All data was audited contemporaneously by the
surgical team and retrospectively by external audit.
Results. The incidence of SSI, including superficial and deep incisional
infection, organ space infection, wound disruption, anastomotic leak and
other wound occurrence, was 14% (25 of 173 patients). The rate of
superficial and deep infection was 11% in clean cases & 15% in clean-
contaminated cases. Adherence to a timing of preoperative antibiotics
protocol occurred in 81% of patients with SSI. Adherence to an intraopera-
tive temperature control protocol occurred in 52% of patients with SSI. SSI
occurred in 16% and 14% of patients adherent to timing and temperature
protocols. The incidence of SSI in patients with a preoperative serum
albumin of 5/ vs/3.5 mg% was 21% vs 13% (p/0.19). The incidence of
postoperative mortality in the patients who developed SSI was 8% vs 1.4% in
patients without an SSI (p/0.05). Mean length of stay9/SEM was 169/2
days in patients with SSI vs 109/1 without SSI (p/0.001). Direct hospital
costs9/SEM were $18,9279/4,682 in patients with SSI vs $12,2469/1,082
without SSI (p/0.038). Age, gender, ASA class, and length of surgery had
no influence on the rate of SSI.
Conclusions. SSI is a significant problem following pancreatic resection
leading to increased morbidity, mortality, length of hospitalization and costs.
Improvement in adherence to SSI prevention guidelines is possible. SSI is
common in patients adherent to protocol guidelines, however, suggesting that
alternative prevention strategies are needed.
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MUC4 is a useful biomarker in determining resectability in patients
with localized adenocarcinoma of the pancreas
Aaron R. Sasson, MD, Christophe Nemos, PhD, Erik Moore, Karen Taylor,
RN, Nicolas Moniaux, PhD, Michael A. Hollingsworth, PhD, Surinder K.
Batra, PhD
University of Nebraska, Omaha, NE; Eppley Institute, Omaha, NE
Background. Surgical resection is the mainstay of treatment for patients
with pancreatic cancer. A high resolution computed tomography is the single
best imaging modality for staging pancreatic cancer. Approximately, 10 to
20% of patients with potentially resectable disease have radiographically
occult metastatic disease or locally advanced unresectable tumors. Recently,
we and others have shown that a mucin, MUC4 , could be used as a
diagnostic and prognostic marker for pancreatic cancer.
Objective. To determine the ability of MUC4 to predict resectability in
patients with localized (non-radiographically detected metastatic disease)
pancreatic cancer.
Methods. Patients with suspected or proven adenocarcinoma of the pancreas
were evaluated with a triple phase contrast CT scan to determine
resectability. Resectability was defined as the absence of metastatic disease,
patent superior mesenteric and portal vein and presence of a fat plane around
the superior mesenteric artery. Blood was collected pre-operatively and
MUC4 mRNA was quantified by real time RT-PCR in the peripheral blood
mononuclear cells (PBMC). MUC4 mRNA expression is expressed as the
number of MUC4 mRNA transcripts per internal control of GAPDH
transcripts.
Results. Thirty two patients with histologically proven adenocarcinoma of
the pancreas were available for analysis. Ten patients had locally advanced
(n/3) and metastatic disease (n/7) identified during staging laparoscopy
and laparotomy (Group I). Group II comprised of 21 patients who under-
went complete surgical resection (R0 or R1) and one patient who declined
surgery after undergoing a staging laparoscopy (which determined resect-
ability). The two groups were similar in demographic and clinical features,
including tumor location (head vs. body/tail). The mean MUC4 level in
Group I was 0.791, range 0.296 to 2.26 (SEM 0.187). In comparison, the
mean MUC4 level in Group II was 0.207, range 0 to 0.957, (SEM 0.058),
P/0.0006 (Student’s t-Test). In contrast, there was no statistical difference
between the mean CA 19/9 levels in Group I and Group II, 503 U/ml and
1579 U/ml, respectively ( P/0.33).
Conclusion. MUC4 , a novel biomarker for pancreatic cancer, is elevated in
patients with locally advanced or radiographically occult metastatic disease.
In this present study, we demonstrated that MUC4 could be useful in
predicting resectability. Further studies would be needed to determine its
effectiveness in selecting patients who would benefit from staging laparo-
scopy.
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Transampullary pancreatic duct stenting for distal pancreatectomy:
Impact upon post-operative pancreatic fistula
Craig P. Fischer, MD, MPH
Univ of Texas-Houston, Houston, TX
Purpose. Pancreatic fistula remains a frequent complication following distal
pancreatectomy, with an incidence ranging from 10/35% in published series.
The ampulla of vater has been implicated in the development of pancreatic
fistula following distal pancreatectomy, possibly by the development of
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ductal hypertension leading to duct -closure failure. The purpose of this
study was to evaluate the impact of transampullary pancreatic duct stenting
(TAPDS) upon the development of pancreatic fistula following distal
pancreatectomy.
Methods. From March 2002 to June 2005, 50 patients underwent distal
pancreatectomy. The indication for surgery was suspected cystic neoplasm
in 32 (64%), pancreatic ductal adenocarcinoma in 8(16%), pancreatic
neuroendocrine tumor in 5 (10%) and chronic pancreatitis in 5(10%). 12
consecutive patients underwent distal pancreatectomy with intraoperative
placement of a 4.0 french silastic, transampullary stent and direct suture
ligation of the pancreatic duct followed by traditional suture -closure of the
pancreatic parenchyma. The remaining patients underwent operation with-
out TAPDS and identical closure of the pancreatic duct and parenchyma.
The rate of pancreatic fistula, intraabdominal abscess and length of hospital
stay (LOS) is compared.
Results.
Conclusions. TAPDS in this limited series was associated with a decreased
incidence of pancreatic fistula and length of stay, when compared to patients
who did not undergo TAPDS. TAPDS deserves further evaluation for
its potential role in limiting this common complication following pancrea-
tectomy.
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Staple line reinforcement with bioabsorbable mesh reduces leak rate
following distal pancreatectomy
Reuben I. Thaker, MD, MPH, Brent D. Matthews, MD, David L. Linehan,
MD, Steven M. Strasberg, MD, John C. Eagon, MD, William G. Hawkins,
MD
Washington University School of Medicine, Department of Surgery, St
Louis, MO
Introduction. Pancreatic leak remains a significant cause of mor-
bidity following distal pancreatectomy. In recent prospective studies leak
rates as high as 29% have been reported. We examine our recent attempt to
reduce postoperative leaks by use of a reabsorbable polytrimethylene
carbonate mesh (Seamguard), to reinforce the staple line in distal pancrea-
tectomy.
Methods and procedures. We retrospectively examined the 35 distal
pancreatectomies performed by three surgeons over the last 12 months 7/1/
04/7/1/05 (31 open, 4 laparoscopic). All surgeons routinely perform stapled
pancreatectomies on select patients (thin soft pancreas), using a 4.5 mm
stapler. They had the option of placing the bioabsorbable mesh over the
stapling device prior to firing. Cases were reviewed, including 60 day follow
up, and chi-square analysis was performed comparing mesh use with leak
rate, other complications, surgeon, mortality and length of stay. Similarly, we
analyzed the two groups for potential confounding variables including age,
sex, intraoperative complication, and extensive additional procedures. In
addition, we compared the overall leak rate for the current 12 months with
the previous 12 months, when mesh reinforcement was not selectively used.
For this study pancreatic leak was defined as amylase rich fluid from the drain
at any time, or intraabdominal collection requiring drain placement or IV
antibiotics.
Results. There were 0 leaks in the 16 patients where the staple line was
reinforced with mesh, and 5 leaks in 19 patients, 26% without mesh [p/
0.03]. No other variable differed between groups. There were no mortalities
in either group. The 14% overall leak rate (5 of 35 cases) during the past 12
months when mesh was an option, compared favorably to the 28% leak rate
the previous year (6 of 21 cases) [p/0.19].
Conclusions. Bioabsorbable mesh reinforcement of the staple line lowered
our pancreatic leak rate and was not associated with increased complications.
We recommend a prospective randomized evaluation of this technique.
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Expendable metallic enteral stenting for duodenal obstruction: A
single centre experience
Andre´ Roy, MD, Otmane Nafidi, MD, Marylene Plasse, MD, Re´al
Lapointe,MD, Richard Le´tourneau,MD,Michel Dagenais, MD
Centre hospitalier de l’Universite´ de Montre´al, Montre´al, PQ, Canada
We report our initial experience with self-expandable metallic stent in the
palliation of malignant gastric and duodenal obstruction in order to avoid the
significant morbidity and mortality associated with surgical bypass in patients
with advanced malignancies.
Methods. Between 02/2002 and 09/2005, enteral stenting with self-expand-
able metallic stent (Wallstent†, 20/22 mm diameter, 6/9 cm long) for
palliation of malignant duodenal obstruction was attempted in 30 patients
(12 women, 18 men; mean age 63 years; range, 37/82 years).
Results. Patient’s diagnoses were pancreatic (n/17; 56%), gallbladder (n/
6; 20%), bile duct (n/3; 10%), gastric (n/2; 6%) and colonic metastatic
hilar nodes (n/2; 6%) cancer. The level of obstruction was antro-pyloric
(n/2, 6.6%), first (n/10, 33.3%), second (n/12, 40%) and third (n/4,
13.3%) part of the duodenum, the entire length of the duodenum (n/1, 3%)
and gastrojejunal anastomosis (n/1, 3%). Enteral stenting was successful in
25/30 (83%) patients. The stricture could not be negociated despite multiple
attempts in 4 patients and one had severe gastroparesis without mechanical
obstruction. Biliary stenting was necessary in 23/25 patients: percutaneously
in 11 patients (nine biliary expandable stents and two internal/external
drains) and endoscopically in 12 patients. Biliary drainage was performed
before, at the time of or after the duodenal stent insertion in 19, 3 and 1
patients, respectively. Five patients (20%) experienced complications: 1
duodenal perforation (surgically treated with death on day 14), 2 tumoral
stent obstructions (1 patient received a 2nd stent on day 152), 2 patients with
inadequate stent length (successful revision with 2nd stent). Median hospital
stay was 10 days (range, 1/116). Relief of obstructive symptoms was
successful in 21/25 (84%) patients. Oral diet was resumed in 24 (96%)
and satisfactory in 21 (84%) patients. 17 (68%) patients died from disease
progression, 1 (4%) from stent insertion and 7 (28%) are still alive. The
median survival was 27 days.
Conclusion. Endoscopically inserted self-expandable metallic duodenal
stents for malignant gastric outlet obstruction is feasible in 83% of patients
with low morbidity and mortality. It provides a minimally invasive alternative
to surgical palliation with satisfactory restoration of oral diet in 84% of
stented patients.
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Laparoscopic distal pancreatectomy: A case series
Joe Hines, MD, Howard Reber, MD
UCLA, Los Angeles, CA
Distal pancreatectomy is recommended for resectable lesions of the body and
tail of the pancreas. The technological advance of laparoscopic distal
pancreatectomy has been described, but the safety and utility of this approach
for these lesions has yet to be established.
Methods. This report is a retrospective case series of ten patients undergoing
laparoscopic distal pancreatectomy from June 2004 to August 2005.
Results. 10 patients underwent laparoscopic distal pancreatectomy for a
variety of solid and cystic tumors identified and evaluated by MRI or CT and
EUS. For cystic tumors, the use of EUS guided aspiration was used to guide
treatment recommendations. Mean age for the group was 55.1 years. Average
operative time was 149 minutes, blood loss 130 cc, and length of hospital stay
4 days. All but one case was completed laparoscopically. Eight cases were
completed with splenic preservation and two required splenectomy. Pathol-
ogy revealed five serous cystic tumors, two mucinous cystic neoplasms (6.5
and 6.9 cm), two islet cell tumors, and one IPMN. One islet cell tumor was
an insulinoma. Postoperative complications occurred in 2 patients, and
included urosepsis and a pancreatic leak that resolved with catheter drainage.
There were no operative deaths.
Conclusions. This single institutional case series, like other cases series of
this type, demonstrate acceptable results for benign lesions of the pancreas
resected by laparoscopic distal pancreatectomy. However, preoperative
imaging and evaluation has not advanced enough to determine malignancy
preoperatively for many of these lesions. Therefore, frozen section of the
margin and specimen should be performed intraoperatively to guide the
extent of operation. Whether the laparoscopic approach to malignant distal
pancreatic lesions is acceptable will require a randomized trail, and until then
is a dubious approach.
TAPDS No TAPDS P value
Number 12 38 Na
Pancreatic
Fistula
1/12 (8.3%) 11/38 (28.94%) PB/0.05
Intraabdominal
abscess
2/12 (16.7%) 3/38 (7.9%) n.s.
Length of Stay 7.2 days9/1.2 13.69/5.6 PB/0.05
Comparison of Mesh Reinforcement vs Standard Staple Line 2004/05
leak following distal
pancreatectomy*
extensive
initial surgery
intra-operative
complication
other life-threating
complication
laparoscopic
cases
mesh-reinforced staple line 0/16 7/16 1/16 3/16 2/16
no mesh at resection line 5/19 7/19 1/19 1/19 2/19
Select variables for the two treatment groups, full list in methods. *p/0.03
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Assessment of complications after pancreatic surgery: A novel
grading system applied to 633 patients undergoing pancreatico-
duodenectomy
Pierre-alain Clavien, Michelle L. Deoliveira Clavien, Jordan M. Winter,
Markus Schaefer, Steven Cunningham, Charles J. Yeo
Zurich University Hospital, Zurich, Switzerland; Johns Hopkins Medical
Institution, Baltimore, MD
Objective. To define a simple and reproducible classification of complica-
tions following pancreatico-duodenectomy (PD) based on a therapy-oriented
severity grading system.
Background. While mortality has become a rare event after PD, morbidity
rates have remained high. The lack of standardization in evaluating and
grading morbidity after PD has severely hampered meaningful comparisons
over time and among centers. We adapted a novel classification of complica-
tion by intervention [1], and used it to grade the complications in patients
undergoing PD in a single North American center. A particular focus was
placed on delayed gastric emptying (DGE) and pancreatic fistula.
Material and methods. The classification was applied to a consecutive
series of 633 patients operated upon between February 2003 and June 2005
for benign (n/167) and malignant (n/466) diseases. Each complication
was graded from the information available in a database, and missing
information was obtained from the chart. The complications in the database
were easily converted into grades based on the therapy used to treat the
complications. Pancreatic fistula was defined as output /50 ml/d of amylase-
rich fluid after postoperative day 10. Uni and multivariate analyses were
performed to link respective complications with pre and intraoperative
parameters (e.g.; gender, age, dignity, tumour stage, type of surgery: pylorus
preserving vs. standard PD, operative time and blood loss). The impact of the
severity of complications (grading) on length of hospital stay and long-term
survival was also analyzed.
Results. 263 (41.5%) patients did not develop any complication. Overall
complication rate was 58.5%. 62 (10%) patients had only grade 1 complica-
tions (no need for specific intervention), 192 patients (30%) had grade 2
complications (need for drug therapy such as antibiotics). Grade 3
complications (need for invasive therapy) occurred in 85 patients (13.5%),
grade 4 (organ dysfunction with ICU stay) in 19 patients (3%), and grade 5
(death) in 12 (2%). 57 patients (9.0%) developed pancreatic fistula, of which
33 (58%) were classified as grade 2 , 17 (30%) as grade 3 , 5 (9.0%) as grade
4 , and 2 (3%) as grade 5 . DGE was noted in 80 patients (12.7%), 50% of all
DGE cases were scored as grade 2 , 46% were scored as grade 3 . To assess
whether the incidence of pancreatic fistula has changed over times we
analysed a series of 227 patients treated between 1987 and 1990, and found
comparable rates (8% vs. 9%). Only cardiovascular disease was found to be
predictive for complication severity (p/0 .009 ). In patients with malignant
diseases, grade 3 or 4 pancreatic fistula was associated with poorer long-term
survival compared to those with grade 2 severity pancreatic fistula (p/
0.008).
Conclusion. This study demonstrates the applicability of a new classification
in grading complications following pancreatic surgery. This approach enabled
to disclose similar rates of fistula over the past 15 years and a correlation
between the severity of postoperative fistulae and long term survival in
patients with malignant disease. This novel approach may enable a
standardized, objective and reproducible assessment of pancreas surgery
enabling meaningful comparison among centres and over time.
Reference
[1] Ann Surg 2004;240:205/13.
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Laparoscopic distal pancreatic resection reduces complications of
pancreatic resection for benign disease
Swee H. Teh, MD, Daniel Tseng, MD, David Le, MD, John G Hunter,
MD, Brett C. Sheppard, MD
Oregon Health & Science University, Portland, OR
Introduction. Despite the current growing interest in laparoscopic pancrea-
tic resection, the role of laparoscopic distal pancreatic resection is unclear due
to the paucity of published literature. The aim of this study was to provide
one of the first comparisons of the perioperative outcome of open distal
pancreatic resection (DPR) to laparoscopic DPR for benign pancreatic
disease.
Methods. We conducted a retrospective study of commonly accepted
outcome parameters for open and laparoscopic DPR performed for benign
pancreatic disease between June 2002 and June 2005.
Results. There were 16 patients in the open DPR group and 12 patients in
the laparoscopic DPR group with the mean age of 51.5 and 53.4 years. A
presumptive diagnosis of benign pancreatic neoplasm was reached based on
the findings from the preoperative clinical, radiographic and endoscopic
ultrasound evaluations. The final pathology for the open and laparoscopic
DPR groups were neuroendocrine neoplasm (7 and 5, respectively), benign
cystic neoplasm (3 and 3), symptomatic pancreatic pseudocyst (1 and 2),
chronic pancreatitis with ductal dilatation (1 and 2) and intraductal papillary
mucinous neoplasm (1 and 1). One patient in each group had sinistral portal
hypertension. The operative characteristics and perioperative outcomes are
demonstrated in Table 1. There was no perioperative mortality. Intention to
treat analysis for splenic preservation showed 1/6 patients in the open group
and 5/8 in the laparoscopic group had their spleen preserved (p/0.086). One
patient in the laparoscopic DPR group had a low output pancreatic fistula
which resolved with drainage alone. One patient in the open DPR group had
a pancreatic fistula which presented as an intraabdominal abscess. The mean
hospital stay was 10.6 days in the open DPR group and 6.2 days in the
laparoscopic DPR group (p/0.001).
Conclusion. Laparoscopic distal pancreatic resection is technically feasible,
is safe and associated with less perioperative morbidity and a shorter hospital
stay than open DPR. Splenic preservation remains a technical challenge
regardless of approach. In centers with the appropriate expertise, laparo-
scopic DPR should be considered as the procedure of choice for putative
benign lesions of the pancreatic body and tail.
Parallel Free Paper Session VII: Biliary
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Resistin-Like Molecule Alpha Reduces Gallbladder Optimal Tension
Hayder H. Al-Azzawi, MD, Abhishek Mathur, MD, Debao Lu, MD,
Deborah Swartz-basile, PhD, Attila Nakeeb, MD, Henry A. Pitt, MD
Indiana University, Indianapolis, IN
Introduction. Diabetes is associated with an increased incidence of
gallstones. Both animals and human data from our laboratory suggest that
insulin resistance is associated with increased gallbladder volume and
impaired gallbladder emptying. Resistin and resistin-like molecule alpha
(RELM-a) are newly described adipose- derived hormones that are believed
to mediate insulin resistance. However, no data are available on the influence
of resistin or RELM-a on gallbladder motility. Therefore, we tested the
hypothesis that daily administration of resistin or RELM-a would cause
insulin resistance and diminish gallbladder contractility.
Methods. In two sequential studies 40 eight-week old nondiabetic C57BL/6J
lean female mice were fed a chow diet for four weeks. In Study A, 10 mice
received 20 mg of resistin IP while in Study B 10 mice received 20 mg of
RELM-a IP for seven days. In each study, 10 control mice received an equal
volume of saline IP for seven days. At 12 weeks all animals were fasted
overnight and underwent cholecystectomy. All gallbladders were placed in a
muscle bath for determination of optimal length and tension, the tension at
which the maximal response to acetylcholine (ACh) 105 M is achieved, and
for response to neuropeptide Y (NPY 108,7,6 M) and cholecystokinin
(CCK 1010,9,8,7 M). Serum was obtained for determination of
resistin, RELM-a, glucose and insulin levels. HOMA index, a measure of
insulin resistance, was calculated.
Results. In Study A, serum resistin levels were higher in the resistin group
(1159/25 vs 359/3 pg/ml, pB/0.01) while in Study B, serum RELM-a was
detected only in the RELM-a group (36.7 ng). Results for optimal tension
(mg), glucose (mg/dl), insulin (ng/ml) and HOMA index were:
Study Group
Optimal
tension Glucose Insulin HOMA
A Saline 1159/10 1409/19 0.089/0.02 0.79/0.2
Resistin 1359/12 1459/22 0.089/0.01 0.69/0.1
B Saline 2289/20 1139/11 0.169/0.03 1.09/0.2
RELM-a 1509/13* 1489/19 0.209/0.03 1.89/0.3*
*pB/0.02 vs Saline.
Gallbladder responses to ACh, NPY and CCK did not differ between groups
in Study A or B.
Conclusion. These data suggest that in nondiabetic lean mice daily 20 mg
intraperitoneal injections of 1) resistin do not alter insulin resistance or
gallbladder optimal tension, but injections of 2) resistin-like molecule alpha
increase insulin resistance and reduce gallbladder optimal tension. Therefore,
we concluded that resistin-like molecule alpha may play a role in insulin-
resistance mediated gallbladder dysmotility.
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Aggressive surgical resection for cholangiocarcinoma: A single center
experience
Manousos Konstadoulakis, MD, Sasan Roayaie, MD, Francesco D’amico,
MD, Myron E Schwartz, MD
Mount Sinai Medical Center, New York, NY
Background. Surgery remains the only curative option for cholangiocarci-
nomas. In the current study we present our experience with resection for hilar
cholangiocarcinoma (HC).
Patients and methods. We reviewed the medical records of 73 patients
undergoing exploration for HC between 1988 and 2004. Type I & II tumors
were treated with bile duct resection, hilar lymphadenectomy and hepatico-
jejunostomy while type III & IV also underwent partial hepatectomy.
Resectability rate, operative mortality, and factors contributory to long-
term survival were investigated.
Results. Resection was possible in 59 patients (80.8%), 51 of whom (86.4%)
underwent major hepatic resection. Hepatectomy was accompanied by
vascular resection/reconstruction in 16 patients (31.4%). Fourteen (19.2%)
cases were unresectable. Tumor-free resection margins were obtained in 4/8
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(50%) of patients undergoing only bile duct resection and in 35/51 (68.6%)
undergoing hepatectomy. Negative margins were more common with right-
sided hepatic resections (80% vs. 20%, p/0.049). The in-hospital mortality
and morbidity rates were 6.8% and 25.4% respectively. In a mean follow-up
period of 38.79/41.1 months (median 26.2 months), 29 (49.2%) patients
died. Actual 1-year, 3-year and 5-year survival rates were 84.9%, 54.1% and
41.2% for hepatectomy patients and 87.5%, 33.3% and 25% for patients
with bile duct resection only. Factors adversely associated with patient
survival rates following a potentially curative resection were lymph node
metastases, preoperative weight loss and inferior vena cava resection. Multi-
variate analysis identified preoperative weight loss and inferior vena cava
resection as independent factors predictive of survival. Patients resected with
microscopically positive margins had significantly better 5-year survival
compared to unresectable cases (34% vs. 0%, p/0.0045).
Conclusions. Resections, including major hepatectomy with vascular
reconstruction, can be performed with good outcomes in patients with HC.
The high incidence of positive margins in patients who had left hepatectomies
might be reduced by extending the resection to include segments V and VIII.
Patients resected with positive margins had better survival than unresected
patients, implying benefit for noncurative resection. Resections should be
approached with caution in patients requiring vena caval resection or with
significant preoperative weight loss.
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Bacteria entombed in the center of cholesterol gallstones induce
fewer infectious manifestations than bacteria in the matrix of
pigment stones
Lygia Stewart, MD, J. Mcleod Griffiss, MD, Gary A. Jarvis, PhD, Lawrence
W. Way, MD
UCSF/SF VAMC, San Francisco, CA; UCSF, San Francisco, CA
Purpose. We previously reported bacteria in pigment centers of cholesterol
stones, but their clinical significance is unknown. We determined whether
bacterial location in the stone (pigment center vs stone matrix) influenced
infectious manifestations, and compared the bacterial virulence factors of
bacteria from pigment and predominantly cholesterol stones.
Methods. 304 patients were studied. Gallstones and bile were cultured. 110
stones were examined with SEM. Bacterial serum/bile IgG, complement-
killing (patient and control serum), and in-vitro TNF production was
determined. There were 146(48%) predominantly cholesterol stones(CS)
and 158(52%) pigment stones(PS). Severe infections were defined as
bacteremia, cholangitis, abscess, hypotension, or organ failure.
Results. 25% of CS and 69% of PS contained bacteria (PB/0.0001). SEM
demonstrated bacteria in the pigment portions of stones and agreed (96%)
with positive stone cultures. PS had more bacterial isolates than CS (2.1 vs
1.3, PB/0.05). PS bacteria(PSB) were more often present in bile (table), and
bacteremia was more common in cases with PS bacteria vs CS bacteria
(CSB) (table). CSB caused more severe infections than sterile stones, but less
than PSB: PSB, 54%; CSB, 17%; sterile stones, 0% (PB/0.0001). Serum and
bile from patients with CSB had less bacterial-specific IgG (table). CSB
produced more slime (table). PSB were more often killed by patient’s serum
than CSB, but control serum killed both equally (table). TNF production of
the groups was similar (table).
Conclusions. Bacteria are readily cultured from cholesterol stones with
pigment centers, allowing for analysis of their virulence factors. PCR is
unnecessary for detection of these bacteria. Bacteria sequestered in pigment
centers of cholesterol stones cause infectious manifestations, but less than
bacteria in the stone matrix. Possibly because of their isolation, CSB were less
often present in bile and blood, produced more slime, induced less IgG, were
less often killed by patient’s serum, and demonstrated fewer infectious
manifestations than PSB. In an in-vitro setting, CSB and PSB induced
similar levels of TNF, suggesting that once they escape from the CS, they can
induce inflammatory mediators. This is the first study to analyze the clinical
relevance of bacteria within cholesterol gallstones.
PS
Bacteria
CS
Bacteria
P
value
Stone bacteria in bile 80% 57% P/0.008
Stone bacteria in blood 18% 3% P/0.043
Serum/Bile IgG (scale 0/4) 3.6/2.8 2.9/1.7 PB/0.02
Bacterial-killing Patient sera 59% 25% P/0.016
Bacterial-killing Control sera 38% 29% P/NS
Slime /100 16% 39% P/0.04
TNF production 960 pg/ml 830 pg/ml P/NS
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The role of CCK-HIDA scan and cholecystectomy in patients with
biliary symptoms and normal ultrasound
Sameh A. Fayek, MD
Department of Surgery, Fairview Hospital, Cleveland Clinic Health System,
Cleveland, OH
Purpose. ‘‘Biliary dyskinesia’’ refers to postprandial right upper abdominal
pain and fatty food intolerance without cholelithiasis. The number of
cholecystectomies performed for dyskinesia has increased. Cholecystokinin
stimulated hepatobiliary 99 m-Tc iminodiacetic acid scintigraphy (CCK-
HIDA) has been suggested as a diagnostic tool and predictor of outcome.
Controversy exists in defining an ‘‘abnormal’’ ejection fraction (EF) and its
accuracy in outcome prediction. This study was designed to evaluate the
success of cholecystectomy in cases of acalculous cholecystitis, identify
predictors of outcome and define the role of CCK-HIDA in decision-
making.
Methods. Adults with symptoms of gallbladder disease and negative
ultrasound were all evaluated with CCK-HIDA scan. Other tests were
performed as needed. Patients with cholelithiasis, acute cholecystitis with
sepsis or in the ICU were excluded. Cholecystectomy was performed when
no cause was found to explain the complaint. Patients were divided into 2
groups, group A with EF 5/35% and group B with EF /35%. Long-term
results were evaluated. Success was indicated by improved symptoms, if
patients were satisfied or would agree to surgery again.
Results. 51 patients were included, 46 females, mean age 42.6 years. 49
patients had recurrent symptoms, 43 with classic gallbladder pain. 170
endoscopic and radiographic studies were performed without being able to
explain patient’s symptoms. All had CCK-HIDA and cholecystectomy.
Groups were demographically similar [group A 31 patients; group B 20
patients]. Mean follow up was 17.4 months. Overall success was 67%,
subgroups A and B had similar results (68% vs. 65% respectively) with no
correlation to EF. Age nor pain reproduction during CCK predicted
outcome. Patients with typical symptoms had better results (70% vs. 50%
if atypical symptoms, p/0 .42 ). Females showed more favorable outcomes
(70% vs. 40% in males p/0 .32 ). Most common pathology was chronic
cholecystitis (39/51), of whom only 67% improved after surgery. The 3
patients found to have stones did not improve.
Conclusions. Biliary Dyskinesia is a challenge. Cholecystectomy provides
improvement in 70% of patients with typical symptoms after exclusion of
other causes. Outcomes of males and cases with atypical symptoms are less
favorable. Clinical evaluation is a good predictor of outcome. Careful patient
selection is important to assure good results.
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Factors influencing recurrence following curative resection in stage II
gallbladder carcinoma
Dong Sup Yoon, MD., Joon Seong Park, MD., Kyung Sik Kim, MD.,
Jin Sub Choi, MD., Woo Jung Lee, MD., Hoon Sang Chi, MD., and Byong
Ro Kim, MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Aim. Despite of advances in hepatobiliary imaging techniques, most patients
with gall bladder cancer are diagnosed at advanced stage and the prognosis is
very poor. Recent studies showed that aggressive radical resection for
advanced stage gallbladder carcinoma could give acceptable prognosis.
However, recurrence remains frequently the main problem after curative
resection of advanced stage gallbladder carcinoma. The aim of this study was
to identify patterns of recurrence and the factors affecting recurrence of
curative resection with stage II gallbladder carcinoma.
Material and method. Between January 1991 and December 2003, 100
patients received radical curative resection for gallbladder carcinoma at
Yonsei University Medical Center. Of these, 77 patients were defined as stage
II gallbladder carcinoma according to the UICC classification(6th edition).
Among 77 patients, 67 patients were reviewed, and analyzed to assess
predictors of recurrence.
Results. Among 67 patients, 38 patients (56.7%) had recurrence. The mean
length of time to recurrence was 21.1 months (9/ 26.7 months) and the most
common site of recurrence was intra-abdominal organs: liver, aortocaval
lymph nodes. Infiltraing type and poorly differentiation was identified as
independent prognostic factor of recurrence after curative resection for stage
II gallbladder carcinoma.
Conclusion. In conclusion, the fact that a higher probability of recurrence is
anticipated in cases of infiltrating type and poorly differentiation tumor
support that the effective postoperative adjuvant modality should be
developed for these high risk group patients.
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Biliary tract cancer: disease demographics and current trends in
surgical intervention
James T. McPhee, MD, Maksim Zayaruzny, MD, MPH, Giles F. Whalen,
MD, Demetrius E. Litwin, MD, MBA, Mary E. Sullivan, MS, Frederick A.
Anderson, PhD, Jennifer F. Tseng, MD
University of Massachusetts Medical School, Worcester, MA
Purpose. Biliary tract cancers usually present at advanced stages, and are
curable only in conjunction with complete surgical resection. We evaluated
current population-based data for biliary tract cancer and investigated trends
in surgical resection.
Methods. The National Inpatient Sample (1998/2003) was used to identify
10,169 patients (/50,262 nationally) discharged from U.S. hospitals with a
primary diagnosis of biliary tract cancer. The ICD-9 codes for intrahepatic
bile duct, extrahepatic bile duct, and gallbladder cancer were used. Patients
were classified by surgical intervention (hepatic resection, bile duct resection,
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pancreaticoduodenectomy [PD], or cholecystectomy [CCY]). The primary
outcome measure was in-hospital mortality.
Results. By weighted analysis 50,262 patients (/8,377/year) were dis-
charged with a primary diagnosis of biliary tract cancer (33.7% intrahepatic
ductal, 33.5% extrahepatic ductal, 32.8% gallbladder). 55% of patients were
female; 75% of patients were white; 78% of patients were /60 years old.
In-hospital mortality for all patients was 10.9%. An estimated 14,132
patients (28.1%) underwent one of the four operations. An estimated 1,744
(3.5%) patients underwent PD (90% for extrahepatic bile duct lesions);
mortality was 8.7%. An estimated 2,604 (5.1%) patients underwent hepatic
resection (55.3% for gallbladder and 34.3% for intrahepatic ductal cancer)
with a mortality of 4.0%. An estimated 1,812 (3.6%) patients underwent
bile duct resection (61.8% for extrahepatic ductal cancer) with a mortality of
4.5%. An estimated 16,512 patients were discharged with a diagnosis of
gallbladder cancer, of whom 9,023 (54.6%) underwent an operation (CCY
80.4%, hepatic resection 16.0%, duct resection 3.35%, and PD .011%). Of
all biliary tract cancer patients, 54.6% were treated at an urban teaching
hospital and 35.5% were treated at an urban non-teaching hospital. Of those
patients that underwent hepatic resection, PD, bile duct resection, and
CCY, a respective 77.3%, 68.6%, 82.1% and 42.4% were done at urban
teaching hospitals.
Conclusions. The diagnosis of biliary tract cancer carries considerable risk
of in-hospital mortality. Surgical procedures are performed on a minority of
patients, with the implication that the majority of patients are deemed
unresectable. Carcinoma of the gallbladder is the exception with /50% of
patients undergoing a resection. These results suggest that patients with
biliary tract cancers might benefit from earlier diagnosis, allowing for more
effective treatment including surgical intervention.
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Surgical resection for proximal cholangiocarcinoma
Sean Cleary, MD, Reid Adams, MD, Shimul Shah, MD, Paul Greig, MD,
Bryce Taylor, Bernard Langer, MD, Steven Gallinger, MD, Alice Wei, MD
Toronto General Hospital, Toronto, ON, Canada; University of Virginia,
Charlottesville, VA
Introduction. Until recently, the outlook for patients diagnosed with
cholangiocarcinoma has been very poor. Conservative surgical resection has
been met with limited success due to high rates of local recurrence.
Improvements in diagnostic strategies and an aggressive surgical approach
have led to an overall increase in the number of patients who undergo a
potentially curative resection in many specialized centres. We sought to
review our experience with proximal cholangiocarcinoma to test the hypoth-
esis that a change to a more aggressive approach has led to an increase in the
rate of radical resection, an increase in the rate of curative (R0) resection and
an improvement in overall survival with acceptable perioperative morbidity
and mortality.
Methods. A retrospective review was performed using hospital and
surgeon databases to identify patients who underwent a resection for
proximal cholangiocarcinoma at the Toronto General Hospital and Mount
Sinai Hospital between Jan 1, 1984 and Jan 1, 2000. Non-parametric
data was compared by chi-square test and Fisher’s exact test. Univariate
and multivariate analysis of disease free survival was performed using
Mantel-Cox Log Rank Test and Cox proportional hazards model, res-
pectively.
Results. Sixty-six patients underwent resection for proximal cholangiocar-
cinoma. Median (9/SD) age was 59.19/12.8 years. There were 3 (4.5%)
perioperative deaths and 7 patients had a R2 resection. A total of 56
patients underwent a resection with curative intent. Eight tumours were
classified as Bismuth Type 1, eleven Type 2, eighteen Type 3a, thirteen
Type 3b and six Type 4, respectively. In the entire series, 34/56 (60%)
resections included hepatic lobectomy, including 17 trisegmentectomies.
27/34 (80%) of resections after Jan 1, 1994 included liver resection.
Mean disease-free survival was 64.49/8.2 months and median survival was
46.39/16.6 months. Hepatic resection (p/0.004), caudate lobe resection
(p/0.036) and Stage 1 or 2 tumours (p/0.05) were associated with
microscopically negative (R0) margins. Lack of jaundice at presentation
(p/0.036), hepatic trisegmentectomy (p/0.05) and tumour stage
(p/0.02) were associated with improved disease-free survival by univariate
analysis. Only jaundice at presentation was an independent predictor
of disease free survival by multivariate analysis (HR/5.8; 95%CI
1.23/27.1).
Conclusions. Aggressive surgical resection for proximal cholangiocarcinoma
can be performed safely and is associated with a higher rate of R0 resection.
However, locally advanced disease continues to be associated with high rates
of tumour recurrence.
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High dietary carbohydrates decrease gallbladder volume and en-
hance cholesterol crystal formation
Abhishek Mathur, MD, Marine Megan, None, Hayder H. Al-azzawi, MD,
Debao Lu, MD, Deborah Swartz- Basile, PhD, Attila Nakeeb, MD, Henry
A. Pitt, MD
Indiana University, Indianapolis, IN
Introduction. Dietary fat is a known risk factor for cholesterol gallstone
formation. In some animal models diets with a high percentage of sucrose or
glucose also have been shown to cause gallstones. In addition, limited human
data suggest that diets high in refined carbohydrates may be lithogenic.
However, no data are available on the role of dietary carbohydrates on
gallbladder volume or on cholesterol crystal formation. Therefore, we tested
the hypothesis that a high carbohydrate diet would alter gallbladder volume
and enhance cholesterol crystal formation.
Methods. At eight weeks of age 60 lean C57BL/6J and 36 leptin deficient
obese Lepob female mice were fed a 45% carbohydrate diet while an addi-
tional 60 lean and 36 obese mice were fed a 75% carbohydrate diet for 4
weeks. All animals then underwent cholecystectomy, and gallbladder bile
volume was recorded. Bile was then pooled, filtered and maintained in a water
bath at 378C for 14 days. Bile was observed daily under polarized light
microscopy for cholesterol crystal formation. Birefringent crystals were count-
ed in ten high power fields, and crystal observation time as well as crystal mass
were determined. Data were analyzed by ANOVA and Student’s t test.
Results. Results for gallbladder (GB) volume, crystal observation time
(COT) and crystal mass (total number) in the lean and obese animals on the
45% and 75% carbohydrate (CHO) diets are presented in the table. Only
liquid, not solid, crystals were observed.
Conclusions. These data suggest that a high carbohydrate diet 1) decreases
gallbladder volume, 2) shortens cholesterol crystal observation time, and 3)
increases crystal mass. We conclude that dietary carbohydrates may play a
role in cholesterol gallstone formation both by altering biliary motility and by
enhancing crystal formation.
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Percutaneous metallic stents insertion for management of combined
malignant biliary and duodenal obstruction
Mariano Gimenez, MD, Horacio B. D’agostino, Claudio J. Scho¨nholz, MD,
Martin Pilat, MD, Paul Jordan, MD, Kenneth Manas, MD
Veronica Prieto Ventura, Hospital F. Santojanni, Buenos Aires, Argentina;
LSUHSC-Shreveport, Shreveport, LA
Purpose. To describe the indications, routes and results of percutaneous
insertion of metallic stents for relief of combined malignant biliary and
duodenal obstruction.
Materials and methods. The study involves 8 patients (men, 6; women, 2)
with obstructive jaundice and vomiting from duodenal obstruction. Locally
invasive pancreatic carcinoma was the cause of biliary and duodenal
obstruction in all patients. Diagnostic workup included CT scan of the
abdomen and upper GI endoscopy. A percutaneous approach was indicated
after endoscopic attempts failed to resolve malignant obstructive jaundice
and duodenal obstruction. Biliary and duodenal obstruction occurred
synchronically in 4 patients, while duodenal obstruction was clinically
apparent after biliary stent placement in 4 patients. Ultrasound and
fluoroscopy were used for biliary stent insertion guidance. Duodenal stents
were placed under fluoroscopic guidance in a retrograde fashion using the left
biliary access (4 patients), combined endoscopic-transbiliary (2 patients) and
transgastric (2 patients). Wallstents 10/42/68 mm and 20/60/90 mm
were used for resolving biliary and duodenal obstruction, respectively.
Multiple stents were used in 6 patients. Patients were placed on a liquid or
semisolid diet. Parameters evaluated were relief of symptoms and survival.
Results. Metallic stent placement resulted in gradual clearance of obstruc-
tive jaundice in all patients. Immediate relief of duodenal obstruction was
complete in 6 patients and partial in 2 patients. Two patients had
postprocedure vomiting caused by stent migration requiring insertion of
another stent with endoscopic assistance. There were no other procedure
associated complications. Liquid and low residue oral feedings was resumed
in all patients. Survival of patients post biliary and duodenal stent placement
ranged from 49/166 days (average, 92 days).
Conclusion. A percutaneous transhepatic or transgastric approach may be
used to insert metallic stents for successfully manage combined malignant
biliary and duodenal obstruction when the endoscopic approach is not
feasible.
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Bile duct injuries related to t tubes. A comorbid factor in the spectrum
Miguel-angel Mercado, MD, Carlos Chan, MD, Hector Orozco, MD,
Alexandra Barajas-olivas, MD
Instituto Nacional de la Nutricio´n Salvador Zubira´n, Mexico City, Mexico
Introduction. T tubes can be placed in the bile ducts either open or
laparoscopically for several reasons such as: extraction of stones, biliary
reconstruction after liver transplant and in end to end anastomosis in
Study
Group
GB Volume
(ml)
COT
(days)
Crystal
mass
Lean 45%CHO 10.89/0.5 10.09/1.0 1.79/1.7
Lean 75%CHO 7.49/0.4* 3.09/0.0* 11.79/2.3*
Obese 45%CHO 25.69/1.9* 8.69/1.2 5.09/1.9
Obese 75%CHO 6.79/0.6$ 3.79/0.3§ 29.09/20.1
*pB/0.05 vs lean 45%, $pB/0.001 vs obese 45%, §pB/0.05 vs obese 45%.
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iatrogenic injuries. Inadequate placement of the T tube, long term stay and
technical difficulties that can affect the outcome, can lead to an injury that
usually requires a biliodigestive reconstruction.
Methods. In a 15 year period (1990/2005) a total of 343 patients have been
referred to our university hospital and team for biliary reconstruction. We
reviewed the files of those patients in which the injury was due to
misplacement and/or abnormal long term stay of the T tube. Type of injury,
type of reconstruction and long term outcome were evaluated as well as
comorbidities.
Results. In 42 cases a T tube related injury was identified (13%). All injuries
were classified as Strasberg E, with demonstration of a fistula (internal and/or
external) to adyacent viscus (18 duodenum, 5 jejunum-ileum, 3 colon) the
rest were external. In all cases an hepatojejunostomy was done, the
duodenum and small gut fistulas were closed and in the 3 cases with colonic
injury, a right hemicolectomy was done. The postoperative evolution was
adequate without major complications and with a longer hospital stay. In 39
of 42 (92%) good postoperative results were obtained. One case required
reoperation 22 months after the first surgery, due to recidivant cholangitis.
Conclusion. Inadequate placement of the T tubes and long term stay can
produce complex biliary injuries with comorbidities like fistulas to the
adjacent viscera. Placement of T tubes need a careful surgical technique
and their indication must be carefully assessed.
Parallel Free Paper Session VIII: HPB Potpourri
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The outcome of 261 cases of living related liver transplantation:
egyptian registry in four years
Ibrahim K. Marwan, MD, Ibrahim T., Elmeteny M., Fayez A., Hosny A.,
Kamel R., Elmalet O., Hatata Y, Khaled A., Hegab B.
Abd-Elwaha, National Liver Institue, Cairo, Egypt
Background. Living related liver transplantation (LRLT) is known to be an
established acceptable therapeutic modality for end stage liver diseases,
especially when cadaveric liver transplantation is not available in some
countries like Egypt.
Aim. is to present the early results of 261 cases received LRLT in four years
according to the Egyptian Registry data collected from eight centers
performing LRLT.
Patients and results. 261 patients with end stage liver diseases received
LRLT from August 2001, there were 221 adults(84.67%) and 40(15.33%)
patients in the pediatric age group. The mean age in the adult group was
53.65 years, while in the pediatric age group the mean of age was 8.73 years.
The main indication in the adult patients was HCV infections, 195 out 221
patient (88.24%). Hepatocellular carcinoma (HCC) were in 44 pa-
tients(22.56%) of the HCV patients. Biliary Atresia (BA) case represents
35% of the pediatric patients. Post-transplant clinical recurrence of HCV re-
infection was 25% of HCV cirrhotic patients, 10% of them need to receive
anti-viral treatment. Regarding biliary complications, bile leak or stricture,
were observed in 22.98% of all cases either adults or pediatrics. The operative
mortality was occurred in seven recipients and donor mortality was one
donor three months postoperatively due to biliary leak followed by sever
infection, septicemia and multy organ failure. The overall mortality was 64
out of 261 cases (24.5%). In the adults group mortality was 25.8% whereas in
pediatric age group was 17.5%.
Conclusions. Living related liver transplantation is a potentially safe
procedure especially in centers where no cadaveric liver transplantation.
The initial results are encouraging and that progress in this field is remarkable
especially for adults patients to improve there quality of life and for children
to cure them.
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Real-time imaging of large volume microwave ablations
Andy David Strickland, MD, Peter Clegg, PhD, Mosheir El Abassy, MD,
Bruno Morgan, MD, Nigel Cronin, PhD, David Lloyd, MD
University Hospitals of Leicester, Leicester, United Kingdom; Medical
Devices Technology Group, Department of Physics, Bath, United Kingdom
Accurate real-time imaging is of great value when using ablative techniques as
a combination of adequate tumour treatment with minimal damage to
surrounding tissue is desired.
Aims. The object of this experiment was to observe and characterise the
ultrasound appearances after the induction of a microwave lesion and to
examine the correlation between the macroscopic ablation diameter and that
as measured by ultrasound in ex-vivo bovine liver and in-vivo porcine hepatic
parenchyma. The second aim was to investigate lesion temperature distribu-
tion in both these two tissue types.
Methods. A newly designed microwave applicator was used to produce
volumes of ablation in the hepatic parenchyma. An intra-operative ultrasound
(IOUS) was placed perpendicular to the microwave applicator and the image
captured for analysis every thirty seconds of treatment for a maximum of three
minutes and 1 minute post treatment. Real-time thermal data was gained
using thermocouples mounted in an aluminium jig at 1 cm intervals attached
to a data acquisition unit. A Consultant Radiologist assessed the ultrasound
images and an estimation of the ablation diameter was made and compared to
the maximum macroscopic diameter measured of the induced lesion.
Results. Thirteen ex-vivo and 39 in-vivo lesions were examined using the
intra-operative ultrasound. Following the application of power, the image was
initially unchanged though the region immediately adjacent to the tip became
hypoechoic. Almost immediately came a sudden expansion in the imaged
lesion size in which the signal changed to one of high echogenicity. This
highly echogenic signal or ‘‘thermal cloud’’ increased until the treatment
ceased. IOUS estimation of ablation diameter in ex-vivo liver consistently
over estimated the macroscopic size of the lesion and this discrepancy
increased as treatment times increased. IOUS estimation of ablation diameter
was however much more accurate in the in-vivo setting and close correlation
was noted when the data was analysed using a Bland and Altman plot.
Thermal data was acquired from both ex-vivo and in-vivo experiments.
Accurate readings were however difficult to obtain due to the difficulty in
maintaining good contact between the tissue and thermocouples.
Conclusions. IOUS is both a widely available and useful method for the
real-time, in-vivo estimation of microwave ablation diameter. Real-time
thermal monitoring may be a useful tool for real-time monitoring of
microwave ablations but difficulties in maintaining good tissue contact are
likely to hamper its use clinically.
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Effect of surgeon volume on healthcare resource utilization for
orthotopic liver transplantation
John E. Scarborough, Carlos E. Marroquin, MD, Ricardo Pietrobon, MD,
PhD, Theodore N Pappas, MD
Duke University School of Medicine, Durham, NC
Purpose. Length of hospital stay and routine discharge (i.e. to home instead
of a short-term hospital, skilled nursing facility, etc.) are important
determinants of healthcare resource utilization and cost. We examined the
relationship between these variables and surgeon volume for orthotopic liver
transplantation (OLT). We hypothesized that higher surgical volume will
result in improved healthcare utilization for OLT.
Methods. Patients undergoing OLT were extracted from the Nationwide
Inpatient Samples Database for the years 1990/2001. Surgeon volume was
divided into low- (1 OLT per year), intermediate- (2/9 per year), and high-
volume (more than 9 per year) categories. Multiple logistic regression models
were then used to estimate the risk-adjusted association between surgeon
volume and length of hospital stay (LOS), percentage of patients discharged
to home, and postoperative mortality.
Results. A total of 7,013 patients undergoing OLT were extracted from the
database and analyzed. Patients undergoing OLT performed by low-volume
surgeons had a significantly higher likelihood of extended length of stay
compared to patients undergoing OLT performed by high-volume surgeons
[low-volume LOS 23.49 days (95% confidence interveal 18.94 /29.13),
intermediate-volume 21.81 days (95% CI 16.59/28.67), high-volume 19.38
days (95% CI 15.20/24.72) pB/0.001]. There was also a linear trend for an
increasing percentage of patients being discharged to home with higher
surgeon volume. Low surgeon volume was associated with higher post-
operative mortality, but not at a statistically significant level.
Conclusions. Surgeons who perform a high volume of OLT procedure use
healthcare resources more efficiently than low-volume surgeons.
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Resection of hepatic colorectal metastasis involving the caudate lobe:
Perioperative outcome and survival
Eddie K. Abdalla, MD, Timothy M. Pawlik, MD, MPH, Daria Zorzi, MD,
Steven A. Curley, MD, Thomas A. Aloia, MD, Dario Ribero, MD, Andrea
Muratore, MD, Axel Andres, MD, Gilles Mentha, MD, Lorenzo Capussotti,
MD, Jean Nicolas Vauthey, MD
UT MD Anderson Cancer Center, Houston, TX; Institute for Research and
Cure of Cancer, 10060 Candiolo (to), Italy; University Hospital Geneva,
Geneva, Switzerland
Purpose. To examine clinical features and outcome of patients who
underwent hepatic resection for colorectal metastasis (CRM) involving the
caudate lobe.
Methods. Consecutive patients who underwent hepatic resection for CRM
between 1990 and 2004 were analyzed from a multicenter database.
Demographics, operative data, pathologic margin status, recurrence, and
survival were analyzed.
Results. Of 580 patients identified, 40 (7%) had CRM involving the
caudate. Six had isolated caudate CRM and 34 CRM involving the caudate
plus one or more other hepatic segments. Patients with caudate CRM were
more likely to have synchronous primary colorectal cancer (61% vs. 36%;
P/0.005) and multiple CRM (69% vs. 51%; P/0.02) and required
extended hepatic resection more often than patients with non-caudate
CRM (59% vs. 18%; PB/0.001). Only 4 patients with caudate CRM
underwent a vascular resection; all had primary repair (vena cava, n/3;
portal vein, n/1). Perioperative complications (25% vs. 28%) and 30-day
operative mortality (0% vs. 1%) were similar (both P/.05). Pathological
margins were positive in 6 (15%) patients with caudate CRM and in 43 (8%)
with non-caudate CRM (P/0.10). At a median follow-up of 41 months, 25
(63%) patients with caudate CRM recurred compared with 219 (40%)
patients with non-caudate CRM (P/0.002). Patients with caudate CRM
were more likely to have intrahepatic disease as a component of recurrence
(caudate: 50% vs. non-caudate: 25%; P/0.01). One patient with caudate
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CRM recurred at the parenchymal transection margin; no patient recurred
on the vena cava or portal vein. Patients with caudate CRM had a worse
5-year disease-free and overall survival than patients with non-caudate CRM
(disease-free: 20% vs. 44%, P/0.02; overall: 38% vs. 58%, P/0.009)
(Figure).
Conclusions. Patients with caudate CRM often require an extended hepatic
resection due to the anatomic location of the metastasis and the multifocality
of the disease, but vascular resection is rarely necessary. Although caudate
CRM often occur in the setting of more extensive intrahepatic disease
compared with non-caudate CRM, surgical resection is warranted.
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Hepatic resection for colorectal metastases / a Canadian perspective
Peter J. Horton, MD, John B. Martinie, MD, Jeffrey S. Barkun, MD,
Prosanto K. Chaudhury, MD, Peter Metrakos, MD
Royal Victoria Hospital, Montreal, PQ, Canada
Background. In 2004 the results of a postal survey in the UK, which
assessed the views of consultant surgeons managing patients with colorectal
liver metastases, were published (Ann R Coll Surg Engl 2004; 86: 420 /4).
Aim. To establish current opinions, practice and referral patterns for hepatic
colorectal metastases by general surgeons in Canada who have declared an
interest in colorectal cancer and to compare practice in the United Kingdom
(UK) and Canada.
Patients and methods. A postal questionnaire, identical to the British one,
was sent to members of the Association of Colon and Rectal Surgeons of
Canada (ACRSC). Contact details for 72 members were obtained from the
ACRSC website.
Results. The response rate was 33.3% of which 84% were from surgeons
treating patients with colorectal cancer in Canada. The surgical practice of
ACRSC members was largely colorectal disease, median 95% (range 10 to
100%) and the referral base was large with a median one million people
(range 50,000 to 4,000,000). Joint clinics with an oncologist were held by
56% of those who replied. The liver was assessed for metastases prior to
colorectal resection by 84%, 42% using ultrasound and 74% CT. All agreed
that solitary hepatic metastases were resectable. Bilobar disease with the
largest lesion /3 cm and metastases /5 cm were considered contra-
indications to resection by 44% and 47% respectively. The best time to resect
hepatic metastases was felt to be within the first 6 months after colorectal
resection by 74%. Patients with previous liver resections, extra-hepatic
disease or a solitary pulmonary metastasis were considered potentially
resectable by 88%, 75% and 94% respectively. Thirty-nine percent would
consider giving pre-operative chemotherapy to patients with resectable
disease. Only two surgeons performed anatomical liver resections, one was
working outside Canada and the other described himself as a liver surgeon.
Non-anatomical resections or radio frequency ablation of metastases were
performed by 12% of those who replied. Access to liver surgeons was
described as good or very good by 89%. The median surgeon performed /
60 colorectal resections per year and referred median 5 patients per year
(range 0 to 15) to a liver surgeon and median 10 patients per year (range 1 to
20) to an oncologist. Only 62% of UK surgeons and 69% of surgeons in the
Canadian survey considered patients with more than three unilobar
metastases to be resectable.
Conclusion. The findings of this Canadian survey are similar to the findings
of the original survey from the United Kingdom. The relatively small
percentage of patients being referred would suggest that patients with
multiple metastases are not being considered for resection.
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Decision analysis supports the use of diagnostic laparoscopy in
hepatobiliary and pancreatic malignancies
Tun Jie, MD, Univ Minnesota Department of Surgery; Kambiz Kosari, MD
Univ Minnesota Department of Surgery; Timothy Sielaff, MD, Virginia
Piper Cancer Institute
The utility of diagnostic laparoscopy in avoiding nontherapeutic laparotomy
in hepatobiliary and pancreatic cancer surgery remains controversial. This
study employs a single institution data set in combination with a range of data
from the literature to determine the cost-effectiveness and utility of diagnostic
laparoscopy as the last diagnostic test before laparotomy in this patient
population.
Methods. Data were acquired for this IRB approved study of 254 patients
with hepatobiliary and pancreatic cancer who were considered candidates
for curative resection. All of these patients underwent complete disease
specific staging. No patients included in this study required surgery for
specific symptom palliation. Demographic and logistical clinical and institu-
tional cost data were used in a state-transitional Markov model developed
to analyze the cost-effectiveness of two surgical approaches: Diagnostic
laparoscopy prior to laparotomy (DL, n/124) vs. Laparotomy (L, n/130).
The primary end point was cost effectiveness of the initial hospitalization for
all patients and surgical interventions (therapeutic and non-therapeutic
procedures).
Results. Diagnostic laparoscopy was 95.7% sensitive in identifying
contraindications to resection. The hospitalization costs (DL $16,895 v
L 16,908) and length of stay (DL 5.4 v L 6.7 days) were not different
between the two groups. Two-way sensitivity analysis (Figure 1) showed that
over the range false negative detection rates for DL published in the
literature, DL can be considered cost effective. The cost per patient saved
from nontherapeutic laparotomy ranged between /$4000 and $11000
(Figure 2).
Conclusions. Using single institution and literature based data analysis,
decision analysis demonstrated that diagnostic laparoscopy was cost effective
as the ‘‘last diagnostic test’’ in patients with hepatobiliary and pancreatic
malignancies prior to laparotomy. Laparoscopy avoids nontherapeutic
laparotomy and its associated morbidity.
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Treatment of post liver transplantation biliary anastomotic stenosis
with temporary expandable stents
Michel Dagenais, MD, Otmane Nafidi, MD, Marylene Plasse, MD, Re´al
Lapointe, MD, Richard L. E´tourneau, MD, Andre´ Roy, MD
Centre hospitalier de l’Universite´ de Montre´al, Montre´al, PQ, Canada
We report two cases of post liver transplantation (LT) biliary anastomotic
stenosis managed by temporary metallic expandable stents instead of
repetitive balloon dilatation and placement of plastic stents.
Methods. Two patients with a biliary anastomotic stricture after LT were
referred for endoscopic management. Case #1: A 63-year-old man with
cryptogenic cirrhosis underwent LT in 10/2003. Four weeks post-operatively,
elevated liver function tests and intrahepatic bile duct dilatation at ultrasound
were found. In the first endoscopic retrograde cholangiography (ERC), the
bile duct was tortuous with an anastomotic stricture and a plastic stent was
placed. The stricture persisted for 6 months despite numerous ERCs with
balloon dilatation and plastic stent insertion and a temporary metallic
expandable stents (Wallstent†) was deployed. Case #2: A 49-year-old
woman who underwent LT for ethylic cirrhosis in 2/2000 presented in 6/
2004 with elevated liver function tests and intrahepatic bile duct dilatation at
ultrasound. A biliary anastomotic stricture was demonstrated by magnetic
resonance cholangiography. She underwent 3 ERC’s with balloon dilatation
and plastic stent insertion in the next 6 months. Finally a temporary metallic
expandable stent was placed.
Results. Case #1 remained asymptomatic for 9 months and the metallic
expandable stent was removed easily. The bile duct was normal without
residual stenosis. Case #2 was asymptomatic with normal liver function tests
for the next 6 months. Retrieval of the metallic expandable stents was
achieved without difficulty. The cholangiography showed an excellent
response with absence of significant stricture.
Conclusion. The optimal approach of biliary anastomotic stricture after
LT has not been established. A temporary metallic expandable stent
placed endoscopically is technically feasible, avoids multiple balloon
dilation and stent change and can be removed when placed appropriately.
More experience with longer follow-up is required for this promising
approach.
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FDG-PET in the staging and surveillance for patients with cholan-
giocarcinoma
Siddhartha Rath, MD, Kerry W Byrnes, MD, Markus V John, MD, David
Lilian, MD, Lester W Johnson, MD, Richard H Turnage, MD, Gazi B
Zibari, MD
Louisiana State Health Sciences Center in Shreveport, Shreveport, LA;
Louisiana State Health Sciences Center in Shreveport, Monroe, LA
Introduction. Whole-body FDG PET has become a valuable tool in both
staging and surveillance of multiple malignancies. Cholangiocarcinoma is a
rare entity that frequently will present late in its course. Computed
tomography has become the gold standard in staging cholangiocarcinoma,
however it has its weak points. The purpose of this study is to assess the value
of conventional FDG-PET in both the staging and surveillance of patients
with cholangiocarcinoma.
Methods. All patients with a diagnosis of cholangiocarcinoma from 1999/
2004 were identified and reviewed retrospectively. Patients who underwent
PET scanning as part of their staging preoperative workup and surveillance
were selected. Concomitant computed tomography scans were reviewed
when available. Pathology reports and operative findings were reviewed in
detail. The sensitivity of both PET imaging and computed tomography was
determined.
Results. Thirteen patients with cholangiocarcinoma who underwent FDG-
PET scanning were identified. A total of 19 PET scans were obtained. Eight
PET scans were performed as part of pre-operative or staging workup and
eleven underwent PET for surveillance. All patients who had pre-operative
PET scans underwent surgery, (7 laparotomies, 1 laparoscopy), and in all
cholangiocarcinoma was confirmed by histology. The sensitivity of PET in
detecting primary disease was 100%. In two patients distant disease existed
and PET scan accurately identified one of these. Eleven surveillance (post-
operative) PET and CT scans were performed in seven patients. The
sensitivity of PET in detecting recurrence was 100%. In comparison,
computed tomography detected recurrence with a sensitivity of 33%.
Conclusion. PET scan is a valuable tool for pre-operative staging of
cholangiocarcinoma and compares favorably to conventional computed
tomography as a surveillance tool.
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Reversing multidrug resistance through the suppression of MDR1
gene by rnai in human hepatoma cells
Chen Xiaoping, Qi Wang, Jian Guan, Zhi-yong Huang, Wan-guang Zhang,
Bi-xiang Zhang
Tongji Hospital, Tongji Medical College, Huazhong University of Science
and Technology, Wuhan, China
Background/Aims. Over expression of P-glycoprotein, encoded by the
MDR1 gene, is the major reason leading to multidrug resistance (MDR).
Recent developments of RNA interference (RNAi) technology make it
possible to reverse MDR by suppressing MDR1 gene with RNAi, however,
whether MDR could be reversed by RNAi-mediated MDR1 suppression in
hepatoma cells remains unknown.
Methods. For reversing MDR by RNAi technology, two different short
hairpin RNAs (shRNAs) were designed and constructed into pGenSil-1
plasmid, respectively. They were then transfected into a highly adriamycin-
resistant HepG2 hepatoma cell line (HepG2/ADM). The RNAi effect on
MDR was evaluated by real-time PCR, cell cytotoxicity assay and Rhoda-
mine123 (Rh123) efflux assy.
Results. The stable transfected clones showed varied degrees of reversal of
MDR phenotype. Surprisingly, the MDR phenotype was completely reversed
in two transfected clones.
Conclusions. This study demonstrates that MDR can be reversed by
the shRNA-mediated RNAi in HepG2/ADM cells, which provides a
valuable clue as to sensitizing multidrug-resistant hepatoma cells to anti-
cancer drugs.
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Laparoscopic resection for choledochal cyst
Juan Pekolj, MD, PhD, Christian Bertona, MD, Rodrigo Sa´nchez Claria´,
MD, Martı´n Palavecino, MD, Oscar Mazza, MD
Eduardo De Santiban˜es, Hospital Italiano, Buenos Aires, Argentina
Background. choledochal cysts are an infrequent pathology in adult
population. The surgical resection is the gold standard treatment because
of the possibility of cancer development.
Objective. to show technical tips for the laparoscopic resection of
choledochal cysts (Type I in Todani’s classification).
Population. a 44 year-old female patient with abdominal pain. The
ultrasound and MRI showed a choledochal cyst (Type I in Todani’s
classification).
Method. closed pneumoperitoneum, the intraoperative cholangiography
showed a pathological bilio-pancreatic junction. The hepatic artery was
dissected, clipping the pyloric and gastroduodenal artery. The proximal neck
of the cyst was dissected and cut. The posterior wall was separated from the
portal vein. The distal neck was ligated and sectionated. An extracorporeal
Roux-en-Y loop was performed (through the umbilical access). A hepatico-
jejunostomy was done. A cholangiography by transjejunal punction con-
firmed the patency of biliodigestive anastomosis. An abdominal drainage was
left in place.
Results. the patient was discharged at the 4th postoperative day without
complications. In the long-term follow-up the patient is asymptomatic and
with normal liver function tests and ultrasound controls.
Conclusions. type I (in Todani’s classification) choledochal cysts can be
laparoscopically resected following the steps described for the open proce-
dure. This approach must be performed by surgeons with experience in
laparoscopic suturing techniques.
V14
Systematic subsegmentectomy for hepatocellular carcinoma: Tech-
niques and results
Keiichi Kubota, MD, PhD
Dokkyo University Hospital, Tochigi Pref., Japan
The characteristics of hepatocellular carcinoma (HCC) include intrahepatic
metastasis via the portal vein and multi-centric occurrence. Systematic
subsegmentectomy (SSS) for hepatocellular carcinoma (HCC) was devel-
oped for extirpating possible areas where HCC can metastatize via the portal
branches (Makuuchi et al. Surg Gynecol Obstet, 164: 68/72, 1987). At my
department, the first choice of surgical technique for resecting HCC is SSS.
In this presentation, I will show my techniques of resection of segments 5 and
6, which includes all techniques for SSS.
Indication criteria. When the indocyanin green retention rate at 15 min is
less than 30%, SSS is indicated for resecting a HCC. When the rate exceeded
30%, non-SSS was indicated.
Patient. A 64-year-old male with ICG15 of 17% had a HCC in the anterior
segment and was scheduled to undergo anterior segmentectomy.
Techniques. Both abdominal and thoracic cavities were opened by
J-shaped incision. The anterior branches of the right hepatic artery
and portal venous branch were dissected and taped. But the HCC was
found to extend to the posterior segment and subsequently the
procedure was changed from anterior segmentectomy to resection of
segments 5 and 6. The Cantlie line was first marked. The portal branch
to the segment 7 was demonstrated by intraoperative ultrasound (IOUS),
and was punctured. 5 ml of Indigocarmine was injected. The stained
area was marked by electrocautery. Then the portal branch to the
segment 6 was punctured and Indigocarmine was injected. This
procedure clarified the border between the segments 6 and 7. Then
the same procedure was repeated for the branch to the segment 8.
Finally the segments 5 and 6 were clearly marked. Under Pringle
maneuver, the liver parenchyma was divided between the segments 4
and 5. Branches of the middle hepatic vein were carefully divided. The
anterior glisson was exposed and small branches to the segment 5 were
ligated and divided. Finally the glisson of the segment 6 was divided
and resection of segment 5 and 6 was completed. The operation time,
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Pringle time and bleeding amount were 374 min, 97 min and 413 ml,
respectively. His postoperative course was uneventful. Another video of
resection of segment 5 and ventral part of segment 8 performed by the
same techniques will be also demonstrated.
Conclusion. By injecting Indigocarmine, the resection area is clearly
demonstrated, which can make it easy and safe to perform SSS.
V15
Use of novel device for parenchymal transection: anatomic
(R trisegmentectomy) and non-anatomic hepatic resection
Joseph Espat, Evan Ong, MD
W Scott Helton, MD, UIC, Chicago, IL
Various devices and energy modalities are presently available to asisst in the
parenchymal transection phase of hepatic resection. The primary goals of
these modalities is to accelerate the operation, reduce blood loss and prevent
bile leaks. Although there are a finite number of hepatic resections performed
annually in the United States, the liver has become a common clinical
platform for device and energy source validation.
In cosidering energy source directed parenchymal transection, cryoablation
has all but become obsolete, microwave energy looms on the future horizon
however at present radiofrequency-based devices are the common available
standard. In recent months there has been a resurgence in the promotion of
presently available RFA devices as aids to hepatic resection. Herein, we
present our initial experience with the recently FDA approved 4-pronged
RFA device. This video highlights the use of this technology in atypical
(non-anatomic) hepatic resection and in anatomic (righ trisegmentectomy)
resection for the same diagnosis; hepatic hemnangioma. Outlined and
presented within the context of the video are the pre-operative evaluation
considerations and radiographic pre-operative planning strategy. Specific to
the device employed, the potential limitations, use and demonstration of use
are presented.
V16
Laparoscopic treatment of cholecysto-duodenal fistula and choledo-
cholithiasis
Sebastiano Lacitignola Sr., MD, Martino Minardi, MD, Achille Nigri, MD,
Luigi Caliandro, MD, Anselmo Rosellini, MD, Roberto Palmieri, MD,
Giovanni Gabrieli, MD
Martina Franca Hospital, Martina Franca, Italy
In this video we present the case of 62 year old woman suffered for
gallbladder and CBD stones with cholecysto-duodenal fistula diagnosed
intraoperatively.
During hospital stay the patient was given on US and CT scan that confirmed
the diagnosis of cholecysto-coledochal stones.
She had laparoscopic cholecystectomy utilizing the American technique.
After pneumoperitoneum, we dissected carefully and we identified a
cholecysto-duodenal fistula sutured by ENDO GIA 45.
Than the cholecystectomy was performed. Through the cystic duct we
realized cholangiography that showed big stones in the CBD.
Through a longitudinal choledochotomy the stones was removed and T-tube
was inserted.
A cholangiography was made through the T-tube that showed a normal
biliary tree. No complications were present after surgery and patient
went to home after eight days. A new cholangiography was performed
after three weeks and T-tube was removed. The hepatic and biliary tests
were normal. After one year US, CT scan and blood tests continue to be
negative.
AV17
Liver resection under in situ cooling perfusion
Prof. Dr. Hauke Lang, Zentrum fur Chirurgie, Universitatsklinikum Essen
Abstract. Text Not Available .
V18
Laparoscopic left lateral segmentectomy using vapor pulse coagula-
tion system
Marwan Abouljoud, MD
Henry Ford Hospital, Detroit, MI
In this video the technique of laparoscopic left lateral segmentetcomy using
vapor pulse coagulation is demonstrated.
Patient is 28 yo female who presented with epigastric discomfort and early
satiety. Evaluation revealed a 6 cm liver mass in the left segment suspected of
large FNH. This was followed for some time but patient was subsequently
referred for surgical resection due to persistent pain. Laparoscopic resection
was planned and informed consent obtained.
The 5 port technique for peritoneal access and dissection is used in the
manner described by D. Franco et al. The left triangular ligament, round
ligament and falciform are divided. Ultrasound of the liver is performed to
outline the tumor and vascular structures. Parenchymal transection along the
falciform ligament is performed using bipolar vapor plasma coagulation. The
device (Plasma Kinetic System, Gyrus Medical, Maple Grove, MN)
generates up to 200 watts of RF output with a variable amplitude sinusoid
waveform between 320 kHz and 450 kHz. PK sytem cutting forceps are used
for liver dissection using gentle fracture technique, grasping, retraction,
coagulation and cutting with the retractable integrated blade. Left hilar
structures and hepatic veins are then stapled and divided with an endo-GIA
(Tyco, Mansfield, CT). Specimen removal was done with endo-catch (Tyco)
through a 6 cm Pfannensteil incision. Fibrin sealant was applied to the
resection liver surface (Tisseel, Baxter, Deerfield, IL).
Patient did remarkably well and left the hospital on POD 3. Estimated blood
loss was B/100 ml. There were no complications.
Posters of Distinction / Session I
POD 1
Treatment modalities, health resource utilization, and medical costs
in privately insured patients diagnosed with hepatocellular carci-
noma (HCC)
Carole J. Dembek, MS, Elise M. Pelletier, MS
Boston Scientific Corporation, Marlborough, MA
Purpose. To determine treatment modalities, health resource utilization
(HRU), and medical costs for privately insured patients with newly diagnosed
hepatocellular carcinoma (HCC).
Materials and methods. Patients diagnosed with HCC between January
and December 2002 were identified from a nationally representative
private payer claims database by ICD-9 diagnosis codes, using the date of
the first diagnosis as the "index date". Patients were required to be
continuously enrolled in a health plan for 12 months prior to and following
the index date. Patients less than 18 years of age or with a prior diagnosis of
hepatocellular carcinoma or metastatic tumors to the liver were excluded
from the analysis. Treatment rates, HRU, and medical costs were tracked for
12 months.
Results. The study included 297 HCC patients. The average age was 54.6
years; 52.2% were male. In the 12 months following the HCC diagnosis,
22.6% of patients received at least one treatment modality, with 3.0%
receiving a liver transplant and 8.1% undergoing liver resection. Other
treatments included radiofrequency ablation (2.0%) and transcatheter
arterial chemoembolization (TACE) (5.4%). Less than 1.0% of patients
received cryotherapy. Over 12 months, patients had an average of 1.5 hospital
admissions, 9.3 outpatient services, and 14.8 physician encounters. Total
medical costs during this same 12-month period were $37,203 (median
$10,430). Inpatient hospital facility costs accounted for 45% of these total
costs.
Conclusions. While liver transplantation and resection remain the gold
standards for treatment of HCC, less than 12% of privately insured patients
received one of these procedures and less than 23% received any treatment.
With the wider availability of new local/regional therapies, further analysis
may be warranted to determine if treatment rates have increased and how
this has impacted the costs of treating privately insured HCC patients over
time.
POD 2
Improved outcomes in postoperative and pancreatitis-related visceral
pseudoaneurysms
Nicholas J. Zyromski, MD, Carlos Viera, MD, Michael Stecker, MD, Attila
Nakeeb, MD, Henry A. Pitt, MD, Keith D. Lillemoe, MD, Thomas J.
Howard, MD
Indiana University, Indianapolis, IN
Visceral pseudoaneurysm (PSA) formation is a rare but highly lethal
complication of both pancreatic surgery (POSTOP) and pancreatitis
(PANC). Multiple small series have documented high mortality; none has
compared POSTOP and PANC. Angiography and/or urgent surgery are
treatment options, however optimal therapy remains unclear. We hypothe-
sized that the natural history of PSA is different in these two clinical settings.
Methods. Single institution review (1995/2005) of all patients with PSA
occurring POSTOP or after PANC.
Results. 35 patients had PSA. POSTOP patients (n/12) presented a
median of 23 days after surgery (range 2/90 days). Eleven of 12 presented
with blood in a surgical drain or gastrointestinal (GI) bleeding. Eight of 12
had documented pancreatic fistula. In contrast, presentation in PANC
patients (n/23) included typical acute pancreatitis (12), pain without
inflammation (9), and GI bleed (4). Seventeen PANC patients had existing
pseudocysts. Computed tomography identified PSA in 2 of 3 POSTOP and
11 of 18 PANC patients in whom it was the first diagnostic test. One
POSTOP patient required emergent surgery and died. No patient in the
PANC group needed surgery for hemorrhage. Angiography was performed in
11 POSTOP (with two initial false negatives) and in all 23 PANC patients.
One patient in the PANC group did not have embolization, and 2 required
early repeat angiography for a second PSA. Two patients needed percuta-
neous drainage of abscess directly related to embolization. Results of
angiography and overall mortality are shown in Table 1. PSA arose most
commonly from the gastroduodenal (POSTOP 5/11, PANC 8/23) and splenic
(POSTOP 4/11, PANC 8/23) arteries. Three patients had multiple PSA.
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Conclusions. 1) PSA have a different clinical presentation in the settings of
POSTOP (bleeding more common) and PANC (abdominal pain more
common). 2) In clinically stable patients, abdominal CT may demonstrate
PSA. 3) Angiography with embolization is the first line of therapy in most
patients, but may need to be repeated. 4) Postoperative pancreatic fistula
increases the risk of PSA. We conclude that a high index of suspicion and
low threshold to perform therapeutic angiography has led to improved
outcomes for patients with postoperative and pancreatitis-related visceral
pseudoaneurysms.
POD 3
Loss of E-cadherin MRNA and gain of osteopontin MRNA are useful
markers for detecting early recurrence of HCV-related hepatocellular
carcinoma
Yukihiro Iso, MD, Tokihiko Sawada, MD, PhD, Toshie Okada, MD, Mitsugi
Shimoda, MD, PhD, Keiichi Kubota, MD, PhD
Dokkyo University Hospital, Tochigi, Japan
We investigated whether expression of E-cadherin (Ecad)- and osteopontin
(OPN)-mRNA could predict early recurrence of HCV associated hepatocel-
lular carcinoma (HCV-HCC) after curative resection.
Forty-four HCV-HCC patients who underwent curative hepatectomy were
divided to 3 categories. Category 1: patients whose HCC recurred (3 mR/
: n/6) or did not recur (3 mR-: n/38) within 3 months, category 2:
patients whose HCC recurred (6 mR/: n/4) or did not recur (6 mR-:
n/34) between 3 and 6 months, and category 3: patients whose HCC
recurred (1 yR/::n/4) or did not recur (1 yR-: n/30) between 6 months
to 1 year. Level of expression of Ecad- and OPN-mRNA was quantitatively
analyzed by real-time PCR. Expression-level of Ecad and OPN was
calculated by following formula: t/(copy of Ecad or OPN/ copy of
GAPDH) A˚/1000. The correlations between t-values and recurrence of 3,
6, and 12 months after operation were investigated. Whether conventional
parameters such as serum AFP-level, tumor diameter, number of tumor,
and histrogic findings could predict early recurrence of HCV-HCC, was
also investigated.
Serum AFP-levels tended to be higher in 3 mR/, 6 mR/, 1 yR/ than in
3 mR-, 6 mR-, 1 yR-, however, the differences were not significant. Other
conventional parameters did not correlate with early recurrence of HCV-
HCC after operation. The t-value for Ecad was significantly lower in
3 mR/ than in 3 mR- (0.4 and 28.1, respectively, pB/0.05), in 6 mR/
than in 6 mR- (4.0 and 30.6, pB/0.05), and in 1 yR/ than in 1 yR-
(9.2 and 32.9, respectively, pB/0.05). Although the t-value for OPN was
relatively higher in 3 mR/ than in 3 mR- (92.6 and 65.7, respectively,
p/0.57), in 6 mR/ than in 6 mR- (457.1 and 58.15, respectively,
p/0.24), and in 1 yR/ than in 1 yR- (221.8 and 53.5, respectively,
p/0.06), the difference was not statistically significant in all categories. In
two of the 3 patients whose t-values for Ecad were more than 10.0 and
recurred within 12 months after operation, t-value for OPN was more than
100.0. Also, in two of 3 patients whose t-values for Ecad were less than
1.0 and did not recur within 12 months after operation, t-value of OPN
was less than 100.0.
By combining expression data of the two molecules, more accurate diag-
nosis and the assessment of malignant potential for HCV-HCC should be
possible.
POD 4
Surgical management of terminal biliary stenosis in chronic pan-
creatitis: Resection versus bypass
Thomas Schnelldorfer, MD, David B. Adams, MD
Medical University of South Carolina, Charleston, SC
Introduction. Patients with biliary obstruction associated with chronic
pancreatitis can be managed with pancreatic head resection or pancreatico-
biliary bypass procedures. The outcome of both operations is evaluated in
this study.
Methods. The records of 313 consecutive patients who underwent
operative treatment for chronic pancreatitis from 1995 through 2002 were
retrospectively reviewed and analyzed. 54 patients required surgical
management of pain associated with chronic pancreatitis along with biliary
and pancreatic ductal obstruction. This included 18 patients undergoing
pancreaticoduodenectomy and 36 patients undergoing lateral pancreatico-
jejunostomy with choledochoduodenostomy (n/30) or choledochojejunost-
omy (n/6).
Results. Pancreatic head resection was associated with a higher rate of
perioperative morbidity (resection 50% vs bypass 25%, pB/0.05) and
hospital length of stay (resection 169/3.6 vs bypass 89/1.3 days, pB/0.02)
when compared to bypass. ICU stay was similar in both groups (resection
17% vs bypass 11%, p/0.05). Six patients were lost to follow-up after the
first clinic visit and 7 patients died in the follow-up period. The mean
follow-up of the remaining 41 patients was 379/4.7 months. Serum alkaline
phosphatase levels significantly decreased after bypass procedure (preopera-
tive 4259/58 units/L vs follow-up 1249/8 units/L, pB/0.004). After
resection the decrease was less extensive (preoperative 3199/68 units/L vs
follow-up 2109/58 units/L, p/0.05). One patient with autoimmune
sclerosing pancreatitis developed biliary obstruction 2 weeks after resection
ending in fatal cholangitis after initial recovery with percutaneous drainage.
Biliary stenosis of the anastomosis was present in one patient 24 months
after resection requiring re-operation. Good pain control was achieved in
58% after head resection and 69% after drainage. One patient in the bypass
group developed pancreatic cancer on follow-up without evidence of a
preoperative mass.
Conclusion. Pancreatico-biliary bypass for biliary obstruction from chronic
pancreatitis has similar long-term outcomes to pancreatic head resection.
Bypass is associated with a lower perioperative morbidity and shorter hospital
length of stay than resection, but incorporates the risk of missing cryptic
pancreatic cancer. Pancreatico-biliary bypass should be considered for
patients with severe pancreatic inflammation with its attendant prohibitive
operative risk. Asymptomatic patients or patients with suspicion for neoplasm
by serologic, cytological, or endoscopic ultrasound exam should undergo
resection.
POD 5
Our experience of liver transplantation and non-surgical manage-
ment of patients with budd-chiari syndrome
Taha H. Khan, MBBS, Amer Aldouri, Magdy Attia
Peter Lodge, c/o Prof Lodge, Department of Liver Transplantation,, Leeds,
United Kingdom; Prof Lodge, Department of Liver Transplantation,, Leeds,
United Kingdom
Background. Budd-Chiari Syndrome (BCS) occurs as a result of obstruc-
tion of venous outflow at any level from the small hepatic veins to the junction
of the inferior vena cava with the right atrium and occurs in 1/100,000 of the
general population worldwide.
Methods. We reviewed our experience of 26 adult patients who presented to
our liver unit from January 1999 to August 2005 and were diagnosed with
BCS and then underwent medical, surgical or in some cases both interven-
tions. We assessed their short-term and long-term outcomes, including
specific complications with regards to their interventions.
Results. Ascites was the commonest clinical feature on presentation (19
patients). At presentation predisposing factors included, Benign Myelodys-
plasia, Myeloproliferative disease, Pregnancy, Caval Web, Phospholipid
antibodies, homozygous MTFHR, Low Prot C & ATIII, OCP and idiopathic
factors.
Twenty two of a total 26 patients were initially managed medically (e.g.
venoplasty, stent, TIPSS and/or warfarin) and the remaining four required
immediate liver transplants. Of the 22 patients treated medically 5 ultimately
required liver transplantation (LT). Therefore in 17 patients in our unit their
BCS has been managed by medical methods only and the median survival in
these 17 is 35 months (range 2/73) with 10 patients developing post
procedural complications and requiring further non-operative interventions
and deaths reported in 2 cases.
Of those 9 patients requiring LT the median survival is 35 months (range 1/
71) with 2 patients developing post operative complications (one patient
developed a wound infection and the second required a laparotomy for
bleeding). BCS eventually reoccurred in 2 cases post-LT and this has
been managed satisfactorily with non operative management. No graft
failures and two deaths have been reported, one due peritonitis (2 and half
years after transplant) and the second two days after transplant due multi-
organ failure.
Conclusion. Liver transplantation for BCS provides good long-term survival
with acceptable morbidity. Patients with BCS should be managed in a centre
with access to all modalities of therapy including medical, interventional
radiological techniques and surgical intervention because improvement or
progression of the liver disease is unpredictable and worsening liver failure
can occur.
POD 6
Laparoscopic hepatic debulking in the treatment of polycystic liver
disease
Alan J. Koffron, Laura Kulik, MD, Michael Abecassis, MD
Northwestern University Medical School, Chciago, IL
LAPAROSCOPIC HEPATIC DEBULKING in the TREATMENT OF
POLYCYSTIC LIVER DISEASE
Polycystic liver disease (PCLD) remains a significant clinical dilemma.
While hepatic synthetic function is maintained, liver enlargement may
Table 1.
Group
PSA initially
identified
Embolization
successful
Overall
mortality
Postop 9/11 (82%) 11/11 (100%) 4/12 (33%)
Panc 23/23 (100%) 22/23 (96%) 1/23 (4%)
All patients 32/35 (91%) 34/35 (97%) 5/35 (14%)
Presentations 51
produce profound discomfort and surrounding organ dysfunction in many
patients. Percutaneous aspiration and operative fenestration is associated
with uniform recurrence, and open resection, while effective at reduction in
liver size, is oftentimes morbid and non-curative. In this study we present
our experience in laparoscopic hepatic debulking (LHD) in the treatment of
PCLD, reviewing hepatic involvement, resection magnitude, technique, and
outcome.
We performed 26 LHD at our institution from 1/02/9/05. Symptomatic
patients were imaged using CT or MRI preoperatively to assess intrahepatic
cyst involvement, vascular/biliary anatomy, exclude solid neoplasms, and
map spared hepatic parenchyma. Symptoms included pain, early satiety,
respiratory/GI compromise, hemorrhage, biliary obstruction, abdominal
distension. Resections, performed by the same operative team, ranged from
multiple, bilobar segmentectomies to subtotal liver resection; techniques
included harmonic scalpel, ligasure, sequential endostapling and saline-
enhanced caurtery. Vascular and biliary control was achieved using endosta-
pling and intracorporal surturing. The experience was then analyzed for
operative time, blood loss, complications, resolution of symptoms, and
evolution of technique.
Results. Radiographic estimate of liver size reduction ranged from 20
to 84% (mean 62). Mean operative time 260 minutes, mean blood loss
450 ml, and all patients experienced complete resolution of symptoms. 4/26
(15%) patients experienced post-operative bile leak with 2/4 requiring
subsequent endoscopic biliary decompression, and 2/26 patients experienced
transient ascites, and 1/26 developed a port site infection and adynamic
ileus. No patient required reoperation, repeat debulking (4/38 months
follow-up, mean 18 mo.), or hepatic decompensation. Mean length of stay
was 2.5 days.
In summary, our experience finds LHD provides a safe, effective treatment
for symptomatic PCLD. Patients achieved relief of symptoms, which, thus far
appears more durable than traditional therapies. Despite massive resection of
liver mass, careful resection of segments replaced by cysts avoids hepatic
decompensation, affords enhanced surgical recovery and minimal morbidity.
While the bile leak rate is high, no patient required reoperation or prolonged
treatment. This study suggests that LHD is a viable option in the treatment of
symptomatic PCLD.
POD 7
Adhesion molecules under volume therapy in a pig model of acute
severe pancreatitis
Helge Kleinhans, MD, Oliver Mann, MD, Jussuf Kaifi, MD, Felix
Reinknecht, MS, Bente Hansen, MS, Paulus G Schurr, MD, Marc Freitag,
MD, Jakob R Izbicki, MD, PhD, Tim G Strate, MD
University Medical Center, Hamburg, Germany
Adhesion molecules play an important role in many inflamatory processes.
Expression of PCAM-1 (CD 31), VCAM-1 (CD 106), P and E-
SELECTIN on vascular endothelial is essential for regulating leucocyte
trafficking from blood vessels into tissue during inflammatory deseases.
Sequestration of inflammatory cells within the pancreas is generally belived
to be an important event in the evolution of acute severe pancreatitis. The
aim of this study was to evaluate the therapeutic approach of volume
therapy with HBOC-301 with and without isovolemic hemodilution (IHD)
with regard to the survival rate and expression of adhesion molecules in
pancreatic tissue in pigs suffering from acute necrotizing pancreatitis.
Methods. 39 pigs were anesthetized and intubated. After laparotomy the
pancreatic duct was canulated. AP was induced by a combination of
intravenous cerulein and intraductal glycodeoxycholic acid. 75 min. after
induction of AP animals were randomized to IHD with 10% HES plus
HBOC-301 (/0.6 g dl-1 plasmatic Hb; Oxyglobin†, Biopure, USA)
(IHD/HBOC) or to HBOC-301 (/ 0.6 g dl-1 plasmatic Hb) (HBOC),
or to IHD with Ringer‘s solution (IHD RINGER) to a hematocrit (Hct) of
15%. After six hours abdomen was closed and animals were extubated.
After six days surviving animals were sacrified. For immunostaining of
vascular adhesion molecules pancreatic tissue was frozen in liquid nitrogen.
Slides were stained with monoclonal pig antibodies (Ab) against PECAM-
1, VCAM-1 E- and P- SELECTIN. Fluorescein isothiocyanate (FITC)-
conjugated IgG was used as a secondary Ab. Evaluation of expression
FITC-stained adhesion molecules was based on the method described by
Tang and Hendricks for detection of PECAM. After immunostaining
images of pancreatic vessels were captured using a digital camera and
image software. To evaluate the relative fluorescence intensity the mean
brightness value of the green channel was determined using Photoshop 5.0
(Adobe Systems, CA, USA. Statistical analyses were performed using the
Kruskal-Wallis and Hohn?s test (significance pB/0.05).Results. The survival
rate at the end of the observation period was higher in the IHD/HBOC
group(pB/0.001) and in the HBOC-group(pB/0.001) compared to the
Ringer group (p/0,001). The expression of adhesion molecules did not
differ among the groups. Conclusion. The therapeutic application of
HBOC-301 was able to improve survival after induction of severe AP.
The endothelial cell surface expression of PCAM-1, VCAM-1, P and E-
SELECTIN in the pancreatic tissue is detectable but did not show
significant differences in this model.
POD 8
A prospective evaluation of CT features predictive of high intra-
abdominal pressure and abdominal compartment syndrome in
critically ill patients
Ahmed Al-bahrani Jr., MBBS, Ghalib Abid Jr., MBBS, Sarah O’shea Sr.,
Stephen Lee Sr., Basil Ammori Sr., MD, MBBS
Manchester Royal Infirmary, Manchester, United Kingdom
Background and aims. Abdominal compartment syndrome (ACS) is
defined as raised intra-abdominal pressure (IAP) associated with organ
dysfunction. Different cut-off levels of IAP have been applied ranging
between 12/18 mmHg. Various ccomputed tomography (CT) features of
ACS have been proposed. The aim of this study is to validate the CT features
of ACS by relating them to actual clinical measurement of IAP in critically ill
patients.
Methods. Critically ill patients with intra-abdominal sepsis or severe acute
pancreatitis had their IAP measured indirectly using intra-vesical pressure.
Their CT scans that were obtained within 24 hours of IAP measurement
were reviewed independently by two Radiologists who were blinded for the
IAP reading. A 7-point scale score and the total CT score was calculated.
These features were correlated with the IAP and independent predictors of a
high IAP were detected.
Results. This prospective study included 48 abdominal CT scans for 24
patients (8 patients with intra-abdominal sepsis, 16 patients with severe
acute pancreatitis) all of who had organ failure. Significant correlations
were observed between the two radiologists with regard to scoring 5/7 CT
features and the total score. The round belly sign (RBS), bowel wall
thickening (BWT), compression of solid abdominal organs and the total
score correlated significantly with the IAP (pB/0.0001, pB/0.0001, p/
0.010 and pB/0.0001 respectively). Multivariate regression analysis identi-
fied RBS and BWT as independent predictors of a high IAP (12 mmHg
or more) with sensitivity and specificity of 70% and 86% for the former
sign and 78% and 72% for the latter sign. The sensitivity and specificity
of the total CT score in predicting a high IAP was 70% and 86%,
respectively.
Conclusions. Of seven recognised CT features of high IAP, the round belly
sign and bowel wall thickening independently predicted an IAP of 12 mmHg
or greater.
POD 9
Resistance of pancreatic cancer to chemotherapy in vitro is related to
tumor-stromal interaction
Qiang Dai, PhD, Matthew A. Firpo, PhD, Jill D. Coursen, MS, Courtney L.
Scaife, MD, Sean J. Mulvihill, MD
University of Utah, Salt Lake City, UT
Pancreatic cancer is characterized by a highly malignant phenotype
associated with rapid progression and metastasis. Its treatment is limited
by innate or acquired resistance of pancreatic cancer cells toward
chemotherapeutic drugs. Fibrosis is a common histological finding in
ductal pancreatic adenocarcinoma and stromal fibroblasts create a context
that may promote tumor progression. The effects of tumor-stroma
interaction on chemoresistance have been studied in a transwell co-culture
model, but the effects of direct mesenchymal-epithelial cell contact are
poorly understood. In the present study, we built a cancer cell/fibroblast
co-culture system with MiaPaCa2, a human pancreatic cancer cell line,
stably transfected with red fluorescent protein (RFP) in direct contact with
human T31 fibroblasts. In this co-culture system, the proliferation and
survival rates of pancreatic cancer cells can be monitored based on RFP
fluorescence intensity. We tested the effects of gemcitabine and etoposide
in the co-culture system (Table). Proliferation rates were determined by
subtracting initial RFP intensity from RFP intensity (in the same well) 48
hours after initiation of drug treatment. Relative proliferation was then
determined by dividing proliferation rates by the mean proliferation rate of
untreated control cells. Statistical analysis was performed on proliferation
rate data using ANOVA and Fisher’s PLSD. The sensitivity to cytotoxic
drugs was significantly reduced when fibroblasts were present in the co-
culture system. Our results suggest the possibility that pancreatic cancer
Relative Proliferation of Pancreatic Cancer Cells
Control
Gemcitabine
(3 mM)
Etoposide
(1 mM)
RFP-MiaPaCa2 cells only 1.009/0.06 0.659/0.02* 0.759/0.02*
RFP-MiaPaCa2:T31
fibroblasts (10:1)
1.009/0.02 0.869/0.02* 0.939/0.02
RFP-MiaPaCa2:T31
fibroblasts (5:1)
1.009/0.03 0.969/0.03 0.919/0.07
*PB/0.0001 vs. corresponding control, n/8/group.
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induced fibrosis may be responsible for chemoresistance in vivo . This novel
co-culture model may be a valuable system for study of tumor-stromal
interaction.
POD 10
Incidence of artery related complications in donor’s liver with
arterial back table reconstruction
Rafael J. Maurette, MD, Gabriel E. Gondolesi, MD, Gonzalo Rodriguez-laiz,
MD, Susan Lerner, MD, Sukru Emre, MD
Mount Sinai Hospital, New York, NY
The back table reconstruction (BTR) of the liver allografts due to anatomical
variations may have increase the risk of hepatic artery thrombosis (HAT) and
graft loss. The aim of this study was to evaluate the risk of HAT and outcome
in patients received allografts with BTR.
Method. From 04/1989 to 12/2003, 2230 liver transplants (LT) were
performed. Adult patients received whole donor livers with BTR were
included. The donor/recipient demographics, operative data, and type of
the back table reconstruction were collected. The incidence of HAT, hepatic
artery stenoses, bile leak and biliary stenoses were recorded. The graft and
patient survivals were calculated.
Results. 1738 of 2230 LTs fulfilled the inclusion criteria. Only 177 met the
criteria of BTR that was the focus in this study. The reconstruction type and
complications are shown in table 1. There were 43 complications in 30
patients (17%); 14 arterial complication (7.9%) and 29 biliary complication
(16.4%). The incidence of HAT in this series was 5%. The incidence of HAT
of this series does not differ from the general incidence of HAT in OLT
reported in the literature. There were not statistically difference between the
type of reconstruction and the incidence of HATor Biliary complication (p/
0.93 and p/0.96). The overall survival was at 1, 2 and 5 years was 80%,
75.5% and 67% respectively. The graft survival at 1, 2 and 5 year was 75.2%,
70% and 63.4%.
Conclusion. Using liver allograft that required complex arterial back table
reconstruction did not increase the incidence of HAT or arterial related
complication. Both graft and patient survival in allograft with complex back
table reconstruction were similar to the general series of OLT. The type of
arterial reconstruction is not a risk factor for HAT.
Reconstruction Type N %
SMA to Celiac trunk 81 45.7
SMA to Splenic 12 6.7
RHA to GD 42 23.7
RHA to Splenic 15 8.4
Graft 6 3.3
Left artery reconst. 10 5.6
Other 11 6.2
Complications (n/30 patients) N %
Bile duct stricture 11 6.2
Bile leak 18 10.1
HAT 9 5
HA disruption 3 1.6
HA aneurysm 2 1.1
POD 11
National survey of the specialist management of pancreatic cancer in
the United Kingdom
Kolitha S. Goonetilleke, MBBS, Ajith K. Siriwardena, MD FRCS
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom
Introduction. Recent trends in pancreatic cancer have seen the care of these
patients become progressively centralised to specialist units. Although
surgical volume-outcome data favour these changes in service delivery, it is
not clear whether there has been a parallel standardisation in practical aspects
of cancer care. This study surveys specialist pancreatic cancer surgical
practice in the United Kingdom with particular reference to assessment
pathways, peri-operative care including procedural steps and outcome.
Methods. A postal questionnaire survey was undertaken in 2005 of the
membership of the Association of upper Gastrointestinal Surgeons of Great
Britain and Ireland (AUGIS) with the consent of the Society’s Council. From
517 members questioned for the calendar year 2004, there were 160 replies
giving a crude response rate of 31%. However, only 57 respondents
performed pancreaticoduodenectomy (PD). Cross-checking with the main
sister society-the Pancreatic Society-confirmed that there were a similar
number of pancreatic surgeon members.
Results. Summating the respondents answers there were 734 PD carried out
in the UK in 2004. In-hospital mortality was 24 (3.3%). When cross-checked
with Office of Population Censuses and Surveys (OPCS4) codes held at
government (UK Department of Health), there were 822 PD suggesting
capture of 89% of resections. In pre-operative staging: in addition to CT and
ERCP, CA 19/9 was used by 63%, endoscopic ultrasound by 47% and
routine laparoscopy by 47%. Routine pre-operative biliary drainage was used
by 51%. At operation: 63% carry out station 8 lymphadenectomy and 50%
intra-operative pancreatic resection margin frozen section. Reconstruction is
by pancreaticojejunostomy for 91% with 38% undertaking feeding jejunost-
omy. From a range of offered definitions, 82% use definition of Amylase rich
discharge (/3/serum amylase) beyond 7th post-operative day as describing
pancreatic fistula.
Conclusions. This survey has captured self-reported data on the majority of
pancreaticoduodenectomies undertaken in the UK in 2004. Overall, reported
mortality is low. There is consensus over pre-operative staging but not in the
use of EUS, laparoscopy or pre-operative biliary drainage. The consensus
over description of pancreatic fistula was unexpected but moves towards
standardised nomenclature for pancreatic surgical complications. Overall, the
findings provide a unique insight into the current management of pancreatic
cancer across a single European country.
POD 12
Short tandem repeat polymorphism in the ‘‘ECRG2’’-gene as sus-
ceptibility factor for pancreatic carcinoma but not for chronic
pancreatitis in western population
Robin Wachowiak, MD, Jussuf Kaifi, MD, Vaceslaf Kalinin, PhD, Paulus
Schurr, MD, Georgina Costes, MS, Petra Merkert, MT(ASCP), Tim Strate,
MD, Emere Yekebas, MD, Jakob Robert Izbicki, MD
University hospital Hamburg Eppendorf Department of general surgery,
Hamburg, Germany; university hospital hamburg eppendorf department of
general surgery, Hamburg, Germany; university hospital hamburg eppendorf
department of gerneral surgery, Hamburg, Germany
Purpose. Recently a new a novel esophageal related gene 2 (ECRG2) was
identified and especially in the noncoding region of exon 4 in this gene a short
tandem repeat polymorphism (STR) was found. For this polymorphism 3
genotypes (TCA3/TCA3, TCA4/TCA3, TCA4/TCA4) are existing. Since it
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was described that this Gene is nearly homologous to a tumor associated
Kazal-type serine protease inhibitor that may play also an important role in
the genesis of chronic pancreatitis and consecutively pancreatic carcinoma.
The aim of this study was to evaluate if the ECRG2 polymorphism is a
genetic susceptibility factor for chronic pancreatitis and pancreatic adeno-
carcinoma in Caucasian population
Material and methods. Genomic DNA mostly extracted from lym-
phocyte DNA of 136 patients chronic pancreatitis and 157 patients with
pancreatic adenocarcinoma were analysed to examine the impact of this
ECRG2 STR polymorphism on risk of these two diseases in case control
studies. Blood-DNA of 150 healthy Caucasian subjects served as a control.
Polymorphism analysis was performed by PCR based capillary electrophor-
esis. Statistical evaluation was performed by odds ratios and their 95%
confidence intervals.
Results. In the patients with chronic pancreatitis (CP) compared to the
control group there was no increased risk of CP compared to those carrying a
special type of genotype. In the case of pancreatic carcinoma the result
indicated that subjects carrying the TCA4/TCA4 polymorphism were at an
increased risk to those with the 2 other genotypes, with the adjusted odds
ratio being 3.00.(95% confidence interval 0,7/9,9).
Conclusion. The ECRG2 STR polymorphism seems to have no role as a
genetic susceptibility factor for chronic pancreatitis. An association between
STR genetic polymorphism and pancreatic carcinoma in the case of people
carrying the TCA3/TCA4 polymorphism could be found. Therefore the
TCA3/TCA4 allele could play a role as an additive risk factor in the
development of pancreatic cancer.
POD 13
The effect of anti TGF-(1 monoclonal antibody on liver regeneration
in biliary obstructed rats
Mehmet Ali Deneme, MD, Engin Ok, MD, Tarik Artis, MD, Can Kucuk,
MD, Alper Akcan, MD, Zeki Yilmaz, MD
Erciyes University Medical School, Kayseri, Turkey
Background. Transforming growth factor b(TGF-b)is a potent inhibitor of
hepatocyte DNA synthesis and liver regeneration. TGF-b1 expression
progressively increases in obstructive jaundice. We investigated the effect of
TGF-b1 inhibition on liver regeneration in obstructive jaundiced rats.
Methods. Male wistar-albino rats were divided into 3 groups as sham,
control and study. Common bile duct was ligated and divided and 7 days
later, 70% partial hepatectomy (PHx) was performed to study and control
groups. Anti TGF-b1 monoclonal antibody (10 mg) was administred to the
study group. Rats were allowed to survive for 48 and 72 hours. Hepatic
regeneration rate (HRR), AST, ALT, total and conjugated bilirubin and
TGF-b1 levels were measured. Mitotic index (MI) and proliferating cell
nuclear antigen (PCNA) labeling index(LI) were evaluated as histopathologic
parameters.
Results. The total and conjugated serum bilirubin in control and study
groups were 11.99/1.2/10.19/1.1 before PHx, and they gradually increased
up to 17.2/15 mg/dL at 48th hr and 19.4/17.5 mg/dL for 72nd hr. The levels
in control group were comparable with the study group (p/0.05).
TGF-b1 expression was significantly lower in sham group compared with
biliary obstructed rats before resection (160.29/5.9 and 181.49/9.5 respec-
tively) (p/ 0.036). It was 253.99/ 20.6 in control group at 48th hr and
255.99/ 19.3 at 72nd hr, in study group levels decreased to 138.79/ 7.1 and
151.39/ 8.4 at 48th and 72nd hr respectively (p/ 0.00). AST and ALT
levels increased with PHx. These levels were 1508 IU/mL and 1288 IU/mL
respectively in control group at 48th hr and 1177 IU/mL and 935 IU/mL at
72nd hr. In study group they were 1216 IU/mL and 846 IU/mL at 48th hr
(p/0,00) and 695 IU/mL and 471 IU/mL at 72nd hr respectively (p/
0,00). HRR were higher in the study group at all time periods (pB/0.01).
MI was increased with by application of the antibody vs. control group at
48th and 72nd hr (p/0.00). PCNA LI was also significantly higher in study
group than in control group at both 48th and 72nd hr (p/0.00). In control
group PCNA LI and MI reached to a peak level at 48th hr (6.49/0.6 and
4.89/0.7 respectively) and decreased at 72nd hr (3.99/0.6 and 3.29/0.9
respectively). In study group PCNA LI and MI followed a similar course
and had a peak level at 48th hr (19.69/1.1 and 10.79/1.6 respectively) and
decreased at 72nd hr (11.69/0.8 and 8.79/1.4 respectively). MI and PCNA
levels were significantly different at 48th and 72nd hr between both group
(pB/0.05).
Conclusion. TGF-b1 blockage with Anti TGF-b1 monoclonal antibody after
liver resection in obstructive jaundiced rats, improved liver regeneration both
morphologically and functionally.
POD 14
Application of the endo GIA stapler in the parenchymal phase of liver
resection
Arianeb Mehrabi, Arash Kashfi, MD, Navid Roshanaei, MD, Peter Schem-
mer, Jan Schmidt, MD, PhD, Helmut Friess, Markus W. Bu¨chler, MD, PhD
Department of Surgery, University of Heidelberg, Heidelberg, Germany
Liver resection (LRx) has evolved over the years from finger fracture
technique to the more advanced techniques such as cavitron ultrasonic
surgical aspirator (CUSA) and hydro-jet, to improve the safety and speed of
LRx. The aim of this study was to compare clinical results of the LRx by means
of Endo GIA stapler in the parenchymal phase with the results of the CUSA.
In the last 3 years 247 patients underwent LRx by means of Endo GIA stapler
(right hemihepatectomy: 27,9%, left hemihepatectomy: 11,3%, extended
right hemihepatectomy: 14,6%, extended left hemihepatectomy: 5,3%,
segmental resection: 40,9%). At first, the liver capsule was opened by
electrocautery. The parenchyma was gradually squeezed by a vascular clamp
and was stapled and split with Endo GIA stapler.
The indication of LRx in 396 patients (stapler and CUSA) was liver
metastasis 244 (67%), HCC 43 (12%), CCC 38 (10%), FNH 16 (4%),
hemangioma 12 (3%), and others 16 (4%). Perioperative data were
prospectively evaluated regarding the operation duration (hh:mm), blood
loss (ml), intraoperative substitution of packed RBCc and/or FFPs (packs),
duration of ICU stay (days) and the number of the complications (surgical
and internal) as well as deaths (within the hospital stay). The data were
compared with 149 consecutive LRx performed by CUSA (Table 1; */pB/
0.05). The data are represented as average value.
By the application of the Endo GIA stapler for the parenchymal phase of
LRx, duration of operation and the ICU stay could be significantly reduced in
comparison to CUSA. Additionally, the blood loss as well as the quantity of
the transfused packed RBCs and FFPs could be significantly reduced.
Moreover, the use of stapler led to a reduction of the surgical and internal
complications. Also, postoperative outcome could be affected positively by
the application of the stapler. The use of stapler in parenchymal phase of LRx
represents a fast and careful simplification of the operation.
POD 15
Clinical study of gallblader carcinoma identified after simple chole-
cystectomy as an initial operation
Hyung-il Seo, MD, Seong Hoon Kim, MD, Woo Jin Lee, MD, Hong Suk
Park, MD, Yung Il Kim, MD, Soon-ae Lee, MD, Eun Kyung Hong, MD,
Joong-won Park, MD, Chang-min Kim, MD, Sang-jae Park, MD
National Cancer Center, Koyang, Republic of Korea
Purpose. Gallblader carcinoma (GBC) is a rare neoplasm with poor
prognosis. With the introduction and the wide acceptance of laparoscopic
surgery, the diagnostic rate of incidental GBC increased. We report our
experience with reoperated GBC diagnosed after simple cholecystectomy.
Methods. From March 2001 to July 2005, 17 patients with a postoperative
diagnosis of GBC after prior simple cholecystectomy referred to our center
for curative reoperation. The types of simple cholecystectomy were open
cholecystectomy in 5 cases, and laparoscopic cholecystectomy in 12 cases.
Types of reoperation were hepatic wedge resection with lymph node
dissection (HWR /c LND, n/9), HWR with LND and bile duct resection
(HWR /C LND and BDR, n/4), right hemihepatectomy (RH) with LND
and BDR (n/1), extended RH with LND, BDR and caudate lobectomy
(n/1) and extended left hemihepatectomy with LND and BDR (n/1).
Residual tumor is defined to be the remnant tumor tissue detected on
reoperation; in bile duct, liver, lymph node, lymphatics, vessels and nerves.
Results. No patients died postoperatively, and the median hospital stay was
18.5 days (range, 8/44 days). Median interval between 1st and 2nd
operation was 23.5 days (range, 6/44 days). Five complications occurred
in 4 patients. 1 patient received intraoperative transfusion. The depth of
tumor invasion in 17 patients was as following; 15 cases in T2, 1 in T3, and 1
in T4. There was no residual tumor in eight out of 17 patients after
reoperation. In the other 9 patients, residual tumor was identified; 2 cases in
liver, 7 in lymph node, 3 in bile duct, 6 in lymphatics, 3 in vessels and 3 in
nerves. Three patients recurred and two of them died. After the curative
reoperation, median follow-up was 14.7 months (1/53 months) and 1-year/
2-year survival was 90.9%/79.6%. By the univariate analysis, lymphatic,
vascular and neural invasion were the significant factors for recurrence.
Conclusion. Reoperation of GBC diagnosed after simple cholecystectomy is
safe and may be effective for reducing local recurrence. Lymphatic, vascular
and neural invasion may have a dismal effect on survival in GBC patients
identified after simple cholecystectomy.
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The role of laparoendoscopic ‘rendez vous’ to treat associated
cholelithiasis and choledocholithiasis: Multicentric experience with
a personal technique
Andrea Percivale, MD, Saccomani Giovanni, MD, Riccardo Pellicci, MD
OSPEDALE SANTA CORONA, Pietra Ligure-Savona-It, Italy
Introduction. Laparoscopic cholecystectomy (LC) represent the treatment
of choice in the management of cholelithiasis: questioning remaining about
the management of associated choledocholithiasis. Role of sphinterotomy
before LC in patients with suspected common bile duct stones (CBD),
LRx
technique
Operation
duration
Blood
loss RBC FFP
ICU
stay
Morbidity
(surgical
and
internal) Mortality
Stapler
(n/247)
03:33* 816* 0.9* 0.8* 2.2* 19% and
15%*
2.4%*
CUSA
(n/149)
04:13 1463 1.7 1.3 2.8 23% and
21%
3.4%
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laparoscopic bile duct exploration, open CBD exploration and postoperative
ERCP are still under evaluation. More recently the ‘rendez vous’ procedure is
emerging. We report our experience of routine intra-operative cholangio-
graphy (IOC) followed either by per-operative ERC in one step, or by
transcystic drain and post-operative ERC; to facilitate Vater papilla cannula-
tion we inserted a transcystic guidewire to be catched by a duodenoscope.
Papillotome was then inserted over the guide wire to ensure easy and safety
cannulation of CBD.
Report. 51 patients were treated successfully in one step and 31 in two steps:
the mean operative time was 1689/39 min and 1369/41 respectively. The
mean hospital stay was 6.49/3.4 days and 8.79/4.0 days respectively. Seven
patients with positive IOC for stones for whom per-operative ERC was not
available, showed a normal post-operative transcystic cholangiogram and
therefore ERCP was cancelled. Twenty out of 51 patients treated in one step
and five out of 31 treated in two steps had raised serum amylase which
resolved spontaneously. One patient affected by gall bladder abscess and
microlithiasis was converted to laparotomy and developed postoperative
pancreatitis. Four ERCP complications were observed, consisting of mild
bleeding of the papilla treated by endoscopic adrenaline injection.
Conclusion. We believe per-operative ERC with this novel technique
described should be considered as treatment of choice for choledocholithiasis
associated to cholelithiasis. When single staged treatment is not possible a
two step rendez-vous technique should be preferred, although this is
associated with a longer hospital stay and a possible risk of unsuccessfull
endoscopic bile duct clearing.
P2
The role of the surgical treatments after transcatheter arterial
chemoembolization for hepatocelluar carcinoma with portal vein
invasion
Ryota Saito, MD, Yuji Ishii, MD, PhD, Kyonsu Son, MD, Hiroaki Shiba,
MD, PhD, Takuya Nojiri, MD, PhD, Tadashi Uwagawa, MD, PhD, Kumiko
Kitajima, MD, PhD, Takeyuki Misawa, MD, PhD, Yuichi Ishida, MD, PhD,
Katuhiko Yanaga, MD, PhD
Jikei University School of Medicine, Tokyo, Japan
Aim. Hepatocellular carcinoma (HCC) with portal vein invasion (Vp) is
associated with poor prognosis. The aim of this study was to evaluate the
effects of preoperative transcatheter arterial chemoembolization (TACE)
followed by surgical treatments for patients with HCC and Vp.
Methods. 44 patients with HCC complicated by Vp2 (n/16), 3(n/22) or 4
(n/6) between November 1994 and November 2004 was studied. Vp 2, 3,
and 4 is a clinical stage classification of Liver Cancer Study Group of Japan,
and targeted two or more-Vp cases in this study (Vp2: Tumor thrombus in
the second branch of the portal vein, Vp3: Tumor thrombus in the first
branch of the portal vein, Vp4: Tumor thrombus in the portal trunk or
extending to a branch on the opposite side). The mean age of the patient was
60.19/11.4 years. Hepatic resection was performed in 24 of 44 patients with
Vp (Vp2: 13/16, Vp3: 9/22, Vp4 2/6), of whom 10 underwent hepatic
resection alone (Hx group). The other 14 of 24 patients underwent TACE
before hepatic resection (TACE/Hx group). Of the remaining 20 of the 44
patients did not fulfill the criteria for hepatectomy, 15 underwent TACE
alone and 5 received regional chemotherapy.
Results. The 5-year survival rates for the 44 patients was 32.9% overall,
45.6% for Vp2, 28.1% for Vp3, and 4.0% for Vp4. Five-year survival rate of
Hx group was 40% for Vp2, and 28.4% for Vp3, while that of TACE/Hx
group was 61.4% for Vp2, and 57.1% for Vp3.
Conclusion. For patients with HCC complicated by Vp2 or vp3, TACE
followed by hepatic resection may be recommended to improve the outcome.
The surgical resection with preoperative TACE for Vp2 and Vp3 may be able
to expect the improvement of the prognosis.
P3
Quantitative analysis of plasma dna in human severe acute pan-
creatitis
Anil Bagul, William Newman, MD, Ajith K Siriwardena
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom; Department of Paediatrics, Manchester Royal Infirmary,
Manchester, United Kingdom
Introduction. Release of genomic DNA into plasma as a result of necrotic
and apoptotic pathways is a feature of a range of human tumours. Severe
acute pancreatitis (AP) is characterized by inflammation but may also be
associated with accelerated apoptotic and necrotic pathways. This study uses
quantitative real-time PCR to measure free circulating DNA in patients with
severe AP.
Methods. Plasma DNA was measured in three groups: healthy non-disease
controls, patients with histologically confirmed peri-ampullary cancer and
patients with severe AP (APACHE II score ]/8 within 48 hours of admission
to hospital). DNA was purified using the QIAamp DNA micro kit (Qiagen,
Valencia, CA) and quantified using the RNAseP transcription assay and
quantitative PCR in 12 patients with pancreatic cancer, 20 controls (elective
cholecystectomy) and 43 patients with severe acute pancreatitis. In pancrea-
titis patients, baseline samples were taken on admission and further samples
taken at a median of 5 days into the disease course. Data are expressed as
median (range). Statistical comparisons assume non-parametric distribution
of data and accept significance at the PB/0.05 level.
Results. Plasma DNA levels on admission in patients with acute pancreatitis
were lower than in non-cancer controls 0.40 (0.05/0.79) compared to
1.60(0.45/9.10) [PB/0.001;95% CI 0.67 to 1.2; Mann-Whitney U test]. In
patients with acute pancreatitis, DNA levels fell during the disease course
0.40(0.05 /0.79) compared to 0.08(0.00/0.53) [B/0.0001; 95% CI 0.05 to
0.12; Wilcoxon’s signed ranks test]. Free DNA [1646.8 (1389/2071)] in
pancreatic cancer patients was dramatically elevated compared to pancreatitis
patients and controls. When entered into a logistic regression model for
prediction of mortality, DNA levels were non-significant and only admission
logistic organ dysfunction score was positively correlated with adverse
outcome. Linear regression analysis comparing the presence of necrosis on
CT to admission DNA level showed that the correlation coefficient r/0.58
(r2/0.34) was significantly different from zero (95% CI 0.33 to 0.76; power
for 5% significance 97.2%).
Conclusion. This is the first study to use quantitative PCR to measure free
plasma DNA in severe acute pancreatitis. Although levels are increased
compared to controls and there is a strong correlation with necrosis, much
greater values are seen in pancreatic cancer. Whilst accelerated DNA
breakdown in pancreatitis is an explanation for these novel findings, the
results suggest that necrotic and apoptotic pathways in severe inflammation
differ from those in cancer.
P4
Inactivation of tgf-beta-signaling pathway and cell cycle deregulation
in human hepatocellular cancer (HCC) cell lines and human HCC
tissues
Krit Kitisin, MD, Natarajan Ganesan, PhD, Sang Soo Kim, PhD, Eugene
Volpe, PhD, Wilma Jogunoori, PhD, Kirti Shetty, MD, Lopa Mishra, MD,
MBBS, Lynt Johnson, MD
Georgetown University, Washington, DC
Hepatocellular cancer (HCC) is the fifth most common solid malignancy
worldwide and is increasing in the United States. Nearly 500,000 cases
of HCC are diagnosed each year, prognosis remaining extremely poor.
Recent studies in human HCCs reveal the emergence of transforming growth
factor-beta (TGF-beta) as a key signaling pathway in suppressing these
cancers through Smad proteins and adaptor proteins such as the embryonic
liver fodrin (ELF). TGF-beta can induce antiproliferative gene responses by
inhibiting cellular progression in G1 phase. Arrested cells in the G1 phase
display downregulation in expression of Cdk2, Cdk4, cyclin D2, cyclin D3
and cyclin A. Escape from this response is a hallmark of many cancer cells.
Importantly, elf/mice develop HCC spontaneously in 35% (7/20).
Aims. 1. To determine whether ELF and Smads are inactivated in human
HCC cell lines 2. To analyze the changes in cell cycle regulation in wild type
mouse embryonic fibroblasts (MEF) and elf-/- MEF cell lines.
Methods and results. 1. Expression of ELF and other proteins involved in
the TGF-beta signaling pathway, particularly Smad2, Smad4 and TGF-beta
receptor II (TBRII), were examined in human HCC cell lines SNU-182,
SNU-398, SNU-449, and SNU-475. ELF expression was lost in one human
HCC cell line (SNU-398), and decreased in another (SNU-475). Smad 2
expression was lost in all five HCC cell lines. TBRII expression was lost in
three cell lines (SNU-398, SNU-182, and SNU-475). 2. Immunohistochem-
ical labeling of human HCC revealed a marked decrease in ELF, Smad4 and
TBRII expression. 3. Immortalized elf-/- MEF cell lines showed a marked
increase in Cdk4 and cyclin D1 levels.
Conclusions. Diminished or absent ELF expression in mouse and human
HCC as well as cell cycle deregulation suggests that the disruption of TGF-
beta and the loss of ELF can serve as a primary event in progression towards
a fully transformed phenotype. As we know, patients with HCC are faced
with a poor prognosis despite treatment through liver resections or liver
transplantation. Tumor recurrence is common and poses poor clinical
outcomes. Therefore, exploration of the mechanisms behind inactivation of
the TGF-beta signaling pathway and its restoration hold promise for new
therapeutic approaches in human hepatocellular cancer.
P5
Role of endogenous canabinoid as a prognostic marker of hepatocel-
lular carcinoma
Yuji Ishii, MD, PhD, Ryota Saito, MD, Hideki Kanai, MD, Takeyuki
Misawa, MD, PhD, Yuichi Ishida, MD, PhD, Katsuhiko Yanaga, MD, PhD
Jikei University School of Medicine, Tokyo, Japan
Purpose. The endogenous cannabinoid (CB) is a lipid mediator which
induces various physiologic actions such as vascular relaxation, tumor
proliferation, neurologic analgesia, and apoptosis. In this study, the sig-
nificance of endogenous CB (2-AG: 2-arachidonoylglycerol-2, AEA: ana-
ndamide) and the expression of CB1 and CB2 receptors in chronic liver
disease were evaluated.
Patients and methods. Serum level of 2-AG and AEA were measured by
high performance liquid chromatography combined with mass spectrometry
(LC/MS) in patients with hepatocellular carcinoma (HCC, n/21) or liver
cirrhosis (LC, n/9) and in healthy volunteers (n/24). Moreover, of the two
patients with LC who developed HCC, values before and after the deve-
lopment HCC were compared. The clinical stage of the Liver Cancer Study
Group of Japan of patients with HCC consisted of Stage I in 6, II in 3, III in
4, and IV in 8 patients. The expression of CB1 & 2 receptors were examined
by immunohistochemical analysis using the resected samples of HCC.
Presentations 55
Results. The serum AEA and 2-AG levels in healthy volunteers were 1959/
174 pg/ml and, 1,8729/853 pg/ml, respectively. In patients with HCC, the
mean levels of AEA and 2-AG were 597.19/632.2 pg/ml and 15,424.59/
6,924 pg/ml, respectively, which were significantly higher than those in the
healthy volunteers (pB/0.01). On the other hand, in patients with LC,
although 2-AG was significantly higher than healthy volunteers, AEA did not
achieve a significant difference. Although the 2-AG level of stage IV patients
was significantly higher than other patients (pB/0.01), AEA did not correlate
with the stage. The 2-AG levels of the two patients before the development of
HCC were significantly higher than the other seven patients with LC. In the
two patients, the elevation ratio (before/after HCC) of 2-AG was higher than
that of AEA. The 2-AG levels in three of six patients with early HCC (Stage
I) who developed early recurrence was significantly higher than the other
three patients. In the imunohistolochemistry of HCC, the expressions of CB1
receptor correlated with dedifferentiation of HCC.
Conclusion. The serum 2-AG seems to be a surrogate marker of HCC
carcinogenesis, progression and recurrence. CB1 receptor antagonist may
have a role in the development of new treatment for HCC.
P6
Influence of body mass index on rsectable hepatocelllular carcinoma
Shao Bin Cheng, MD, Cheng Chung Wu, MD, Yee Jee Jan, Tse Jia Liu, MD,
Feng Ku P’eng, MD
Taichung Veterans General Hospital, Taichung, Taiwan Republic of China
Obesity may increase the risk for hepatocellular carcinoma (HCC) in
cirrhotic patient. Obesity has been reported to influence the prognosis of
breast cancer, gastric cancer colon cancer and esophageal cancer. At present,
no report regarding the relationship of obesity and HCC. Moreover, because
of obesity may be more susceptibility of liver failure, the role of liver resection
for HCC in obese patients needs an appraisal.
We retrospectively review 545 HCC patients who underwent a curative liver
resection between January 1997 and June 2005. Base on the preoperative
body mass index (Body weight (kg)/body height(m2)), 185 patients were
classified as overweight group (BMI /25 kg/m2). Compare the clinicao-
pathological characteristics, early and long term results after liver resection
with the other 365 patients (normal group), we found that group 1 patients
had an older age, high incidence of associated fatty liver, poorer liver function
(showed as higher ICG 15-min retention rate), smaller tumor size, less
incidence of vascular invasion, low incidence of satellite nodule’s and more
favorite tumor stages. No significant differences could be found in the
operation time, amount of blood loss and blood transfusion rates between the
two groups. No patients died after liver resection. The complication rates in
group 1 and group 2 were 16.1% and 21% respectively (p/0.118).
Patients of group 1 have a significantly greater disease-free survival and
actuarial rates than group 2 patients. Multivariate analysis showed that the
independent factors influenced the prognosis of HCC were necessity of blood
transfusion, serum a-fetoprotein level and TNM tumor stages. Base on our
observation, we concluded that obesity did not have negative impact on HCC
for liver resection. Because group 2 patients are usually associated with poor
tumor characteristics, obese patients has a better long-term results. However,
BMI is not an independent prognostic factor for HCC.
P7
Hepatitis B X gene expression affects sensitivity of hepatocellular
carcinoma (HCC) to herpes oncolytic viral therapy
Tae-jin J. Song, MD, Michael Hezel, MD, Prasad S. Adusumilli, David P.
Eisenberg, MD, Yuman Fong, MD
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New
York, NY
Background. The HBx gene in the hepatitis B genome encodes the
HBx protein, which is an inhibitor of the p53 apoptosis pathway and an
activator of MAPK pathway, and is thought to decrease sensitivity of hepa-
titis B related HCC to conventional therapies. Herpes simplex viruses (HSV)
have shown promise in killing of HCC in preclinical studies but appear to
depend on the MAPK pathway. The current studies were performed to
determine if HBx expression in HCC altered sensitivity to oncolytic viral
therapy.
Methods. HCC cell lines were use, including the oncolysis-sensitive line
HepG2, and the resistant line SK-HEP-1. Both HepG2 and SK-HEP-1 do
not have any hepatitis B gene integration. HBx expressing plasmid vector
pcDNA3-HBx-FLAG (gift of Dr. Schneider, New York University) was used
to transfect the HCC cell lines. Cell killing by the oncolytic herpes virus
G207 virus at MOI (multiplicity of infection; virus/cell)/0.01, 0.1, and 1
was tested. Combinations of virus and chemotherapy (floxuridine (FuDR) or
mitomycin-C (MMC)) or radiation were also tested.
Results. The transfection efficiency was confirmed with HBx ELISA and
western blots.
The HBx expression had no effect on efficacy of G207 for the HCC cell lines
at any MOI. HBx expression also did not have any effect on oncolysis in the
setting of concurrent chemotherapy or radiation therapy.
Conclusion. HBx status may not affect the oncolytic viral sensitivity. Thus,
tumors that have integration of hepatitis DNA, which represents the majority
of HCC in the Far East, remain candidates for treatment with novel herpes
oncolytic viruses.
P8
Current practice of phosphate administration in liver surgery: An
international survey
Carol-anne Moulton, MBBS, Steven Gallinger, MD
Toronto General Hospital, Toronto, ON, Canada
Background. Hypophosphatemia has been suggested to be a cause of major
post operative morbidity following major liver resection. A multifactorial
cause has been suggested for this, including ATP depletion and repletion
during liver regeneration, glucose administration (with subsequent increase
in oxidative phosphorylation), postoperative respiratory alkalosis, and pre-
operative nutritional depletion. Some experts have questioned whether
hypophosphatemia ever becomes clinically relevant in liver resection patients
since there are normally large phosphorus reserves and an efficient buffering
system. Advice on phosphate replacement following liver surgery has varied
significantly. To obtain an understanding of current practice worldwide, a
survey was sent to all members of the IHPBA who registered an email address
with the organization.
Methods. A total of five hundred and twenty-five emails were sent. The
email initially explained the purpose of the survey. The survey was conducted
and completed electronically and all responses were anonymous. Surgeons
were asked whether they performed liver surgery and those who responded in
the affirmative completed the rest of the survey. Surgeons were then
questioned whether they routinely check phosphate levels following liver
resections and what their practices were in the setting of hypophosphatemia.
Results. One hundred and sixty-seven email questionnaires were returned as
the wrong or no longer current email address. Out of 358 surveys that
reached the end user, 104 surgeons responded after 3 reminder emails were
sent (response rate of 29%). 101 out of 104 respondents currently performed
liver surgery. Out of the 101 surgeons who were performing liver surgery, 71
(70%) did not check phosphate levels routinely following liver surgery. Of the
30 who did routinely check levels, 6 (20%) did not replace phosphate if
hypophosphatemia was found.
Conclusion.
Checking phosphate levels following liver surgery was not performed
routinely by the majority of surgeons who responded to our survey. Though
phosphate replacement makes theoretical sense following liver surgery, actual
practice suggests that the majority of liver surgeons are not concerned about
post operative phosphate levels. Further clinical studies are required to
identify the role, if any, of phosphate replacement following liver surgery.
P9
Initial evaluation of PET/CT in patients with hepatic metastases from
colorectal carcinoma
John B. Martinie, MD, Peter J. Horton, MD, Prosanto K. Chaudhury, MD,
Peter Metrakos, MD, Royal Victoria Hospital, Montreal, PQ, Canada
Background. Standard 18F-FDG PET has been used for years to accurately
stage patients with hepatic colorectal metastases and to exclude those with
extensive tumor burden or unsuspected distant metastasis. Unfortunately,
the lack of discrete anatomical information limits it’s usefulness in planning
major hepatic resections. Combined PET/CT imaging has recently become a
standard pre-operative staging tool at our institution in order to improve on
this shortcoming.
Aim. Our principle endpoint was to correlate PET/CT images directly with
histopathological findings and determine sensitivity and specificity. A
secondary aim was to investigate the effect of neo-adjuvant chemotherapy
on PET/CT accuracy.
Patients and methods. All patients at the Royal Victoria Hospital who had
a PET/CT as part of their pre-resection work-up for hepatic colorectal
metastases between September 2004 and 2005 were identified. We excluded
patients with extensive, milliary disease, vague and indeterminant pathology
and/or PET/CT reports, and those who had an aborted procedure without
pathology results. Retrospective review of patients medical records was
performed. All patients had prior resection of their primary colon cancer and
neo-adjuvant chemotherapy prior consideration for hepatic resection. In-
dividual lesions identified on PET/CT reports were compared with operative
notes and pathology descriptions for correlation.
Results. 38 lesions were identified in 19 patients. The median age was 59
years (range 39 to 75 years). 10 were male, 9 female. The median number of
hepatic metastases was 2 (range 1 to 5). The overall sensitivity was 85% with
a specificity of 80% and positive-predictive value of 96.5%. There were 28
positively identified metastases (true positives) and five missed metastatic
lesions (false negatives) found. All five of these missed lesions were
approximately 1 cm in size, and none larger than 1.2 cm. There was one
false positive.(Although the SUV was only 4.3, which is considered border-
line for a metastatic lesions.) Perhaps the most interesting finding in our
study is the finding of four "true negatives." These were lesions initially
suspected of being metastases, which disappeared after chemotherapy on
follow-up imaging, (including a 6-week delay prior to PET/CT). At the time
of resection, these lesions were still visible grossly or on ultrasound, but
contained no viable tumor on histopathology.
Conclusion. PET/CT has a high sensitivity and specificity in patients with
hepatic colorectal metastases even in patients who received neo-adjuvant
chemotherapy. We believe that our initial findings are promising and warrent
further study.
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P10
Refined indications for palliative resection of metastatic renal cell
carcinoma to the pancreas
Aram N. Demirjian, David F. McDermott, Charles M. Vollmer, Michael B.
Atkins, Mark P. Callery
Beth Israel Deaconess Medical Center and Harvard Medical School,
Boston, MA
The pancreas is a rare location for metastatic disease, with only 2/11% of all
pancreatic tumors being of non-primary origin. It is also uncommon for renal
cell carcinoma (RCC) to metastasize to the pancreas (1/3% of cases), and
when it does, it typically occurs late following index nephrectomy. It is not
known whether all pancreatic metastases need be resected, since today’s
chemo- and biologic therapies are increasingly effective in controlling
advanced disease.
Six patients with symptoms ranging from none to acute upper gastrointestinal
(UGI) bleeding are presented. One asymptomatic 54-year-old patient was
diagnosed with a non-functioning pancreatic neuroendocrine tumor, but was
found on laparoscopic enucleation to have a single 17-year latent RCC
metastasis. By contrast, another 75-year-old patient has presented with
multifocal pancreatic RCC that remains asymptomatic, and he will undergo
anti-angiogenic therapy. Four patients, however, presented with recurrent
gastrointestinal bleeding ranging from occult to life-threatening. A 69-year-
old female who underwent right radical nephrectomy in 1996 had persistent
UGI bleeding requiring transfusion nine years later. Another 68-year-old
male suffered a hemodynamically severe UGI bleed 18 years following
nephrectomy. A 48-year-old female, 5 years after index nephrectomy, and 4
years after an initial pancreatic metastasectomy, presented in shock with UGI
bleeding. In these cases, all patients had RCC metastases that had eroded
into the duodenum, and were successfully controlled by palliative pancrea-
ticoduodenectomy or completion pancreatectomy. A 67-year-old male, 11
years after index nephectomy, presented with a small ampullary lesion and
occult UGI bleeding. After diffuse metastatic involvement of the pancreas
was discovered, no resection was undertaken, and his disease has effectively
been controlled medically with no further bleeding in the ensuing 3.5 years of
therapy.
Conclusions. RCC metastases to the pancreas typically occur long after
index nephrectomy. While clinical presentation is variable, palliative resection
should be reserved for those who develop complications such as UGI
bleeding, and in other series, obstructive jaundice. Palliative debulking
resections do not appear to be indicated since today’s new biologic therapies
effectively and reliably control disease over long periods.
P11
The association between central venous pressure, pneumoperito-
neum, and venous air embolism in laparoscopic hepatectomy
Shiva Jayaraman, MD, Anand Khakhar, MD, MBBS, Honji Yang, MD,
Daniel Bainbridge, MD, Douglas Quan, MD
University of Western Ontario, London, ON, Canada
Laparoscopic hepatectomy (LH) is increasingly employed in select cases.
However, the safety and outcomes following LH have yet to be elucidated.
The risk of venous gas embolism is increased during liver resection because of
the large number of venous tributaries encountered during parenchymal
transection. This risk may be significantly increased with positive pressure
carbon dioxide pneumoperitoneum during laparoscopy. This may be further
exacerbated when using low CVP anesthesia as is commonly used to
minimize hemorrhage during open liver resection. To determine the risk of
carbon dioxide venous air embolism, we performed hand-assisted laparo-
scopic left hepatic lobectomy in 20 domestic pigs. They were divided into
three groups: Positive Gradient (normal pressure pneumoperitoneum (12/
14 mmHg) and low CVP (5/7 mmHg), Negative Gradient (low pressure
pneumoperitoneum (7/8 mmHg) and normal CVP (10/12 mmHg), and
Neutral Gradient (normal pressure pneumoperitoneum(12/14 mmHg) and
normal CVP (10/12 mmHg) or low pressure pneumoperitoneum (7/8
mmHg) and low CVP (5/7 mmHg). Trans-esophageal echocardiography
(TEE) was used intra-operatively to assess for the presence of air embolism in
the suprahepatic vena cava and the right side of the heart. The TEE was
recorded and analyzed postoperatively by blinded observers. Carbon dioxide
embolism was also monitored using end-tidal CO2 measurements and
compared to the TEE. Carbon dioxide embolism was demonstrated in
14 of the 20 cases. The majority of detectable gas emboli were single, small
gas bubbles associated with dissection of the major hepatic veins. There
was no statistically significant difference in the occurrence of gas emboli
between the groups. Thirteen of the 14 animals experienced no significant
hemodynamic changes intraoperatively. One pig in the Positive Gradient
group experienced hypotension in relation to gas embolism. However, the
effects were only transient and did not preclude safe completion of the
operation. In conclusion, we demonstrate that carbon dioxide embolism
during LH does frequently occur. The clinical significance of this finding
appears to be nominal, however, care must be taken when dissecting around
large veins and awareness of potential venous air embolism by the surgical
and anesthesiology teams is essential. Further evaluation of this phenomenon
is required.
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Anatomic hepatic resections for the treatment of intrahepatic stones
Francisco Pacheco, MD, Fernando Pimentel, MD, Juan Francisco Guerra,
MD, Matı´as Guajardo, MD, Erwin Buckel, MS, Gustavo Pe´rez, MD, Sergio
Guzma´n, MD, Luis Iban˜ez, MD, Jorge Martı´nez, MD, Nicolas P Jarufe, MD
Department of Digestive Surgery. Faculty of Medicine., Pontificia Universi-
dad Cato´lica de Chile, Santiago, Chile
Introduction. Intrahepatic stones (IHS) can be associated to serious
complications and its treatment is reason for controversy.
Objectives: The aim of this study was to evaluate clinical data, peri-
operative and long-term results of anatomic hepatic resections for IHS.
Patients and methods. Clinical data, immediate and long-term outcomes
of a cohort of 30 consecutive patients who underwent anatomic hepatic
resections for IHS between November 1986 and May 2005 were analyzed.
Immediate outcomes included stone clearance rate, operative morbidity and
mortality. Long-term results were concerned to stone recurrence rate.
Statistical analysis was obtained with Fisher‘s exact test.
Results. Mean age was 48.8 years. Eighteen patients (60%) were men. All
patients were symptomatic, emphasizing abdominal pain 14 (46.6%),
cholangitis 13 (43.3%) and pancreatitis 3 (10%). Abdominal ultrasound
was diagnostic in 27 patients (90%). Endoscopic retrograde cholangiopan-
creatography (ERCP) was performed in 16 patients (53.3%) and 7 of 9
patients of the last 5 years had magnetic resonance cholangiopancreatogra-
phy. Nine patients had stones in rigth biliary tree, 17 in left biliary tree and 4
patients had bilateral disease. The most frequent surgical procedure (16
cases) was left lateral segmentectomy (53.3%), two of them underwent
laparoscopic resection. Right posterior segmentectomy was performed in 7
cases, right hepatectomy in 4, segmentectomy V and VIII in 1 patient, left
hepatectomy in 1 case and segmentectomy II, III and VII in 1 patient. Eight
of 9 cases (89%) with right IHS had history of open biliary surgery in contrast
to 7 of 17 (41%) patient with left IHS (pB/0,006). Morbidity was 13%.
There were no re-operations and no mortality in this series. Biopsies showed
Caroli?s disease in 17 cases (56.6%), 4 of them were bilateral. The immediate
stone clearance rate was 87%. With a median follow-up of 57.9 months
(range 6/193), recurrent stones were found in five patients (16.6%), all of
them successful treated by ERCP. One case developed bile duct stricture
solved by Roux en Y biliary reconstruction two years later.
Conclusions. Anatomical hepatic resection is a safe and effective surgical
treatment for IHS with low rate of residual disease. There is a relationship
between history of biliary surgery and development of IHS in the rigth biliary
tree that may be explained for unsuspected right artery lesion during
cholecistectomy.
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Regeneration of chronically damaged liver by subpopulation of
CD34 stem cells
Nagy Habib, Natasa Levicar, Madhava Pai, Faisal Al-allaf, Ioannis Dimar-
akis, Jonathan Welsh, Long Jiao, Joanna Nicholls
Myrtle Gordon, Imperial College, London, United Kingdom
Two main types of stem cell, embryonic and adult, have been proposed as
sources for cell therapy of tissue damage and degeneration. Ethical difficulties
and practical problems, like contamination with non-human antigenic
material, beset the application of embryonic stem cell lines. As a result, the
search for adult human stem cell populations with broad tissue potential is
likely to intensify. We have isolated, from mobilised and leukapheresed blood,
a morphologically and phenotypically homogeneous subpopulation of
CD34/ cells (/1%) that exhibits the necessary properties. Using nested
RT-PCR we have demonstrated that these cells (OmniCytes) and/or their
progeny generated within 2 weeks in culture express genes corresponding to
stem cells (Rex-1, Oct-4, Nanog) and hematopoietic (CD34, CD133,
CXCR4), hepatic (albumin, alfa-1 antitrypsin, vimentin, HGF, HNF3-B,
transferrin) cell differentiation. Animal studies have shown that OmniCytes
do home and engraft into chronically damaged nude mice liver. Furthermore,
we have performed a phase I safety, toxicity and feasibility clinical study in
patients with liver insufficiency. The study involved the collection of bone
marrow cells by leukapheresis and subsequent infusion of stem cells into the
patient’s portal vein. The treatment proved to be safe for the patients and no
obvious toxicity was observed. We have demonstrated the feasibility and
safety of G-CSF administration and mobilization, leukapheresis and intra-
hepatic transfer of CD34/ stem cells in patients with chronic liver disease.
Our study documents the existence of stem cells that can be directly and
reproducibly isolated from an accessible in vivo source and have considerable
promise for the clinical application of liver cell therapy.
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Risk factors for postoperative prolonged hyperbilirubinemia after
living-donor liver transplantation
Tadafunmi Asaoka, MD, Shigeru Marubashi, MD, Naoki Hama, MD, Keizo
Dono, MD, Kunihito Goto, MD, Astushi Miyamoto, MD, Hiroshi Takeda,
MD, Hiroaki Nagano, MD, Koji Umeshita, MD, Morito Monden, MD
Osaka university, Osaka, Japan
Background and purpose. Living-donor liver transplantation (LDLT) is
often complicated with prolonged hyperbilirubinemia. We aimed at deter-
mining risk factors for postoperative prolonged hyperbilirubinemia.
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Object and methods. Portal venous pressure (PVP) was continually
measured during surgery at anhepatic phase, after reperfusion, and
on postoperative day 1 in 23 patients among 44 LDLT recipients be-
tween January 1999 and August 2004. Prolonged hyperbilirubinemia was
defined as normalization of bilirubin less than 2.0 mg/dl took more than
30 days after LDLT. We analyzed the recipient and donor factors, operative
factors as well as PVP, and compared them between the 10 patients with
prolonged hyperbilirubinemia and 13 patients with excellent liver function
recovery.
Results. There was no mortality in these patients. Prolonged hyperbilir-
ubinemia was associated with a low value about MELD score, CPT score,
preoperative T-Bil, and PVP after reperfusion ( P B/0.05), whereas graft size,
ischemic time, operative bleeding, and portal pressure during anhepatic
phase were similar between the groups. Allograft functions were better in the
patients with lower PVP after reperfusion (less than 25 mmHg).
Conclusion. It is suggested that preoperative liver function and portal
pressure after reperfusion are risk factors for prolonged hyperbilirubinemia
after LDLTs.
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Hepatic arterial infusion chemotehrapy in the surgical management
of bilobar colorecltal liver metastasis
Astushi Shimizu IV, MD, PhD, Yoshikazu Yasuda V, MD, PhD, Nobuyuki
Hohjoh IV, MD, Hideo Chiba IV, MD, PhD, Yoshito Nihei III, MD, Keisuke
Yamashita IV, MD, PhD, Hideo Nagai V, MD, PhD
Jichi Medical School, Tochigi, Japan
Purpose. Hepatic resection remains main treatment for colorectal liver
metastases(CRLM). Still they were often uneresectable at initial presentation
because of small remnant liver volume or their ill-location and are associated
with dismal prognosis. Therefore, we have used hepatic arterial infusion
chemotherapy(HAI) for patients with unresectable CRLM. Furthermore,
after down- staging chemotherapy, rescue liver surgery for initially unresect-
able metastases has been performed in selected HAI responders. The purpose
of this study was to assess the benefit of HAI and hepatic resection after
preoperative chemotherapy.
Methods. From September 1992 to July 2005, 46 initially unresectable
CRLM patients received HAI after resection of primary colorectal cancer. Of
these 23 patients completed a full course of HAI, taking 15 g of 5-FU or more
and were designated as a HAI group. Surgery was reconsidered in case of
documented response to HAI and performed in selected cases when all
tumors could be removed. Eligible candidates for the port replacement but
did not receive any HAI were analyzed as a control group. The primary
endpoint was survival rate.
Results. The median survival time was 23 months in HAI group and
7 months in control group (pB/0.05). Six patients underwent hepatectomy
after neoadjuvant chemotherapy. There were four 3-year survivors.
Conclusion. HAI for unresectable CRLM is an effective regional therapy
making rescue hepatic resection a possible treatment option and may
contribute to the survival benefit of a small subset of the patients.
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Hepatic resection for colorectal liver metastases: The value of
prognostic scoring systems
Luca Aldrighetti, Carlo Pulitano`, MD, Marcella Arru, MD, Renato Castoldi,
MD, Marco Stella, MD, Elena Orsenigo, MD, Francesca Gavazzi, MD,
Gianfranco Ferla, MD, Valerio Di Carlo, MD, Carlo Staudacher, MD
Scientific Institute H San Raffaele, Vita-Salute San Raffaele University
School of Medicine, Milan, Italy
The unavailability of reliable prognostic indexes for predicting recurrence
after hepatic resection for metastatic colorectal cancer remain a significant
problem. Several investigators have proposed prognostic scoring systems of
varying complexity to improve patient selection for surgical therapy and as
criteria for stratification of patients in clinical trials. The purpose of this
retrospective study was to compare the validity of three different scoring
systems, the clinical risk score (CRS) defined by Fong et. al, the score system
defined by Nordlinger et. al (NSI) and the score system defined by Makuuchi
et al (MSI).Medical records of 297 undergoing potentially curative hepatic
resection for colorectal metastases between February 1991 and December
2002 were included in the study. The CRS assesses 5 variables, nodal status
of the primary lesion, disease-free interval, number of hepatic metastases, size
of the largest metastasis, and preoperative CEA level.
The NSI assesses 7 preoperative prognostic criteria, age older than 60 years,
stage of primary, /4 liver metastases, synchronous disease, size of largest
lesion /5 cm, CEA level /30 ng/ml, and positive margins. The MSI
assesses 3 variables, nodal status of the primary lesion, CEA level /50 ng/ml,
positive hilar nodes. The calculated CRS NSI, and MSI were analyzed with
respect to patient postoperative survival.
The individual CRS, NSI, and MSI were found to be highly predictive of
long-term outcome (P/0.0043) (P/0.0001), and (P/0.0001) respectively.
Clinical risk score remains highly predictive of survival when grouped into
scores of 0 to 2 and 3 to 5 (P/0.0016). Nordlinger scoring index was also
highly predictive of survival when grouped in three category according the
risk group (P/0.0001). Five year survival rates for CRS of 1 and 2 were
found to be 46% and 28.6%, respectively; and for scores of 3 was 21.8%. No
patient with a CRS greater than 3 survived at 5 years. 5-year survival rates for
NSI in low risk group and intermediate risk were found to be 68.2% and
40.6%, respectively; and for high risk was 9%. 5-year survival rates for MSI of
1 and 2 were found to be 45.1% and 6%, respectively; No patient with a MSI
score greater than 3 survived at 5 years.
This study validates the CRS, NSI, and MSI as highly predictive of patient
outcome, but supplementary investigation is needed to substantiate the
finding that patients with a higher score are inappropriate for resection. The
clinical role in patient selection will have to be defined in prospective
studies.
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Synergistic inhibition of pancreatic cancer growth by inositol hex-
aphosphate and peptide YY
David W. Mcfadden, MD, Dale R. Riggs, Barbara J. Jackson
West Virginia University, Morgantown, WV
Purpose. Inositol Hexaphosphate (IP6) is a naturally occurring polypho-
sphorylated carbohydrate abundant in foods with high fiber content. Peptide
YY (PYY) is an endogenous gastrointestinal hormone that has been shown to
inhibit the growth of several cancers. We have reported that both IP6 and
PYY exhibit significant inhibition of pancreatic cancer cell growth in vitro
when applied as single agent treatment. We hypothesized that, when
combined, IP6 and PYY would synergistically inhibit cancer growth. Such
synergism might allow lower dosage regimens and lessen both the cost and
side effects of cancer therapy.
Materials and methods. The PANC1 pancreatic cancer cell line was
cultured using standard techniques and treated with both corn and rice
derived IP6 at 0.1 mM and 0.2 mM doses, PYYat 500 pM, and combination
treatment of IP6 plus PYY. Cell viability was measured by MTT at 72 hours.
Determination of statistical significance was performed by analysis of
variance. Post hoc comparison of individual concentration means with the
control was completed using the Tukey-Kramer Multiple Comparison test.
All data are reported as means and standard deviations.
Results. Significant reductions (pB/0.05) in cellular proliferation were
observed with both corn and rice derived IP6 and at both concentrations
tested. IP6 (Corn) caused a reduction in growth of 12.2/4.2% (0.1 mM)
and 25.1/10.4% (0.2 mM). IP6 Rice treatment produced a reduction in
growth of 18.2/9.2% (0.1 mM) and 20.89/10.1% (0.2 mM). PYY alone
also reduced cellular proliferation (9.1%9/3.2). When corn IP-6 and PYY
were combined, inhibition of cell growth increased to 32.3 9/7.9% (0.1
mM) (pB/0.001) and 30.49/7.2% (0.2 mM) compared to either single
agent treatment (P B/0.001). When IP6 Rice was combined with PYY,
inhibition of cell growth increased to 29.19/8.8% (0.1 mM) and 34.29/
7.2% (0.2 mM) (pB/0.001) as compared to either single agent treatments
(PB/0.04).
Conclusions. Inositol Hexaphosphate (IP6), a common dietary polypho-
sphorylated carbohydrate with proposed anti-cancer properties, significantly
decreased pancreatic cancer cellular growth as a single agent and exhibited
synergistic effects when combined with PYY. Our findings support that
combination therapy with IP6 and PYY has the potential to become an
effective adjunct for pancreatic cancer treatment. Both agents are naturally
occurring substances and well tolerated clinically. Further in vivo and human
studies are planned to evaluate the safety and clinical utility of these agents in
patients with pancreatic cancer.
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Renal injury following hepatic resection, microwave ablation,
cryotherapy and radiofrequency ablation, at different volumes of
treatment
Fateh Ahmad, MD, MBBS, Andrew D. Strickland, MD, MBBS, David M.
Lloyd, MD, MBBS
Department of Hepatobiliary Surgery, Leicester, United Kingdom
Background. Hepatic cryoablation has been implicated as a causative
factor in the development of a systemic inflammatory response syndrome.
This serious complication can result in multi organ dysfunction, often
affecting the renal system. With several alternative techniques now in
clinical use, this study examined the renal responses to three different forms
of hepatic ablation, including cryotherapy, radiofrequency ablation and
microwave tissue ablation. The levels of the enzyme retinol binding protein
(RBP) in urine are a sensitive indicator of acute tubular necrosis in the
kidney. This was measured together with routine histological assessment of
the kidneys.
Methods. Following laparotomy, adult rats underwent ablation/resection of
15%, 33% or 66% of the total liver volume. Control rats underwent a sham
laparotomy. At 48 hours, the animals were culled and urine obtained directly
from the bladder. These were analysed for the presence of RBP using
standard enzyme-linked immunosorbent assays. Kidney samples were
salvaged for histology and immunohistochemistry.
Results. Following 15% ablation/resection, there was no significant differ-
ence in levels of RBP between any of the treatment groups. At 33% ablation
volumes, the resection, cryoablation and RFA groups showed higher average
levels of RBP than the controls and the MTA group. Following 66% ablation/
resection, all the treatment groups exhibited higher RBP levels than the
controls. However, these differences were not significant in the 66% MTA
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group. Histologic sections of the kidneys following 66% hepatic cryoablation
and RFA revealed the presence of inflammatory foci containing lymphocytes,
macrophages and neutrophils, along with features consistent with acute
tubular necrosis. These changes were suggestive of an acute injury caused by
an inflammatory response and were not seen following 66% MTA or
resection.
Conclusion. Renal impairment caused by hepatic ablation is seen following
large volume cryoablation and RFA. Large volume resection and MTA
appear not induce a significant systemic inflammatory response resulting in
renal damage.
P19
Mirizzi’s syndrome-results from a large western experience
D. Gomez, S. H. Rahman, R. Balasubramaniam, K. R. Prasad, G. J.
Toogood, M. J. Mc Mahon, J. P. A. Lodge, P. J. Guillou, K. V. Menon
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Mirizzi’s syndrome is a rare complication of long-standing gallstone disease.
We report our experience in a series of 33 patients with Mirizzi’s syndrome
who were managed at our institution over an 11-year (1994/2005) period.
Patients with a definitive or possible diagnosis of Mirizzi’s syndrome stated in
radiology reports were identified using the hospital’s radiology computer
coding system at our institution.
The median age of diagnosis was 70 (range: 35/90) years and male to female
ratio was 15:18. Liver function tests on admission were deranged in all our
patients. Pre-operative diagnosis was achieved in 28 patients with USS (n/
4), CT scan (n/3), MRCP (n/10) and ERCP (n/11). The type I Mirizzi’s
syndrome was reported in 27 patients. Eighteen patients were treated with
laparoscopic cholecystectomy of which six patients were converted to open
cholecystectomy. Six patients had endoscopic biliary stent insertion only and
three were conservatively managed. Six patients had type II Mirizzi’s
syndrome of whom four patients were treated with cholecystectomy and
Roux-en-Y hepaticojejunostomy. One patient underwent an open subtotal
cholecystectomy with closure of the gallbladder remnant and one had a
percutaneous biliary stent insertion only. The morbidity rate in our study was
29% (n/8) and the mortality rate was 6% (n/2). The median follow-up
period in 28 patients were 6 weeks.
We conclude that USS is an appropriate first-line investigation followed by an
MRCP in cases suspected to have Mirizzi’s syndrome. ERCP should be
reserved for patients that are unfit for surgery or require biliary drainage prior
to definitive surgery. Laparoscopic cholecystectomy for type I Mirizzi’s
syndrome is a feasible and safe option with a low threshold for conversion to
an open procedure. Patients with type II Mirizzi’s syndrome can be treated
with Roux-en-Y hepaticojejunostomy or subtotal cholecystectomy and
closure of the gallbladder remnant.
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Left portal vein hypoplasia/atresia: A potentially fatal condition in
right hepatic lobectomy
Ian Soriano, MD, Cosme Manzarbeitia, MD
Albert Einstein Medical Center, Philadelphia, PA
Background. The importance of anatomic variations in the hepatic
vasculature is essential in pre-operative or intra-operative evaluation. Recent
advances in imaging technology have found a greater prevalence of variations
than initially thought, though atresias remain quite uncommon. As the
number of hepatic resections increase and as right lobes continue to be
procured for living donor liver transplantation, unsuspected rare variants
involving the left sided vasculature present the potential for catastrophic
results. Among these is the presence of atresia of the left portal venous
system.
Patient and methods. A 36-year-old woman underwent an uneventful
standard right hepatic lobectomy for multiple, rapidly enlarging, sympto-
matic hepatic adenomas. At laparotomy, the right lobe was much larger than
the left, and had multiple large (1 to 1.5 cm) short hepatic veins draining
directly into the inferior vena cava in addition to the main right hepatic vein.
The hilar vessels were dissected to their bifurcations and the right sided
structures were taken individually, but the left sided structures were left
undisturbed in order to prevent injury or post-operative torsion.
Results. Post-operatively, the patient had progressive liver failure and
imaging revealed portal vein thrombosis. On re-exploration, full hilar
dissection revealed the left portal vein to be severely hypoplastic (2 mm
diameter), and intra-operative ultrasound showed concomittant segmental
atresia of the intra-hepatic portion of the left portal vein. Thrombectomy was
unsuccessful, with no outflow post-intervention. Retrospective critical review
of the pre-operative MRI showed limited portal branching within the left
lobe, but no definite evidence of atresia/hypoplasia. She was listed for
transplant, but progressed to brain death before a donor liver could be
obtained.
Conclusion. During right hepatic lobectomy, the left portal anatomy should
be evaluated with either intra-operative ultrasound or routine limited dis-
section in the absence of a pre-operative angiogram delineating the anatomy.
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FDG-pet is superior the CT scanning for detecting hepatic recur-
rence in liver resection patients
Kerry W Byrnes, MD, Mary Whitlock, MD, Quyen Chu, MD, David Lilian,
MD, Lester W Johnson, MD, Richard Turnage, MD, Gazi B Zibari, MD
LSU Health Sciences Center, Shreveport, LA; LSU Health Sciences Center,
Monroe, LA
Patients who have undergone a hepatic resection for metastatic disease
represent a challenging population to detect recurrence. Promising results
have been reported in the past using PET imaging to diagnose both primary
and metastatic liver cancer. The aim of this study was to compare the
accuracy of FDG-PET to CT scanning in the detection of local recurrence in
patients with a history of hepatic resection for malignant disease.
Methods. All patients who underwent hepatic resection for malignancy from
1999 to 2004 were retrospectively reviewed. The results of FDG-PET and
CT scans performed in patients who had suspected recurrent disease after
partial hepatic resection were analyzed. Exclusion criteria included time
interval between studies of more that one month and positive histologic
margin from initial surgery. Recurrence was confirmed by either histopathol-
ogy or clinical progression of disease. The sensitivity and specificity of each
imaging modality was determined.
Results. A total of 85 patients were found to have undergone hepatic
resection, of which 36 patients were identified who underwent concomitant
PETand CT imaging to detect recurrence. The median age of this population
of patients was 63, and included 16 females and 20 males. Initial resections
included 17 wedge resections and 19 partial or complete lobe resections. Of
these, 27 had a previous hepatic resection for metastatic colon cancer, while 9
underwent hepatic resection for primary hepatic malignancy, either hepato-
cellular carcinoma (HCC) or cholangiocarcinoma. The sensitivity of PET
imaging in the detection of metastatic and primary recurrence was 100 and
86% respectively. The sensitivity of CT scanning in the detection of
metastatic and primary recurrence was 41 and 43% respectively. The
specificity of both modalities was 100%, as there were no false positive results.
Conclusion. In this retrospective review, FDG-PET appears superior to CT
scanning in the detection of hepatic recurrence. This includes both primary
hepatic malignancies and metastatic disease. Whether this is due to the loss of
normal architecture in hepatic resection patients or to the confounding
appearance of scar tissue is unknown.
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Experimental evaluation of sealants in liver and transplant surgery
Arash Kashfi, MD, Arianeb Mehrabi, MD, PhD, Peter Schemmer, MD,
PhD, Carsten N. Gutt, MD, MPH, Helmut Friess, MD, PhD, Martha M.
Gebhard, MD, PhD, Jan Schmidt, MD, PhD, Markus W. Bu¨chler, MD,
PhD, Thomas W. Kraus, MD, PhD
Department of Surgery, University of Heidelberg, Heidelberg, Germany;
Department of Experimental Surgery, University of Heidelberg, Heidelberg,
Germany
Bleeding and biliary leaking are major complications in liver and transplant
surgery. To minimize these complications different products for sealing can
be implemented. Until now there are no evidence-based guidelines as to
which product to use for which indication. The aim of the present study is to
evaluate different sealing products in a standardized animal model.
In landrace pigs (n/10, 32/35 kg) we performed either a perforation of the
gallbladder (2 mm hole) to imitate biliary leakage, a partial liver resection
using a stapler (4.5 cm long), a portal vein anastomosis, or an arteriotomy
(aorta, 4 cm long). The induced standardized complications were managed
with three different sealants (TachoComb S [TC], Tissucol [TS], Coseal
[CO]). Filling the gallbladder with bile, once a leakage occurred, volume
and pressure were recorded. The bleeding time and blood loss were
documented in liver resection, portal vein anastomosis, and aorta anasto-
mosis. The data were compared to the control group without sealing product
(n/7).
During the experiments the cardiopulmonary condition of the animals was
stable. The tightness of the perforated, unsealed gallbladder (209/12 mmHg)
could be significantly increased to more than 110% (TC: 469/15, TS: 419/
22, CO: 249/7). In the partial liver resection group, a significant reduction of
blood loss of more than 90% could be reached (TC: 96%, TS: 91%, CO:
93%). The blood loss in the sealed portal vein anastomosis could be
decreased significantly about 92% (TC: 98%, TS: 92%, CO: 89%).
Compared to control group, the amount of blood loss after arteriotomy
and sealing could be decreased more than 98% in the first 20 sec in two-
thirds of the animals.
The implementation of sealing products in different procedures in liver and
transplantation surgery can lead to a significant reduction of blood loss and
bleeding time. Biliary leakage during cholestasis could be well controlled by
sealing with TC and TS. Comparing the products, TC and CO had the best
results in the repair of the liver resection area, and TC and TS had the best
results in the anastomosis experiments. The favorites concerning the
arteriotomy under high pressure conditions were TS and CO. All three
products were identically in their handling and performance.
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Risk factors for pancreatic fistula. Does it have a clinical application
for early identification of patients with high risk to develop pancreatic
fistula after pancreaticoduodenectomy?
Andre S. Matheus, MD, PhD, Andre L. Montagnini, MD, PhD, Jose
Jukemura, MD, Ricardo Jurendini, MD, Sonia Penteado, MD, Emilio E.
Abdo, MD, Jose Eduardo M. Cunha, MD, PhD
University of Sao Paulo, Sao Paulo, Brazil
Operative mortality rates after pancreaticoduodenectomy (PD) have de-
creased dramatically over the past 3 decades and recent series have reported
very low mortality. Nevertheless pancreatic fistula remains the major cause of
morbidity. To analyze the clinical application of risk factors for pancreatic
leakage after pancreaticoduodenectomy, we conducted a retrospective review
of patients undergoing PD.
Methods. Thirty-seven patients who underwent PD at our hospital between
January 2004 and July 2005 were reviewed retrospectively. The primary
diseases were pancreas cancer, ampullary cancer, bile duct cancer, islet cell
cancer, duodenal cancer, chronic pancreatitis, pancreatic cystadenoma,
gastric cancer, and pancreatic metastases. Standard PD was performed for
3 cases and pylorus-preserving PD for 34 cases. A duct-to-mucosa
pancreaticojejunostomy was performed in all patients. Octreotide was not
used as prophylactic treatment after surgery. Four preoperative, two
intraoperative, and five postoperative risk factors with the potential to affect
the incidence of pancreatic fistula were analyzed. Fistula definition was a
drain output of any measurable volume of fluid on or after postoperative day
3 with an amylase content greater than 3 times the serum amylase.
Results. Of the 37 patients, 11 (29.7%) were identified as having pancreatic
leakage after operation. The hospital mortality in this series was 5.4% (2/37),
and the mortality associated with pancreatic fistula was 0% (0/37). General
risk factors including patient age, gender, history of jaundice, preoperative
nutrition, and pathological diagnosis didn’t have any relation with pancreatic
fistula occurrence. Two intraoperative risk factors, pancreatic duct size and
texture of the remnant pancreas, were not found to be significantly associated
with pancreatic leakage. Blood loss, type of resection, and serum amylase
level on postoperative day 1 did not have significantly relation with pancreatic
fistula. The incidence of pancreatic leakage was 81.9% (9/11) in those
patients with abdominal drain amylase level/1000 UI/dL on postoperative
day 1, it was the only risk factor with significantly relation with pancreatic
fistula (pB/0.05).
Conclusion. The level of amylase /1000 UI/dL in the abdominal drain on
postoperative day 1 shows a significant relation with the occurrence of
pancreatic fistula and seems to be the more important factor for early
identification of patients with high risk to develop pancreatic fistula after PD.
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Collision hepatocellular carcinoma of different clonal origins with
distinct positron emission tomography patterns
Majella Doyle, Farrokh Dehdashti, Barry Siegal, Hanlin Wang, Liang Cheng,
William Chapman
Section of Abdominal Transplantation, Department of Surgery, Washington
University, School of Medicine, St Louis 63108, MO; Department of
Radiology, Washington University School of Medicine., St Louis 63110,
MO; Department of Pathology, Washington University, School of Medicine,
St Louis 63110, MO; Department of Pathology, Indiana University, School
of Medicine, Indianapolis, IN; Section of Abdominal Transplantation,
Department of Surgery, Washington University, School of Medicine, St
Louis 63110, MO
Although 18F-fluorodeoxyglucose (FDG) positron emission tomography
(PET) is commonly used to identify occult disease in patients with liver
metastases from colorectal cancer, the results of pre-operative assessment for
hepatocellular carcinoma (HCC) are disappointing. A pilot study at our
institution demonstrated superior detection of HCC when 11C-acetate (AC)
was used as the PET radiopharmaceutical.
A 72 year old lady, with negative hepatitis viral serologies and no evidence of
cirrhosis, who had an alpha fetoprotein level greater than 16,000 ng/mL and
a liver mass in the right lobe, was evaluated as part of this study with both
FDG-PET and AC-PET. Interestingly, FDG-PET showed an intense uptake
in the medial half of the tumor, whereas AC-PET demonstrated an avid
uptake in the lateral half, suggesting a tumor with two distinct components.
At laparotomy, the presence of the tumor in segment 5/6 was confirmed by
intraoperative ultrasound and resection was performed uneventfully. On
gross examination, a 6/5/5.5 cm well-circumscibed and encapsulated
mass was detected. The mass consisted of two clearly distinct nodular
growths side by side without a fibrous septum. The lateral nodule was yellow-
golden in color and comprised the larger portion of the mass. Histologic
examination revealed moderately differentiated hepatocellualr carcinoma
with a trabecular growth pattern and extramedullary hematopoiesis. The
tumor in the medial aspect was pink-tan in color, and microscopically
exhibited well differentiated hepatocellular carcinoma with prominent
pseudoglandular structures. Clonality studies demonstrated different/chro-
mosome inactivation and different loss of heterogeniety (LOH) patterns in
these two tumor components, supporting independent clonal origins.
This case presents an unusual collision tumor occurring in a noncirrhotic
liver in the absence of chronic liver diseases. The distinct PET findings
demonstrate different metabolic activities manifested by tumors derived from
different clonal origins.
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Cysticocholedoco duct with atresia of the biliary common duct and
presence of an accessory cystic duct
Ne´stor A. Go´mez, MD, Jero´nimo J. Gaibor MD., Jorge L. Mejillo´n MD.,
Paola E. Vargas MD., Jorge A. Zapatier MD
Institute of Digestive Diseases, Guayaquil, Ecuador
Introduction. The congenital anomalies of the biliary tract are present in
less than 0.2% with patients with cholecystectomy and common duct
exploration. Cysticocholedocus ducts are rare congenital variants of the
biliary tree.
Case report. A 40 years female patient that seeked medical consultation for
symptomatic gallstones and after laboratory and sonogram exams underwent
an elective minicholecystectomy that developed postoperative jaundice and
abdominal pain. She was reoperated and the intraoperative cholangiogram
(IOC) showed a biliary common duct atresia and presence of an accessory
cystic duct. At surgical reexploration after the IOC, an unique long
cysticocholedocus duct was evidenced in the former surgical intervention.
An hepaticojejunostomy produced relief of the clinical condition, and had a
favorable evolution. The patient was discharged one week later in stable
conditions and returned for follow-up control 1 month later without further
complaints.
Discussion. The anatomical characteristic of the biliary tract make that
these anomalies are not frequently observed, and as result, complications like
biliary peritonitis, biloma, fistulae, duct lesions, etc., occur due to unnoticed
injuries. Abdominal pain and jaundice are the most frequent manifestations
in the biliary surgical complications.
The ultrasound or CT scan contributes in a light way in these cases, being the
endoscopic (ERCP) or magnetic resonance cholangiography (MRC) the
ideal procedures for diagnosis.
We propose an ERCP or MRC in all patients with clinical and surgical history
suggestive of human congenital malformations, and an obligatory IOC in all
patients with biliary diseases, specifically gallbladder pathologies.
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Scelorsing cholangitis secondary to hepatic arterial infusion che-
motherapy
Reza F. Saidi, Michael J. Jacobs
Providence Hospital, Southfield, MI
Hepatic arterial infusion pump (HAIP) chemotherapy is an important
component in the treatment of patients with hepatic metastases. Use of a
hepatic arterial infusion pump is not complication free. Herein, we report an
unusual complication related to (HAIP). The patient was a 58 male who had
history of stage III colon cancer. He subsequently developed solitary liver
metastasis 4 year later and underwent right hepatectomy and placement of
HAIP for metastatic colon cancer to the liver and received FUDR through
the pump. He presented 10 months after this treatment with obstructive
jaundice without any evidence of tumor recurrence. An ERCP was performed
which revealed stricture at the confluence of right and left hepatic duct.
Brushings were negative. Patient had to undergone PTC and placement of
biliary stents.
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Management strategies for unresectable hepatic malignancies in
children:living donor transplantation an valid option
Anil Kotru, MD, Le Chen, MD, William C Chapman, MD, Ross W
Shepherd,, MD, Jeff A Lowell, MD
Washington univ, St Louis, MO; Saint Louis Children Hospital, St Louis,
MO
Background. Management of unresectable liver tumors in children remains
compex problem. Chemotheraphy and surgical resection remain cornerstone
of treatment.Liver transplant (LTx)has emerged as successful alternative for
management of these patients. With ever increasing number of patients
waiting for liver transplant and donor shortage, living donor transplant is a
valid option. We emphasise that this option should be considered timely and
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in highly selected group of patients. We developed a management algorithm
based on our LTx/CTx experience
Results. Of 9 patients listed for LTx (median age 38 mo, 7 hepatoblastoma,
2 undifferentiated mesenchymal sarcoma), 8 were assessed unresectable at
presentation, 1 was deemed resectable, but developed recurrence after
resection. All had CTx, but 7/8 remained unresectable (1 no response, 6
partial response), and 1 developed liver failure during CTx, necessitating
emergent LTx. Using a living/cadaver donor acquisition policy, median
waiting time from listing was 8 days (0.4 to 70). After LTx, 4/9 had CTx, but
CTx was discontinued in 2 because of side effects, 1/4 developed metastates,
dying 12 mo post-LTx. Five had noCTX, 1 of whom developed CTx
responsive metastasis. Survival from listing is 89% (8/9). Of 88 patients listed
by SPLIT (median age 37 mo), survival from listing is 80% (70/88, 3 waiting-
list deaths, 15/78 dying post-LTx,metastates or recurrence in 2/3).
Conclusions. LTx can be highly successful in children with unresectable
hepatic tumors,Timing reamins of essence.In order to reduce waiting time we
advocate pre-CTx, pre-resection consultation with a LTx program to
consider the LTx option in relation to potential resectability and CTx-
unresponsiveness.
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Resection of metastatic adult pancreatoblastoma: A case report
Kristofer M. Charlton-ouw, MD, John D. Allendorf, MD, John A. Chabot,
MD
Columbia-Presbyterian Medical Center, New York, NY
Sixteen cases of adult pancreatoblastoma are in the literature with low 2-year
survival rates. However, prolonged survival can be achieved with aggressive
surgical resection even with microscopic disease outside the surgical margins.
To our knowledge this is the first case of a prolonged survival after resection
of a pancreatoblastoma metastasis followed by resection of the primary lesion.
A 33 year-old man noted right upper quadrant abdominal pain and a 20 lb.
weight loss over the preceding two months. A CT scan of the abdomen and
pelvis showed a large mass in the right lobe of the liver. No other lesions were
noted. We performed an exploratory laparotomy with intraoperative ultra-
sound of the liver and pancreas and a right hepatic lobectomy with
cholecystectomy. A firm 12 cm mass in the right lobe of the liver was
palpable and resected along with surrounding hepatic parenchyma. Addi-
tionally, a pancreatic mass was noted and core needle biopsies obtained. On
frozen section, the pancreatic biopsies showed signs of atrophy and chronic
inflammation. Final pathology from the hepatic lesion showed evidence of a
metastatic endocrine neoplasm. A follow-up CT scan showed ascites and
post-operative changes. Again, no other lesions were seen. The patient was
admitted two and one-half months after his initial operation for resection of
the presumed primary lesion in the head of the pancreas. At his second
exploration, a palpable mass, measuring approximately 5/5/5 cm was
again noted in the head of the pancreas. A pancreatoduodenectomy and distal
gastrectomy were performed. Final pathology showed acinar tumor struc-
tures similar to the previously resected liver mass. Interspersed within the
tissue were squamoid islands typical of pancreatoblastoma. The tumor
infiltrated the main pancreatic duct and tumor cells were seen at the margin
of resection on one slide. There was no lymph node involvement. He received
adjuvant radiation and PLADO chemotherapy. Because the pancreatic mass
was not identified on preoperative imaging, our patient had the liver
metastasis resected before the primary lesion. The resected pancreatic lesion
had tumor cells on the surgical margin on final pathology but after two years
of follow-up, radiation and chemotherapy, our patient has no signs of
recurrence. Aggressive surgical resection should be the mainstay of therapy
for pancreatoblastoma. The goal of surgical resection should be disease-free
margins. The role of adjuvant radiation and chemotherapy when microscopic
disease is found at the surgical margin requires further study.
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Phagocytic, nutritional and immunological assessment in patients
with benign and malignant obstructive jaundice-the influence of
preorerative biliary decompression
Yuichi Ishida, MD, Ryota Saito, MD, Kyonsu Son, MD, Hiroaki Shiba, MD,
Yasuro Futagawa, MD, Tadashi Uwagawa, MD, Takeyuki Misawa, MD, Yuji
Ishii, MD, Katsuhiko Yanaga, MD
Jikei University School of Medicine, Tokyo, Japan
Aim. The Aim of this study was to evaluate the phagocytic, nutritional and
immunologianl status of patients with malignant obstructive jaundice with
the serum total bilirubin level of 5 mg/dl or greater (N/5).
Method. Healthy volunteers (N/9) were assessed as non-icteric control,
while patients with obstructive jaundice due to choledocholithiasis (N/3)
were used as icteric control. We also evaluated the time-course of five patients
with malignant obstructive jaundice before and after percutaneus transhepa-
tic biliary drainage (PTBD).
Nutritional status was assessed by the serum albumin (Alb), prealbumin (PA)
and retinol binding protein (RBP). Cellular immunity was assessed by
phytohemagglutinin (PHA) skin test, antibody dependent cell mediated
cytotoxicity (ADCC) and natural killer assay. Phagocytic activity of phago-
cytes was assessed by phagocytic plaque method.
Results. Nutritional, immunological, and phagocytic status of patients with
benign and malignant obstructive jaundice were severely depressed, which
were not improved by preoperative biliary decompression such as PTBD.
Significant correlation was recognized between nutritional or immunological
status and phagocytic activity of phagocytes.
Conclusion. In spite of preorerative biliary decompression, immunological
and phagocytic status did not recovered sufficiently before the operation.
Intensive nutritional support before surgery seems important in patients with
obstructive jaundice.
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Severe liver ischemia results in impaired renal function without
morphological kidney injury
Matthias Behrends, Yeon Ho Park, MD, Melanie Bedolli, Vivian Tan, MD,
Claus U. Niemann, MD
UCSF, San Francisco, CA
Hepatic ischemia/ reperfusion (I/R) is known to result in dysfunction of
remote organs, such as lung and heart [1]. Although renal dysfunction is
frequently seen in patients with hepatic disease, it has not been established
yet, whether hepatic I/R also results in renal damage, whereas hepatic damage
following kidney I/R has already been described [2]. We therefore investigated
whether or not severe hepatic I/R followed by 24 hours of reperfusion results
in functional or morphological damage of the kidney.
In 7 isoflurane- anesthetized male Wistar rats (300/400 grams) vascular
supply to the left and medial lobe (70% of the liver) was clamped for 75 min,
whereas 4 control animals underwent sham operation. Temperature was
maintained at 378C using a heating lamp. Following 24 hours of reperfusion,
blood and kidney samples were harvested. Transaminases, creatinine and
BUN were assessed. Morphological damage was assessed by histology and
immunohistochemical detection of apoptosis by TUNEL assay.
75 min of liver ischemia followed by 24 hours of reperfusion resulted in a
profound increase of AST (155759/6640 vs. 2119/27 U/L, pB/0.05) and
ALT (68079/4163 vs. 689/8, pB/0.05), when compared to sham, and subtle
changes in creatinine (0.69/0.1 vs. 0.39/0.0 mg/dL, pB/0.05) and BUN
(419/15 vs. 149/1 mg/dL, pB/0.05). Histology demonstrated no kidney
injury 24 hours following liver I/R except for congested glomeruli that were
found in both groups and one kidney following liver I/R displayed tubules
with small protein droplets in tubular epithelium. Similarly, there was a small
number TUNEL positive cells in kidneys from both groups with no
difference between groups.
Liver I/R results in systemic inflammation, which is known to result in
myocardial and pulmonary damage. We could demonstrate that this
inflammatory response impairs kidney function without morphological
damage of the kidney. The lesser injury observed in the present study might
be attributable to 1) preserved antioxidative properties of the in vivo animal
model, and 2) a comparatively long reperfusion time. Earlier studies on
remote injury identified oxidative stress as the mechanism responsible for
organ damage. Oxidative stress represents the first phase of postischemic
damage and subsequent kidney injury may therefore only be transient.
In summary, we demonstrated functional but no morphological kidney injury
24 hours following severe hepatic ischemia/ reperfusion.
References
[1] Weinbroum AA, Hochhauser E, Rudick V, Kluger Y, Sorkine P,
Karchevsky E, et al. J Trauma 1997;43:627/33.
[2] Serteser M, Koken T, Kahraman A, Yilmaz K, Akbulut G, Dilek ON. J
Surg Res 2002;107:234/40.
P31
Percutaneous drainage of sterile acute fluid collections in patients
with severe acute pancreatitis: Does it have a role?
Ahmed Al-bahrani Jr., MBBS, Kais Al-ali Jr., MBBS, Aymen Hamade Jr.,
MBBS, Sarah O’shea Sr., MD, Stephen Lee Sr., MD, Basil Ammori Sr., MD
Manchester Royal Infirmary, Manchester, United Kingdom
Background and aims. Percutaneous drainage of acute fluid collection
(AFC) in patients with acute pancreatitis may be considered as the initial
therapy for culture-positive collections. However, the role of drainage of
sterile AFC is controversial. The aim of this retrospective study was to
identify the influence of drainage of sterile AFC on the risk of subsequent
infection, need for surgery and mortality in patients with severe acute
pancreatitis (SAP).
Methods. Patients with SAP who had AFC on abdominal CT scan
underwent percutaneous fine needle aspiration based on clinical and
radiological findings to determine their microbiological status. Sterile AFC
were drained if large, persistent and associated with organ failure.
Results. Between January 2000 and April 2005, 27 patients (16 male) aged
20/80 years (median, 52 years) were admitted to intensive care or high
dependency units with SAP complicated with AFC. Collections were initially
infected when sampled in 7 patients and sterile in 20 patients, a complication
that was significantly associated with the presence of underlying pancreatic
necrosis (6 of 7 patients vs. 7 of 20 patients, p/ 0.023). Drainage of sterile
collections was associated with a significant increase in the risk of their
subsequent infection compared with no drainage (11 of 14 patients, 79% vs.
0 of 6 patients, p/ 0.002). The median interval between drainage of sterile
AFC and their subsequent infection was 11 days (range, 7/22). Surgery was
less frequently required in patients with sterile collections that were drained
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compared with sterile collections that remained undrained (1 of 14 patients,
7.1% vs. 5 of 6 patients, 83.3%, p/ 0.001). Although secondary infection of
sterile collections was associated with significantly longer HDU/ITU stay
(median, 55 vs. 16 days, p/ 0.011) and hospital stay (median, 105 vs. 35
days, p/ 0.010) compared with AFC that remained sterile, it did not increase
the risk of mortality (3 of 11 patients with infected AFC died vs. 2 of 9
patients with sterile AFC, p/ 0.800).
Conclusions. Although percutaneous drainage of sterile AFC in patients
with SAP reduced the need for surgical intervention, it increased the risk of
their subsequent infection, and prolonged their intensive care and hospital
stay. However, drainage did not affect disease mortality. The value for
percutaneous drainage of sterile AFC remains unsupported.
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Low dose gemcitabine concurrent with radiation therapy for locally
advanced pancreatic cancer
Hiroyuki Baba, MD, PhD, Koji Tsuruta, MD, PhD, Atsutake Okamoto,
MD, PhD
Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
Background and aim. Gemcitabine is a potent radiosensitizer. However,
gemcitabine concurrent with radiation against pancreatic cancer is not well
understood. We conducted a study of concurrent low dose gemcitabine and
extra beam radiation therapy (EBRT) in Japanese patients with locally ad-
vanced pancreatic cancer. The aim was to clarify the efficacy and feasibility.
Method. Patients with pathologically proven, locally advanced adenocarci-
noma of the pancreas were enrolled. Either surgical resection (Whipple’s
procedure or distal pancreatectomy) or bypass (biliary-enteric and/or gastro-
intestinal bypass) was carried out with intraoperative radiation therapy
(IORT). Postoperatively, 2 Gy/day of EBRT was delivered for 25 days. The
radiation was planned so as to cover not only the tumor but also the lymph
nodes of celiac and superior mesenteric artery axis. Gemcitabine dose of 40
mg/m2 was administered intravenously approximately one hour prior to
radiation exposure. This was scheduled twice a week (Day1 and 4 every
week). Tumor markers and CT was used to detremine the efficacy. Adverse
effects were investigated. Local progression was regarded as a steady increase
of the tumor marker or radiological growth of the treated tumor.
Results. Fourteen consecutive patients entered the study. There were eight
males and six females. The median age was 64 years (range, 55/74 years).
Five patients were curatively resected and nine patients received bypass
surgery. In general, the regimen was well tolerated. Only 4 patients were able
to complete the treatment course. The median total gemcitabine dose was
240 mg (range, 200 mg/360 mg). The major treatment limiting toxicity was
leukopenia. Three consecutive patients from the beginning experienced
Grade 3/4 leukopenia within two weeks. Therefore, the infusion schedule
was changed to once a week. No grade 3 leukopenia was experienced there
after. Other toxicities included nausea, diarrhea and thrombocytopenia.
Serum tumor markers showed interesting change. In resected patients, the
decrease rate of CA19-9 and Dupan2 were 83% and 73%, whereas in non-
resected patients, 90% and 76%, respectively. CT showed partial response of
the tumor, showing decreases in size, in all unresectable patients.
Conclusion. Low dose (40 mg/m2) of gemcitabine once a week, concurrent
with radiation is well tolerated and feasible in patients with locally advanced
pancreatic cancer. The outcome of the unresectabloe patients did not differ
from the resected patients in terms of tumor marker decrease. Though this is
a preliminary report, it may contribute to the local control of the disease.
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Reduced severity of liver ischemia/reperfusion injury following
hepatic resection in humans is associated with enhanced intrahepatic
expression of TH2 cytokine
Carlo Pulitano`, MD, Luca Aldrighetti, MD, PhD, Renato Finazzi, MD,
Marcella Arru, MD, Marco Catena, MD, PhD, Gianfranco Ferla, MD
Scientific Institute H San Raffaele, Milan, Italy
Based on previous studies in experimental models, pro-inflammatory Th1
cytokines (i.e. TNF-a and IFN-g) are thought to play a pathogenetic role in
hepatic ischemia/reperfusion injury, while anti-inflammatory Th2 cytokines
(i.e. IL-4 and IL-10) have been associated with reduced liver disease severity.
To test the relevance of these concepts in humans, cytokine expression
profiles were characterized in liver biopsies from patients undergoing hepatic
resection following intermittent portal clamping.
Ten consecutive patients were analyzed for the intrahepatic expression of
TNF-a, IFN-g, IL-4 and IL-10 before and about 90 minutes after the last
reperfusion. In addition, various parameters of liver damage and serum TNF-
a levels were analyzed at 2, 24 and 48 hours after surgery.
When compared with pre-reperfusion liver specimens, all post-reperfusion
biopsies showed significantly increased levels of TNF-a and IFN-g mRNAs.
IL-4 and IL-10 mRNA levels were significantly increased in post-reperfusion
biopsies from six patients (defined as Th2(/) group). Conversely, IL-4 and
IL-10 mRNA levels were reduced in post-reperfusion biopsies from four
patients (defined as Th2(/) group). Importantly, ALT, total bilirubin and
serum TNF-a values from the Th2(/) group were significantly lower than
those observed in the Th2(/) group.
All together, the results described herein suggest that the local early
expression of Th2 cytokines may contribute to attenuate liver injury following
ischemia reperfusion in humans. Th2 cytokines may also have played a role in
the reduction of serum TNF-a levels that followed the initial intrahepatic
induction of the transcript for this cytokine.
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Survival following resection of noncolorectal nonneuroendocrine
liver metastases and colorectal metastases is equivalent
Srinevas K. Reddy, MD, Theodore N. Pappas, MD, Paul C. Kuo, MD,
MBA, Carlos E. Marroquin, MD, Bryan M. Clary, MD
Duke University Medical Center, Durham, NC
Purpose. To compare post-operative and long-term outcomes of patients
undergoing hepatic resection for colorectal (CRM), neuroendocrine (NEM),
and noncolorectal nonneuroendocrine metastases (NCRNEM).
Methods. Records of 197 consecutive patients undergoing resection of
hepatic metastases from 2000/2005 were retrospectively reviewed for
demographics, tumor characteristics, treatment, and post-operative outcome.
Student’s t test, Fisher exact test, Kaplan-Meier survival estimates, and log-
rank test were used to assess significance.
Results. Resections were performed for 139 (71%) CRM, 21 (11%) NEM,
and 37 (19%) NCRNEM. 50% of NCRNEM resections were done for
indications lacking effective chemotherapy options. Indications included
breast cancer (7), gastrointestinal stromal tumors (7), melanoma (8),
genito-urinary cancers (8), sarcoma (3), and miscellaneous cancers (4).
Between CRM, NCRNEM and NEM groups, there were no significant
differences in mean age, number of lesions (2.39/.2, 1.99/.3, 2.99/.6),
involved microscopic margins (10 (7%), 6 (16%), 2 (10%)), or the number of
resected segments (3.19/.1, 2.89/.3, 3.19/.4). NCRNEM were larger than
CRM (6.99/.9 versus 4.69/.3 cm, pB/0.02; NEM 5.79/1.0 cm). Synchro-
nous metastases were more prevalent in CRM patients (92 (66%),
NCRNEM 10 (27%) and NEM 4 (19%), pB/0.001), Disease free interval
to metastases (CRM 11.29/1.4 versus NCRNEM 51.99/11.7 months, pB/
0.001; NEM 35.09/17.0 months) and time from discovery of hepatic
metastases to liver resection (CRM 7.79/.9, NCRNEM 14.39/4.3, NEM
13.69/4.0 months, pB/0.05) were shortest in CRM patients. Pre-operative
extrahepatic disease was least common in CRM patients (5/139 (4%),
NCRNEM 10/37 (27%), NEM 3/21 (14%), pB/0.05). Post-operative
mortality (4 (2%), 0%, 2 (10%)) and morbidity (51 (37%), 11 (30%), 9
(43%)) were similar. Disease-free survival was longest (NEM 44, CRM 22,
NCRNEM 9 months, pB/0.01) and 2-year actual survival highest (NEM
85% versus CRM 58%, pB/0.05; NCRNEM 55%) in the NEM group.
Conclusion. When properly selected, hepatic resection for metastases other
than colorectal and neuroendocrine malignancies can be performed safely
and with acceptable long-term outcome. In this patient population with
limited systemic treatment options, survival is similar to patients undergoing
resection for colorectal metastases.
P35
Octreotide does not prevent pancreatic fistula following pancreatico-
duodenectomy
Joshua M. Aaron, Margo Shoup, MD, Jack Pickleman, MD, Gerard V.
Aranha, MD
Loyola University Medical Center, Maywood, IL
Purpose. Pancreatic fistula (PF) remains a major concern following
pancreaticoduodenectomy (PD). The use of octreotide for prophylactic
prevention of pancreatic fistula remains controversial. The purpose of this
study is to review our experience of octreotide use in 385 patients undergoing
PD.
Methods. This study was a retrospective case review of a prospective
database of 385 patients that underwent PD between June 1990 and
September 2005. A pancreatic leak was defined as amylase-rich fluid greater
than 50 cc in volume (drain amylase greater than 3 times serum amylase) on
the first day after a regular diet. A PF was defined as a pancreatic leak that
persisted more than 2 weeks. Analyses were performed using SPSS for
Windows with significance pB/0.05.
Results. Of these 385 patients, there were 222 males and 163 females with a
median age of 67 years (range, 20/90 years). Overall nonfatal complications
occurred in 128 patients (33.2%) with pancreatic leak occurring in 59
patients (15.3%) and PF occurring in 47 patients (12.2%). Pancreaticogas-
trostomy (PG) was performed on 235 patients (61%), while 150 patients
(39%) underwent pancreaticojejunostomy (PJ). Octreotride was adminis-
tered perioperatively in 204 of the 385 patients (53%). Of the 204 patients
receiving octreotide, 67 (32.8%) had nonfatal complications, 34 (16.7%)
developed a pancreatic leak, 24 (11.8%) developed a PF, and 14 (6.9%)
developed an intraabdominal abscess. Of the 181 patients that did not receive
octreotide, 61 (33.7%) had nonfatal complications, 25 (13.8%) developed a
pancreatic leak, 23 (12.7%) developed a PF, and 12 (6.6%) developed an
intraabdominal abscess. No significant difference was appreciated between
the use of octreotide and the formation of nonfatal complications (p/0.9),
pancreatic leak (p/0.4), PF (p/0.8), or intraabdominal abscess (p/0.9).
Of the 235 patients that underwent PG, 75 (31.9%) developed nonfatal
complications, 32 (13.6%) developed pancreatic leak, 23 (9.8%) developed a
PF, and 14 (6%) developed an intraabdominal abscess. In the 150 patient PJ
group, 53 (35%) developed nonfatal complications, 27 (18%) developed
pancreatic leak, 24 (16%) developed a PF, and 12 (8%) developed an
62 Presentations
intraabdominal abscess. There was no relation in the method of anastomosis
to the formation of nonfatal complications (p/0.5), pancreatic leak (p/
0.2), PF (p/0.07), or intraabdominal abscess (p/0.2).
Conclusion. This large series demonstrates that octreotride nor the method
of anastomosis made no difference in the incidence of pancreatic leak, PF, or
intraabdominal abscess. Therefore, octreotide cannot be recommended to
prevent morbidities such as pancreatic leak, PF, or intraabdominal abscess in
patients undergoing PD.
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A comparative study for the investigation of the biliostatic effect of
two modern sealants in an experimental liver resection model
Arianeb Mehrabi, MD, PhD, Arash Kashfi, MD, Mehrdad Soleimani, MD,
Said H. Fani-yazdi, MD, Marius Paskonis, MD, Jonas Jurgaitis, MD,
Hamidreza Fonouni, MD, Peter Schemmer, MD, PhD, Martha M. Gebhard,
MD, PhD, Jan Schmidt, MD, PhD, Markus W. Bu¨chler, MD, PhD, Thomas
W. Kraus, MD, PhD
Department of surgery, University of Heidelberg, Heidelberg, Germany;
Institute of Experimental Surgery, University of Heidelberg, Heidelberg,
Germany
Background. Mortality after liver resection (LRx) has been in the last 10
years around 10/15%. By the knowledge of the liver segmental anatomy and
improved resection techniques with the help of modern sealants to improve
hemostasis, mortality around 5% is attainable today. The application of
modern sealants has been established in the liver surgery and they have been
known as effective materials for hemostasis after LRx. To what extent the
sealants after LRx have also a biliostatic effect have not been evaluated
adequately so far. Aim of this study was to compare the biliostatic
effectiveness of two modern sealants in an LRx model.
Material and methods. We accomplished a standardized left hemihepa-
tectomy with a resection surface between 50 and 60 cm2 on 27 landrace
pigs(15.8/36.5 kg). The animals were randomized in three groups. In the
control group(n/9)no sealant was applied to cover the resected surface. In
the TachoSil group(n/9)two TachoSil plates were applied over the resected
area. In the TissuFleece group(n/9)the sealing of the resection surface was
done by means of TissuFleece. After 6 days the animals underwent
relaparotomy for evaluation. The volume of ascites(ml)and number of the
bilioma and/or bile leakages were recorded. Moreover, the degree of
intraabdominal adhesions(0 to 3)and liability of the sealants(0 to 3)were
analyzed. The data of the three groups were compared with each another
(*/pB/0.05; Mann-Whitney-U Test).
Results. The results have been provided in Table 1.
Conclusion. In this study for the first time the biliostatic effectiveness of two
modern sealants was evaluated in a standardized liver resection model.
Sealing of the resected surface leads to a significant reduction of the bilioma
formation and/or bile leakage. Regarding the biliostasis a significantly better
result could be obtained by means of TissuFleece with same extent of
intraabdominal adhesion degree. The use of TachoSil led, despite better
adherence to the surface, to a qualitative and quantitative increase in ascites
and increase of bile leakage.
Control TachoSil TissuFleece
Bilioma or bile leakage 56% 40%* 22%*
Degree of intraabdominal
adhesion
1.5 1.4 1.5
Adherence of the sealant
to surface
2.0* 0.5
Ascites (% of the experiments) 45% 54%* 42%
Volume of ascites (ml) 510 633* 437
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Pancreatectomy is still a myth for young surgeons in greece
Irene O. Christodoulou
Democritus University of Thrace, Alexandroupolis, Greece
Aim of this study is to evaluate the opinion of young surgeons about
pancreatectomy.
Materials and methods. A questionnaire was distributed to 65 young
surgeons. Questions were asked about their education in pancreatic surgery,
the number of operations having participated so far and their opinion for the
experience of General Hospitals. The median age of doctors was 38, 5 years
old and all them had acquired the specialty title during the past 3 years.
Results. Young surgeons believe that pancreatectomy is an important
conquest for any surgeon who hopes in a successful career. The 66% of
them believe that a good surgeon should definitely have operated on pancreas
and in 25% they agree that ‘‘the good name’’ of a surgeon depends on
advanced surgery experience. ?he 28% prefer palliative surgery of pancreas
and assume that radical operations on pancreas is a myth. A majority of 72%
believe that only patients with inoperable disease have to loose the chance of
prolonged survival. A percentage of 62% assume that a young surgeon should
be eligible to operate on pancreas. According to the 31% of young surgeons
adequate experience for pancreatic surgery is 6/7 years of general surgery
operations after the end of redidency while the 6,5% believe that some
surgeons will never acquire the necessary qualifications, because many
Surgical Departments do not treat annually an adequate number of cases
of pancreatic surgical disease. Centers of Excellence are an interesting field
for the 97% of young surgeons.
Conclusions. Pancreatic surgery is an attractive but not realistic field for a
young Surgeon in Greece. As 8/9 years are needed for a surgeon until he
takes a position in the National system of Health, hernia surgery is a closer
prospect.
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Operative choledochoscopic laser lithotripsy for impacted intrahe-
patic gallstones: A novel surgical approach
Kenneth Bark, MD, Randall S. Zuckerman, MD, T. Clark Gamblin, MD,
David A. Geller, MD
The Mary Imogene Bassett Hospital, Cooperstown, NY; UPMC, Pittsburgh,
PA
Introduction. Occasionally patients present with hepatic duct stones or
impacted common bile duct stones that either fail or are not amenable to
ERCP extraction. More troublesome are patients with prior surgeries
resulting in altered anatomy that makes traditional endoscopic extraction of
ductal stones very difficult. We present a novel approach to these ductal
stones using a combination of surgery, biliary endoscopy, and laser
lithotripsy.
Methods. We report on five patients with ductal stones that either failed
ERCP or were not candidates for ERCP extraction. Data was collected via
chart review.
Results. The average age of patients was 70.1 years. All patients presented
with hepaticolithiasis and symptoms of cholangitis. Patients had an average of
2.8 failed ERCP or percutaneous attempts at stone clearance (range 2/4). A
combination of surgery and intraoperative biliary endoscopy with laser
lithotripsy (holmium laser) was used in all patients. In four patients the
lithotripter was introduced via a choledochotomy or hepaticodochotomy.
One patient had previously undergone a Roux-en-Y hepaticojejunostomy and
was found to have a large hepatic duct stone sitting above a strictured
anastomosis. Access was gained via an enterotomy in the Roux limb.
Complete stone clearance was obtained in all patients. Average operative
time was 349 minutes. All patients have normal liver function tests (1/9
month follow up).
Conclusions. Laser lithotripsy has been described as an adjunct to ERCP in
the past for stones refractory to balloon or basket retrieval. The combination
of a surgical enterotomy, biliary endoscopy, and laser lithotripsy provides a
novel approach to treat patients with large intrahepatic stones who are not
candidates for or have failed ERCP.
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Transarterial chemoembolization followed by radiofrequency abla-
tion for hepatocellular carcinoma greater than 4 cm in diameter
Ryan Swan, MD, Adeel Khan, MD, Caroline Simon, MD, Damian Dupuy,
MD, Gregory Soares, MD, Howard Safran, MD, David Iannitti, MD
Brown Medical School, Providence, RI
Purpose. To evaluate survival of patients with hepatocellular carcinoma
(HCC) over 4 cm in diameter treated with transarterial chemoembolization
(TACE) prior to radiofrequency ablation (RFA) in comparison to similar
groups treated with RFA or TACE alone.
Methods. Records of patients with HCC over 4 cm treated with RFA (n/
25), TACE (n/17), or TACE followed by RFA (n/8) over a 5-period were
reviewed.
Results. One-year mortality data was available on 92% of patients. The
mean age of the RFA and TACE/RFA groups were similar (70.5 versus 69.1
years), whereas the mean age of the TACE group was significantly lower
(53.8 years). The mean tumor size was similar in the RFA and TACE/RFA
groups (6.4 versus 6.0 cm); however, the mean tumor size in the TACE
group was significantly larger (10.4 cm), representing a patient population
with more advance disease. Chemotherapy regimens consisted of combina-
tions of mitomycin, cisplatin, and doxorubicin, and embolization was
performed with ethiodol or lipiodol, with the addition of polyvinyl alcohol
or 350/500 micron microspheres as indicated. RFA was performed an
average of 50.5 days after TACE. Survival is equivalent at one year for the
RFA and TACE/RFA groups (59.0% versus 62.5%); however, there is a
trend toward improved survival at three months (77.3% versus 100%, P/
0.28) and six months (68.2% versus 87.5%, P/0.39). Interestingly, the
TACE group, with much more advanced disease, seems to do well early in the
treatment course, with 93.8% survival at three months; however, by 12
months they have a much lower survival than either the RFA or TACE/RFA
group, possibly correlating with the early survival benefit seen in the TACE/
RFA group.
Conclusions. RFA is a proven treatment for unresectable HCC; however, it
becomes less effective as the tumor diameter increases. TACE has recently
been show to increase the diameter of coagulation when given prior to RFA
for HCC less than 3 cm, and recent randomized trials show that TACE
improves survival over supportive care. Thus, it is feasible that pre-treatment
with TACE of HCC that is amenable to RFA would improve survival. This
small review fails to show a survival difference at one year; however, the trend
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toward increased survival early in the treatment course is encouraging and
warrants further investigation in a prospective randomized trial.
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Pre-liver transplant locoregional adjuvant therapy for hepatocellular
carcinoma as a strategy to improve long-term survival
Ankit Bharat, MD, Jeffrey A. Lowell, MD, Jeffrey S. Crippin, MD, Niraj
Desai, MD, Surendra Shenoy, MD, M. Lisker-melman, MD, Kevin
Korenblat, MD, Daniel B. Brown, MD, Martin D. Jendrisak, MD, William
C. Chapman, MD
Washington University School of Medicine, Saint Louis, MO
Pre-orthotopic liver transplant locoregional therapy (POLT) for hepatocel-
lular carcinoma (HCC) reduces drop-out rates while awaiting OLT. In this
study we investigated whether POLT improved long-term survival. In
addition, we reviewed our experience with OLT for HCC and correlated
pre-OLT radiological staging with explant pathology.
Methods. Between 1985 and 2005, 95 patients with HCC underwent OLT.
Of these, 44 also received POLT as transarterial chemoembolization, radio-
frequency ablation, percutaneous ethanol injection or a combination.
Results. The 1-,3-,and 5-yr survival, regardless of POLT, was
81.3%,66.1%,and 61.3%, respectively; with median of 134 months. Demo-
graphic data and waiting time were similar between POLT and untreated
groups. Pre-OLT radiological stage (American Liver Tumor Study Group-
2002) was similar (POLT: 2.099/0.74 vs 2.399/0.94; p/0.16). However, at
transplant, POLT group had significant tumor downstaging (1.59/1.44 vs
Untreated: 2.539/1.17; pB/0.01). POLT group had better 5-yr survival
(82.4% vs 51.8%; p/0.01). However, improvement was observed only in
patients with HCC stage 2, 3 and 4 (POLT: 77.6% vs Untreated: 37.4%, pB/
0.01) (Fig.1). Further, POLT was associated with a trend towards lower
recurrence (13.6% vs 20.8%, p/0.42). Explant pathology of 16 POLT
patients revealed no viable tumor cells(pT0). Radiological stage for these
patients was T1/5,T2/9 and T3/2. None of pT0 patients developed
recurrence and had significantly better long-term survival than untreated
patients with similar T1, T2 or T3 disease.
Correlation pattern of pre-OLT radiological stage at listing with explant
pathology distinctly varied (Accurate : POLT 22.7%, Untreated 56.5%;
Underestimated : POLT 20.5%, Untreated 30.4%; Overestimated : POLT
56.8%, Untreated 13.1%; p/0.03)
Conclusions. OLT is a viable treatment option for primary HCC. POLT
significantly downstages the primary tumor and improves long-term survival
in patients with advanced disease. Complete tumor necrosis with POLT
is associated with excellent long-term recurrence-free survival. Pre-
OLT imaging has low correlation with explant pathology that may be due to
tumor down-staging with POLT or net tumor growth in the untreated group.
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Portal caval nodal involvement may not be a contraindication to
resection of colorectal liver metastases
David Lawson Morris, PhD, Francis Cheuk Kin Chu, MBBS
The University of New South Wales, Sydney, Australia
Introduction. The presence of extra hepatic disease has long been
considered a contra-indication to liver resection for colorectal cancer
metastases. A review paper from 2000 found only 5 out of 145 patients
who had undergone a liver resection in presence of portocaval nodal
involvement are still alive at 5 years.
This has recently been challenged by a French Unit, who reported on 5 year
survival rates of 28% in patients with respectable extra hepatic disease.
Importantly, there were 12 patients that had undergone a liver resection with
involved portocaval node, achieving a 5-year survival of 33%. A question that
has not been addressed is what is the survival of patients with portocaval
nodal involvement and resectable liver metastases but were refused surgery
because of positive lymph nodes?
Method. Between 1990 and 2004, 460 liver resections and/or cryoablations
were performed for colorectal cancer liver metastases at the St George
Hospital Liver Unit. Forty-nine patients had liver resection and ablation or
resection of their extra hepatic disease. There were also 20 patients with
potentially resectable liver metastases but were not resected because of
portocaval node involvement. These patients had insertion of Hepatic Artery
Catheter (HAC), and were given a combination of systemic and regional
chemotherapy. During the same period, 29 patients had liver and portocaval
node resection for metastatic colorectal cancer.
The overall 5-year survival of patients with extra hepatic disease that have
undergone a liver resection was 17%. The medium survival for the resection
group (in patients with involved portocaval lymph node) was 30 months, with
a 3 year survival of 17%. The median survival for the HAC group was 16
months, with a 3-year survival of 7%.
Conclusion. Liver resection in the presence of portocaval nodal involvement
shows a significant survival benefit over systemic and regional chemotherapy
alone. Five year survival of 17% can be achieved in patients undergoing a
liver resection with resectable or ablative extra hepatic disease.
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Biological markers as predictors of outcome and margin status for
pancreatic adenocarcinoma after pancreaticoduodenectomy
John D. Christein, MD, Ruth R. Leeth, MPH, Rashmi K. Murthy, Martin
Heslin, MD, Nirag C. Jhala, MD, J. Pablo Arnoletti, MD, Selwyn M.
Vickers, MD
The University of Alabama at Birmingham, Birmingham, AL
Purpose. To determine associations between p16, p53, margin status, and
survival in a population of patients after pancreaticoduodenectomy (PD) for
pancreatic adenocarcinoma.
Methods. All patients undergoing PD for pancreatic adenocarcinoma from
1994/2005 were included in this review. All pathology reports were
examined and updated according to AJCC 6th edition. Specimens from
margin positive (R1) resections and margin negative (R0) resections
matched for stage, age, and gender were immunohistochemically stained
using anti p53 and anti p16 antibodies. Appropriate positive and negative
controls were stained to determine validity. For both p53 and p16,
specimens with a percentage of positive tumor cells greater than the
mean plus 2 standard deviations of cells positive in reactive ductal
epithelial cells were considered positive. The Kaplan-Meier method was
used to determine survival; univariate and multivariate linear regression
analysis was performed to ascertain impact on survival. Student’s t-tests
were used to describe differences between outcomes for R1 and R0
resections.
Results. 150 patients underwent PD for adenocarcinoma from 1994/2005.
Follow-up was available on all but 7 patients (95%) with a median survival
of 26 months. Fifty-three percent were male, and the mean age was 64
years. Twenty-four patients underwent R1 resections (16%). R2 resections
were excluded from this report. Tumor size (pB/0.01) and lymph node
metastasis (pB/0.05) were negative prognostic factors of survival in
univariate analysis; however, only tumor size remained significant in
multivariate analysis (pB/0.01). Margin status did not significantly affect
survival (p/0.12). In the matched subset examining biological markers,
both p53 and p16 results were not significantly associated with margin
status, node status, tumor size, or survival. An inverse relationship between
p16 and p53 positivity was observed (pB/0.01). African Americans were
more likely to be p16 positive (pB/0.01) whereas Caucasians were more
likely to be p16 negative (pB/0.02).
Conclusion. Multivariate analysis determined only tumor size to be
predictive of survival after PD for pancreatic adenocarcinoma. Margin status
was not significantly associated with survival. p53 and p16 are associated with
pancreatic head adenocarcinoma; however, they are not predictive of tumor
size, margin status, lymph node status, or survival. p16, recognized as a
marker for poor differentiation, was more commonly positive in African
American patients and negative in Caucasian patients.
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Histological assessment of the liver resection plane after application
of modern fleece based sealants in a porcine model
Arash Kashfi, MD, Arianeb Mehrabi, MD, PhD, Thomas Longerich, MD,
Said H. Fani-yazdi, MD, Mehrdad Soleimani, MD, Marius Paskonis, MD,
Jonas Jurgaitis, MD, Hamidreza Fonouni, MD, Peter Schemmer, MD, PhD,
Jan Schmidt, MD, PhD, Markus W. Bu¨chler, MD, PhD, Thomas W. Kraus,
MD, PhD
Department of Surgery, University of Heidelberg, Heidelberg, Germany;
Department of Pathology, University of Heidelberg, Heidelberg, Germany
Although different sealants are widely used to improve hemostasis during
liver surgery, the histological interaction of sealants with the hepatic resection
plane has not been studied in depth. The aim of this study was to evaluate
early postoperative pathological changes of the liver surface after resection
following application of two different sealants in a porcine model.
A standardized left hemihepatectomy was performed in 24 young pigs
(239/4 kg). Animals were randomized into 3 groups (n/8 each group):
control group, ready to use fibrinogen-impregnated collagen fleece (Tachosil-
R) and collagen-based fleece in combination with fibrin glue (TissuFleece/
Tissucolduo-R). The resection plane was either sealed with one of the
sealants, or remained uncovered. After 7 days, a relaparotomy was performed
and the liver surface was analyzed histopathologically. The pathological
features were evaluated (Table 1). Semi-quantitative score data are given as
relative percentage of changes compared to normal liver parenchyma.
Results are shown in Table 1. Fibrin exsudation, tissue inflammation,
granulation tissue formation and parenchymal regeneration were significantly
increased in both sealant groups compared to controls. Intraparenchymal
bleeding at the resected surface was significantly reduced in sealants groups.
Application of fibrinogen-impregnated fleece was associated less necrosis
formation and calcification, compared to other groups, whereas micro-
abscess formation was increased.
Application of sealants on the resected liver surface induces granulation
tissue and fibrosis formation as well as parenchymal regeneration, which
may improve healing after liver resection. This could contribute to a de-
crease of local complications. Collagen-based fleece sealing was associated
with more granulation tissue formation than fibrinogen-impregnated fleece
sealing.
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Role of selective internal radiation spheres (SIR-S) in the manage-
ment of hepatocellular carcinoma (HCC)
Alejandro Mejia, MD, Mariam Mouti, MD, Cheryl Levine, PhD, Travis
Vanmeter, MD, Jeff Weinstein, MD, Stephen Cheng, MD, Reem Ghalib, MD
Liver Institute at Methodist Dallas, Dallas, TX
Introduction. Selective internal radiation spheres (SIR-s) is currently FDA
approved for treatment of colorectal liver metastasis. The use of SIR-s in
the management of Hepatocellular carcinoma (HCC) is not well defined,
but adds a potential good option for patients who are not surgical
candidates or as a way of downstaging tumors to become either transplan-
tatble, resectable or thermal-heat-treatable.The aim of this study is to
describe our experience with the use of SIR-s as an adjunctive or single
therapy for HCC.
Methods. This is a case series of 11 patients (9 males, 2 females) with HCC
and liver cirrhosis who have been treated with at least one session of SIR-
spheres. Baseline lab tests were obtained along with abdominal CT or MRI
3/12 weeks prior to the first treatment with SIR-s. Follow-up CT or MRI
were done within 12 weeks after treatment and repeated as indicated.
Results. Patients age range was 51/80 years (mean 68.19/11.1) Child-Pugh
scores ranged from 5 to 8 (Child’s class A-B). The mean tumor size was
5.57 cm (9/ 2.63) in a total of 14 lesions. All patients were treated with at
least 1 session of SIR-spheres with 4 patients having 2 sessions. Radiological
response, defined as any tumor shrinkage on follow-up imaging,occurred in
60% of cases. Tumor burden reduction ranged from 20/90%. Additional
tumor therapy following SIR-spheres included: chemoembolization (3) and
radiofrequency ablation (2); resection (1) and transplantation (1) were
performed without any complications. surgical resection in 1 patient and
liver transplantation in 1. Progression of tumor and death occurred in 3
patients and extra hepatic carcinomatosis despite hepatic response was seen
in 1 patient. Histological confirmation of response was documented in 2
patients at explant and resection,respectively.
Conclusion. Treatment with SIR-spheres was able to downsize lesions in
60% of patients without limiting further surgical or nonsurgical therapies.
Further data need to be collected on safety and efficacy of SIR-s in treating
patients with HCC. In selected patients SIR-s appears to be an alternative
adjunct or single therapy for large HCC tumors.
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3D Ultrasound Imaging of Hepatic Vasculature Using Volume Scan-
ning in the Post-Operative Transplant Patient: Useful Adjunct to
Traditional Color Flow Imaging?
Misty L. Johnson RTR, RDMS, BA, Kenneth David Chavin, MD, PhD
Medical University of South Carolina, Charleston, SC
Emerging technological advances in the way diagnostic medical ultrasound is
used to aid in the visualization of the post operative liver transplant
vasculature is increasing in value thanks to the latest breakthrough called
3D Volume Imaging.
Traditional pitfalls with color flow imaging in the immediate post operative
period are numerous due to several factors including: patient respiration
(ventilator), organ edema, resulting in apparently dampened or absent
arterial flow and vascular vasoconstriction. Sonographers frequently go
through great lengths to try to visualize and image patent hepatic vasculature,
however, currently, angiography must be relied upon ultimately in order to
‘‘rule out’’ acute arterial thrombosis.
We sought to compare current standards of color flow ultrasonography
with recent advanced imaging capabilities incorporating multiple time
frame sweeps overlapping color flow imaging. Initial assessment in prelimin-
ary studies of the hepatic vasculature with this technological breakthrough
has demonstrated that 3D Volume Imaging is a valuable tool that should be
used in addition to traditional color flow imaging to assess patency.
Comparative images clearly demonstrate the differences in imaging techni-
ques and the usefulness of 3D volume imaging as an adjunct to traditional
methods.
Reversal of flow, turbulent flow, thrombosis, and patency of the main intra
and extra hepatic artery are readily visualized using the volume imaging
technique which incorporates raw data coupled with the time element to
capture necessary data. Its usefulness is demonstrated by allowing the
surgical team time to manage their patient more effectively and efficiently
by eliminating the need to rush the patient off to the angiography suite or to
the operating room for re-exploration.
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outcomes of RFA in un-resected liver tumors in Cincinnati Ohio
Mark J. Thomas, MD, Jill Zink, Amit D. Tevar, MD, Steven Rudich, MD,
Joseph F. Buell, MD
Univ. of Cincinnati Medical School, Cincinnati, OH
Radiofrequency ablation (RFA) is a therapy for liver tumors. It remains
unclear if the outcomes are comparable to traditional resections. RFA has
allowed patients to have therapy for cancers that are poorly responsive to non-
surgical treatments, however. We retrospectively analyzed patients with liver
tumors who underwent RFA.
Methods. All charts were evaluated for patient demographics, tumor size
and diagnosis, RFA technique, local recurrences of tumor and evidence of
tumor seeding. All treatments were carried out with a Boston Scientific
RFA generator and monopolar RFA probes of 2.0/4.0 cm diameters.
Each ablation trial was recorded on an individual log. Every tumor was
located with introperative ultrasound (IOUS) and correlated with the
preoperative biphasic CT. Each tumor was documentedby pathology. RFA
probes were placed with IOUS guidance. Probe size, placement and
number of ablations per tumor was at individual surgeon’s discretion.
Each site was re-evaluated by IOUS for adequacy of ablation. Follow-up
of each patient includes post-ablative biphasic CT at 3, 6 and 12 month
intervals.
Results. 115 patients were treated by RFA. Of these patients 69 were male
and 46 female. 63 patients were cirrhotic (35 Hepatitis C, 9 Hepatitis B, 4
Hepatitis B & C, 5 other) with preoperative AFP levels /2839 (9/1243).
There were 73 laparoscopic surgeries, 39 open and one conversion from
laparoscopic to open. Average OR time was 3.6 hrs (9//1.9). Average
number of masses per patient was 1.8 (9/1.2) with an average diameter of
3.3 cm (9/2.3 cm). There was 1.4 ablations per patient (9/0.4) performed
with 85 single ablations, 20 dual, and 10 with 3 or more. On final
pathology there were 68 hepatomas, 17 colorectal metastases, 13 non-
malignant tumors, 12 non-colorectal metastases and 5 cholangiocarcino-
mas. The mean hospital stay was 2 days. There were 5 recurrent
hypervascular lesions. All lesions occurred at the base of the ablated sites
and were associated with an adjacent vessel. One patient was taken back
for re-ablative therapy and had extension of the tumor outside of the liver.
Complications include 3 adjacent organ superficial burns (stomach,
duodenum and lung) and 1 each of non-fatal pulmonary embolism, bile
Table 1 Pathologic features after liver resection (data are in percentages; *:
pB/0.05 compared to control; **: pB/0.05 compared to other sealant).
Control
Fibrinogen-
impregnated
fleece
Collagen-based
fleece and
fibrin glue
Fibrin production 44 97* 93*
Necrosis 78 57*, ** 89
Associated inflammation 41 77* 78*
Intraparenchymal
bleeding
59 37* 33*
Granulation tissue 37 63* 74*
Calcification 67 40*, ** 78
Microabscess 33 90*, ** 67*
Regeneration 56 80* 80*
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leak, liver bleeding, post-ablative ascites and wound infection. There were
2 deaths.
Discussion. IOUS guided RFA is a viable option for cirrhotic and non-
cirrhotic patients. The present series has a complication rate of 7%,
recurrence of 4.3% and mortality rate of 1.7%. Overall complication,
recurrence and mortality rates will decrease as experience is gained with
this technology. Benefits of a laparoscopic approach with acceptable out-
comes will further enhance this population’s quality of life.
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Liver transplantation and liver resection for surgical treatment of
HCC: A 15-year single-center experience
Arianeb Mehrabi, MD, PhD, Arash Kashfi, MD, Natalia Abel, MD, Khaled
Attallah, MD, Peter Schemmer, MD, PhD, Helmut Friess, MD, PhD, Jan
Schmidt, MD, PhD, Markus W. Bu¨chler, MD, PhD, Thomas W. Kraus, MD,
PhD
Department of surgery, University of Heidelberg, Heidelberg, Germany
Surgical therapy offers the only chance for cure of patients with hepatocel-
lular carcinoma (HCC). The role of partial and total hepatectomy with
subsequent liver transplantation was analyzed in a consecutive series of HCC
patients. It was the aim of this study to compare both treatment modalities on
the basis of various clinicopathological prognostic factors including the TNM
system of pathological classification.
Liver transplantations (n/111) and liver resections (n/109) were per-
formed for the following histological diagnoses: HCC without coexisting liver
disease (44%) or associated with various hepatic abnormalities (39%),
fibrolamellar carcinoma (11%), and mixed hepatocholangiocellular carci-
noma (6%). Different determinants for better outcome were analyzed with
regards to the survival rates.
Overall survival rates at 15 years 51% after transplantation and 59%
following resection. For partial hepatectomy , the following factors were
significantly associated with improved long-term outcome: age of 30/50
years, HCC without coexisting liver disease, fibrolamellar carcinoma, solitary
tumor, unilobar location, absence of vascular invasion, portal vein thrombosis
or extrahepatic spread, primary tumor categories pT 2/3, tumor stages II/III,
and curative operation (R0). Regarding liver transplantation , the correspond-
ing determinants were: fulfilled Milan criteria, pT2, absence of portal vein
thrombosis or extrahepatic spread (negative regional lymph nodes, no distant
metastases), and tumor stage II. It could be clearly shown that the pTNM
classification is of clinical value regarding the assessment of prognostic
significance after resection and transplantation. A group of 33 patients had
secondary operation including transplantations and resections, for intrahe-
patic tumor recurrence.
The results of this study demonstrate that liver resection is the treatment of
choice for primary liver cancer while transplantation may be indicated,
especially in cases of nonresectable or recurrent lesions. Thus, the therapeutic
spectrum for HCC should include both partial and total hepatectomy with
liver transplantation, being integrated into one common concept.
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Changes in portal vein haemodynamics after surgical drainage in
biliary atresia patients: A prognostic factor in determining liver
transplantation
Ibrahim K. Marwan, MD, T. Ibrahim*, H. Elaraby**, E. Koraem***
National Liver Institue, Cairo, Egypt
Background. Hepatic portoenterostomy (HPE) is the initial surgical
procedure of choice to restore bile flow in patients with biliary atresia
(BA). Early diagnosis of BA is critical in those patients who undergo the HPE
procedure before 90 days of age and have a better prognosis. Failure of the
surgical procedure and the complications in patients with BA are indications
for liver transplantation.
The aim of this study is to assess the role of colored duplex ultrasonography
in determining the optimal time for liver transplantation in biliary atresia
patients who underwent surgical drainage operations.
Patients and methods. The maximum velocity (Vmax) and cross-sectional
area (CSA) of the portal vein are accepted parameters affected by post-
operative cholangitis and are prognostic for liver transplantation. Thirty cases
of BA underwent surgical procedures were assessed. There were 16 females
and 14 males with a mean of age of 85.77 days at surgery. Hepaticojeju-
nostomy on Roux-en-Y was performed in 3 cases with type I (BA) with mean
of age 111 days, hepatic portocholecystectomy was done in 4 cases with type
II with mean of age 87 days and HPE procedure in 23 patients with type III
with mean of age 84 days. Serum total bilirubin estimations and coloured
duplex ultrasonography were performed for all patients included in the study
before and after surgery. Patients were divided into groups according to the
degree of postoperative cholangitis: group A (19 cases) without cholangitis,
group B (5 cases) with tractable cholangitis and group C (6 cases) with
refractory cholangitis.
Results and conclusion. tractable cholangitis reduces CSA with no
effect on the Vmax. On the other hand, refractory cholangitis reduces both
Vmax and CSA of the portal vein in BA patients. The postoperative
cholangitis aggravates liver functions, liver fibrosis, portal blood flow and
portal vein shrinkage. Duplex ultrasonography as non-invasive procedure is
helpful in determining the optimal time for liver transplantation referral of
BA patients after surgical drainage by measuring CSA and Vmax of the portal
vein. Vmax and CSA are considered useful parameters for evaluating the
hepatocyte recovery after surgical biliary drainage in patients with biliary
atresia.
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Laparoscopic major liver resections using a bipolar vapor pulse
coagulation system
Marwan Abouljoud, MD, Juan Arenas, MD, Atsushi Yoshida, MD, Dean
Kim, MD
Henry Ford Hospital, Detroit, MI
Background. Over the past few years laparoscopic liver surgery has been
gaining wider acceptance among liver surgeons. Reduced pain, early recovery
and return to work have been the major drivers. Various techniques of liver
parenchyma transection have been used and basically rely on individual
experience and evolving technologies. In this report we describe our early
experience using a vapor pulse coagulation device and its first application in
liver resection.
Patients. For the past few years our center has implemented extensive use of
laparoscopic liver procedures. In the last 6 months we initiated a laparoscopic
major liver resection program. 4 patients in whom this new technology has
been used are the subject of this report. Patient 1 : Left segment, focal nodular
hyperplasia, LOS /3 days, no complications. Patient 2 : Left lobe, giant
hemangioma, LOS /3 days, no complications. Patient 3 : left segment, liver
cell adenoma, LOS /3 days, no complications. Patient 4 : Right lobe, giant
hemangioma, LOS /3 days, no complications. There were no bile leaks and
blood loss was estimated B/100 ml in all cases.
Technique. We used a 5 port technique as described by others. Specimens
were retrieved either rmanually or with endo-catch (Tyco, Mansfield, CT).
Liver parenchyma transection was performed using bipolar vapor
plasma coagulation. The device (Plasma Kinetic System, Gyrus Medical,
Maple Grove, MN) generates up to 200 watts of RF output with a
variable amplitude sinusoid waveform between 320 kHz and 450 kHz.
This energy delivery assures excellent tissue and vessel coagulation
and reduced sticking. PK sytem cutting forceps are used for liver dis-
section using gentle fracture technique, grasping, retraction, coagulation and
cutting with the retractable integrated blade. Hilar structures and hepatic
veins are stapled and divided with an endo-GIA (Tyco, Mansfield, CT).
Fibrin sealant was applied to the resection liver surface (Tisseel, Baxter,
Deerfield, IL).
Conclusions. 1) Laparoscopic liver surgery offers patients significant
benefits when properly applied. 2) Bipolar vapor pulse coagulation can be
used safely for liver parenchyma transection. 3) This new technique offers
consistent tissue coagulation and a reproducible technique for liver transec-
tion and coagulation. 4) This technique should be further explored for wider
application in liver surgery.
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End to side (ES) venous outflow reconstruction (VOTR) in adult
piggy-back liver transplantation (PB-LT)
Wojciech G Polak, MD, PhD, Balazs A Nemes, MD, Shungo Miyamoto,
MD, Paul M Peeters, MD, PhD, Koert P Jong De, MD, PhD, Robert J Porte,
MD, PhD, Maarten J Slooff, MD, PhD
University Medical Center Groningen, Groningen, The Netherlands
No consensus exists regarding the optimal reconstruction of the cavo-caval
anastomosis in piggy-back orthotopic liver transplantation (PB-LT). The aim
of this study was to analyze our experience with end-to-side (ES) cavo-
cavostomy. Outcome parameters were patient and graft survival and surgical
complications. During the period of 1995/2002 146 adult full-size PB-LT in
137 patients were performed with ES cavo-cavostomy without the routine use
of temporary portocaval shunt (TPCS). In 12 patients (8%) this technique
was used for implantation of second or third grafts. Veno-venous bypass was
not used in any case and TPCS was performed only in 8 patients (6%). One,
three and five year patient and graft survival were 84%, 79%, 75% and 81%,
74%, and 69%, respectively. The median number of intraoperative transfu-
sion of packed red blood cells (RBC) was 2.0 (range 0/33) and 30% patients
(n/43) did not require any RBC transfusion. Surgical complications of
various types were observed after 49 LT (34%) and none of the complications
was specifically related to the technique of ES cavo-cavostomy. Our
experience indicates that piggyback LT with ES cavo-cavostomy is a safe
procedure, can safely be performed without the routine use of a TPCS, has a
very low risk of venous outflow obstruction and can also be used effectively
during retransplantations.
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Biliopancreatic diversion/duodenal switch for hyperlipidemic pan-
creatitis
Stuart Marcus, MD, Reezwana Chowdhury, Anthony Grieco, MD
NYU School of Medicine, New York, NY
Recurrent pancreatitis is a major complication of hypertriglyceridemia.
Familial hyperchylomicronemia, is a rare autosomal recessive disorder due
to deficiency of lipoprotein lipase or less commonly apoprotein C II, resulting
in hypertriglyceridemia. It is thought that free fatty acids accumulate in high
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concentrations due to hydrolysis of triglycerides by pancreatic lipase leaking
out of acinar cells in and around the pancreas. In this acidic environment,
trypsinogen is activated initiating pancreatic damage. Although pancreatitis
secondary to hypertriglyceridemia is primarily prevented medically with
dietary restriction, biliopancreatic diversion/duodenal switch (BPD/DS), a
malabsorptive surgical procedure, has been reported to be effective. Here we
report a case of a patient undergoing BPD/DS to prevent further attacks of
acute pancreatitis.
A 32 year old female was diagnosed as a child with type I hyperchylomicro-
nemia due to lipoprotein lipase deficiency. She was maintained on a low fat
diet supplemented with medium chain triglycerides. Since age 10, she has
been hospitalized a total of 24 times for acute pancreatitis. During each
admission, her serum lipids revealed fasting triglycerides in the range of
2000/7000 mg/dL (30/190 mg/dL). Although never developing pancreatic
necrosis, she has had Balthazar Grade E pancreatitis by CT scanning.
Despite compliance with her dietary restrictions, the frequency of her bouts
of pancreatitis increased. In 2003, she underwent BPD/DS. Within months
after the surgery, her serum lipid levels were normal. Her BMI, 36.6 kg/mg2
prior to surgery, decreased to 29.1 kg/m2 afterwards. She developed iron
deficiency anemia postoperatively and has been maintained with fat soluble
vitamins and iron supplements, including intravenous Ferrlecit. The patient
has not had any further hospitalizations for pancreatitis, with 26 months of
follow-up.
Hyperlipidemic acute pancreatitis can be life threatening. Patients with
lipoprotein lipase deficiency are often poorly controlled with medical
management and suffer from recurrent episodes of pancreatitis. BPD/DS is
thought to reduce serum triglycerides and cholesterol levels secondary to
decreased absorption and an enhanced neosynthesis of bile acids resulting
from interruption of bile salt enterohepatic circulation. BPD/DS can change
the clinical course of patients with recurrent pancreatitis from refractory
familial hyperchylomicronemia and should be considered as a therapeutic
option.
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Diagnostic potential of acute phase proteins in pancreatic adenocar-
cinoma
Matthew A Firpo, PhD, Steven R. Granger, MD, E. Nicole Omer, MS,
James A. Disario, MD, Courtney L. Scaife, MD, Sean J. Mulvihill, MD
University of Utah, Salt Lake City, UT
Increasing evidence of the role of inflammation in cancer pathogenesis has
prompted a renewed interest in the examination of the acute phase response
during tumor progression. We have previously shown that the acute phase
protein, haptoglobin, is expressed in pancreatic adenocarcinoma (PA) and
that serum levels of haptoglobin are elevated compared to normal controls
and pancreatitis patients. The functional involvement of haptoglobin in
angiogenesis and extra cellular matrix protein folding suggests its direct
involvement in tumor progression. In this study, we examined serum levels of
other acute phase proteins in PA patients to appraise their diagnostic
potential. Levels of serum amyloid A (SAA), ferritin, a1-antitrypsin, C-
reactive protein (CRP) and transferrin were determined by ELISA in
preoperative serum samples from patients with histologically verified PA
and in age-matched normal controls (Figure). Serum levels for each acute
phase protein except transferrin were significantly elevated in PA patients.
These results suggest that serum levels of SAA, ferritin, a1-antitrypsin, and
CRP may be useful biomarkers for PA. Evaluation of the functional role of
these proteins in the pathophysiology of PA is warranted.
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Is a temporary hemiportocaval shunt enough to protect a small-for-
size graft in living donor liver transplantation?
Burckhardt Ringe, MD, Timothy Maroney, MD, William Meyers, MD
Drexel University College of Medicine, Philadelphia, PA
Small-for-size (SFS) syndrome after living donor liver transplantation
(LDLTx) is characterized by imbalance of graft inflow and outflow, resulting
in liver dysfunction. Causes are various mechanisms contributory to each
other, such as hepatic vein obstruction, small graft size, and portal
hyperperfusion. Several authors have suggested portosystemic shunts to
permanently decompress the portal vein system in SFS grafts. We present the
first case with a temporary hemiportocaval shunt (HPCS).
A 52-year old male with end stage liver disease received a right lobe graft from
his sister. Preoperative graft-recipient-body weight ratio (GRBW) was 0.92%.
Actual graft weight was 752 g, GRBW 0.82%. Since the patient had
significant portal hypertension with a recanalized umbilical vein, it was felt
that the graft size was too small to compensate for high portal inflow.
Recipient and graft right portal veins were anastomosed end-to-end, and a
left HPCS as described before was constructed after reperfusion. Six days
after LDLTx the shunt was occluded with a balloon by interventional
radiology, followed by surgical closure at day 12. During this time his right
portal vein pressure dropped from 40 to 16 mmHg. Repeat liver biopsies
showed severe steatosis and necrosis at day 6 which resolved completely
thereafter. At the same time his total bilirubin peaked at 24.9 mg/dL. Three
months after transplant the patient is doing fine with normal liver function.
As we know from clinical experience, liver grafts are particularly vulnerable in
the early phase after transplantation. Whenever graft perfusion is compro-
mised within the first few days, graft failure may occur leading to death or
retransplantation. Recent studies in LDLTx have shown that high portal vein
pressure (/20 mmHg within 1/4 days) is associated with poor graft function
and decreased patient survival. The concept of portal decompression was
introduced to protect a SFS graft from portal overperfusion, and published
data clearly indicate improved graft function and patient survival. It is
unknown, however, whether there are any longterm sequelae of portocaval
shunts in these patients. This lead us to consider a temporary protection from
portal hyperperfusion by a HPCS, and closure after a few days. As we could
demonstrate in this patient, the graft survived the critical phase. We also
learned that deprivation of too much portal veinous blood can lead to graft
steatosis and necrosis, indicating a potential downside of permanent
portocaval shunts in these patients. More data are needed to support this
new idea of temporary protection against portal hyperperfusion in the acute
phase after LDLTx.
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Angiomyolipoma of the liver: two case reports and literature review
Tsuyoshi Hatsuno, MD
Nagoya Medical Center, Nagoya, Japan
Hepatic angiomiolipoma is a rare benign tumor composed of varying
amounts of mature adipose tissue, smooth muscle, and blood vessels. As
the imaging features of hepatic angiomiolipoma depend on the relative
proportion of the tissue component within the tumor, an exact preoperative
diagnosis is not always made easily.
We present one case of hepatic angiomiolipoma in which the size and internal
composition of the tumor changed during the follow-up syudy, and the other
case of multiple hepatic angiomiolipoma.
Case 1. An asymptomatic 66-year-old woman underwent screening abdom-
inal ultrasound, which revealed a well defined hyperechoic mass in the right
hepatic lobe. A CT examination after the drip infusion of an iodinated
contrast material showed a 11/7 cm inhomogeneous mass in the right
hepatic lobe. Three years later, a two phase dynamic incremental CT scan
was performed. The size of mass had decreased to 4/4 cm, and the mass
revealed homogeneous delayed enhancement. On MRI at 1.5 T, the central
portion of the mass was hyperintense on SE T1-weighted images. Fat-
suppressed T2-weighted images revealed loss of the signal within the mass.
These findings suggested hepatic angiomiolipoma. As the patient agreed to
the operation, the partial resection of S5/6 was performed. The pathological
diagnosis was the same as above.
Case 2. A 47-year-old woman was examined with abdominal CT scan, which
showed low density mass about 3 cm in diameter at the anterior segment of
the liver during clinical follow up of HBV carrier, and the lesion was
preoperatively diagnosed as multiple hepatocellular carcinoma by further
examinations. As the tumors existed within the right lobe of the liver, right
hepatic lobectomy was performed. The multiple tumors were pathologically
diagnosed as hepatic angiomiolipoma.It is thought that this disease may be
increasingly detected with an advance in imaging diagnoses. We must strive to
attain the definite diagnosis by every examination and to select therapeutic
guideline.
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Large undifferentiated embryonal sarcoma of the liver successfully
treated with chemotherapy and liver resection
Pedro W Baron, MD, Antranik A Bedros, MD, Fatenah Majlessipour, MD,
Craig W. Zuppan, MD, George Yanni, MD, Linda J Chen, MD, Edson
Franco, MD, Okechukwu. Ojogho, MD, Waldo Concepcion, MD
Loma Linda University, Loma Linda, CA; Stanford University, Palo Alto,
CA
Undifferentiated embryonal sarcoma (UES) is the third most common
malignant liver tumor in children between 6 and 10 years old. They are
usually unresectable and poorly responsive to chemotherapy or radiation.
Survival is dismal. Complete surgical resection combined with perioperative
chemotherapy offers the best long-term results and possibility of cure. We
report 2 cases of UES treated with complete surgical resection in conjunction
with 6 or more cycles of cisplatin, adriamycin, vincristine, ifosfamide and
etoposide.
Presentations 67
Cases. The first case is a 13 year old boy presenting with headache, fever and
upper respiratory symptoms for 3 months. A large asymptomatic mass was
found in the epigastrium (20 x14 cm). Further evaluation revealed a large
right lobe liver mass and posterior cerebellar mass (2.9/2.4 cm). He
underwent excision of the cerebellar mass prior to the liver resection.
Pathology of the cerebellar mass confirmed pilocytic astrocytoma. Following
extensive recovery from craniotomy, he underwent uneventful right triseg-
mentectomy with negative surgical margins. He remains tumor free at 4
years. The second case is an 11 year old boy who complained of fatigue,
anorexia and weight loss. His work-up showed a large right lobe liver mass
(12/8 cm) extending into the medial segment of the left lobe. He underwent
uneventful extended right lobectomy. He continues to be tumor free at 18
months.
Conclusion. Our experience confirms that the best treatment for UES is
aggresive perioperative chemotherapy and complete surgical resection. Size
of the tumor does not appear negatively impact tumor free survival.
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Vaccination against colorectal cancer: A comparison of tumour lysate
preparations from liver metastases
Amer Aldouri, Alison Merick, K. Prasad, Alan Melcher, G. Toogood
HPB & Transplantation Surgery Unit, St James’ University Hospital, Leeds,
United Kingdom
Background. Immunotherapy trials targeting the induction of immune
response against colorectal cancer appear to hold significant promise. Lysates
from resected tumour are readily available and express the full repertoire of
tumour-associated antigens (TAA) for loading onto antigen presenting cells
such as dendritic cells (DC). We studied the preparation of such lysates and
their effect on autologous DC function.
Methods. Fresh tumour samples were collected from 12 patients undergoing
liver resection for colorectal metastases and processed as follows. Samples
were initially homogenised, and then further disaggregated by sonication or
freeze/thaw. The effects of removal of tumour debris by centrifugation were
also examined. DCs were prepared from peripheral blood mononuclear cells
of the included patients and healthy donors by adherence of monocyte
precursors and subsequent culture with IL-4 and GM-CSF. Samples of
tumour lysate were then incubated with DCs. Activation of DC was
measured by expression of maturation markers (CD80, CD86, MHC-II),
and cytokine secretion (IL-12, IL-10).
Results. Our study showed that DCs derived from patients with colorectal
liver metastases respond efficiently to maturation factors. Also we demon-
strated that whole tumour lysate significantly inhibited the ability of DCs
to mature phenotypicaly and centrifuging the lysate reduced the levels of
this inhibition. Dendritic cells uptake the optimal lysate (centrifuged
tumour lysate prepared by homogenisation and freeze-thaw) and upon
maturation secrete more IL-12 than those pulsed with whole tumour
lysate.
Conclusions. This study suggests that centrifuged tumour lysate prepared
by homogenisation and freeze-thaw is optimal for loading of autologous DCs
with TAA for vaccine preparation for metastatic colorectal cancer.
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A prospective study of inline radiofrequency ablation in hepatic
parenchymal transection / its efficacy and complications
Tristan Yan, MBBS, Steven Daniel, None, David Lawson Morris, PhD
The University of New South Wales, Sydney, Australia; Resect Medical, Inc,
Fremont, CA
Introduction. Bleeding during liver transection remains a potential hazard.
This study is to report the efficacy and complications of In-Line Radio-
frequency Ablation (ILRFA) assisted liver resection.
Methods. The blood loss of 25 consecutive patients who underwent ILRFA
assisted liver resection was obtained by weighing swabs and measuring sucker
jar contents during liver resection and calculated in ml per cm2 of the
transection surface area. Postoperative complications were recorded. Five
clinical variables, which might affect blood loss, were analyzed.
Results. The mean blood loss during parenchymal dissection for the ILRFA
group was 3.4/3.2 ml/cm2. Two patients had intra-abdominal collections
and one patient had bile leakage after ILRFA assisted liver resection. Age,
gender, the extent of liver resection, liver quality and Pringle maneuver did
not demonstrate any significant impact on blood loss.
Conclusions. This study showed that ILRFA assisted liver resection was
associated with very low blood loss. This is likely to improve the operative
safety of liver resection for hepatic tumors. There were no significant
postoperative sequelae.
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Pancreatic cancer: Tumor radiographic volume (V/(4/3)(pi)r3)
assesment for therapeutic efficacy
Suhail Sharif, MD, W Scott Helton, MD, Joseph Espat
UIC, Chicago, IL
Introduction. A controversy between surgical and non-surgical specialties
pertains to the evaluation of non-surgical tumor-treatment endpoints.
Surgical specialties place value on survival outcome, whereas non-surgical
oncology specialists value radiographic tumor response (size). A potentially
useful clinical midpoint worth considering is ‘‘change in’’ (D) tumor volume
(TV) rate to assess therapeutic efficacy. CT imaging provides an estimate of
tumor size, but these estimates have limited accuracy for appropriate
calculation of DTV rate.
Purpose. To create a D TV rate curve from longitudinal follow-up acquired
data of metastatic tumor progression in a patient with a single pancreatic
adenocarcinoma peritoneal metastasis. To assess the applicability of DTV
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curves employed in future clinical paradigms in the assessment of non-
surgical therapeutic efficacy.
Case history. 65-yo, underwent pancreatico-duodenectomy for a path-
T3N0M0 acinar cell adenocarcinoma 10/2001. Patient was disease-free until
08/2003 when an isolated segment-VII liver metastasis was identified. After a
full course of gemcitabine, he underwent chemo-embolization 02/2004;
subsequently a further peritoneal metastasis was identified, which serves as
the basis of this report.
Methods. Serial dynamic contrast-enhanced CT scans of the abdomen were
performed every 120 days from 06/2004 to 09/2005. Tumor area was
calculated by multiplying the length (l) and width (w) (A /l/w). Using the
area of the tumor, the radius was calculated by the formula; r /square root
(Area)/P; tumor volume by V/(4/3)(P)r3. A biaxial plot of TV vs. time was
generated using statistical software.
Results. Five-interval TV points were plotted as shown (below). Points 1/4
reveal a consistent D TV rate whereas point 5 reveals an exponential DTV.
Point 6 is an extrapolated value that predicts the future TV in four months
time (11/05 pending ).
Conclusion. Accurate D TV rate may provide clinicians an individual-
specific endpoint for therapeutic (chemotherapy) efficacy assessment (con-
tinue/stop/change). The DTV curve presented chang
ed treatment in this individual patient. In the future, DTV curves may
become part of the care paradigm of non-surgical therapies.
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Hepatic resection for hepatocellular carcinoma in the elderly
Shogo Tanaka, MD, PhD, Hiromu Tanaka, MD, PhD, Taichi Shuto, MD,
PhD, Shigekazu Takemura, MD, PhD, Takatsugu Yamamoto, MD, PhD,
Takahiro Uenishi, MD, PhD, Seikan Hai, MD, PhD, Mitsuharu Matsuyama,
MD, PhD, Kazuhiro Hirohashi, MD, PhD, Shoji Kubo, MD, PhD
Department of Surgery, Iseikai Johtou Central Hospital, Osaka, Japan;
Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University
Graduate School of Medicine, Osaka, Japan; Department of Graduate
Medical Education and General Practice, Osaka City University Graduate
School of Medicine, Osaka, Japan; Department of Surgery, Fujiikai
Ishikiriseiki Hospital, Higashiosaka, Japan
Background/Aims. As a result of increased life expectancy, number
of hepatic resection for hepatocellular carcinoma in elderly patients has
been increasing, however, details of postoperative complications and out-
come is still unclear. We retrospectively investigated elderly patients who
underwent hepatic resection for hepatic resection, compared to younger
patients.
Patients and methods. Clinical records of the 454 patients who underwent
hepatic resection for hepatocellular carcinoma between January 1993 and
June 2004 were reviewed. The 454 patients were divided into two groups; 97
elderly patients (]/70 years, Group A) and 357 younger patients (Group B).
Postoperative complications and prognosis were compared among the two
groups.
Results. The prevalences of female and positivity for hepatitis C virus
antibody were significantly higher in Group A than Group B (p /0.004
and 0.002, respectively). Comorbidity of heart diseases was tended to be
higher in Group A than Group B (p /0.06). There were no significant
differences in liver function including liver cirrhosis, preoperative treat-
ments, and types of hepatic resection among the two groups, however,
intraoperative blood loss was significantly lower in Group A (median, 530
ml) than Group B (median, 850 ml, p /0.016). There were no significant
differences in the incidence of postoperative complications, including
ascites, pleural effusion, bile leakage, abdominal infection, bleeding, and
hepatic failure, among the two groups (Group A; 31 patients (32%), Group
B; 138 patients (38%), p /0.24). Only one patient (1%) in Group A and
12 (3%) in Group B died of postoperative hepatic failure (p /0.32). In
Group A, intraoperative blood loss alone affected postoperative complica-
tions (p /0.034). Among 89 patients in Group A and 318 in Group B who
underwent the first hepatic resection, there were no significant differences
in cumulative and tumor-free survival rates after the operation (p /0.46
and 0.76, respectively).
Conclusion. Our findings indicate that hepatic resection can be done safely
in selected elderly patients with hepatocellular carcinoma, and the prognosis
also is favorable.
POD 17
Referrals for surgical therapy in patients with hepatocellular carci-
noma: A community experience
Thomas S. Helling, MD, Charles E Woodall III, MD
University of Missouri-Kansas City School of Medicine, Kansas City,
MO
Treatment of hepatocellular carcinoma (HCC) is notoriously difficult.
Either because of oncogenic behavior or the frequent association of
cirrhosis, successful therapy is elusive, particularly in cirrhotics. Surgical
removal has been the only modality that has produced long-term
survival. In large series of patients from specialty institutions median
survival in those undergoing resection of HCC lesions has ranged from
30/70 months. Liver transplantation is an effective treatment when
HCC is favorable (limited in size and number) producing long-term
survival in /70% of patients. Less is known about patients unfit for
transplantation or referral to specialty centers. We examined 61 patients
from 3 urban teaching hospitals over 10 years sent for surgical therapy
and who were unfit for transplantation. We examined their suitability for
operation and resection. Sixty-one patients comprised the study group,
age ranging from 35 to 83 years old. There were 44 patients (72%) with
cirrhosis (Childs A, B, C-27, 15, 2), 21 from HCV infection. Staging is
as depicted:
Seven patients (11%) were not operable (5 advanced disease, 2 co-
morbidities). Of the 54 patients operated 32 underwent resection (28) or
cryoablation (4). The reasons for unresectability were unrecognized multi-
focality-10, poor risk for major hepatectomy-5, portal vein/hepatic vein
involvement-3, metastatic disease-2, excessive blood loss prior to hepatect-
omy-2. Eleven of 17 (65%) non-cirrhotics and 21/44 (48%) cirrhotics were
resectable or ablatable. There were 10 deaths-6 following resection, 2
following cryoablation, and 2 following celiotomy. All deaths were in
cirrhotics (Childs A-4, B-5, C-1), 10/44 (23%); 3/11 (27%) following
segmentectomy and 3/9 (33%) following major hepatectomy. Seven deaths
were in patients with HCV (p/NS). From this series the difficulty in
surgically treating cirrhotic patients in an urban practice is evident. From
39% to 73% of patients had advanced local disease. Less than half were
resectable, and, for cirrhotics, the postoperative mortality was high, even after
‘‘minor’’ hepatectomies. Non-cirrhotics fared somewhat better. While HCC
in community practice can be treated surgically in the majority of non-
cirrhotics, cirrhotics are less likely candidates and are associated with
significant postoperative mortality. Non-surgical options should be consid-
ered in this population.
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Identification of a disconnected pancreatic remnant (DPR) predicts
reoperative rates to close pancreatic fistulas in patients with pan-
creatic necrosis
Thomas J. Howard, MD, Jay B. Patel, MD, Kumar Sandrasegaran, MD, Jian
Yu, Atilla Nakeeb, MD, Henry A. Pitt, MD, Nicholas J. Zyromski, MD,
Keith D. Lillemoe, MD
Indiana University, Indianapolis, IN
Pancreatic fistulas after operative de´bridement of pancreatic necrosis (PN)
can resolve nonoperatively or require additional fistula-directed surgery
including internal drainage or resection. Little attention has been placed on
the presence of a viable, disconnected pancreatic remnant (DPR) and its
relationship to post-de´bridement pancreatic fistulas. The aim of this study is
to determine whether the presence of a DPR influences the incidence of post-
de´bridement pancreatic fistulas or the requirement for further fistula-directed
surgery.
Methods. From July 2002 to May 2005, 47 consecutive patients with
PN had preoperative contrast-enhanced imaging (42 CT, 5 MRI)
followed by operative de´bridement and external drainage. Imaging was
interpreted in a blinded fashion by a GI radiologist for Balthazar score,
% necrosis, and the presence of a DPR. Pancreatic fistula was defined as
/50 mL/d of fluid with amylase /3 times the upper limit of normal
serum levels. Clinical data including: necrosis infection status, incidence
of organ failure, hospital and ICU length of stay (LOS), morbi-
dity, number of de´bridements, incidence of pancreatic fistula, fistula-
directed reoperation rate, and mortality were abstracted from the medical
records.
Results. Of the 47 patients evaluated, 60% were male and their mean age
was 549/16 yrs. Patients were divided into those with DPR (N/22) and
those without DPR (N/25). There were no differences in age, sex, etiology
of pancreatitis, number of pancreatic de´bridements, preoperative APACHE
Table of Contents Staging System
Staging System Distribution
TNM T1/29, T2/8, T3/23, T4/1, N1/5
Okuda 1 /36, 2 /24, 3 /1
Barcelona A1/10, A2/4, A4/2, B/30, C/12, D/3
Variable
DPR
(N/22)
NO DPR
(N/25)
p
value
Pancreatic fistula 15 (68%) 13 (52%) 0.37
Nonoperative closure 2 (13%) 8 (62%) 0.02*
Fistula-directed surgery 13 (87%) 5 (38%) 0.02*
Mortality 1 (5%) 1 (4%) 0.72
*/statistically significant.
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II scores,% pancreatic necrosis, incidence of infected necrosis, Balthazar
scores, hospital or ICU LOS between groups.
Conclusions. Pancreatic fistulas develop in the majority of patients with
PN after operative de´bridement and external drainage and many close
nonoperatively. Pancreatic fistulas in patients with a DPR rarely close
nonoperatively, and 87% will require further fistula-directed surgery (internal
drainage or resection) for closure.
POD 19
Descriptive epidemiology of hepatocellular carcinoma in a low-risk
area
Michel Dagenais, MD, Marie-france Raynault, MD, Real Lapointe, MD,
Andre Roy, MD, Richard Letourneau, MD
Centre hospitalier de l’Universite´ de Montre´al, Montre´al, PQ, Canada;
Universite´ de Montre´al, Montre´al, PQ, Canada
A better understanding of the epidemiology of hepatocellular carcinoma can
help implement public health measures like screening and vaccination.
Methods. All the hospitals that reported primary liver tumors (ICD 9151
and 8170/3) in the Quebec Tumor Registry between 1984 and 1991 were
sent questionnaires that were filled by the institution’s Medical Records
Department or by our clinical research nurse. 951 of the 967 cases in the
Registry (95,9% response rate, 108 hospitals) were studied for: history of the
disease, diagnosis, treatments, risk factors, cause of death and socio-
demographic data. Patients that did not have an hepatocellular carcinoma
(n/89) were rejected. Patients that were treated in more than one hospital
(n/73) were identified and counted once. 789 cases of hepatocellular
carcinoma were studied. The main biases of this study are: reliance on
hospital records and on the Quebec Tumor Registry, potential under-
reporting of cases and multiple observers. The main strenghts are: large
sample, high response rate (/95%), study done over 7 years, use of a reliable
data bank. Results. Patients demographic data are: male 74%, cirrhosis in
72.7%, hepatitis B in 9.6%, hepatitis C in 2.9%, born in Canada 65.5%,
mean age at diagnosis 64.5 years, mean age at death 65.8 years, no particular
past or present employment. Patients had advanced disease at diagnosis
(multicentric tumor 52%, metastases 24,3%) and 72.8% received no
treatment. The diagnosis was made at autopsy in 19,8%. Treatment
consisted of: liver resection (n/78), liver transplantation (n/13), che-
motherapy (n/70), intra-arterial chemoembolization (n/16) and per-
cutaneous ablation (n/10). Survival at one six 12 and 60 months was:
56.1%/24.2%/14.7%/5.0% (median 68 days). Poor prognosis indicators were
alpha-foetoprotein /400 ng/ml, cirrhosis, birth outside of Canada and
hepatis C. Conclusion. These results are consistent with other reports from
low incidence areas. The care of patients with hepatocellular carcinoma was
not centralized during the study period. Patients were diagnosed with
advanced disease and survival was poor. Systematic screening of cirrhotic
patients that has become more widespread in the last decade might have
improved these outcomes. This work has been supported by Quebec Health
Research Fund.
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Operative management of life-threatening complications after major
pancreatic surgery for chronic pancreatitis
Thomas Schnelldorfer, MD, David B. Adams, MD
Medical University of South Carolina, Charleston, SC
Introduction. Most life-threatening complications after major pancreatic
surgery resemble operative emergencies. They arise suddenly and unexpect-
edly and call for quick judgment and prompt action. This study evaluates
postoperative surgical emergencies and their outcome in patients who
underwent operative treatment for chronic pancreatitis.
Methods. The records of 313 consecutive patients who underwent pancrea-
ticoduodenectomy (n/78), lateral pancreaticojejunostomy (n/152), and
distal pancreatectomy (n/83) for chronic pancreatitis from 1995 through
2002 were retrospectively reviewed and analyzed. Thirteen patients were
identified with life-threatening postoperative complications requiring emer-
gent operative treatment.
Results. Early complications were massive hemorrhage requiring re-
operation within 24 hours of operation. This included 5 cases with
bleeding from the transected pancreas, transverse pancreatic arteries, cystic
artery, or portal vein tributary. Re-operation controlled hemorrhage in all
cases. Late complications requiring re-operation occurred between post-
operative day 6 and 16. After pancreaticoduodenectomy there were two
patients with afferent limb obstruction causing disruption of the choledo-
chojejunostomy in one. Two patients had gastrojejunostomy or jejunojeju-
nostomy leaks. One patient underwent open drainage of a peripancreatic
abscess associated with surgical drain erosion into the pancreaticojejunost-
omy. Disruption of the pancreatic anastomosis after lateral pancreaticoje-
junostomy with abscess and sepsis occurred in two immunocompromised
patients. Both were treated with excision of the Roux-en-Y intestinal limb
and wide drainage of the pancreas and died within 1 to 4 months after re-
operation. A patient who underwent lateral pancreaticojejunostomy with
biliary bypass developed postoperative pancreatic and biliary leakage with
abscess and small bowel necrosis. Operative intervention for abdominal
wall dehiscence with intestinal evisceration was necessary in one patient
after lateral pancreaticojejunostomy. These complications increased the
average length of hospital stay by 9 to 40 days. No survivors had long-term
adverse effects.
Conclusion. Postoperative hemorrhage is the foremost early life-threaten-
ing complication after major pancreatic surgery for chronic pancreatitis.
Most late emergency complications are related to pancreatic, biliary, or
intestinal leaks causing sepsis between one and two weeks after the original
operation. The majority of these complications can be treated without long-
term deficits.
POD 21
Outcome of laparoscopic cholecystectomy for patients with previous
gastrectomy
Akira Sasaki, MD, Hidenobu Kawamura, MD, Hiroyuki Nitta, MD, Go
Wakabayashi, MD, PhD
Iwate Medical University, Morioka, Japan
Background. Previous gastrectomy has been considered as a relative
contraindication to laparoscopic cholecystectomy (LC). The aim of this
study was to evaluate the safety and effectiveness of LC for patients with
previous gastrectomy.
Patients and methods. From April 1992 to August 2005, 1,060 con-
secutive patients underwent LC. Of these patients, 48 (4.5%) had a previous
gastrectomy; gastric cancer (33) and gastroduodenal ulcer (15). Surgical
procedures that had been performed included distal gastrectomy (32), total
gastrectomy (14), proximal gastrectomy (1), and partial gastrectomy
(1). Analysis of variance was used to compare operative time, blood
loss, operative complication rate, conversion rate, diet resumption, and
postoperative hospital stay between the group with gastrectomy (GG) and the
group without gastrectomy (GWG).
Results. The incidence of choledocholithiasis was significantly higher for
GG vs GWG (31.3 vs 9.0%; p/0.001). Choledocholithiasis was found in 15
patients (31.3%) and removed by endoscopic sphincterotomy (8), laparo-
scopic choledocholithotomy with primary closure of choledochotomy (6),
and open T-tube drainage (1). Adhesiolysis to the anterior abdominal wall
was performed in 32 patients (66.7%). Operative time was significantly
longer for GG vs GWG (111.8 vs 78.0 min; p/0.001). No significant
difference in operatve time for GG was found between the first-half and
second-half patients (111.8 vs 107.4 min). Conversions to an open
cholecystectomy were required in two patients because of marked adhesions
in Calot’s triangle and around the gallbladder. No significant differences
between the two groups in blood loss, conversion rate, operative complication
rate, diet resumption, and postoperative hospital stay.
Conclusions. Previous gastrectomy was not a contraindication to safe LC.
However, previous gastrectomy is associated with an increased need for
adhesiolysis, and a longer operative time.
POD 22
Systematic use of live donor liver transplantation: Differential impact
on children and adults
James V. Guarrera, MD, Chris Reverte, John Francis Renz, MD, PhD,
Benjamin Samstein, MD, Dominique Jan, MD, Milan Kinkhabwala, MD,
Jean Emond, MD
Columbia University Medical Center, New York, NY
Objective. To determine the impact of LD on access and outcomes
compared to deceased donor (DD) transplant and to detect the impact of
the learning curve on LD in adults.
Methods. Survival, waiting list mortality, and the effect of selected outcome
variables were analyzed in 694 transplant candidates.
Results. 113 LD transplants were performed as primary transplants, 73 in
adults (25%), and 40 in children (51%). Patient survival at 1 year was 93%
for children and 87% for adults (p/0.02). In children 1 year survival was
97% for DD and 89% for LD (p/ns), while for adults at 1 years survival was
87% for DD and 83% for LD. Among the 73 LD in adults a marked effect of
experience was noted. In the first 35 cases, graft failure due to technical losses
(nonfunction, thrombosis, or biliary sepsis) occurred in 11 (31%), while only
1 of the subsequent 37 grafts was lost (p/0.0004). This effect was
independent of OR time, blood loss, and preoperative liver function
(MELD).
Conclusion. This study documents the impact of LD on access which is
higher in children than adults, permitting to higher transplant rates and lower
pre-transplant mortality. The marked improvement observed in the outcomes
of adult LD suggests that the benefits increase with experience.
Pediatrics Adults
Total waitlisted
(includes retransplantations)
119 589
DD (%) 49 (41) 221 (37)
LD (%) 40 (34) 73 (12)
Died waiting (%) 5 (4) 88 (15)
Still listed (%) 16 (9) 187 (32)
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Portal vein embolisation before major liver resection for colorectal
liver metastases: Does the presence of bilateral metastases contra-
indicate the procedure?
Valerio Lucidi, MD, Eric Vibert, MD, Angela Palmisano, MD, Daniel
Azoulay, MD, PhD, Rene Adam, MD, PhD, Denis Castaing, MD, PhD
Centre Hepato Biliaire, Hopital Paul Brousse, Villejuif, France
Preoperative portal vein embolisation (PVE) may extent the limits of
resection in case of major hepatectomy. However, in case of bilateral
metastases, the risk of tumor growth induced by liver regeneration in the
non embolized liver (NEL) remains undetermined.
Aim of the study. To evaluate postPVE tumor growth in NEL, post PVE
resecability rates and survivals in patients with bilateral colorectal liver
metastases (CLM) as compared with patients without CLM in the NEL at
time of PVE.
Patients and methods. 104 patients who underwent PVE before
major hepatectomy for CLM were reviewed. The results of the 51
patients with CLM in the NEL (group 1) were compared with those of the
53 patients without CLM in the future remnant liver (FRL) before PVE
(group 2).
Results. Globally, PVE induced a significant gain of volume of FRL from
26,2 Aˆ9/8,4% to 35,7 Aˆ9/11,5%, with a median volumetric gain of
133 Aˆ9/125 cc. In group 1, the number and size of CLM present in the
NEL before PVE significantly increase after PVE: 1.8 nodules pre-PVE vs
2.6 post-PVE (p/0,0002) and 25.7 mm vs 31.1 mm (p/0,02). In group
2, new CLM developed after PVE in 20 patients (37.7%); the median
number and size of these new CLM were 2,21 Aˆ9/1,4 and 21,1 Aˆ9/10,8
mm respectively. Rate of tumor progression, defined as appearance in
NEL of a new nodule or /50% increase in size of existent nodule, was
significantly increased in group 1 as compared with group 2 (64,2%
vs 37.7%, p/0,017). Operative cancellation rates due to tumor progres-
sion after PVE (21.5% in group 1 vs 15% in group 2, p/0.3) and rates
of curative intent resection (66,6% in group 1 vs 71,6% in group 2,
p/0,5) were similar in both groups. Three and 5-years-survivals were
not significantly different between groups 1 and 2, reaching 29,3%
and 7,3% for group 1 and 34,1% and 17,1% for group 2 (p/0,7)
respectively.
Conclusions. In case of bilobar CLM, PVE induces a significant growth of
tumor(s) present in the NEL. However this does not affect resecability rate
and long term survival and therefore, bilateral CLM should not be
considered as an absolute contraindication for PVE.
POD 24
Comparison of the traditional orthotopic liver transplantation with
the modified piggyback technique of belghiti
Arianeb Mehrabi, MD, PhD, Arash Kashfi, MD, Peter Schemmer,
MD, PhD, Bruno M. Schmied, MD, PhD, Peter Sauer, MD, PhD,
Helmut Friess, MD, PhD, Markus W. Bu¨chler, MD, PhD, Jan Schmidt,
MD, PhD
Department of surgery, University of Heidelberg, Heidelberg, Germany
Traditionally, orthotopic liver transplantation (LTx) has consisted of a total
native hepatectomy that included retrohepatic inferior vena cava. The so-
called "piggyback" technique was described by Tzakis and modified by
Belghiti. The Belghiti method consists of a recipient hepatectomy with
preservation of the native retrohepatic IVC and a subsequent side-to-side
caval anastomosis. In this study, a single center’s experience with both
techniques (Traditional vs. Belghiti) is analyzed to determine any significant
differences in survival rate, intraoperative blood loss, operating time, length
of stay in the ICU, and total length of stay in the hospital as well as the clinical
outcome.
We performed the traditional (n/220) and the modified LTx by
Belghiti (n/210) in 413 patients (Age: 50.29/7.7; m/w: 3/2; Child A:
9%, B: 35%, C: 56%; HU: n/33). Peri- and postoperatively collected
data concerning time of surgery (h:mm), time of anastomosis (h:mm),
cold storage time (h:mm), blood loss (ml), intraoperative substitution of
packed red blood cells (RBC), and the number of re-transplantations
(re-LTx) were compared. The data are presented as the mean (*/pB/
0.05; Table 1).
By implementing the Piggyback-Technique the time of surgery, anastomosis
and cold storage could be reduced significantly. Also, blood loss and the
number of substituted packed blood cells and FFPs could significantly be
reduced. The modified Belghiti-Technique is a simplification of the surgical
procedure. The caval outflow was respected during the anhepatic phase.
The technique, requiring only one caval anastomosis, has reduced the
duration of the anhepatic phase as well as the need for venous bypass.
Clinical outcome and quality of liver transplantation could be positively
influenced by optimizing the surgical procedure using the modified technique
by Belghiti.
POD 25
Preshunt liver function remains the prominent determinant of
survival after portasystemic shunting
Alexander Rosemurgy II, MD, Elizabeth Carey, Desiree Villadolid, Donald
Thometz, Daphne Pinkas, Whalen Clark, Sarah Cowgill, MD, Emmanuel
Zervos, MD
University of South Florida, Tampa, FL
Introduction. Liver function has long been regarded as a key determinant in
survival after portasystemic shunting. Forty-five years after the development
of Child Class, we sought to determine if hepatic function is still a primary
determinant between short and long-term survival after portasystemic
shunting.
Methods. 147 patients underwent small diameter prosthetic H-graft
portacaval shunting (HGPCS) more than five years ago. The patients were
categorized into two groups: those surviving less than five years (short-term)
and those surviving more than five years (long-term). Data obtained prior to
shunting determined Child Class and MELD Score. Data are presented as
median, mean9/SD. Mann-Whitney U-test or Chi-squared test for trend,
with significance accepted at pB/0.05, were used to compare short and long-
term survivors.
Results. 94 (64%) patients were short-term (survival 17.7 months, 29.99/
42.21) and 53 (36%) patients were long-term (survival 93.1 months, 108.99/
42.1) survivors. Their average ages at the time of shunting were similar (58,
57.3 9/12.8 years vs. 49, 51.39/13.1 years). There was no significant
difference in the cause of cirrhosis (62% alcohol vs. 53% alcohol, p /
0.73), presence of pre-shunt ascites (61% vs. 55%, p /0.43), or encephalo-
pathy (29% vs. 7%, p /0.11) between short and long-term survivors.
Emergency operations were significantly more common in short-term
survivors than long-term survivors (20% vs. 13%, p /0.026). Preshunt
MELD score was significantly greater with short-term survivors (15, 169/5.8
vs. 11.5, 12 9/3.4, p B/0.0001), though actual survival was superior to
predicted survival by MELD, (Mantel-Haenszel x2 pB/0.001). Preshunt
Child Class was inferior for short-term survivors (6 A, 23 B, 65 C vs. 10 A,
17 B, 26 C, p /0.0204).
Conclusion. Long-term survival after HGPCS is possible even with severe
hepatic dysfunction, though individual predictions must be interpreted with
caution. Though emergency shunting predicted short-term survival, short
and long-term survivors were not otherwise descriptively different. Five
decades ago Dr. Child recognized that hepatic dysfunction plays a significant
role in predicting outcome after portasystemic shunting. Hepatic dysfunc-
tion, as denoted by Child Class and MELD, remains a primary determinant
of survival after portasystemic shunting.
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Recombinant activated factor VIIA is more efficacious at reversing
the coagulopathy associated with advanced liver disease
Fahim Habib, MD, Antonio Marttos, MD, Amir Raza, DDS, Mark
Mckenney, MD, Teofilo Lama, MD, Angeleke Saridakis, MD, Eddy Carrillo,
MD
Memorial Regional Hospital, Hollywood, FL
Objective. To compare the efficacy of Fresh Frozen Plasma (FFP) with that
of recombinant Factor VIIa (rFVIIa) in reversing the coagulopathy associated
with advanced liver disease.
Methods. Retrospective chart review of patients with cirrhosis who received
rFVIIa for bleeding that did not respond to FFP. Prothrombin time (PT) and
International Normalized Ratio (INR) were compared before and after
administration of FFP and of rFVIIa.
Results. Six patient’s (5 male, 1 female) with a mean age of 55 years (range:
44/64) met study criteria. The patient’s received a mean of 75 mcg/Kg
(range: 20/100 mcg/Kg) of rFVIIa. The mean correction in PT was 19.6%
(range: 1.3/59%) for the FFP group and 40.7% (range: 30.2/51.3%) for
the rFVIIa group. The mean correction of the INR following FFP was 32%
(range: 5/75%), while that following administration of rFVIIa was 65%
(range: 49/77%).
.
Liver transplantation
Technique of deaths
Time of
surgery
Time of
anastomosis
Cold
storage
Blood
loss RBC Re-TPL
Number of
deaths
Traditional (n/220) 7:35 1:39 9:23 1980 5,3 20 20
Belghiti (n/210) 5:19* 0:41* 5:39* 1150* 1,5* 9* 6*
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Conclusion. rFVIIa appears to have superior efficacy in correcting the
coagulopathy associated with advanced liver disease. These results need to be
confirmed in a larger cohort of patient’s.
POD 27
LCBDE using 2.8 mm choledochoscope is not assiociated with
pancreatitis risk
Donald E Wenner Jr., MD, Paul Whitwam, MD, David Turner, MD, Jason
M Johnson, DO, Eastern NM Medical Center, Roswell, NM
William Beaumont Army Medical Center, El Paso, TX
Introduction. Endoscopic Retrograde Cholangiopancreatography(ERCP)
with sphincterotomy has become the predominant means to clear stones from
the common bile duct(CBD) in patients with choledocholithiasis. It is well-
known that pancreatitis occurs in 10% of patients following ERCP, with
1% of these patients developing severe pancreatitis. Randomized studies
have also shown that laparoscopic common bile duct exploration(LCBDE) is
as effective as ERCP in clearing the CBD. Additionally, LCBDE costs less
than ERCP and is associated with a shorter hospital stay. This study evaluates
the risk of pancreatitis after LCBDE using a 2.8 mm flexible choledocho-
scope.
Methods. Prospective data was collected on 68 consecutive patients
undergoing LCBDE using a 2.8 mm flexible choledochoscope. Indications
for LCBDE were stones seen on intraoperative cholangiography(IOC)
(n/62) or failure of ERCP to clear stones from the CBD(n/6). The
choledochoscope was guided into either the cystic duct or CBD using the
multi-channel instrument guide(MIG). Stones were manipulated with
irrigation, stone baskets, balloon catheters, and lithotripters with video
guidance provided by the video choledochoscope. Balloon dilation of the
Ampulla was never performed; however, balloon catheters, choledocho-
scope and stone baskets were frequently passed through the Ampulla.
Stone baskets were not pulled through the Ampulla in the open
configuration.
Results. Postoperative amylase levels(Mean79, St.Dev.63) were significantly
lower than preoperative levels(Mean 212, St.Dev.427) (paired T-test, p/
0.05). There were no cases of post-operative pancreatitis and none of the
patients who presented with gallstone pancreatitis had relapse or worsening of
their pancreatitis after surgery.
Discussion. Laparoscopic cholecystectomy with IOC and LCBDE using the
2.8 mm choledochoscope carries a lower risk of post-procedure pancreatitis
than ERCP with sphincterotomy. This study strongly suggests that pre-
operative ERCP based on the clinical suspicion of choledocholithiasis should
be abandoned in favor of LCBDE. LCBDE techniques are evolving, and our
technique using the 2.8 mm video choledochoscope in conjunction with the
MIG, stone baskets, irrigation, balloon catheters, and lithotripsy devices has
been shown to be effective in virtually all cases of choledocholithiasis with no
cases of post-operative pancreatitis.
POD 28
Radiofrequency assisted liver resection: in-vivo porcine testing of a
novel device
Ann P. O’Rourke, MD, Dieter Haemmerich, PhD, David J. Schutt, MS,
James A. Will, DVM, PhD, John G. Webster, PhD, David M. Mahvi, MD
University of Wisconsin, Madison, WI; Medical University of South
Carolina, Charleston, SC
Purpose. Hepatic resection is the standard of care for hepatic malig-
nancies, but is associated with blood loss averaging 600 ml to 1350 ml.
Excessive blood loss is associated with poor patient outcomes. A prototype
radiofrequency (RF) device was developed that combines three innovations
in RF technology: application of bipolar current, blade electrodes in a
linear array, and rapid switching of power between blade pairs. This
unique combination of RF technology creates a plane of coagulated
tissue /1 cm wide in 3 min. Computer modeling of the RF device
predicted coagulation of all blood vessels 5/3 mm within the coagulated
plane. This device is proposed to decrease blood loss and operative time in
hepatic resection. The purpose of this study was to evaluate a novel RF
device in an in-vivo porcine model. We hypothesized that the new device
would effectively coagulate small vessels and thus result in minimal blood
loss.
Methods. In-vivo testing of the RF resection device was performed on an
anesthetized 20/35 kg domestic swine. Each of the four lobes of the
porcine liver was resected after application of the array. The blades were
placed under ultrasound guidance, and impedance controlled power was
applied for 3 minutes. Hepatic inflow was occluded during power
application. Each lobe was resected along the lateral edge of the device.
The cut liver edge was assessed for bleeding or bile leakage. Each piece of
resected liver was digitally imaged and all visible vessels were assessed with
ImageJ software (NIH) to measure the diameter of coagulated blood
vessels.
Results. A total of 8 experiments were performed, utilizing 4 lobes of the
liver each time, for a total of 32 resections. 77% of all visible vessels were
completed coagulated. The maximum measured coagulated vessel was 3 mm.
The minimum measured uncoagulated vessel was 0.6 mm. Post-coagulation
measurements underestimate vessel size by 30%. Of the incompletely
coagulated vessels, all bleeding was easily controlled with ligation. No bile
leaks were identified on the cut surface of the liver. Coagulation was
completed in 3 min for all resections.
Conclusions. This new blade electrode RF device has the potential to
reduce blood loss and operative times in hepatic surgery.
POD 29
Preoperative methylprednisolone administration maintains coagula-
tion homeostasis in patients undergoing liver resection: Importance
of inflammatory cytokine suppression
Carlo Pulitano`, MD, Luca Aldrighetti, MD, PhD, Marcella Arru, MD,
Renato Finazzi, MD, Marco Catena, MD, PhD, Eleonora Guzzetti, MD,
Laura Soldini, MD, Gianfranco Ferla, MD
Scientific Institute H San Raffaele, Milan, Italy
Alterations in hemostatic parameters is a common finding after major
hepatic resection. Hepatic dysfunction following ischemia reperfusion,
removal of significant hepatic volume, and heavy hemorrhage, upset the
coagulation balance because of impaired synthesis of clotting factors,
regulatory proteins, and production of inflammatory mediators. There
is growing evidence that inflammatory cyokines play a significant role
in regulating the hemostatic balance. In order to determine whether
preoperative Methylprednisolone administration has a protective effect
against the development of coagulation disorders, we measured the effect
of preoperative steroids administration on changes in hemostatic para-
meters and plasma levels of inflammatory cytokines in patients undergoing
liver surgery. One-hundred patients undergoing liver resection were
randomized to a steroid group or to a control group. Patients in the
steroid group received preoperatively 500 mg of methylprednisolone.
Serum levels of coagulation parameters, prothrombin time, platelets,
fibrinogen, plasma fibrin degradation products, antithrombin III (AT-III)
and inflammatory mediators, interleukin-6 (IL-6) and tumor necrosis
factor alpha (TNF-a) were measured before and immediately after the
operation and on post operative days (POD) 1, 2, and 5. Decreases in
platelet count and fibrinogen levels, prolongation of prothrombin time,
and increases in the plasma fibrin degradation products were signifi-
cantly suppressed by the administration of Methylprednisolone. The post
operative levels of AT-III in the control group was significantly lower
than in the steroid group at each time point measured after hepatic
resection. Cytokines production were also significantly suppressed by the
PT/INR before and after FFP and rFVIIa
Pre-FFP Pre-FFP Post-FFP Pre-rFVIIa Post-FFP Pre-rFVIIa Post-rFVIIa Post-rFVIIa
Patient # PT INR PT INR PT INR
1 22.1 3.4 19.2 2.6 10.3 0.7
2 65.2 /20 26.6 5.0 14.5 1.5
3 30.8 5.2 27.3 4.9 13.3 1.2
4 20.4 2.9 15.9 1.7 11.1 0.9
5 18.6 2.4 16.7 1.9 11.0 0.8
6 17.5 2.3 15.1 1.7 10.2 0.7
PT: Prothrombin Time, INR: Internation Normalized Ratio.
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administration of Methylprednisolone, and there were significant correla-
tion between plasma levels of cytokines and coagulation alterations. These
findings suggest that preoperative Methylprednisolone administration
inhibits the development of coagulation disarrangements in patients under-
going liver resection, possibly through suppressing the production of
inflammatory cytokines.
POD 30
Phase I study of neoadjuvant chemoradiotherapy with gemcitabine
for resectable pancreatic cancer
Yutaka Takeda, MD, PhD, Shoji Nakamori, MD, PhD, Shigeru Marubashi,
MD, PhD, Atsushi Miyamoto, MD, PhD, Hiroaki Nagano, MD, PhD, Keizo
Dono, MD, PhD, Koji Umeshita, MD, PhD, Morito Monden, MD, PhD
Osaka University Graduate School of Medicine, Suita City, Osaka Pre-
fecture, Japan; Osaka National Hospital, Osaka City, Japan
Purpose. To evaluate the feasibility and tolerance of a preoperative course of
gemcitabine with radiation, a phase I study was performed for resectable
pancreatic cancer.
Materials and methods. Fifteen patients (median age 68 years, range 43/
77 yr, Performance Status 0/1) with Stage III and IVA were included.
Gemcitabine was given weekly for 2 cycles combined with radiation (30 Gy in
20 fractions or 36 Gy in 24 fractions, 1.5 Gy per fraction). The initial dose of
gemcitabine was 400 mg/m2 administered as short intravenous infusion once
a week. At each dose level 3 patients were treated, and if no World Health
Organization grade 4 hematologic or grade 3 other toxicity (considered as
dose-limiting toxicity, DLT) was recorded, dose escalation was applied with
200 mg/m2 increments until the MTD (maximum tolerated dose) was
established.
Results. All patients completed full chemoradiation. There were no
treatment-related deaths.
At the 4th dose level (800 mg/m2), 1 patient experienced DLT. The
recommended dose for the phase II study was considered to be gemcitabine
800 mg/m2 and 36 Gy for radiation. After completion of chemoradiotherapy,
1 patients (6.7%) achieved a partial response and 13 patients (86.7%) a
stable disease. Reduced CA19-9 level of less than half of that at starting time
was observed in 10 of 15 (67%) patients. The 12 of 15 patients underwent a
definitive pancreatic resection. Eight patients died from progressive disease;
50% disease-free survival and overall survival were 8 and 25.1 months,
respectively.
Conclusion. This neoadjuvant combination is well tolerated and can
be safely administered before curative surgery for pancreatic cancer. Based
on this study, the recommended dose for gemcitabine combined with
radiation therapy is 800 mg/m2. Further evaluation of this regimen is
ongoing.
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Gene expression profiling of late onset colorectal liver metastases-a
model for metastatic inefficiency
Michael P Powar, Satyajit Bhattacharya, Robert Hutchins, Brian R David-
son, Fei Huang, Xia Han, Peter Shaw, Rebecca Hands, Ayan Banerjea, Shafi
Ahmed, Stephen A Bustin, Sina Dorudi
Barts and the London, London, United Kingdom; Royal Free Hospital,
London, United Kingdom; Bristol-Myers Sqibb, New Jersey, NJ
Background. In-vivo videomicroscopy and cell-fate analysis have demon-
strated that metastatic inefficiency is primarily due to regulation of post-
extravasation tumour cell growth at secondary sites. Late onset colorectal
liver metastases (detected /12 months following primary tumour resection)
may represent a model to study potential sources of metastatic inefficiency.
Furthermore, late onset metastases display a more favourable phenotype
compared to their early onset counterparts. We investigated the tumour
biology of late onset liver metastases compared with those detected at
presentation or within 12 months of the primary, using DNA microarrays.
Methods. 26 colorectal liver metastases were snap frozen at the operation
(12 Late onset and 14 Early onset) and stored at /708C. Total RNA was
extracted using the RNeasy mini kit (Qiagen) with quantity and quality
assessment using the 2100 Bioanalyzer (Agilent Technologies). Microarray
experiments were performed using the Affymetrix HG-U133A GeneChip
representing 22,283 gene transcripts. Data analyses to identify informative
genes were performed using GeneSpring 6.2 (SiliconGenetics).
Results. 1984 genes were found to be differentially expressed between late
and early onset colorectal liver metastases (Welch-t-test pB/0.05). To identify
candidate genes that exhibited the most significant and consistent expression
changes we selected genes that were differentially expressed by at least 1.5-
fold in greater than 50% of the samples. A total of 328 genes satisfied these
criteria and characterise a late onset metastasis signature. Late onset
colorectal liver metastases displayed under-expression of paracrine growth
factor receptors and over-expression of anti-angiogenic factors.
Conclusions. We have identified an expression signature characteristic of
late onset colorectal liver metastases that is indicative of inefficient post-
extravasation tumour cell growth and may be responsible for the observed
favourable phenotype. Further work to evaluate the use of these genes as
potential molecular markers or therapeutic targets is required.
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The natural course of intraductal papillary mucinous neoplasm
(IPMN) of the pancreas: Clinical-pathological correlation
Menahem Ben-haim, MD, Nir Lubezky, MD, Richard Nakache, MD, Joseph
Klausner, MD
Tel-Aviv Sourasky Medical Center, Tel-aviv, Israel
Introduction. The true incidence, chronological course and the clinical-
pathological correlation in pancreatic IPMN are poorly defined.
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Methods. Analysis of a prospective database of pancreatic resections for
IPMN since 2002 and a retrospective pathological revision of all pancreatic
cancer specimens since 1995. Cases were divided into 3 groups: Asympto-
matic patients with pre-operative diagnosis of IPMN (group 1), symptomatic
patients with pre-operative diagnosis of IPMN (group 2) and patients with
pancreatic cancer in whom revision of the specimen revealed background of
IPMN (group 3). The groups were compared for demographics, clinical
presentation, pathological findings and outcome.
Results. The diagnosis of IPMN was confirmed in 39 cases (group 1, n/9;
group2, N/15; group3, N/15). IPMN was present in 10.8% (15/138) of
all resected pancreatic cancer specimens. The mean ages (range) in each
group were 65, (46/77); 68.4, (50/83) and 74.7 (57/86). The clinical
presentation in group 2 vs. group 3 included abdominal pain (60% vs. 43%),
weight loss (15% vs. 43%), obstructive jaundice (15% vs. 64%), pancreatitis
(7.6% vs. 36%) or new onset of diabetes (7.6% vs. 36%). Invasive cancer was
found in 11% of group 1 (one case), 0% of group 2 and 100% of group 3.
Patient survival was 100%, 93% and 50%, respectively (mean follow-up, 2
years). Recurrence of IPMN was documented in 2 cases.
Conclusions. IPMN is the etiology of invasive cancer in 10% of pancreatic
adenocarcinoma cases. We can assume a 5 to 10 years interval since presence
of IPMN and the development of invasive cancer. Obstructive jaundice,
weight loss and new onset of diabetes are suggestive of invasive cancer, but
differentiating on clinical basis alone is impractical. Prognosis of benign
IPMT following resection is favorable. Prognosis of malignant IPMN is poor,
but better than of pancreatic ductal adenocarcinoma.
P61
Bile duct injuries: A review
Amit S. Khithani, Tilakdas Sudhakar Shetty, MS, Rajeev Mahashankar Joshi,
MS
B.Y.L Nair Hospital,T.N Medical College, MUMBAI, Mumbai, India
Background. Bile duct injuries and their sequelae present a formidable
challenge, with varying management protocols as well as long-term results.
While emphasis needs to be laid on the basic fundamental of safe dissection
in the hepatocystic triangle, optimal treatment and excellent long-term
outcome should be the goal. Opinion differs as regards efficacy of various
treatment modalities. Debate persists about the results, complications, cost-
benefit ratio and restenosis rate of endotherapy vis-a`-vis surgery.
Methods. Clinical data of 52 patients with bile duct injuries treated in a
single referral unit over a 6½ year period (from Feb’98 to July’04) were
analysed. All the cases were following either open (n/20) or laparoscopic
cholecystectomy (n/30) Endoscopic injury (n/2). The information regard-
ing the time of biliary injury and its presentation were carefully ascertained as
also the level of injury after a study of the cholangiographic anatomy.
Results. Majority of the patients underwent a Roux-en-Y hepatico-jejunost-
omy (n/41). Postoperative morbidity was due to wound infection (4
patients), anastomotic leak (3) and cholangitis, hemetemesis and pancreatitis
(1 each), all of whom were treated conservatively. There was no mortality in
our series. Following treatment 49 patients remained asymptomatic with
normal biochemical parameters while 3 patients required repeat intervention
for anastomotic stenosis and recurrent attacks of cholangitis. All patients are
on a regular follow up with a median follow up of 30 months. An attempt is
also made to derive an algorithm to offer the best possible solution to a
difficult problem.
Conclusion. As in most biliary diseases the management of the bile duct
injuries is a team effort between an interventional radiologist, therapeutic
endoscopist and an experienced surgeon. Reconstructive surgery, a hepatico-
jejunostomy is the gold standard.
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The risk-index of pancreatico-duodenectomy in patient over 65-years
Yukihiro Iso, MD, Tokihiko Sawada, MD, PhD, Junji Kita, MD, PhD,
Mitsugi Shimoda, MD, PhD, Keiichi Kubota, MD, PhD
Dokkyo University Hospital, Tochigi, Japan
Pancreatico-duodenectomy (PD) makes it possible to remove tumors and
lymph nodes en-block in patients with pancreatico-biliary cancers. However,
it carries surgical risks due to extensive resection. Especially, PD in elderly
patients should be considered as a high risk. In this study, we retrospectively
evaluated morbidity of PD in patients over 65-years old.
Between April 2000 to September 2005, 54 PD for patients over 65-years
were performed at our department (G1). Of 54 cases, there were 7 cases over
80 years and 34 cases over 70 years. Diagnosis included cancers of papilla of
Vaters (n/9), pancreatic head cancers (n/16), bile duct cancers (n/15),
gall bladder cancers (n/2), duodenal cancers (n/4), and others (n/8).
Operative data (time, blood loss), and postoperative data (hospital stay,
survival months) were compared with those patients under 64 years (G2:n/
33). And, Risk Index (RI) for postoperative death, postulated by Lloyd et al.
(Br J Surg 92,2005) was calculated in G1 and G2.
Operation times of G1 and G2 were 606.9 min and 682.4 min, respectively
(p/0.099), and intraoperative blood losses of G1 and G2 were 789.4 ml and
680.0 ml, respectively (p/0.53). Postoperative hospital stays of G1 and G2
were 69.9 days and 57.5 days, respectively (p/0.043). Survival periods of
G1 and G2 were 16.68 months and 19.79 months, respectively (p/0.45). RI
of G1 and G2 was 0.267 and 0.141, respectively (p/0.049). Median value of
RI of G1 was 0.21, which means that 21% of operation-related death could
have occured, however, there was no operation-related death in G1 and G2.
PD can be performed safely in elder patients as in younger patients, as long as
with adequate operative procedure and peri- and post-operative management
are performed.
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Clinicopathological features of patients with concomitant intraductal
papillary mucinous neoplasm of the pancreas and pancreatic endo-
crine neoplasm
Brian K. P. Goh, MD, London L. P. J. Ooi, MD, MBBS, Yu Meng Tan, MD,
M. Priyanthi Kumarasinghe, MD, Yaw Fui Alexander Chung, MD, Pierce K.
H. Chow, MD, PhD, Wai Keong Wong, MD
Singapore General Hospital, Singapore, Singapore; National Cancer Centre,
Singapore, Singapore
Background/Aims. The occurrence of concomitant pancreatic endocrine
neoplasm (PEN) and intraductal papillary neoplasm (IPMN) of the pancreas
has rarely been reported. We describe our experience with 3 patients with this
association and review the existing literature.
Methods. From 1990 to 2005, 65 patients who underwent surgery for a
PEN or IPMN were retrospectively reviewed. Forty-three patients had a
PEN, 19 had an IPMN and 3 had both an IPMN and PEN. The 3 patients
with concomitant IPMN and PEN are the focus of the current study and
their clinicopathological features are reported together with 7 patients
previously reported in the literature.
Results. There were 10 patients with a median age of 62 years (range, 40/73
years). The male to female ratio was equal. Seven of 10 patients were
symptomatic and the most common symptoms were abdominal pain (n/5),
jaundice (n/2) and loss of weight (n/2). The median size of the endocrine
neoplasms was 14 mm (range, 5/30 mm) and they occurred in the head (n/
3), body (n/2) and tail (n/5). Seven of the PENs were classified as benign,
2 were potentially malignant and 1 was frankly malignant with lymph node
involvement. None of the endocrine neoplasms were functioning. The
IPMNs were found in the tail (n/4), head (n/3), head and body (n/1),
body (n/1) and the entire pancreas (n/1). Five of these neoplasms were
benign, 2 were borderline and 3 were malignant (one carcinoma in situ).
Conclusion. The occurrence of concomitant IPMN and PEN is more
frequent than would be expected. However, it is difficult in the present
analysis to determine if this association is more than just fortuitous.
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A novel salvage technique to correct hepatic venous outflow obstruc-
tion after piggyback liver transplantation
Ian W. Udell, Neal R. Barshes, MD, Timothy C. Lee, MD, Christine A.
O’mahony, MD, John A. Goss, MD
Baylor College of Medicine, Houston, TX
Background. Vascular anastomosis of the recipient inferior vena cava (IVC)
to donor suprahepatic IVC during ‘‘piggyback’’ orthotopic liver transplanta-
tion (OLT) has caused hepatic venous outflow obstructions (VOOs) during
reperfusion. Various approaches have been performed to correct such
stenoses.
Objective. Describe the technique and long-term effectiveness of cavoca-
vostomy to correct VOO associated with adult piggyback liver transplants.
Methods. Records of all adult patients who underwent piggyback OLT from
12/1998 to 1/2005 were reviewed for hepatic VOOs. All piggyback liver
transplants at our institution are done in a similar fashion. The donor
infrahepatic IVC is oversewn on the back table. The donor suprahepatic IVC
is anastomosed to a common cuff fashioned from the recipient’s middle and
left hepatic vein, with the posterior wall performed in a running anastomosis
and the anterior wall performed in an interrupted fashion. The portal vein
and hepatic artery anastomosis are performed with running and interrupted
anastomoses, respectively.
Results. Three patients required additional treatment to facilitate hepatic
venous outflow. All patients received cadaveric whole organs. VOO was
diagnosed in all cases immediately after the hepatic arterial anastomosis upon
seeing significant liver distention and discoloration. Cavocavostomy was then
performed in an end-to-side fashion only after failed attempts at repositioning
both graft and patient. A triangle-shaped cavostomy incision was made to
create a defect in the recipient infrahepatic IVC. An end-to-side anastomosis
was then made between the donor infrahepatic IVC and this cavostomy using
a running polypropelene suture. In all cases, VOO was immediately resolved,
and rapidly improved reperfusion and venous outflow was observed. One
patient developed paracentesis resolved acites within one week after
transplantation. Another patient developed mild rejection shortly after
OLT which was resolved with immunosuppressive therapy. Liver transami-
nases normalized within one week of transplantation in all patients. All
patients remain alive without graft loss ranging between 9 and 50 months
post-transplant.
Conclusions. A cavocavostomy created between the donor infrahepatic IVC
and the recipient infrahepatic IVC allowing retrograde flow is an effective
graft salvage option for patients with hepatic VOOs after piggyback OLT. In
all three cases, the procedure resulted in improved reperfusion and elimina-
tion of hepatic VOOs. No complications related to the procedure have been
observed, and venous outflow remains adequate in all patients.
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Prognostic factors analysis of 200 consecutive hepatic resection for
hepatocellular carcinoma
Hyung-il Seo, MD, Sang-jae Park, MD, Seong Hoon Kim, MD, Woo-jin
Lee, MD, Yung Il Kim, MD, Soon-ae Lee, MD, Eun Kyung Hong, MD,
Joong-won Park, MD, Chang-min Kim, MD
Natioal Cancer Center, Koyang, Republic of Korea
Purpose. The long-term outcome after hepatic resection for hepatocellular
carcinoma (HCC) is somewhat disappointing because of the frequent tumor
recurrence. The purposes of this study are to evaluate prognostic factors and
to suggest the data to improve the long-term outcome of hepatic resection for
HCC.
Methods. A retrospective survey was carried out in the consecutive 200
patients undergoing hepatic resection for HCC from April 2001 to June
2004. The various clinicopathologic factors were analyzed for overall survival
(OS) and the disease free survival (DFS) by the univariate test (log-rank test)
and multivariate test (Cox regression model).
Results. There was one hospital mortility and 23% morbidity after
hepatectomy. Intraoperative transfusion was given 20 patients (10%).
Median follow up period was 19 months (range, 2/43). The 1-year, 2-
year, and 3-year OS after hepatic resection for HCC were 90.5%, 86.8% and
76.2%. The 1-year, 2-year, and 3-year DFS were 65.5%, 54.3% and 49.4%,
respectively. By the univariate analysis for OS, aspartate aminotransferase
(AST), Child-Pugh classification, Edmondson-Steiner histologic grade,
microvascular invasion, major vessel invasion, alpha-fetoprotein (AFP),
TNM stage, intraoperative transfusion, surgical margin involvement and
complication were the siginificant factors. By the multivariate analysis, Child-
Pugh classification, Edmondson-Steiner histologic grade, major vessel
invasion and complication were independent risk factors for OS. Whereas
viral marker, Child-pugh classification, microvascular invasion, major vessel
invasion, AFP, TNM stage, surgical margin involvement and complication
were the significant risk factors for DFS, the independent predictive factors of
DFS were viral marker, microvascular invasion, major vessel invasion,
surgical margin involvement and complication.
Conclusions. Hepatic resection for HCC has become safe. To improve the
long-term outcome of hepatic resection for HCC, the patients with poor liver
function or major vessel invasion should be precluded in hepatic resection, if
possible, and adequate surgical margin and avoidance of complication are
mandatory.
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Wandering gallbladder: Case report and review of literature
Angel Morales, MD, Alan Tyroch, MD, Leonardo Mitsuy, MD
Texas Tech University Health Sciences Center, El Paso, TX
The literature on the wandering gallbladder is scant and less than 10 cases
have been reported. A wandering gallbladder has abnormal mobility of the
fundus and body, and is usually attached to the biliary system only by the
cystic duct and its mesentery.[1] Its characteristic propensity to torse on its
mesentery places it at risk for necrosis.[2] We present an unusual case of a
wandering gallbladder, dilated biliary tree and necrotizing pancreatitis.
Case report. A 70 year-old female was admitted to our hospital due to acute
diarrhea and resolving pneumonia. She had a past medical history of
Sjogren’s syndrome, Raynaud’s disease and systemic lupus erythematosus.
She had a white blood cell count of 4.9/103/?l, a total bilirubin of 0.5 mg/dl,
AST 146 IU/L, ALT 91 IU/L and alkaline phosphatase of 123 IU/L.
Abdominal computerized tomography (CT) showed a dilated pancreatic,
common bile duct (CBD) and intrahepatic ducts. It also showed a low-lying
gallbladder (Image 1). Magnetic resonance imaging of the abdomen showed
a possible point of obstruction at the distal CBD.
Endoscopic retrograde cholangiopancreatography (ERCP) was performed
which showed a periampullary diverticulum and a dilated pancreatic duct. It
was not possible to cannulate the CBD. The patient developed post-ERCP
pancreatitis, and two days later, an acute abdomen. Intraoperative findings
during exploratory laparotomy were hemorrhagic, necrotizing pancreatitis,
and a wandering gallbladder (Image 2). Due to hemodynamic instability,
the patient was transferred to the ICU with a packed abdomen. On
subsequent exploration, a cholecystectomy was performed. Intraoperative
cholangiogram showed a dilated biliary duct system without apparent
obstruction (Image 3).
Discussion. Despite being described as early as 1952, few articles exist that
discuss the wandering gallbladder. In its classical presentation, the wandering
gallbladder’s mesentery allows torsion with subsequent gangrene of the
organ.3[3],[4] Although the presence of a wandering gallbladder and transient
hyperbilirubinemia due to intermittent torsion of the CBD has been
described, it is difficult to know whether this is the cause for the dilated
biliary tree in our patient, and whether this predisposed our patient to a
severe hemorrhagic pancreatitis. To our knowledge, this is the first described
case of a wandering gallbladder, dilated biliary tree and necrotizing
pancreatitis post-ERCP. The analysis of more cases like this one should
improve our understanding of the clinical implications of the wandering
gallbladder.
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A new anatomical definition of resectability based on multiple staged
hepatic resections leaving part of segment iv and caudate
Peter J. Horton, MD, Prosanto K. Chaudhury, MD, John B. Martinie, MD,
Peter Metrakos, MD
Royal Victoria Hospital, Montreal, PQ, Canada
Background. Although increasingly complex staged hepatic resections for
colorectal metastases are being performed, there is no general agreement on a
definition for resectability of hepatic lesions. Current definitions of resect-
ability are usually based on number and distribution of colorectal metastases
and hepatic function but vary between institutions. A generally accepted
definition of respectability is lacking, centres cannot compare outcomes and
clinical trials are difficult to design.
Aim. To arrive at a new definition of resectability based on the anatomy of
liver remnants.
Case reports. Three patients presented with multiple bilateral hepatic
colorectal cancer metastases.
Patient 1 : A forty-four year old woman underwent a left lateral segmentect-
omy (LLS) and right PV embolization. Four months later she underwent a
right hemihepatectomy (RHH) and non-anatomical (NA) resection of
segment IVB.
Patient 2 : A fifty-three year old man underwent a RHH. Six months later he
returned for a LLS and NA resection of segment IVB.
Patient 3 : A forty-eight years old woman underwent a RHH and NA
resections of segment II, III and IV. Five months later she returned for a
LLS and NA resection of IVB.
Results. Pre- and post-resection tri-phasic CT scans and MRCPs used to
reconstruct the vascular and biliary anatomy of the liver remnants revealed
that parenchyma retained at least one branch of the hepatic artery, portal vein
and hepatic vein and were drained by at least one bile duct.
Proposed new definition of resectability. Anatomical criteria : Minimum
anatomical requirements for resection to be technically feasible are that the
liver remnant remains (1) supplied by at least one branch of the portal vein
and (2) drained by at least one branch of the hepatic vein. (3) The
parenchyma must retain a draining bile duct connected to the bowel and
(4) sufficient good quality liver must be left behind at all times in order to
avoid precipitating liver failure. We leave a minimum of 25% of the liver mass
behind after each resection and consider that leaving parenchyma with a
patent hepatic artery is not essential but is highly desirable, especially if
hepatic regeneration is to take place.
Discussion. This anatomical definition of resectability is independent of the
indication for liver resection. It takes no account of tumour biology and
resection for colorectal metastases should only be attempted if an R0
resection is possible.
Conclusion. We propose a new definition of hepatic resectability based on
functional anatomy. The definition separates whether resection can be
performed from whether it should be performed. We recommend that it is
adopted in future clinical trials.
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‘‘Technological’’ approach versus clamp crushing technique for
hepatic parenchymal transection: A comparative study
Luca Aldrighetti, MD, PhD, Marcella Arru, MD, Carlo Pulitano`, MD,
Marco Catena, MD, PhD, Renato Finazzi, MD, Gianfranco Ferla, MD
Scientific Institute H San Raffaele, Vita-Salute San Raffaele University
School of Medicine, Milan, Italy
Parenchymal liver transection represents a fundamental phase of liver
surgery. Serious intraoperative bleeding, together with injuries to vital
structures of the liver remnant, may occur, leading to substantial morbidity
and mortality. We evaluated the feasibility and effectiveness of combining two
different electronic devices, the ultrasonic dissector and the harmonic scalpel,
during hepatic resection.
One hundred consecutive patients underwent liver resection using ultrasonic
dissector (UD) plus harmonic scalpel (HS), between Jannuary and Decem-
ber 2004 (UD/HS group). The ultrasonic dissector was used to fracture
liver parenchyma and the uncovered vessel were sealed using the HS. Surgical
outcomes were compared with 100 consecutive patients who underwent liver
resection using the clamp crushing method (CC group).Operative variables,
postoperative liver function, hospital stay, and type and number of
complications were compared.
The two groups were equivalent in term of demographic and pathologic
variables.
The UD/HS group had a decreased blood loss (500 mL versus 700 mL, P/
0.005).
Blood transfusions were necessary in 22 patients in the UD/HS group
and in 36 patients in the CC group (P/0.029). Final pathologic
analysis identified 4 patients in the UD/HS group and 12 patients in
the CC group with hystologic tumor exposure at the transection surface
(P/0.037).
Postoperative major complications, in particular fluid collection and biliary
fistula, were significantly less frequent in the UD/HS group (2 versus 9,
P/0.030). A longer operative time was recorded in the UD/HS group
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(385 versus 330 minutes, P/0.001). Median hospital stay was 7 days (range
5/53) in the UD-HS and 8.5 (5/60) in the CC group (P /0.02).
The combined use of UD with HS allows liver resection to be safely
performed, with the advantage of reducing blood losses and surgical related
complications. The only major disadvantage may be a longer transection
time. A prospective randomized trial is needed to clarify the clinical benefits
of liver resections performed using these novel techniques.
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Surgical treatment of hepatic epithelioid hemangioendotheliomas
Arash Kashfi, MD, Arianeb Mehrabi, MD, PhD, Hamidreza Fonouni, MD,
Peter Schemmer, MD, PhD, Peter Sauer, MD, Helmut Friess, MD, PhD,
Markus W. Bu¨chler, MD, PhD, Jan Schmidt, MD, PhD
Department of Surgery, University of Heidelberg, Heidelberg, Germany;
Department of Internal Medicine, University of Heidelberg, Heidelberg,
Germany; Departmen of Surgery, University of Heidelberg, Heidelberg,
Germany
Hepatic epithelioid hemangioendothelioma (HEH) has a very low incidence
with unclear malignant potential. In the present work we analyze 400
published cases and describe 4 female patients with HEH, who were treated
curatively in our institution.
Of four patients with HEH, liver transplantation (LTx) was performed (two
cadaveric and one living donated) in 3 patients. In one patient a right sided
hemihepatectomy with partial resection of the diaphragm was performed. All
patients were seen in our transplantation and oncology outpatient clinics on a
regular basis with follow up periods from 1 to 12 years. No adjuvant
chemotherapy was applied. Till present, no tumor recurrences or metastases
could be observed.
In the literature, most HEH patients (male to female: 2 to 3) presented right
sided upper abdominal pain and/or weight loss. In most cases, the tumor had
spread throughout the liver and presented as multiple nodular lesions. About
27 to 45% of all tumors metastasized, mostly to the lungs and bones. The
keys toward diagnosis included radiology, histology and detection of cells
expressing factor VIII-related antigens. Liver transplantation was the most
common therapeutic modality. The 5-year overall survival rate in all patients
varied from 43 to 55% and is significantly higher in comparison to other
malignant hepatic tumors.
Early detection and surgical intervention can offer a curative treatment to the
patient. First choice treatment is radical liver resection or LTx. Regarding the
long waiting lists for LTx, and unclear dignity of this tumor with a progressive
growth pattern, living donor LTx represents a potentially important role for
patients with a non-resectable tumor.
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C4D as a marker of acute rejection after liver transplantation
Maximilian Schmeding, MD, Ulf P. Neumann, MD, PhD, Jan Michael
Langrehr, MD, PhD, Anja Dankof, MD, Veit Krenn, MD, PhD, Peter
Neuhaus, MD, PhD, Charite´ Berlin, Berlin, Germany
Introduction. Acute rejection represents a major complication following
liver transplantation mediated by the activation of T-cell related mechanisms.
Histological examination of liver biopsy remains the gold standard for
diagnosis today. Histomorphological diagnosis of acute rejection can be
difficult especially in hepatitic-C positive patients when hepatitis-C reinfec-
tion of the transplant is always a potential differential diagnosis as the cause
for elevated liver enzymes and histological alterations.
In these cases exact diagnosis is particulary important as steroid-pulse
therapy for supposed rejection would aggrevate the HCV-reinfection.
C4D as a marker of the activated complement cascade today plays a highly
valued role in diagnosis of acute rejection in kidney transplantation where
humoral mechanisms are involved to a greater extent than in liver
transplantation. In this study we investigate whether C4D is present in acute
rejection following liver transplantation and if it may serve as a specific
marker for differential diagnosis in hepatitis-C reinfection cases.
Methods. We performed retrospective analysis of 97 liver biopsies from liver
transplanted patients who had either experienced acute rejection, hepatitis-C
reinfection or displayed no pathological alterations serving as controls.
Every specimen was taken due to the clinical suspicion of acute rejection or as
protocol biopsies 1,3 or 5 years after LTX. Tissue samples were subjected to
C4D specific immune-histological staining and evaluated by two independant
pathologists.
Results. 23 of 34 patients who had been diagnosed with acute cellular
rejection displayed C4D-positive staining in their liver biopsy (67,7%)
whereas 4 of 34 patients with hepatitis-C reinfection were tested positive
for C4D (11,8%). In the control group 2 of 29 specimen showed C4D
positivity (6,9%).
Discussion. In this study we were able to demonstrate for the first time that
humoral components, represented by C4D activation, do play a role in acute
rejection following liver transplantation. Our data shows highly significant
differences regarding C4D expression between rejection biopsies and controls
(pB/0,001). Concerning the difficult task of distinguishing between acute
rejection and hepatitis-C reinfection we could find impressive significant
differences in C4D expression (pB/0,001).
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Laparoscopic liver resection at the university of cincinnati
Joseph F. Buell, MD, A. D. Tevar, MD, M. J. Thomas, MD
University of Cincinnati, Cincinnati, OH
Laparoscopic hepatic resection is a procedure in evolution. Initial experiences
were limited to benign and smaller lesions. This current study examines the
experience to date of one center with a minimally invasive approach to
tumors.
Methods. We retrospectively examined the patient and tumor characteristics
of all laparoscopic resections performed at the University of Cincinnati over
the last three years.
Results. 130 resections have been performed in 110 patients. The mean
patient age was 52.99/15.5 yrs. The majority of patients 54% underwent
resection for benign disease. Malignant diagnoses included: CRC n/16,
HCC n/13, Non-CRC n/20, Cholangiocarcinom n/2. Fourteen (12.7%)
of the patients were cirrhotic ranging from Child’s A to C. The mean
tumor size was 4.99/3.8 cm. Resections performed included 2 trisegmentec-
tomies, 3 caudates, 16 right lobes, 11 left lobes, 66 multi-segment resections
and 32 uni-segment resections. Parenchymal transection was performed
utilizing a combination of TissueLink and Autosuture 2.5 staplers. Mean
EBL was 2389/259 cc with 9 (8%) of patients requiring transfusion. 31
patients had prior abdominal surgery including 2 with prior hepatic resection.
27 patients had concomitant procedures, including: cholecystectomy n/20,
Diaphragm resection n/3, subtotal gastrectomy n/1, colectomy n/1,
nephrectomy n/1, and RFA n/1. Mean surgical margin was 1.29/1.3 cm.
To date no local or in field recurrences were noted at any margin. Two
operative conversions were encountered. The complication rate for this series
was 12.7%. These included: bile leak n/2, operative re-bleed n/3,
pulmonary embolism n/2, death n/2, hepatic insufficiency n/1, other
n/4. Both deaths were in cirrhotics and were related to patient co-
morbidities.
Conclusions. Laparoscopic hepatic resection is a procedure in evolution.
The resection margin obtained appears to be oncologically sound with
no tumor recurrence noted in this current series. As with any major
hepatic resection series the combined mortality of this series was under
2%. The safety of the procedure is directly related to the co-morbidities of the
patients.
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Differential kinetics of CD 105 and TGFB in the early stages of human
acute pancreatitis
Saurabh Jamdar, Abdul Al-Mowallad, Shant Kumar, Ajith K Siriwardena
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom; Department of Experimental Pathology, University of
Manchester, Manchester, United Kingdom
Aims. Increased cell-surface expression of CD 105 (endoglin) is an
important component of the endothelial response to injury. CD 105-
mediated signal transduction by transforming growth factor beta (TGF-b)
has been implicated in extracellular matrix deposition, remodelling
and angiogenesis in acute pancreatitis. However the importance of the
interaction of TGF-b with CD105 during the critical early phases of acute
pancreatitis is unknown. This study investigates expression of CD105 and
TGF-b in plasma during the early stages of the disease course of severe acute
pancreatitis.
Methods. Forty-one patients with a clinical diagnosis of severe acute
pancreatitis (APACHE II /8) constitute the study population. Venous
samples were taken at admission and on the 5th hospital day. Enzyme-linked
immunosorbent assay (ELISA) was performed for CD105, TGF-b1, TGF-
b3, CD105/TGF-b1 and CD105/TGF-b3 complexes. Data are presented as
median (range). Statistical comparisons assume non-parametric distribution
of data and significance is accepted at the PB/0.05 level.
Results. TGF-b1 levels were significantly elevated on admission 850
(71/2200 pg/ml) in patients with acute pancreatitis compared to control
98 (0/1253) [PB/0.05 Mann-Whitney U-test] and were further elevated
in the delayed samples (2321 [951/4080] pg/ml). In contrast, admi-
ssion CD105 levels were similar to those in controls (4.6 [0/60] ng/ml
vs 11 [0/61] ng/ml). In the delayed samples there was a significant re-
duction in levels of CD105 (0 [0/39.4] ng/ml vs 4.6 [0/60] ng/ml).
Levels of TGF-b3, CD105/TGF-b1 and CD105/TGF-b3 complexes
did not significantly differ between controls or patients at either sampling
time-point.
Conclusions. This is the first report to investigate the interplay between
plasma expression of CD105, TGF-b1, TGF-b3 and ligand-complexes in
acute pancreatitis. The results of this study confirm previous findings
that increased expression of TGF-b1 is a feature of severe acute pancreatitis.
The absence of a parallel elevation in CD105 or CD105/TGF-b ligand-
complexes is previously unreported and suggests that angiogenesis mediated
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by the interaction between CD105 and TGF-b is not an early feature of this
disease.
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Laparosocpy-assisted right hepatic lobectomy employing the liver-
hanging maneuver
Hiroyuki Nitta, MD, Akira Sasaki, MD, Hidenobu Kawamura, MD,
Hidenori Itabashi, MD, Tomohiro Fujita, MD, Toru Obuchi, MD, Koichi
Hoshikawa, MD, Yuichiro Takeda, MD, Masahiro Takahashi, MD, Osamu
Funato, MD, Ryoko Sasaki, MD, Go Wakabayashi, MD, PhD
Iwate Medical University School of Medicine, Morioka, Japan
Background. Laparoscopic liver resection has been used to perform limited
liver resection. Partial resection and left lateral segmentectomy can be safely
performed laparoscopically. To perform right hepatic lobectomy laparosco-
pically, we employed the liver-hanging maneuver with minimal access.
Meticulous hepatic parenchymal dissection can be achieved under direct
vision through right sub-costal mini-laparotomy.
Methods. Indication for laparoscopy-assisted right hepatic lobectomy
includes tumor size less than 10 cm without invading right portal vein and
middle hepatic vein. Cholecystectomy and mobilization of the right liver
were performed with pneumoperitoneum. Before starting liver resection,
pneumoperitoneum was quitted to avoid possible CO2 embolism through
the cut surface of the liver. An 8 cm of sub-costal mini-laparotomy was
made, and intra-operative ultrasonogram was performed to identify all the
major vessels and bile ducts. We started to ligate the right hepatic pedicle
before parenchymal dissection. Hepatic parenchymal dissection was per-
formed through the mini-laparotomy with a laparoscopic coagulating
scissors and an ultrasonic dissector using the liver-hanging maneuver.
All the vessels and bile dusts appeared on the cut surface of the liver were
ligated and divided directly through the mini-laparotomy. The right hepatic
pedicle, short hepatic veins, and the right hepatic vein were divided with GIA
stapling.
Results. From November 2002 to July 2005, seventy-six patients underwent
laparoscopic liver resection. Of these 76 patients, eight patients underwent
laparoscopy-assisted right hepatic lobectomy for hepatic cancer. The 6 men
and 2 women had a mean age of 57 years (range, 24/77 years). Four had
hepatocellular carcinoma and four had colorectal metastases. Mean operation
time and blood loss were 288 minutes (range, 230/360 minutes) and 821 g
(range, 290/1498 g). Median postoperative hospital stay was 16 days (range,
10/154 days). Only one patient experienced bile leakage. One patient
required blood transfusion.
Conclusions. Laparoscopy-assisted right hepatic lobectomy emplying the
liver-hanging maneuver performed within the indications described above
was safe and associated with a favorable postoperative clinical course.
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Extended resection for gallbladder cancer with advanced primary
and regional nodal disease
Srinevas K. Reddy, MD, Theodore N. Pappas, MD, Bryan M. Clary, MD
Duke University Medical Center, Durham, NC
Background. Radical resection for gallbladder cancer is well established. A
radical cholecystectomy as traditionally involving a ‘‘segment 4B/5’’ excision
allows for adequate margin near the fundus of the gallbladder but is
associated with a minimal margin at the base of the cystic plate. Whether
an extended right hepatectomy (whereby the plane of transection is well to
the left of the cystic plate) would decrease the risk of local/regional recurrence
in the liver and porta hepatis is not clear. The authors review a consecutive
five-year experience in which such an aggressive approach was commonly
performed on patients without medical contraindications.
Methods. Records of 15 consecutive patients undergoing hepatic resection
for gallbladder carcinoma from 2000 /2005 were retrospectively reviewed
for demographics, tumor characteristics, treatment, and post-operative
outcome.
Results. The local-regional stage of patients undergoing resection included
T1N0 (1), T2N0 (3), T3N0 (4), T4N0 (1), T2N1 (3), and T3N1 (3),
reflecting a number of patients with advanced disease. 10/15 patients
presented as incidental findings following cholecystectomy. Five patients
underwent a local wedge excision of the gallbladder fossa without bile duct
excision (one each with T1N0, T3N0, and T2N1 disease and two with T2N0
disease). The remainder (10) underwent an extended right hepatectomy with
bile duct excision. All patients had a portal lymphadenectomy. Four of 15
patients underwent pre-operative right portal vein embolization. Seven
patients underwent adjuvant chemoradiotherapy. Pathology included adeno-
carcinoma (11/15), papillary carcinoma (3/15), and squamous cell carcinoma
(1/15). Of the patients undergoing resection following incidental presenta-
tion, one had residual cancer noted microscopically. All resections were
microscopically margin negative. There were no post-operative deaths and 6/
15 patients experienced post-operative morbidity. At a median follow-up of
11 months, 12 patients are NED at 5, 5, 6, 8, 10, 11, 14, 23, 26, 37, 48, and
52 months. One is AWD (T3N1) at 5 months. Two patients (T2N1, T3N0)
died at 2 and 24 months. All three recurrences occurred at distant sites
(peritoneal, nonadjacent liver). Four node positive patients are NED at 11,
14, 48, and 52 months (5/6 received adjuvant therapy).
Conclusions. In patients with advanced local-regional disease, an aggressive
surgical approach can be performed safely. Whether an extended hepatect-
omy portends a better oncologic outcome is not clear from this small series,
but the data suggest that patients with regional nodes and thick primary
tumors can achieve long-term survival with an aggressive approach.
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Successful hepato-pancreatoduodenectomy in consecutive 8 patients
with biliary tract diseases
Keiichi Kubota, MD, PhD, Mitsugi Shimoda, MD, Junji Kita, MD, Tokihiko
Sawada, MD, PhD
Dokkyo University Hospital, Tochigi Pref., Japan
Introduction. Thanks to improved surgical techniques and perioperative
care, the respective morbidity and mortality rates after hepatectomy and
pancreatoduodnectomy (PD) have decreased significantly. However, hepato-
pancreatoduodenectomy (HPD), which is one of the invasive procedures, still
presents high postoperative morbidity and mortality rates. Small remnant
liver and intra-abdominal hemorrhage caused by pancreatic fistula are
considered associated with the poor outcome. In this study, we describe
our surgical technique and report successful 8 cases of HPD.
Methods. Between April 2000 and September 2005, 415 hepatectomies
were performed at our department. 8 of the 415 patients underwent HPD
under preoperative diagnoses of biliary malignancies (Bile duct cancer: 6,
gallbladder cancer: 2). There were 5 males and 3 females with a median age
of 66 years (41/79). Their median ICG15 was 7% (4/16).
Surgical technique. Right (RHPD) or left lobectomy (LHPD) is decided
according to the dominant localization of the cancers. When RHPD was
considered necessary, portal embolization was performed irrespective of the
size of the future remnant left liver. In 2 weeks, regeneration of the left lobe
was confirmed and subsequently HPD was performed. Hepatetomy was
preceded by PD. Thereby two-staged PD including exteriorization of the
pancreatic juice, covering of the major vessels by omental graft and second-
look pancreatico-jejunostomy, was employed. Pancreatico-jejunostomy was
performed 3 months after HPD.
Results. 4 RHPDs and 4 LHPDs were performed successfully. Their median
operation time, Pringle time and bleeding amount were 838.5 min
(744/1205), 54.5 min (36/61) and 1122 ml (596/1800), respectively. In
one patient, rupture of pseudo-aneurysm occurred and was successfully
treated by TAE. Otherwise, there was no morbidity and mortality. Second-
look anastomosis was performed successfully in all patients. 5 patients are
alive without any signs of recurrence with a median observation period of
6 months (1/22), while 3 patients died of cancer.
Conclusion. By employing portal embolization and two-staged PD, HPD
can be performed safely as an established procedure with acceptable disease-
free survival period in selected patients with biliary cancers.
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Extended hepatectomy. A safe procedure in malignant liver lesions
Juan Francisco Guerra, MD, Francisco Pacheco, MD, Sergio Guzma´n, MD,
Matı´as Guajardo, MD, Alessandra Gederlini, Luis Iba´n˜ez, MD, Jorge
Martı´nez, MD, Nicolas P Jarufe, MD
Department of Digestive Surgery. Faculty of Medicine., Pontificia Universi-
dad Cato´lica de Chile, Santiago, Chile
Introduction. Extended hepatectomy is a major surgical procedure and
usually has been associated with a high perioperative risk. The aim of this
study is to compare the surgical results in patients who underwent a hepatic
resection of more than two Couinaud’s segments versus an extended
hepatectomy (more than four segments).
Methods. A prospective database of patientes who underwent resective liver
surgery from August 2002 to June 2005 was reviewed. Non-anatomical,
unisegmental and laparoscopic resections were excluded. There were two
groups. Group I: Extended Hepatectomies; Group II: Hepatic resections
from 2 to 4 segments. Demographic characteristics, indications for surgery,
technical aspects, use of hemocomponents, post-operative liver function,
morbidity and mortality were reviewed. Statistical significance was obtained
by the Kruskal-Wallis test.
Results. In this period, 34 hepatectomies were performed and 29 procedures
achieved the inclusion criteria. Group I: (n/14), mean age 52 years. Group
II: (n/15), mean age 55 years. Hepatobiliary malignancy was the surgical
indication in all cases in Group I (9 liver metastases, 5 primary liver tumors).
Mean number of resected segments were 5.5 (margin 5/6) for Group 1, and
2.3 for Group II (margin 2/4). Mean operative time were 283 and 199
minutes, respectively (p/0.025). Mean red blood cell units transfused were
2.69 and 0.85 in each group (p/0.009). Mean post-op hospital stay was 13.6
days por the first group and 7.3 for the second group (p/0.004). In Group I,
4 of 14 patients developed a postoperative complication and 1 of 15 in Group
II (p/0.1). Post-operative liver failure was present in two patients from
Group I, one of them died. In Group II, 1 patient died secondary to liver
failure.
Conclusions. Extended hepatectomy is a safe procedure for hepatobiliary
malignancy even when a large amount of liver parenchyma is resected.
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The prevalence of non-alcoholic steatohepatitis in surgical specimens
of hepatocellular carcinoma in a japanese university hospital
Seikan Hai, MD, Hiromu Tanaka, MD, Shigekazu Takemura, MD,
Takatsugu Yamamoto, MD, Shogo Tanaka, MD, Satoshi Yamamoto, MD,
Tsuyoshi Ichikawa, MD, Shintaro Kodai, MD, Hiroji Shinkawa, MD, Shoji
Kubo, MD
Osaka City University, Osaka, Japan
Purpose. Some hepatocellular carcinomas recently have been reported to
originate from non-alcoholic steatohepatitis. We investigated prevalence of
non-alcoholic steatohepatitis in patients with hepatocellular carcinoma.
Methods. Clinical records of 481 patients who underwent liver resec-
tion for hepatocellular carcinoma in our department from January 1991
to December 2003 were reviewed. Diagnosis of non-alcoholic steato-
hepatitis was based on typical histopathology and exclusion of other known
etiologies of hepatocellular carcinoma, including viral infection and alcohol
abuse.
Results. Only two patients with hepatocellular carcinoma (0.4%) were
diagnosed as having non-alcoholic steatohepatitis. These patients had
non-insulin dependent diabetes mellitus and had no history of alcohol
consumption or blood transfusion. All serologic markers for hepatitis B and C
viruses were negative. Noncancerous hepatic tissue showed non-alcoholic
steatohepatitis with moderate hepatic fibrosis in one patient and cirrhosis in
another.
Conclusion. Clinical follow-up and screening for hepatocellular carcinoma
is necessary in patients with hepatic fibrosis caused by non-alcoholic
steatohepatitis, although this form of hepatitis may be an uncommon cause
of hepatocellular carcinoma in Japan.
P78
Clinical relevance of intra-abdominal pressure in severe acute
pancreatitis
Ahmed Al-bahrani Jr., MBBS, Ghalib Abid Jr., MBBS, Adrian Holt Jr., MD,
Ajith Siriwardena Sr., MD, Rory Mccloy Sr., MD, Jonathan Benson Sr.,
None, Jane Eddleston Sr., MD, Basil Ammori Sr., MD
Manchester Royal Infirmary, Manchester, United Kingdom
Background and aims. Intra-abdominal hypertension (IAH), defined as
intra-abdominal pressure (IAP) of more than 15 mmHg, has been shown to
contribute to organ failure in patients with abdominal trauma, sepsis or
surgical emergencies. This study aims to investigate the clinical significance
of IAH in patients with severe acute pancreatitis (SAP).
Methods. Patients admitted to intensive care unit (ITU) or high dependency
unit (HDU) with SAP had their intra-vesical pressure measured daily to
reflect IAP. The clinical data, multiorgan dysfunction (MODS), sequential
organ failure (SOFA), APACHE II and lung injury (LIS) scores were
recorded daily.
Results. Eighteen patients (11 males) with a median age of 58 (range,
21/80) years admitted with SAP consented for the study. Eleven patients
(61%) developed IAH (median peak IAP 20 mmHg, range 16 /34 mmHg),
while abdominal compartment syndrome (ACS; defined as IAH/organ
failure) developed in 8 (44%) patients. On the days of their measurement IAP
and IAH correlated significantly with MODS (pB/0.0001, p/0.011), SOFA
(p/ 0.003, p/0.03) and APACHE II scores (p/ 0.002, p/0.028); IAP also
correlated with LIS (pB/0.0001). Both admission and peak IAP correlated
significantly with the duration of ITU/HDU stay. Multivariable regression
analysis identified mechanical ventilation as a positive predictor of IAH while
the presence of abdominal drain(s) was a negative predictor.
Conclusions. IAH and ACS are frequent findings in patients with SAP. IAP
correlates positively with severity of organ failure, and high admission and
peak IAP are associated with prolonged ITU stay. Insertion of abdominal
drains reduces IAP and may be considered as a therapeutic option in patients
with SAP and IAH.
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Hepatocellular carcinoma biology in the setting of the cirrhotic
hepatitis virus B-infected liver: Is a little bit of a bad thing actually
a good thing?
Nuh N Rahbari, MD, Eunjie K Klegar, MD, Wei Luan, MD, Spiros P Hiotis,
MD, PhD
Bellevue Hospital/NYU School of Medicine, New York, NY
Introduction. Patients with Hepatitis B Virus infection (HBV) are at long-
term risk of developing cirrhosis, as well as Hepatocellular Carcinoma
(HCC). Either of these two complications of HBV can independently pose
great challenges in the appropriate management of a complex patient
population. Current wisdom suggests that the coexistence of both cirrhosis
and HCC leads to even more difficult patient management, and a worse
prognosis. In this study we have examined well-established prognostic
indicators for HCC in an HBV patient population, to determine whether
the presence or absence of cirrhosis impacts upon the clinical-pathologic
features of this cancer.
Methods. 90 patients with HBV and HCC were treated at a city hospital in a
large metropolitan environment between the years of 1993 and 2005. Patients
were entered into a prospective database between the years of 2001 and 2005,
but data was collected retrospectively prior to that time. HBV status was
determined according to serologic studies as well as PCR for viral loads.
Cirrhosis was diagnosed according to histopathologic examination of biopsy
or resection specimens, or by criteria seen on axial imaging studies. Several
well-established features predictive of HCC prognosis were evaluated
according to the presence or absence of cirrhosis.
Results. Among several variables examined, unfavorable HCC prognostic
features were significantly associated with the absence of cirrhosis. Large
tumor size (/5 cm), the presence of metastatic disease upon initial
presentation, and high serum alpha-Fetoprotein levels (/2000 ng/ml) were
all associated with the absence of cirrhosis (pB/0.05, chi square test). None of
the evaluable unfavorable prognostic indicators were associated with the
presence of cirrhosis.
Conclusion. Although the coexistence of cirrhosis and HCC poses difficult
management dilemmas, favorable tumor biology appears to be associated
with the presence of cirrhosis in the HBV patient population. An explanation
for this association is not currently apparent, although several theoretical
explanations may be applicable. These include the possibility that the
chronically inflamed hepatic environment in the cirrhotic patient may also
provide some defense mechanisms against HCC. Further research is
necessary to validate this controversial observation, and to clarify the possible
underlying mechanisms responsible.
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Evidence of anti-angiogenic activity of the selective cyclooxygenase-2
inhibitor rofecoxib in human colorectal cancer liver metastases
C. Ritchie Chalmers, Daniel J. Wilson, Philip J. Robinson, Janice Ward,
Mark A. Hull
Giles J Toogood, St James’s University Hospital, Leeds, United Kingdom
Background and hypothesis to be tested. The mechanism(s) underlying
the anti-neoplastic activity of selective cyclooxygenase-2 (COX-2) inhibitors
is unclear. We tested the hypothesis that the selective COX-2 inhibitor
rofecoxib has anti-angiogenic activity in human colorectal cancer (CRC) liver
metastases.
Methods. Anti-angiogenic activity of rofecoxib on CRC liver metastases in
vivo was analysed by dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) of the liver before and after treatment of patients
with rofecoxib 25 mg daily for 28 days. Unlike previous studies, measure-
ments were taken from central and peripheral regions of each tumour for
comparison. At the same time, serum levels of the pivotal angiogenic factor
vascular endothelial growth factor (VEGF) and the endogenous anti-
angiogenic factor endostatin were also measured.
Results. The study was terminated early following the withdrawal of
rofecoxib, at which time five patients had received rofecoxib therapy
and four patients had completed DCE-MRI analysis. Treatment with
rofecoxib was associated with a mean 15.6% decrease in the initial area
under the curve at 60 seconds and a mean 36.4% decrease in the transfer
constant (permeability-surface area product; pB/0.01) in the periphery
of metastases, but was associated with an increase in the same para-
meters in the central region of two tumours. Rofecoxib therapy was
associated with a mean 25.3% (95%CI 10.2/40.5%) increase in serum
endostatin levels (p/0.02). However, there was no significant alteration in
serum VEGF levels.
Conclusions. DCE-MRI of CRC liver metastasis vascularity in vivo
supports the hypothesis that rofecoxib has anti-angiogenic activity. Pre-
liminary evidence suggests that one mechanism of action may be to increase
circulating endostatin levels in CRC patients.
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The presence of the intermediary segment at the level of the lateral
divisions of liver’s parenchyma. Study on corrosion casts
Petru L. Matusz, MD, PhD
University of Medicine and Pharmacy, Timisoara, Romania
Liver’s parenchyma segmentation is based mainly on the distribution of the
segment of divergence of the portal hepatic vein. At the level of the left lateral
division there are the left lateral posterior segment-segment II and the left
lateral anterior segment-segment III. At the level of the right lateral division
there are the right lateral anterior segment-segment VI and the right lateral
posterior segment-segment VII.
On a study material of 156 corrosion casts we analyzed the presence of the
intermediary segment at the level of the lateral divisions of liver’s parench-
yma. The corrosion casts were made by injecting with plastic of the vasculo-
ductal elements, followed by the corrosion of the hepatic parenchyma with
hydrochloric acid.
The left lateral division has two segments in 91.03% cases and three segments
in 8.97% cases. The presence of the left lateral intermediary segment is due
to the presence of an extra lateral branch. In 1.92% cases it is a superior
lateral branch and in 7.05% cases an inferior lateral branch.
The right lateral division has two segments in 78.85% cases and three
segments in 21.15% cases. The presence of the right lateral segment is due to
the presence of an extra lateral branch, originating in: the posterior branch
(from its trifurcation) in 0.64% cases, from the bifurcation of the superior
lateral posterior trunk in 12.82% cases and from the bifurcation of the
inferior lateral posterior trunk in 7.69% cases.
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The presence of the left lateral intermediary segment was always associated
(100% cases) with the dorso-petal type of liver (in which the left hepatic lobe
is bigger in dimensions, with reduced anteversion or even retroversion, and
the contact between the diaphragm and liver’s diaphragmatic face is on a
smaller surface). The presence of the right lateral intermediary segment was
associated only in 54.76% cases with the morphologic aspect of dorso-petal
liver (namely, in the case of trifurcation of the posterior branch of portal
hepatic vein and in the case of bifurcation of the inferior lateral trunk from
the posterior branch of the portal hepatic vein).
The presence of the intermediary segment at the level of the lateral divisions
of liver’s parenchyma equalize the volumes of parenchyma attended by
second order ramifications of the portal hepatic vein at this level. This
morphologic aspect has to be considered when practicing regulated hepatic
resections.
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Liver molding: A series of liver remnants derived from less than two
segments
Peter J. Horton, MD, Prosanto K. Chaudhury, MD, John B. Martinie, MD,
Peter Metrakos, MD
Royal Victoria Hospital, Montreal, PQ, Canada
Background. Extensive hepatic resections are being performed more
frequently for colorectal cancer metastases, each with the aim of achieving
an R0 resection. Frequently, the location of tumour within the liver and
tumour growth between resections hinders this goal.
Definition of liver molding. Hepatic moulding is the planned re-shaping
of liver parenchyma through directed liver atrophy and regeneration
producing a relative re-positioning of tumour within the mass of liver
parenchyma that facilitates resection. It is a multi-modal approach
which employs hepatic resection, hepatic artery and/or portal vein emboliza-
tion and ablative therapies to induce regeneration of tumour-free paren-
chyma while simultaneously controlling tumour growth elsewhere with
chemotherapy.
Aim. We reviewed our experience with hepatic molding in patients under-
going liver resection who were ultimately left with less than two hepatic
segments, even when including the caudate.
Case series. Patient 1 : A 44 year old woman underwent a left lateral
segmentectomy (LLS) and right portal vein (PV) embolization. Four months
later she underwent a right hemihepatectomy (RHH) and non-anatomical
(NA) resection of segment IVB.
Patient 2 : A 53 year old man underwent a RHH. Six months later he returned
for a LLS and NA resection of segment IVB.
Patient 3 : A 48 year old woman underwent a RHH and NA resections of
segment II, III and IV. Five months later she returned for a LLS and NA
resection of IVB.
Patient 4 : A 58 years old male underwent an extended RHH including the
caudate plus NA resection of segment II and III in a single procedure. A
subcutaneous continuous infusion pump was inserted into the hepatic artery
for post-operative chemotherapy.
Patient 5 : A 49 years old woman underwent an extended RHH leaving some
of segment IV. Eighteen months later she underwent a NA resection of a new
lesion in segment III. The surgery compromised the hepatic venous drainage
of the segment III which underwent atrophy. Twenty-five months later she
underwent a NA resection of the remnant of segment IV for a further
recurrence near the hilum.
Results. All patients received chemotherapy and tolerated surgery well.
An R0 resection was achieved in all cases. The median number of opera-
tions per patient was 2 (range 1 to 3) and staged resections were per-
formed over a median 10 months period (range 4 to 44 months). Follow-up
has been for median 11 months (range 2 to 31) without evidence of
recurrence.
Conclusion. The principles behind hepatic molding permitted five patients
with multiple bilateral hepatic colorectal metastases to undergo extensive
resections that ultimately left liver remnants derived from less than two
segments.
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Analysis of appropriate porcine liver donor size for xenotransplanta-
tion
Hamidreza Fonouni, MD, Arianeb Mehrabi, MD, PhD, Mehrdad Soleimani,
MD, Arash Kashfi, MD, Said H. Fani-yazdi, MD, Peter Schemmer, MD,
PhD, Bruno Schmied, MD, PhD, Carsten Gutt, MD, PhD, Jan Schmidt,
MD, PhD, Markus W. Bu¨chler, MD, PhD, Thomas W. Kraus, MD, PhD
Department of surgery, University of Heidelberg, Heidelberg, Germany
Liver transplantation has become a viable treatment for an increasing number
of patients suffering from end stage liver disease. Because organ donation has
pace with demand, each year a greater number of patients lose their life while
awaiting organs. Some of this deficit is being met by the use of splitting of ca-
daveric organs or organs from living donors, but these sources are insufficient.
Xenotransplantation (XTx) from pig to human could provide a solution if
immunologic and other associated problems are solved. The aim of this study
was to analyze structural surgical aspects for XTx using porcine livers.
This study was performed on landrace pigs (n /20) under general
anesthesia. After a midline abdominal incision, hepatic hilum was prepared
and common bile duct, common hepatic artery, portal vein and inferior vena
cava (IVC) were identified. The length (L) and diameter (D) of each vessel
and bile duct in mm as well as the weight of liver (kg) were measured.
Two different weight categories (group A: 20 /25 kg and group B: 30/35 kg)
were defined. The mean of all livers’ weight was 696.69/91.3 gr. The mean of
results are shown in the [Table 1].
We could show that there is a clear correlation between weight of the pig and
weight of liver (r/0.78), length of the vessels, and length of bile duct.
However, there is no significant correlation between weight of the pig and
diameter of the vessels or bile duct. Then, transplantation centers can
estimate the size of pig’s liver, length of its vessels and bile duct by only
weighing the pig. Within a short time, xenotransplantation could enable
patients to receive a life saving animal organ as an alternative to an allograft
and good size matched organs are extremely valuable.
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CD34/ve Fibrous sarcoma of liver associated with hypoglycaemia
Gabriel Chan, MD, Peter J Horton, MD, Jeffrey S Barkun, MD, John B
Martinie, MD, Prosanto K Chaudhury, MD, David Hill, PhD, Earl Marliss,
MD, Peter Metrakos, MD
Royal Victoria Hospital, Montreal, PQ, Canada; Lawson Health Research
Institute, London, ON, Canada
Background. CD34/ve fibrous sarcomas of liver are rare tumours that are
derived from haematopoietic stem cells, but are rarely associated with
hypoglycaemia. Hypoglycaemia associated with other malignancies has
been linked to insulin like growth factor-2 (IGF-2) production.
Aim. We report a rare CD34/ve fibrous sarcoma of the liver and investigate
the cause of the patient’s persistent hypoglycaemia.
Patients and methods. A 70-year-old man presented with a symptomatic
hypoglycaemia and a large mass in the right lobe of the liver, which was
initially felt to be unresectable. There was no evidence of metastases. The
hypoglycaemia was not suppressed by steroids or embolization of the right
portal vein, performed to induce hypertrophy of the left liver. He required
parenteral nutrition to maintain his blood glucose levels at the low end of
the normal range and consequently was unable to leave hospital. He
underwent a laparotomy and a 4 Kg exophytic nodular tumour was
resected. Blood glucose levels returned to normal. Sections of tumour and
normal liver were frozen in liquid nitrogen. Serum was obtained pre- and
post-resection and stored with protease and RNAase inhibitors. Serum
insulin and glucagon levels were measured. Histology and immunohisto-
chemistry was performed on the liver. Tissue and serum was subjected to
reverse transcription (RT) polymerase chain reaction (PCR) and quantita-
tive (Q) PCR analysis with emphasis placed on detecting and measuring
levels of IGF-1 and 2 and insulin like growth factor binding proteins
(IGFBPs) 1 to 6.
Results. Histology revealed a highly cellular tumour with a high mitotic
index that stained positive for CD34, CD99, Bcl-2 and vimentin on
immunohistochemistry. The tumour was classified as a CD34/ve fibrous
sarcoma of haematopoietic stem cell origin. Serum insulin and glucagons
levels were low despite the hypoglycaemia. IGF-1 was not elevated in the
serum and results for IGF-2 are awaited. The patient re-presented eight
months following resection with widespread pulmonary metastases. He
remains normoglycaemic.
Conclusion. Persistent hypoglycaemia in this patient was due to a rare
CD34/ve fibrous sarcoma of the liver. The hypoglycaemia was asso-
ciated with a low serum insulin level and was resistant to suppression by
steroids. The hypoglycaemia was successfully managed by resection of the
tumour.
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Rex shunt / a treatment option for extrahepatic portal thrombosis in
adults
Marwan Abouljoud, MD, Aditya Bansal, MD
Henry Ford Hospital, Detroit, MI
Background. Recently, the Rex shunt meso-portal shunt has been used
successfully to remedy extra-hepatic portal hypertension due to portal vein
thrombosis in chidren. Review of literature reveals that this technique has
Weight of livers
(g)
Suprahepatic IVC
(L/D)
Infrahepatic IVC
(L/D)
Hepatic artery
(L/D)
portal vein
(L/D)
Bile duct
(L/D)
Group A (20/25 kg) 609.5 88.5/14 41.1/16.5 8.1/3.3 23.3/14.1 39.1/5.7
Group B (30/35 kg) 773.1 91.5/14.7 48.7/16.8 14.5/3.3 28.3/15.3 47/5.5
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only been performed in pediatric population. We now report the first adult
case successfully treated with this novel technique.
Patient report. A healthy 56-year-old male presented to our insti-
tution with bleeding esophageal and gastric varices. He was diagnosed
with portal vein thrombosis of unknown etiology. Patient had no cirrhosis
or any hypercoagulable state. Repeat CT scan (fig.1)and mesenteric
angiography confirmed portal, splenic and mesenteric vein thrombosis and
splenomegaly. Peripheral mesenteric veins were patent and appeared en-
gorged. Rex shunt was planned in view of normal looking liver and its known
advantages.
In the operating room the liver was diminutive in size but otherwise normal
in appearance. There was extensive collaterals and apparent mesenteric
venous congestion. A 9 mm mesenteric vein was isolated proximal to the
location of the superior mesenteric vein trunk. Round ligament was taken
down and the hilar plate released as well. The left portal vein was dissected
into the filar plate and a bubble-assisted ultrasound showed patency of
the vein well into the liver, but there was some narrowing of the right portal
vein.
A 13 cm segement of left superficial femoral vein was then dissected and was
an excellent size match. The vein was then anastomosed to the mesenteric
vein branch in an end-side fashion. The vein conduit was then passed in a
retro-colic, retro-gastric, ante-pancreatic fashion and anastomosed to the left
portal vein. Shunt flow measured 600/800 ml/min. Follow-up CT angio-
graphy at 9 months (Fig. 2) shows a patent shunt and upper endoscopy
showed resolution of varices.
Conclusions. We demonstrate that the Rex shunt, previously applicable only
to children, can be applied to select adults suffering from a similar disease
process and intact liver function. We argue that this option should be
explored in all adults in this setting prior to proceeding with splenectomy and
devascularization or porto-systemic shunting.
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Simple mesothelial CYST of the retroperitoneum with elevated CA
125 and CA 19-9
Ne´stor A. Go´mez, MD, Jorge A. Zapatier MD., Paola E. Vargas MD.,
Jero´nimo J. Gaibor MD., Jorge L. Mejillo´n MD
Institute of Digestive Diseases, Guayaquil, Ecuador
Introduction. Simple mesothelial cyst are benign abdominal masses,
characterized by an inner surface of one or multiple layers of cubil
mesothelial epithelium. We present a case of a rare mesothelial cyst located
in retroperitoneum that expressed high Ca 19-9 and Ca 125.
Case report. A 55-years-old man that presented abdominal and thoracic
pain. Physical examination and laboratory test were all normal, except for a
marked elevation of Ca 125 and Ca 19-9 (538.5 U/ml and 315 U/l
respectively). Both, abdominal sonography and CT scan suggested the
presence of hepatic cyst (fig. 1). It was close to the aorta and surrounded
by the hepatic artery, therefore guided biopsy was ruled out. The cyst was
surgically excised, noting that it was located in retroperitoneum, adjacent but
without involving the hepatic left lobe and pancreatic head. Microscopic
examination revealed an inner layer of mesothelial cells that contained fluid of
inflammatory characteristics without neoplasic changes. The patient was
discharged 5 days later and returned at 1 month for follow-up presenting no
further complains.
Discussion. Retroperitoneal cyst can be considered benign tumors.
Abdominal pain and distention are the most frequent manifestations. The
diagnosis can usually be made with ultrasound or CT scan, but preoperative
biopsy is useful to determine other causes or presence of malignancy. Total
surgical excision is the treatment of choice in order to improve symptoms and
avoid complications or recurrence. Ca 125 may raise as an expression of
stimulated mesothelial cells, but there is no reported association with elevated
Ca 19-9 titers. We highlight the rarity of its location, and the expression of
tumor markers.
Bibliografia
[1] Maj SK Maurya, Lt Col FB Both, Lt Col DK Ghosh, et al. Retro-
peritoneal Cyst. MJAFI 2003;59:73/74.
[2] Kurtz RJ, Heimann TM, Holt J, et al. Mesenteric and retroperitoneal
cysts. Ann Surg 1986;203:109/12.
[3] Moreno-Hurtado C, Blesa-Sa´nchez E, Cabrera-Garcı´a R, et al. Quistes
mesoteliales intraabdominales. Vox Paedia´trica 2002;10(2):28/31.
[4] Pabst T, Ludwig C. CA 125_a tumor market? Schweiz Med Wochenschr
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Transabdominal lesser SAC flexible peritoneoscopy with pancreatic
biopsy-evaluation of procedure feasibility
Lucas A. Julien, MD, Ozanan Meireles, MD, Bryden J. Stanley, DVM, Keith
N. Apelgren, MD, Jeffrey M. Gauvin, MD, Donald N. Reed Jr., MD
Michigan State University Colleges of Human and Veterinary Medicine, East
Lansing, MI
Introduction. Pancreatic tumors demand histologic or cytologic confirma-
tion for diagnosis and subsequent treatment. The current available methods
of pancreatic biopsy are limited and pose undesirable risks. Our group has
demonstrated that Lesser Sac Flexible Peritoneoscopy (LSFP) for pancreatic
evaluation and biopsy is feasible in animal model. This novel procedure, is
less invasive than standard laparoscopic procedures, requires less instrumen-
tation and is potentially more accurate for tissue sampling than current
radiological assisted methods.
Methods. For this project, 2 Canines averaging 30 Kg were utilized as an
animal model in the surgical suite at the Michigan State University (MSU)
College of Veterinary Medicine. Under general anesthesia a conventional
flexible gastroscope was inserted into the abdomen through a 10 mm
laparoscopic port. Once, pneumoperitoneum was achieved, the gastroscope
was advanced through the epiploic foramen (Winslow) providing visualiza-
tion and access to the pancreas and adjacent structures within the lesser sac.
The pancreas was evaluated and biopsied for histological confirmation. The
dogs were euthanized under general anesthesia following LSFP. MSU AUC
Animal Use Committee has approved this procedure.
Results. This study demonstrates Lesser Sac Flexible Peritoneoscopy is
feasible in animal model with current flexible gastroscope. The pancreas and
surrounding organs were evaluated under direct visualization with adequate
picture quality. The gastroscope forceps, used for biopsy, provided sufficient
pancreatic tissue, which was confirmed histologically. There were no
complications during the procedure.
Conclusions. This procedure combines laparoscopic and endoscopic
techniques and represents a novel method of minimally invasive access to
the lesser sac, making possible pancreatic biopsy under direct visualization.
This method is feasible in an animal model using commercially available
gastroscope. LSFP has the potential to improve patient care going beyond the
reach of current CT and US- guided biopsy methods for evaluation of the
pancreas.
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Targeted RNA intervention prevents lung injury following hepatic
cryoablation
Sean C. Glasgow, MD, Sabarinathan Ramachandran, PhD, T. Mohanaku-
mar, PhD, William C. Chapman, MD
Washington University, St. Louis, MO
Introduction. Large-volume hepatic cryoablation can result in acute lung
injury similar to ARDS. Prior research has shown that levels of IL-1b and
activation of NF-kB-dependent pathways are prominent in the inflammatory
response. We sought to reduce hepatic and pulmonary inflammation by
inhibiting both liver-specific and systemic IL-1 signaling in this model of
ischemia-reperfusion (I/R) injury.
Methods. Following sequence selection utilizing cultured murine alveolar
macrophages, an optimized liposome-encapsulated IL-1b-specific siRNA
sequence was delivered either systemically or via the portal vein to transgenic
HLL mice (5’ H IV-LTR-L uciferase; 5’ HIV-LTR is an NF-kB promoter).
HLL and IL-1 receptor 1 knockout mice (IL1R1KO) then underwent 35%
hepatic volume cryoablation. NF-kB activity in HLL mice was assessed by ex
vivo bioluminescence, serum cytokines and lung chemokines assayed by
ELISA, and pulmonary neutrophil content measured using a myeloperox-
idase (MPO) assay. Data were analyzed by ANOVA and expressed as mean9/
SEM.
Results. Systemic IL-1b siRNA pretreatment effectively reduced circulating
IL-1b levels at 4 hours post-hepatic injury (2039/39 pg/mL vs. 5009/68 for
controls and 4459/23 for IL1R1KO; p B/0.05). IL-6, a downstream pro-
inflammatory cytokine, also was suppressed in IL-1 signaling pathway-
deficient mice (IL-1b siRNA: 1039/29 pg/mL; controls: 9789/313;
IL1R1KO: 439/13; p B/0.05). NF-kB activation in the non-injured liver
remnant of HLL mice pretreated with IL-1b siRNA was less than observed in
controls (637549/10250 vs. 1771389/21040 for controls; p B/0.05).
Pulmonary NF-kB was also significantly reduced in both siRNA-treated
and IL1RiKO mice. Lung MPO content at 24 hours was unchanged from
baseline in systemic IL-1b siRNA-treated animals (0.229/0.02 DOD/min/mg
protein vs. 0.299/0.02; p B/0.05). Similarly, mice receiving liver-specific
delivery of IL-1b siRNA exhibited significantly lower pulmonary MPO
compared to nonsense siRNA controls (graph).
Conclusions. Liver injury-induced lung inflammation is mediated predo-
minantly by IL-1b. Knockdown of IL-1b expression prior to hepatic
cryoablation led to significant reductions in both pro-inflammatory cytokine
production and hepatic and pulmonary NF-kB activation. Similar RNA-
targeted interventions delivered to donor livers may have a role in diminishing
graft dysfunction resulting from I/R injury.
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Adult nesidioblastosis: An under diagnosed entity?
Anand C. Patel, MD, Maurice E. Arregui, MD, James E. Meacham, MD
St. Vincent Hospital, Indianapolis, IN
Purpose. Until recently, adult nesidioblastosis has been considered a rare
cause for hypoglycemia. With increasing awareness, this diagnosis is
becoming more recognized. We present our experience.
Materials and methods. From 4/04 to 8/05, five patients were referred for
surgical evaluation of hyperinsulinemic hypoglycemia in which insulinoma
was not found. A retrospective review was performed. Analyses of patient
demographics, diagnostic studies, surgical therapy and outcomes are
presented.
Results. All patients are female; ages range from 32 /49 years. Three had
bariatric surgery. All had symptoms of neuroglycopenia. At the time of
referral they were presumed to have an insulinoma. Evaluation includ-
ed CT scan with islet cell protocol, abdominal ultrasound and/or
endoscopic ultrasound. Four patients underwent a 72-hour fast and
selective pancreatic arterial calcium stimulation with hepatic venous
sampling for insulin. All demonstrated a greater than three fold rise in
stimulated insulin levels. Two had open and one laparoscopic splenic
sparing extended distal pancreatectomy. All had thorough exploration and
intraoperative ultrasound. Three final pathologies demonstrated nesidio-
blastosis. The fourth patient has a positive calcium stimulated insulin
study, and the decision for surgery is pending. The only patient who did
not undergo a 72 hour fast nor calcium stimulated arterial injection was
referred with a fine needle biopsy of a pancreatic tail mass seen on CT
consistent with an islet cell tumor. At laparoscopic exploration with
ultrasound no tumor was found. A biopsy was performed. This showed
architectural and cytologic islet cell atypia but nondefinitive features of
nesidioblastosis. This patient’s evaluation is still in progress. Three patients
have undergone successful definitive therapy with resolution or marked
improvement of hypoglycemia. One patient awaits surgery, and another
remains under investigation.
Conclusions. Nesidioblastosis is a rare and frequently undiagnosed disorder
causing hyperinsulinemic hypoglycemia. An increased awareness of this
entity following our initial case has enabled us to more readily diagnose a
hitherto rare condition. The diagnostic evaluation of hyperinsulinemic
hypoglycemia using CT scan, EUS, and a monitored 72 hour fast will assist
in excluding more commonly recognized causes of hyperinsulinism. Selective
pancreatic arterial calcium stimulation with hepatic venous sampling for
insulin provides diagnostic evidence of islet cell hyperfunction and is
necessary for gradient guided resection. Laparoscopic pancreatic resection
is a feasible approach for this disease.
P90
The management of intrahepatic recurrence after curative treatment
of colorectal liver metastases: is aggressive surgical treatment
justified?
Tristan Yan, MBBS, K. Lian, MBBS, David L. Morris, PhD
The University of New South Wales, Sydney, Australia
Introduction. The management of intrahepatic recurrence after potentially
curative surgical treatments of colorectal liver metastases is not well defined.
This series is to evaluate the long-term survival results and prognostic
determinants after aggressive surgical treatment for intrahepatic recurrence.
Methods. Prospectively collected clinical information of 382 patients with
colorectal liver metastases treated with resection with or without cryotherapy
in our institution between 1991 and 2005 was analyzed. Fifty-five patients
had isolated intrahepatic recurrence and were treated with redo liver
resection, cryotherapy or both. The long-term survival results and the
prognostic indicators for survival of these 55 patients were reported.
Results. The median survival of the 55 patients after the surgical treatments
of the liver recurrence was 53 months (range 2 to 97 months), with 1- to
5-year survival of 94%, 89%, 61%, 56% and 49%, respectively. Nine factors
were found to be significant for survival: largest size of hepatic lesion,
completeness of initial liver operation, CEA level before and after the initial
liver surgery, liver disease-free interval, surgical margin for hepatic recur-
rence, operation type for hepatic recurrence, CEA level before and after redo
liver surgery.
Conclusions. Aggressive surgical treatment such as resection with or
without cryotherapy can achieve long-term survival in a high proportion of
patients with intrahepatic recurrence after curative surgery for colorectal liver
metastases.
P91
Assessment of the role of angiogenesis and hypoxia for tumour
invasion in colorectal cancers and their liver metastases
Rajasundaram R. Rajaganeshan, MBBS, David Jayne, MD, MBBS, Pierre
Guillou, MD, MBBS, Graeme Poston, MD, MBBS
Raj Prasad, St James’s University Hospital, Leeds, United Kingdom;
University Hospital Aintree, Liverpool, United Kingdom
Purpose of the study. Hypoxia induces tumour angiogenesis and anaerobic
metabolism via up-regulation of HIF-1a. pVHL regulates proteosomal
degradation of HIF-1a. This study aimed to determine the relationship
between HIF-1a, pVHL, angiogenesis (CD31, VEGF) and anaerobic
metabolism (CAIX, GLUT-1) at the invasive margin of colorectal cancer.
Methods. A tissue microarray (TMA) was constructed using cores from the
margin and centre of 85 colorectal cancers and 55 liver metastases.
Immunohistochemistry was performed using antibodies against HIF-1a,
pVHL, VEGF, CD-31, CAIX, and GLUT-1.
Results. MVD was significantly increased at the margin compared to the
centre in primary cancers (p/0.003) and liver metastases (p/0.02). MVD
was associated with increased VEGF (primary p/0.05, liver p/0.02) but
not HIF-1a expression. HIF-1a, CAIX, Glut-1, and VEGF expression at the
tumour margin was significantly higher than at the tumour centre for both
primary and liver metastases HIF-1a (primary pB/0.001, liver p/0.001),
CAIX (primary p/0.013, liver p/0.05), Glut-1(primary p/0.015, liver
p/0.002) and VEGF(primary p/.001, liver p/0.05).
HIF-1a was positively correlated to pVHL expression (pB/0.001) in primary
cancers. Significant correlation was present between the primary and liver
metastases tumour margin of VEGF and pVHL ( Pearsons VEGF p/0.006,
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pVHL p/0.031). Similar results were also obtained with pVHL at and
tumour centre (Pearsons p/0.010).
On univariate analysis, HIF-1a, VEGF and pVHL were predictive of disease-
free survival in primary cancers but not liver metastases (HIF-1a p/B/0.01;
VEGF p/0.01; pVHL p/0.02).
Conclusions. Angiogenesis & anaerobic metabolism is increased at the
invasive margin of colorectal cancers and their liver metastases.
P92
Hepatectomy and lung radiofrequency ablation for hepatic and
subsequent pulmonary metastases from colorectal carcinoma
Tristan Yan, MBBS, Julie King, None, Derek Glenn, PhD, David L Morris
The University of New South Wales, Sydney, Australia
Introduction. Resection of colorectal pulmonary metastases can achieve
20/40% 5-year survival, but only in a small group of patients. The
management of colorectal pulmonary metastases after hepatectomy is not
well defined.
Methods. This clinical study consists of 30 patients, who originally had liver
resections for colorectal liver metastases and subsequently developed
pulmonary metastases, which were then treated with lung RFA. The primary
aim is to report the survival outcome of lung RFA. The secondary aim is to
assess the prognostic indicators for survival after lung RFA. From June 2000
to January 2005, 30 patients were entered into the study. Lung RFA was
performed percutaneously under local anesthesia and conscious sedation,
with fluoro-CT guided imaging, using the RITA 1500 generator. All patients
were reviewed at one week, one month and every three months thereafter by
assessing their chest CT scans. The follow-up was complete.
Results. The median survival after lung RFA was 32 months (range 5 to 50
months). The 3-year survival rate was 45%. The following 5 factors were
found to be significant, affecting survival in the univariate analysis: size of the
largest pulmonary metastasis (p/0.032), proximity of metastases to major
pulmonary vessels (p/0.003), pre-lung RFA CEA level (p/0.013), post-
lung RFA CEA level (p/0.022) and the use of adjuvant chemotherapy post
lung RFA (p/0.029). Proximity of metastases to major pulmonary vessels
was also significant in the multivariate analysis.
Conclusions. Lung RFA is a relatively safe and effective procedure and may
have a useful role in the management of inoperable colorectal pulmonary
metastases, especially bilateral pulmonary metastases.
P93
Cholangiocarcinoma: Outcomes associated with surgical treatment
Hiromichi Ito, MD, Richard S. Swanson, MD, David C. Brooks, MD,
Michael J. Zinner, MD, Stanley W. Ashley, MD, Edward E. Whang, MD
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background. The aim of this study was to evaluate contemporary outcomes
associated with the management of cholangiocarcinoma.
Methods. The medical records of 114 consecutive patients with cholangio-
carcinoma treated at our institution from 1/1982 through 1/2005 were
reviewed. Survival was analyzed using the Kaplan-Meier method (mean
follow-up: 12 months, 0/81 months). Prognostic factors were analyzed
(univariate Log-Rank test).
Results. Mean patient age was 65 years. Sixty-one (54%) patients were
female. Sixty-seven percent of patients presented with jaundice, 36% with
abdominal pain and 20% with weight loss. Fifty-seven (50%) patients had
hilar tumors, 21 (18%) patients had intrahepatic tumors, and 33 (29%)
patients had mid or distal tumors. Fifty-eight (51%) patients underwent
laparotomy or laparoscopy. Twenty-three (20%) patients underwent poten-
tially curative resection (9 pancreaticoduodenectomies, 7 resection of
common bile duct (CBD), 4 major hepatectomies, 3 hepatectomies with
CBD resection). There were two (3%) procedure-related mortalities.
Overall 1-year and 5-year survival rates were 40% and 6%, respectively.
Patients who underwent curative resection had higher 1-year and 5-year
survival rates (68% and 16%, respectively) than patients who underwent
palliative surgery or no surgery (33%and 3%, respectively, pB/0.05). Of 23
patients who underwent curative resection, T stage and microscopic margin
status were significant prognostic factors (5-year survival rates: 34% vs
0% for T1/2 vs T3/4, 30% vs 0% for margin negative vs margin positive,
pB/0.05).
Conclusion. The overall survival for patients with cholangiocarcinoma
remains poor. Although radical surgery is safe, it is associated with long-
term survival only in a highly select subset of patients with cholangio-
carcinoma.
P94
A transfusion risk score for predicting perioperative blood transfu-
sion in liver surgery
Carlo Pulitano`, MD, Marcella Arru, MD, Marco Catena, MD, PhD, Renato
Finazzi, MD, Laura Bellio, MD, Silvano Rossini, MD, Gianfranco Ferla,
MD, Luca Aldrighetti, MD, PhD
Scientific Institute H San Raffaele, Milan, Italy
Despite the recent improvements in surgical and anesthetic techniques, the
risk for major intraoperative blood loss and of the resultant blood transfusion
remain. Given the high cost of autologous blood donation for elective
surgery, it would be desiderable to predict which patients are most likely to
benefits from the procedure. This study was therefore designed to develop a
point score system for predicting the risk of blood transfusion in liver surgery,
in order to identify patients who could benefit from preoperative blood
conservation strategies.
A database of 320 patients undergoing elective hepatic surgery at a teaching
hospital was used for the analysis. Twenty-five preoperative variables were
analyzed to determine their univariate association with perioperative blood
transfusion. Significant variables were entered into a multiple logistic
regression model, and a transfusion risk score (TRS) was developed. The
predictive utility of this point score system was validated by examining the
area under the receiver operating characteristic (ROC). Factors indepen-
dently associated with blood transfusion included preoperative hemoglobin
B/12.5 mg/dL, tumor size /4 cm, necessity of a full exposure of vena cava,
additional surgical procedures, and cirrhosis. Each significant variable was
assigned one point, and the total score was compared with the transfusion
rate of each patient. The frequency of blood transfusion on the basis of their
point scores was 2 percent for patients with score 0, 4% for patients with
score 1, 44% for patients with score 2, 76% for patients with score 3, 94% for
patients with score 4, and 100% for patients with score 5. The calculate area
under the receiver operating characteristic curve was 0.88. The number of
units transfused was significantly correlated with the TRS (P/0.0009).
Patients with two or more points, identified as being at high risk for a
perioperative blood transfusion, should be preferentially encouraged to utilize
the autologous blood donation program, which would maximize the benefits
of such a program. In contrast, patients with one point or less, who are at low
risk for a postoperative blood transfusion, could be informed of such status
and not be encouraged to donate autologous blood. The results of this study
suggest that it is possible to predict, with a reasonable degree of accuracy,
which patients undergoing elective hepatic resection may receive a perio-
perative blood transfusion. The use of TRS could lead to substantial saving
by improving the cost-effectiveness of the autologous blood donation
program.
P95
Pancreatic cancer: A case of conversion to resectability by preopera-
tive chemo-radiation
Marjorie K. Dougherty, MS, PA-C, Mellena D. Bridges, MD, Christopher B.
Hughes, MD
Mayo Clinic Jacksonville, Jacksonville, FL
Pancreatic adenocarcinoma is the fourth leading cause of cancer-related
death in the US. Of the 29,000 new cases each year, fewer than 20% will have
resectable tumors and 80% will die within 12 months of diagnosis (1).
Surgery has been the only effective treatment. Although recurrence rates are
high, post-operative adjuvant therapy consisting of local radiation and
systemic chemotherapy has improved median survival (2). However, post-
operative therapy is delayed or abandoned in at least 25% of patients due to
surgical complications such as pancreatic leaks (3). Greater emphasis is now
being placed on preoperative chemoradiation as a means of increasing
numbers of patients completing therapy. In our case, preoperative chemor-
adiation afforded resection in a patient initially deemed unresectable.
A 62 y/o male presented to the emergency room with a 5-day history of
jaundice. MRI revealed a 3.0/2.2/3.7 cm mass abutting the portal vein
and encasing the common hepatic artery with no hepatic metastasis(Figure
1a). CA19-9 was 426 m/mL. FNA confirmed adenocarcinoma. Due to
encasement of the common hepatic artery, the patient was deemed
unresectable. The patient received radiation therapy over 5 weeks consisting
of a 3-field, 3-D conformal technique of 4680 cGy (180 cGy/fraction for 26
fractions). Chemotherapy with gemcitabine 220 mg/2 doses followed by
450 mg/4 doses was completed concurrently with radiation. After comple-
tion of combined chemoradiation, MRI showed regression of tumor from the
common hepatic artery (Figure 1b).
With the changes in arterial involvement afforded by chemoradiation, the
patient underwent surgical resection. At surgery, the tumor was separable
from the hepatic artery. Pathology showed G2 moderately differentiated
pancreatic adenocarcinoma with negative margins and nodes. The patient’s
post-surgical course was uncomplicated. Beginning 6 weeks postoperatively,
the patient received 2 weeks of directed radiation therapy (total 1980 cGy at
180 cGy/fraction). Chemotherapy with gemcitabine was continued for 6
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months (432 mg/2 doses followed by 1800 mg/13 doses. The patient is
doing well with no evidence of recurrence at 18 months follow-up.
Effects of preoperative chemoradiation treatment on pancreatic adenocarci-
noma can be directly measured. In this case, such treatment allowed
conversion of an unresectable tumor to a resectable one.
P96
Improved CT differential enhancement of tumor from normal liver
using a vasodilator to change angiogenic blood flow
John R. Haaga, MD, Agata Exner, PhD, Christopher Siegel, MD, PhD,
Anthony B Post, MD, Dean A Nakamoto, MD
University Hospitals of Cleveland, Case Western Reserve University School
of Medicine, Cleveland, OH
Purpose. To determine if the vasodilator acetazolamide can produce
differential enhancement of tumor tissue as compared to normal liver, based
on the absence of smooth muscle in the wall of neoangiogenic vessels of
tumor.
Materials and methods. A VX2 tumor was inoculated in livers of 5 male
NZW rabbits. Liver perfusion maps were created 28 days after initiation of
the tumor by tracking contrast enhancement on eight sequential CT images
before and after IV injection of acetazolamide (50 mg/kg). Regions of interest
were manually drawn at the peripheral rim of untreated tumor and distal
normal liver tissue. Arterial and portal perfusion was calculated by measuring
the slope of the time-density curve before (arterial) and after (venous) peak
splenic enhancement and normalizing by the vascular input. A mean percent
change in perfusion before and after CAI injection was calculated.
Results and discussion. Untreated tumors showed a marked decrease in
perfusion after AZ administration, while normal liver perfusion increased
substantially. Differences between normal and tumor flow were statistically
significant for arterial, (p/0.01), venous (p/0.04) and total (p/0.02)
perfusion.
The paradoxical enhancement produced by the administration of acetazol-
amide prior to the duplicate CT scan is most likely based on the absence of
smooth muscle in the wall of the tumor vascularture.Histologic analysis
confirmed the absence of vascular smooth muscle in tumor neovascular-
ity.The absence of smooth muscle in tumor vessels and the paradoxical blood
flow has been documented in numerous animal models but this represents
the first use of this principle to enhance the conspicuity of lesions on CT
scans. Further refinement of this method might permit better differentiation
and specificity for primary diagnostic studies as well as post RF ablation
evaluations.
Conclusions. Administration of a systemic vasodilator, acetazolamide, prior
to contrast enhancement produces differential enhancement between normal
and tumor tissue which is greater than that observed with simple contrast
enhancement. This ‘‘paradoxical enhancement’’ well documented in the
basic literature, offers the potential for improving primary diagnosis of tumor
as well as differentiation of benign from malignant tumors.
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Surgical strategy for hepatic tumors with bile-duct tumor thrombus
Keiichi Kubota, MD, PhD, Junji Kita, MD, Mitsugi Shimoda, MD, Tokihiko
Sawada, MD, PhD
Dokkyo University Hospital, Tochigi Pref., Japan
Introduction. Hepatic tumors with bile-duct tumor thrombus (BTT)
include hepatocellular carcinoma (HCC), cholangiocellular carcinoma
(CCC) and metastatic tumors (Meta). Since HCC and CCC are prone to
develop in the damaged liver, their treatments become difficult with high
morbidity and mortality rates. The aim of this study is to establish an effective
surgical strategy for hepatic tumors with BTT.
Patients and methods. From April, 2000 to September, 2005, 415
hepatectomies were performed at our department. Preoperative US and
CT suggested the presence of BTT in 11 patients (Median age: 66, Male/
Female: 9/2, HCC/Meta/CCC: 5/3/3). Their median indocyanine green
retention rate at 15 minutes was 13% (4/18). The surgical treatments of the
11 patients were retrospectively discussed.
Surgical strategy. When a patient showed jaundice, biliary drainage was
performed for the future remnant lobe. A hypervascular tumor on angio-
graphy received TAE for occluding intra-tumoral shunts and reducing the
sizes of BTTs. When the serum bilirubin levels were decreased to less than 5
mg/dl, portal embolization (PE) was performed. Hepatic resection was
performed for patients with the bilirubin levels of less than 2 mg/dl.
Results. 5 patients required biliary drainage. 5 patients (HCC/Meta/CCC:
2/1/2) required extended right lobectomy with (n/4) or without (n/1) bile
duct resection, which was preceded by portal embolization (PE). In 2
patients with HCC, PE was preceded by TAE. Central bisegmentectomy and
anterior segmentectomy with bile duct resection were performed in one
patient each. The remaining 4 patients underwent left lobectomy, extended
left lobectomy, extended resection of segment 4 and partial resection. After
TAE, in 2 patients, BTTs reduced their sizes significantly and subsequently
surgical procedures were changed from right lobectomy to anterior segmen-
tectomy with bile duct resection and from left lobectomy to extended
resection of segment 4. Their median bleeding amount, Pringle time and
operation time were 866 ml (320 /2505), 54 min (28/140) and 609 min
(280/812), respectively. There was no postoperative mortality. 4 patients
(HCC/Meta/CCC: 2/1/1) are alive without recurrence, while 7 developed
recurrence (liver/lung: 4/3). One patient with Meta underwent resection of
the lung metastasis on POD 308 and is doing well without recurrence on
POD 1481. 9 of the 11 patients are alive with median survival period of 512
days (151/1481).
Conclusion. Our surgical strategy including biliary drainage, TAE and PE
makes it possible to achieve zero mortality with a sufficient median survival
period for patients with hepatic tumors with BTT.
P98
Under-detection of spigelman stage IV duodenal polyposis in familial
adenomatous polyposis (FAP) by application of the st. marks criteria
Kant J. Shah, MBBS, Ashneel Darmalingam, Helen Denley, Ajith K.
Siriwardena
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom; Department of Histopathology, Manchester Royal In-
firmary, Manchester, United Kingdom
Background. Prophylactic colectomy has decreased the incidence of colonic
cancer in patients with the familial adenomatous polyposis (FAP) syndrome
and duodenal cancer and desmoids are now the leading causes of death.
Management of the duodenal cancer risk is complex: although the majority of
patients have duodenal polyps, only a small minority go on to develop cancer.
Management guidelines for endoscopic surveillance relating to use of side-
viewing scope, frequency of procedure and number of biopsies have been
reported by the St.Mark’s group. This study provides an appraisal of the
application of these criteria in a surveillance programme.
Methods. This study was carried out in a major European University
Teaching Hospital, housing both a regional genetics service and a regional
HPB service. All patients undergoing duodenal biopsy for the calendar year
2004 were identified from Histopathology records. Non-FAP patients were
excluded to leave a final population of 9 (catchment population 3.5 million
people). The endoscopy records of these patients were retrieved. All
histopathology was then reappraised by an individual HPB histopathologist
who was blind to outcome and these results pooled with endoscopy and
photographic data to calculate a Spigelman score. The derived Spigelman
stage was then matched with St.Marks registry guidance to assess whether
compliance and care were satisfactory.
Results. The results are seen in the table. Both patients classified as
Spigelman IV were stage III previously and both had carcinoma at operation.
One has since died nine months post-resection from metastatic disease.
Conclusion. This is a small series and thus interpretation must be cautious.
Although valuable, the Spigelman score may not detect those individuals with
stage 3 disease at high-risk for malignant progression.
Calculation of Spigelman stage and comparison of recommended to actual management.
Pt
number
Number of
polyps
Max size
(mm) Histology Dysplasia
Spigelman
Score
Spigelman
Stage Recommended Rx Actual Rx
1 1 2 2 2 7 3 2 yr endo 12 month endo
2 2 1 1 2 6 2 3 yr endo 12 month endo
3 1 1 1 1 4 1 5 yr endo 12 month endo
4 1 3 3 2 9 4 1/2 yr endo or surgery PD
5 1 3 2 2 8 3 2 yr endo 12 month endo
6 1 1 1 1 4 1 5 yr endo 12 month endo
7 3 1 1 1 6 2 3 yr endo 12 month endo
8 1 3 2 2 8 3 2 yr endo 12 month endo
9 3 3 2 3 11 4 1/2 yr endo or surgery PD
Rx/treatment; PD/pancreaticoduodenectomy.
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Hepatectomy provides prolonged survival for isolated non-colorectal
liver metastasis
Steven A. Earle, MD, Eduardo A. Perez, MD, Juan C. Gutierrez, Daniel
Sleeman, MD, Alan S. Livingstone, MD, Dido Francesci, MD, Joe U. Levi,
MD, Leonidas G. Koniaris
University of Miami, Miami, FL
Introduction. The benefit of hepatectomy for non-colorectal metastasis
remains poorly defined and controversial. We, therefore, examined our
single-institution experience.
Methods. A retrospective review of the prospective medical records of 95
patients who underwent a hepatic resection for a non-colorectal liver
metastasis from 1990/2005 was performed. Patient demographics, tumor
characteristics, treatment, and long-term outcomes were analyzed. Descrip-
tive statistics, Kaplan-Meier survival, uni- and multivariate analysis using the
COX regression model were performed.
Results. The median age at time of surgery was 58 years (range 19/83
years). The primary tumor sites were categorized as follows: sarcoma (19
cases, 20%), neuroendocrine (18 cases, 18.9%), foregut (16 cases, 16.8%),
breast (10 cases, 10.5%), renal (10 cases, 10.5%), gynecologic (10 cases,
10.5%), adrenocortical (5 cases, 5.3%), melanoma (4 cases, 4.2%), and
lung (3 cases, 3.2%). The thirty-day postoperative mortality was 3.1% and
16% of patients developed postoperative complications (most commonly
perihepatic collections requiring drainage). Mean hospital stay was 8 days
(range 4/25 days). The median time of survival from the initial cancer
diagnosis in this select group of patients is 97 months with a 5-year
survival rate of 70%. The median time of survival from the date of liver
resection is 36 months, with a 5-year survival rate of 35%. The median
survival times since time of initial diagnosis for a non-foregut primary vs. a
gastrointestinal primary were 111 months vs. 49 months (p/0.000).
Median survival times since initial diagnosis were greater for an interval of
time between the initial diagnosis and the liver metastasis diagnosis of /24
months vs. B/or equal to 24 months (/120 months vs. 57 months, p/
0.000) Primary tumor type and the length of the interval between the
initial cancer diagnosis and the liver metastasis diagnosis are significant
prognostic factors for overall survival. No treatment dependent variables
(initial treatment modality, extent of liver resection, margins, and compli-
cations) were found to be significant prognostic factors on the multivariate
analysis.
Conclusions. In properly selected patients with a variety of malignancies
metastatic to the liver, palliative benefit and prolonged survival may be
enjoyed through liver resection, especially in patients with metastases from a
non-foregut primary site and an interval from initial diagnosis to liver
metastasis diagnosis greater than 2 years.
P100
Does the pre-operative detection of minute lesions in the liver
improve the prognosis of the colorectal liver metastases?
Zenichi Morise, MD, PhD, Atsushi Sugioka, MD, PhD, Ryoichi Kato, MD,
PhD, Junko Fujita, MD, PhD, Sojun Hoshimoto, MD, Takazumi Kato, MD
Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Background. Although hepatectomy for CRC metastases has become the
established procedure, there are still several controversies. Among them,
there is a question, ‘‘How do the preoperative imagings for minute liver
metastases contribute the prognosis?’’. We evaluate the impacts of CT-A and
-AP as a preoperative imaging in our series.
Materials and results. Hepatectomy for CRC metastases, as a complete
resection, was performed for 188 patients, 221 times from 1974 to 2004 in
our hospital. Overall 5, 10 years survival rates after the hepatectomy are
41.4%, 32.7%, respectively, and the survival rates of the patients with
multiple liver metastases are 28.5%, 18.8%, respectively
During the period between 1990 and 2000, single detector helical CT
was used for pre-operative examination. There are 85 patients who under-
went the examination before hepatectomy. Among them, there are 37
patients who underwent pre-operative evaluating CT during angiography,
and 48 who did not. The backgrounds (age, sex, number and size of
metastases, time of diagnosis, differentiation, stage, and lymph-node
metastases of original site) were compared and there is no significant
difference between them.
We had previously reported that using CT during angiography as a
pre-operative evaluation improves the detecting rate of minute meta-
stases and non-recurrent rate in the liver (104th Annual Meeting of
AGA, 2003). However, after more than 5 years follow-up periods, the
actual 5-year-survival rates of the patients with and without CT-during
angiography are 42.6 and 43.2%, respectively. There is no significant
difference between them. The recurrent sites after the hepatectomy
were the residual liver (59.7%), lung (31.3%), colorectal local region
(13.4%), and lymph-nodes (10.4%). The patients who developed recurrence
only in the liver were 37.3% and 68% of those patients underwent repeat
hepatectomy.
Conclusion. Present data shows that the benefits from the approach to
improve the detection for minute liver metastases are limited. It is thought
that this partially owes to the fact that the patients with recurrences only in
the liver, who would benefit, are only one third of all recurrent patients and
tend to undergo repeat hepatectomy. The strategy would be needed, which
can deal with extra-hepatic small metastases and intra-hepatic micro (below
the recognizing level)-metastases (PET-CT for detecting extra-hepatic
metastases, repeat surgery and (neo-)adjuvant chemotherapy for liver
micro-metastases etc).
P101
The significance of multidrug resistance in tumor tissuse detected by
spect and reverse by bromocriptine in clinical liver cancer patients
Zhang Wanguang, Chen Xiaoping, Zhang Zhiwei, Zhang Bixiang
Tongji Hospital, Tongji Medical College, Huazhong University of Science
and Technology, Wuhan, China
Aim. To explored whether P-glycoprotein (Pgp) and the other pumps,
multidrug resistance-associated protein (MRP) and lung resistance protein
(LRP), affect tumor accumulation and efflux of 99mTc-MIBI in liver cancer,
and reverse multidrug resistance(MDR) of liver cancer patients by bromo-
criptine.
Methods. 78 liver cancer patients who underwent surgery were examined.
Preoperation, 99mTc-MIBI SPECT was performed 15 min and 120 min after
injection of 20 mCi 99mTc-MIBI. After 2 days ingestion of beomocriptine(2.5
mg tid), 99mTc-MIBI SPECT was performed precisely according the same
methods in those 78 cases. Postoperation,Pgp, MRP and LRP expression
were investigated by Western Blotting and immunohistochemistry. The
messenger RNA (mRNA) level of Pgp, MRP and LRP was determined by
RT-PCRResults. On 99mTc-MIBI SPECT, 68 of 78 (87.2%) patients with
hepatocellular carcinoma had no 99mTc-MIBI uptake in tumor lesions. P-gp
expression was observed in tumor tissues of all the patients without 99mTc-
MIBI uptake (PB/0.017). No appreciable correlation was found between the
liver cancer 99mTc-MIBI images and the expression of MRP or LRP on the
level of protein or mRNA.
Conclusions. 99mTc-MIBI SPECT is useful for noninvasively predicting the
presence of MDR1 gene-encoded P-gp in patients with HCC. For the first
time, we report the approaches using bromocriptine may be selectively
applicable to the treatment of clinical MDR.
P102
Laparoscopic management of splenic artery aneurysms
Uthaiah Kokkalera, MD, Siddharth Bhende, MD
Guthrie/RPH, Sayre, PA
Purpose of study. To demonstrate that laparoscopic exlcusion of
splenic artery anuerysms is a safe and effective management for this surgical
entity.
Splenic artery aneurysms (SAA) are rare clinical entities that carry the risk
of rupture and fatal hemorrhage. They are now found in escalating
prevalence and are identified earlier due to the easy availability of advanced
imaging techniques. Historically, surgical approach to management of
SAA has consisted of laparotomy with resection of the aneurysm and a
possible splenectomy. Recently, angiographic interventions and laparo-
scopic SAA exclusion has been shown to provide adequate therapy without
the morbidity associated with open aneurysmectomy and splenectomy.
In patients with previous abdominal surgery, a planned hand assisted
approach may be needed. We present two patients with SAA who were
successfully managed laparoscopically with splenic preservation. Hand
assisted approach was needed in our second patient as the patient had
a prior history of gastric bypass surgery. Both patients had an unevent-
ful postoperative course and were discharged home on postoperative day
one. Follow up CT scans one year later demonstrated no flow in the
aneurysm.
P103
Nonresectable huge hepatocellular carcinomas treated with cryosur-
gery in combination with tace
Zhi-yong Huang, MD, PhD, Xiao-ping Chen, Zai-de Wu
Tongji Medical College, Tongji Hospital, Wuhan, Hubei Province, China
Objective. Hepatic resection is the most effective treatment for hepatocel-
lular carcinoma (HCC). Huge HCC with median or severe grade of cirrhosis,
especially when the tumor extends out of half liver or has multiple
intrahepatic metastatic lesions, is not feasible for resection. Exploring an
effective treatment for these HCCs is in urgent need.
Methods. The clinical data of 10 huge HCCs with median or severe grade of
cirrhosis undergoing cryosurgery and transarterial chemoembolization
(TACE) admitted in our center from May, 2003 to August 2005 were
retrospectively analyzed. The safety, postoperative complications and ther-
apeutic effects were evaluated.
Results. Combined cryosurgery and TACE is safe in treating huge HCCs
with median or severe grade of hepatic cirrhosis, the complications included
pleural effusion, liver and renal dysfuncation, intra-abdominal hemorrhage.
The 6-month survival was 80%. Among the survivors, two have survived for
more than 1 year, and one for more than 2 years.
Conclusion. Combined cryosurgery and TACE is an effective method for
treating huge HCCs with median or severe grade of hepatic cirrhosis
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Liver transplantation for non-hepatocellular and non-cholangiocar-
cinoma neoplasms in meld era
T. Mark Earl, MD, J. Kelly Wright, MD, D. Lee Gorden, MD, C. Wright
Pinson, MD, David S. Raiford, MD, Michael K Porayko, MD, Sunil K.
Geevarghese, MD, Beau S. Kelly, MD, Ravi S. Chari, MD
Vanderbilt University Medical Center, Nashville, TN
Introduction. Transplantation has been shown to be an effective treatment
modality for several non-hepatocellular, non-cholangiocarcinoma (NHNC)
tumors of the liver when resection is not feasible. NHNC tumors include
hepatic hemangioendothelioma (HEHE), hepatic adenomatosis (HA), and
metastatic neuroendocrine tumors and these conditions frequently occur in
non-cirrhotic livers with normal hepatic function. Therefore listing with
calculated MELD scores may result in long wait times with possible
tumor spread, or in the case of HA, malignant degeneration, rupture or
hemorrhage. In contrast, patients with Stage II hepatocellular carcinoma
(HCC) receive MELD exemption regardless of hepatic functional status,
reducing wait list time and risk for disease progression. We believe MELD
exemptions are necessary for patients with NHNC tumors to allow timely
transplantation.
Methods. All liver transplants performed at Vanderbilt from February
2002 to June 2005 were included. The institutional liver transplant
database was searched and patients transplanted for NHNC tumors were
identified.
Results. During the study period 216 liver transplants have been performed
at Vanderbilt University Medical Center. Median wait list time for a MELD
score of 24 was 132 days (Interquartile Range 47 to 416 days). Three patients
(1.4%) during this time period have undergone liver transplantation
for NHNC tumors. The first is a 52 year old blood group A female with
HEHE not amenable to resection whose calculated MELD score was
6 points. A petition for exemption to 24 points was awarded and
transplantation was performed 14 days following approval. The second
patient is a 23 year old blood group O female with biopsy proven HA
and a calculated MELD of 7. A petition for exemption was submitted for
24 points and transplantation was subsequently performed 76 days follow-
ing exemption approval. The third patient is a 62 year old blood group A
female with a calculated MELD of 27 who had liver insufficiency several
months following extensive resection for metastatic carcinoid. Transplanta-
tion was performed 6 days after listing.
Summary. Transplantation for unresectable NHNC tumors is possible in
the current era of the MELD scoring system. In order to achieve acceptable
wait list times and prevent tumor progression, MELD exemptions compar-
able to patients with Stage II HCC should be sought.
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S-1 plus cisplatin combination therapy for the patients with primary
liver carcinomas
Zenichi Morise, MD, PhD, Atsushi Sugioka, MD, PhD, Junko Fujita, MD,
PhD, Sojun Hoshimoto, MD, Takazumi Kato, MD
FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE, Toyoake,
Aichi, Japan
Background and aim. S-1 is a fourth-generation oral fluoropyrimidine and
attracts considerable interest for the activity against gastric cancer. Even up to
76% response rate was reported in S-1 plus Cisplatin combination therapy.
Also, 5FU plus Cisplatin combination therapy had been employed against
primary liver carcinomas (HCC and CCC) for years. We herein examined the
effect and adverse effects of S-1 plus Cisplatin combination therapy for
primary liver carcinomas.
Cases and results. 2 patients with HCC and 3 with CCC were employed for
this study. They all had far-advanced diseases at the time of the therapy
initiation. HCC patients are both males and had recurrences after hepatec-
tomies for the primary lesions, one had multiple disseminated metastases in
both lungs and the other had massive recurrent liver tumor with rapidly
growing portal vein tumor thrombus. CCC patients are all females and had
multiple lung metastases after two times hepatectomies, extended lymph-
node metastases (with the swelling of Virchow’s LN), and disseminated
multiple intrahepatic and peritoneal metastases after the palliative surgery,
respectively. Their ages were in the range of 42 /65 (mean: 55.6) years old.
They had no histories of pre-treatment.
The protocol of the therapy is 3 week-period of S-1 (80 mg/m2/day) oral
administration combined with 2 intravenous administration of CDDP
(30/50 mg/m2) during the period. With two (or more) weeks of intermis-
sion, the therapy was repeatedly performed 2/7 times for each patient.
Although 2 patients with HCC developed leukopenia and thrombocytopenia,
the therapy was well tolerable in the outpatient basis.
Three patients had PR and the other 2 had NC response with the therapy.
Two patients with CCC underwent palliative surgery during the period. They
are all alive 3, 9, 9, 10, 11 months after the initiation of the therapy.
Conclusion. S-1 plus Cisplatin combination therapy is a potential therapy
for advanced primary liver carcinomas and well tolerable in the outpatient
basis.
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Hepatobiliary and pancreatic procedures in renal transplant reci-
pients
Rod Mateo, MD, Talley Whang, Gagandeep Singh, MD, Linda Sher, MD,
Nicolas Jabbour, MD, Robert Selby, MD, Yuri Genyk, MD
Keck-USC School of Medicine, Los Angeles, CA
Introduction. For many patients with end-stage renal disease, kidney
transplantation offers the possibility of long-term survival. No reports
document immunosuppression as a risk factor for increasing hepatic,
pancreatic, or biliary disorders in transplant recipients, although an im-
munosuppressed state can predispose these patients to a poor prognosis after
infection or malignancy. We present our transplant center’s experience with
hepatic, pancreatic, or biliary disease in kidney transplant recipients.
Method. Of 213 patients who received a kidney transplant between May,
2000 and August, 2005, 5/213 (2.3%) were identified to have had one or
more surgical hepatic, pancreatic, or biliary diseases since transplantation. A
retrospective case review was performed to examine presenting symptoms,
supporting laboratory and diagnostic studies done, surgical outcomes, and
the peri-operative management of immunosuppression.
Results. The most common presenting sign and symptom were a leukocy-
tosis and abdominal pain. Three patients had cholecystitis, with one leading
to gallstone pancreatitis. Another patient developed choledocholithiasis
requiring common bile duct exploration, and a fifth patient was diagnosed
with a hepatic mass requiring partial hepatectomy. Dosing of immuno-
suppressive medications and target levels were adjusted according to the
presence of malignancy and/or degree of infection or inflammation. The
average length of hospitalization was 15.2 (1/49) days. No peri-operative
deaths, surgical or hepatobiliary complications, or rejection episodes or graft
loss occurred.
Conclusion. Prompt diagnosis and timely surgical intervention prevented
the development of inflammatory and infectious states subsequent to hepatic,
pancreatic, or biliary diseases. Careful perioperative management of im-
munosuppression contributed to a favorable outcome in each case by finding
the optimal balance of maximum healing against the risk of graft rejection.
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Pancreatic rest prenesented as submucosal duodenal lesion
Reza F. Saidi, Michael J. Jacobs, MD
Providence Hospital, Southfield, MI
Ectopic pancreas is pancreatic tissue found outside the usual anatomic
location of the pancreas. It is often an incidental finding in clinical practice
and can be found at different sites in the gastrointestinal tract. We describe
a case ectopic pancreas in the duodenal bulb. This is a 53-year-old female
with symptomatic gastroesophageal reflux disease found to have a hiatal
hernia. She underwent endoscopic studies and evaluation as well as
monitoring and was confirmed to have reflux disease. During the course of
her evaluation for epigastric pain and reflux, she was also found to have a
submucosal lesion in D-1 of the duodenum for which a biopsy was
unremarkable. The patient underwent Nissen fundoplication. Upon explora-
tion a palpable lesion could be identified in the superior posterior aspect of
the D-1. The tissue did have the appearance of pancreatic tissue that was
excised and sent for pathologic diagnosis. Frozen section resulted in
pancreatic rest.
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Autoimmune pancreatitis: A challenging condition for clinicians and
surgeons
Roberto M. Gamarra, Jason Mishal, Edward Yousif, Michael Jacobs, MD,
Luis Maas, MD
Providence Hospital, Southfield, MI
Introduction. Autoimmune pancreatitis (AIP), a distinct pancreatic dis-
order, has been increasingly recognized in clinical practice. It is characterized
by its multiple presentations, suggestive histopathology and a high respon-
siveness to steroid treatment. This report illustrates two patients with this
condition.
The patients. Patient A is a 79 year-old male who presented with painless
obstructive jaundice treated with a biliary stent. A 1.2/1 cm mass adjacent
to the common bile duct was seen on endoscopic ultrasound (EUS), without
lymphadenopathy. A Whipple’s procedure was performed, but no malignancy
was found. Two years later he developed recurrent abdominal pain. A CT
scan revealed multiple pseudocysts and active pancreatitis in the tail and
body. The biopsy of the previously resected mass was reviewed and
reinterpreted as AIP. Prednisone was started and the patient improved
rapidly.
Patient B is a 56 year-old female who presented with epigastric pain but an
unremarkable physical examination and ultrasound. Laboratory findings
demonstrated only an elevated lipase and sedimentation rate. CT and MRI
scans revealed pancreatic edema and were suspicious for malignancy. After
surgery, the histopathology was consistent with AIP. The patient opted for
surveillance and has remained asymptomatic.
Discussion. Prospectively evaluated criteria for diagnosis of AIP do not
exist and clinicians must rely on clinical, laboratory, and imaging findings.
AIP may be primary or secondary to other autoimmune diseases.
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Increased serum IgG and positive autoantibodies may be suggestive of
AIP. Imaging often reveals focal or diffuse parenchymal inflammation, but
neither imaging nor laboratory findings are sufficient for diagnosis.
Pathology specimens demonstrate lymphocytic infiltration and fibrosis.
EUS-obtained biopsy specimens may provide adequate histologic samples.
Although our patients were not initially diagnosed with AIP, the
subsequent review of the pathology specimens obtained during surgery
supported the diagnosis of AIP and allowed for institution of proper
treatment and follow-up.
Conclusions. + AIP remains an elusive diagnosis to make. + Patients who
have been diagnosed with idiopathic pancreatitis after surgery may benefit
from review of their pathology specimens to exclude AIP. + As our ability to
diagnose AIP improves, more patients will avert unnecessary surgery and will
obtain prompt and effective medical therapy
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Goal of hepatectomy for hepatocellular carcinoma associated with the
injured liver caused by viral infection
Masamichi Moriguchi, Yuki Kimura, Kazuto Inoue, Tokio Higaki, Tadatoshi
Takayama
Nihon University, Toyko, Japan
Hepatectomy is now eshtablished as the first-line therapeutic option for
hepatocellular carcinoma (HCC). However, it is highly reccurence rate in the
remnant liver after curative resection. Reccurence in the remnant liver could
originate either intrahepatic metastasis (IM) or multicentric occurrence
(MO). We should not confuse the two kind of reccurence. It is considered
that IM should be reduced and then disappeared as some time goes by. So,
the recurrence after that time is limmited to be MO only. If it should be
achieved the disease-free survival until no appearance of IM, it is said to be
real surgical cure. The purpose of this study was to evaluate the point that
was not affected by IM after hepatectomy.
We analyzed 242 cases in curative hepatectomy with injured liver caused by
viral infection. Mean and median follow-up times were 1134 and 969
days.We estimated a point of agreement between trend of disease-free
survival curve and that of natural carcinogenesis.
The recurrence rates at 1, 2, 3, and 5 years were 27.2, 52.6, 64.1, and 79.3%,
respectively. It was drawn the same curve between disease-free survival and
natural carcinogenesis over 3.5 years after hepatectomy.
We purpose in this study that surgical cure of hepatectomy for HCC
associated with the injured liver caused by viral infection was limited to
more than 3.5-years disease-free survives.
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The spectrum of iatrogenic common bile duct injuries and their
outcome after surgical repair
Umut Sarpel, MD, Manousos M Konstadoulakis, MD, Sasan Roayaie,
Myron E Schwartz, MD
The Mount Sinai School of Medicine, New York, NY; Recanati-Miller
Transplantation Institute, New York, NY
Background. The purpose of this study was to characterize patients
undergoing operative repair of iatrogenic bile duct injuries and to identify
factors that are independently predictive of outcome.
Methods. The charts of all patients with biliary injury treated between 1989
and 2005 were reviewed. Survival was estimated using Kaplan-Meyer curves,
and variables tested using the chi-square test.
Results. Forty-eight patients were identified as having undergone surgery
for biliary injury. Causes of injury were laparoscopic or open cholecys-
tectomy (36) and other procedures (12) including abdominal trauma,
palliative hepaticojejunostomy, pancreaticoduodenectomy, right nephrect-
omy, hepatic artery embolization, hepatic artery infusion pump use, hepatic
tumor resection, and choledochal cyst excision. Surgical repairs included
Roux-en-Y hepaticojejunostomy (28), hepaticojejunostomy with hepatect-
omy (8), primary bile duct repair over a T-tube (4), revision of
hepaticojejunostomy (4), bile duct externalization (2), and liver transplan-
tation (2). The two patients requiring transplantation developed secondary
biliary cirrhosis from stricture formation. Median follow-up was 38
months. There were 8 deaths, 7 of which were perioperative; actuarial
5-year survival was 78%. Age /60 years (OR/6.6), and treatment other
than Roux-en-Y hepaticojejunostomy or primary repair (OR/5.2) were
associated with perioperative mortality. Neither history of previous repair
nor time between injury and repair affected mortality. Late postoperative
cholangitis leading to nonsurgical procedures was observed in 7 patients;
none has required reoperation.
Conclusions. Patients who survive the immediate perioperative period
following repair of iatrogenic bile duct injury have excellent survival and
good quality of life. Age /60 years and the need for treatment other than
primary repair or Roux-en-Y hepaticojejunostomy are risk factors for
perioperative mortality.
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Hepatitis is a matter of national health policy
Irene O. Christodoulou
Democritus University of Thrace, Thessaloniki, Greece
Medical care targets not only to the elongation of patients’ survival but also to
the promotion of quality of life. In Greece, studies of quality of life have
become important recently, but the use of independent indicators is rare.
Evaluation policy and re-examination of health services have been assumed as
secondary matters for long.
Public health status expresses the social-economic level and the conditions of
hygiene in each nation. Chronic infection from hepatitis B is very frequent
and it could be used as an indicator of public health. Hepatitis rates, an
important cause of cirrhosis of liver or hepatocellular cancer, affects
dramatically public health.
In Greece chronic infection cases of hepatitis has been decreased (3%).
However due to the increase of drugs addicts and the entry of immigrants
from countries with bigger percentages of infection there exists need of re-
planning on the subject of massive vaccinations. Also hepatitis C, second in
frequency in Greece among cases of hepatitis, presents an increasing rate.
Thrace is a region of high epidemiological interest due to the existence of
high risk groups, like gipsies and muslims. These people leave under low
socio-economical conditions.
It would not be an exaggeration to characterize hepatitis as a useful indicator
of public health but also a tool for evaluation of National Health System’s
policy.
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Synchronous resection of colorectal primary tumor and liver
metastases
Tristan Yan, MBBS, Denis King, PhD, David L Morris, MBBS
The University of New South Wales, Sydney, Australia
Introduction. Patients with synchronous colorectal liver metastases are
thought to have a less favorable prognosis. Surgical treatment options are
controversial, be it synchronous resection or staged resection. The aim of this
paper is to evaluate synchronous resection of colorectal liver metastases.
Methods. A long-term retrospective analysis of prospectively collected
clinical data of 103 patients with synchronous colorectal liver metastases
was performed. Morbidity, mortality, recurrence and survival results of
synchronous resection (Group I) and staged resection (Group II) were
compared. Kaplan-Meier analysis was used to identify significant prognostic
indicators.
Results. The median length follow-up was 24 months (range 1 to 112
months). The overall median survival was 37 months (range 1 to 112
months), with 1-, 3-, and 5-year survival rates of 89%, 52%, and 36%,
respectively. The median survival of patients who underwent a synchronous
resection was 37 months (range 1 to 110 months) versus that of patients who
underwent a staged resection, which was 36 months (range 2 to 112 months)
(p/0.900). Two factors were found to have significant impact on survival:
small hepatic metastasis (5/4 cm) and low postoperative CEA level (5/5 ng/
ml).
Conclusions. Synchronous resection achieves same survival results as that of
staged resection and it avoids a second major operation.
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Factors predicting postoperative cytokine response in patients under-
going liver resection
Carlo Pulitano`, Luca Aldrighetti, MD, PhD, Marcella Arru, MD, Renato
Finazzi, MD, Marco Catena, MD, PhD, Eleonora Guzzetti, MD, Laura
Soldini, MD, Gianfranco Ferla, MD
Scientific Institute H San Raffaele, Milan, Italy
The human body reacts to surgical stimuli, through various systemic
responses including the endocrine, immune, metabolic, and cytokine
systems. However, extended damage may result in an exaggerated systemic
response with an overwhelming activation of immune cells and the release, of
various mediators of stress. In particular, increased levels of inflammatory
cytokines have been correlated with higher postoperative mortality and
morbidity rates.
Inflammatory cytokines are thought to play a significant role in many adverse
immune mediate events following liver surgery, including: hepatic ischemia-
reperfusion (I/R) injury following portal clamping, postoperative organ
dysfunction, and immune suppression by surgical stress itself. This study
was conducted to evaluate factors predicting perioperative response of
proinflammatory cytokines following liver resection. Seventy-eight patients
undergoing hepatic resection for benign and malign diseases were enclosed in
the study. The inflammatory cytokines Interleukin-6 (IL-6) and Tumor
necrosis factor alpha (TNF-a) were measured by ELISA preoperatively and
on post operative day (POD) 1, 2, and 5. Length of stay, and type and
number of complications were recorded. Il-6 serum levels reached a peak on
POD1 and declined thereafter, TNF-a levels peaked later on POD2 and
declined thereafter. The peak concentrations of IL-6 in the patients with
complications were significantly higher than those in the patients without
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complications. The peak concentration of IL-6 was significantly correlated
with the length of surgery, blood losses, and intraoperative blood product
requirement. Significantly higher levels of IL-6 after operation were present
in the patients with chronic liver disease and hyperbilirubin. No significant
correlation was found with TNF-a. IL-6 levels may represent a sensible and
specific predictive marker of surgical stress and postoperative complications.
Patients with a healthy liver adapted to surgical stress more easily than did
patients with a diseased liver. Furthermore, the present study suggests that
the increased complications rate associated with blood transfusion and blood
transfusion may be due to increased levels of IL-6.
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Expression of corticotropin-releasing factor (CRF) family of neuro-
peptides in the human liver
Irene O. Christodoulou, Ekaterini Chatzaki, MD, PhD
Democritus University of Thrace, Alexandroupolis, Greece
Background/Aims. The Corticotropin Releasing Factor (CRF) system,
consisting of CRF and the homologue neuropeptides urocortins, their
receptors CRF1 and CRF2, and a specific binding protein (CRF-BP), holds
the principle role in mediating the response to stress stimuli. Besides their
expression in the brain, CRF peptides and receptors have been found in
multiple peripheral sites.
Methods. We investigated the expression of CRF, Ucn, CRF receptors and
CRF-BP in the human liver, using RT-PCR and immunohistochemistry.
Results. Ucn but not CRF gene transcripts were detected in RNA isolated
from normal human liver biopsies. Ucn immunoreactivity was localized
to hepatocytes of the hepatic parenchyma and was not observed in the
capsule, portal areas and connective tissue. CRF1 and CRF2(a) receptor
gene expression was also found, and receptor protein had similar distri-
bution to Ucn in the hepatocytes of the human liver tissue. Finally,
CRF-BP gene expression was shown as well as low levels of protein immu-
noreactivity.
Conclusions. The CRF system is expressed in normal human hepatocytes,
Ucn being the major ligand, possibly acting in an autocrine manner through
activation of the CRF receptors expressed locally. Further study is required to
enfold the biological role of these effectors in the liver physiology and
pathogenesis.
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Excluded posterior right hepatic duct drainage after roux-en-y
hepaticojejunostomy
John J. Brems, MD, Ken Pierce, Gerard Aranha and Marc Borge, MD
Loyola University, Maywood, IL
Excluded Posterior Right Hepatic Duct Drainage After Roux-en-y Hepati-
cojejunostomy.
The hepatic ductal anatomy has many variations. One of the more common is
the cystic duct arising from the right hepatic duct. This has led to the right
hepatic duct being injured during laparoscopic cholecystectomies.
We report four cases referred to us, in which the right hepatic duct was
excluded, when a Roux-en-y hepaticojejunostomy was performed. We believe
that the surgeons mistaken the right hepatic duct for the cystic duct and
excluded it from the anastomosis. The four patients presented with post-
operative biliomas. The excluded right hepatic duct was identified by
percutaneous transhepatic cholangiogram (PTC). A bililary catheter was
inserted into the un-drained duct to decompress it. After the inflammation
from the bilioma subsided, the patients underwent re-exploration and the
excluded duct was incorporated into the Roux-en-y hepaticojejunostomy.
Surgeons need to be cognizant of aberrant hepatic ductal anatomy when
performing hepaticojejunostomies. If there is doubt, a cholangiogram should
be performed. Also, if patients develop persistent bile leaks after Roux-en-y
hepaticojejunostomies, consideration of an excluded hepatic duct should be
entertained and a PCT obtained.
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